

## A pedometer-based walking intervention in 45- to 75-year-olds, with and without practice nurse support: the PACE-UP three-arm cluster RCT

*Tess Harris, Sally Kerry, Christina Victor, Steve Iliffe, Michael Ussher, Julia Fox-Rushby, Peter Whincup, Ulf Ekelund, Cheryl Furness, Elizabeth Limb, Nana Anokye, Judith Ibison, Stephen DeWilde, Lee David, Emma Howard, Rebecca Dale, Jaime Smith, Rebecca Normansell, Carole Beighton, Katy Morgan, Charlotte Wahlich, Sabina Sanghera and Derek Cook*



**National Institute for  
Health Research**



# A pedometer-based walking intervention in 45- to 75-year-olds, with and without practice nurse support: the PACE-UP three-arm cluster RCT

Tess Harris,<sup>1\*</sup> Sally Kerry,<sup>2</sup> Christina Victor,<sup>3</sup> Steve Iliffe,<sup>4</sup> Michael Ussher,<sup>1</sup> Julia Fox-Rushby,<sup>5</sup> Peter Whincup,<sup>1</sup> Ulf Ekelund,<sup>6,7</sup> Cheryl Furness,<sup>1</sup> Elizabeth Limb,<sup>1</sup> Nana Anokye,<sup>5</sup> Judith Ibison,<sup>1</sup> Stephen DeWilde,<sup>1</sup> Lee David,<sup>8</sup> Emma Howard,<sup>1</sup> Rebecca Dale,<sup>1</sup> Jaime Smith,<sup>1</sup> Rebecca Normansell,<sup>1</sup> Carole Beighton,<sup>1</sup> Katy Morgan,<sup>2</sup> Charlotte Wahlich,<sup>1</sup> Sabina Sanghera<sup>5</sup> and Derek Cook<sup>1</sup>

<sup>1</sup>Population Health Research Institute, St George's, University of London, London, UK

<sup>2</sup>Pragmatic Clinical Trials Unit, Queen Mary University of London, London, UK

<sup>3</sup>Gerontology and Health Services Research Unit, Brunel University London, London, UK

<sup>4</sup>Research Department of Primary Care and Population Health, University College London, London, UK

<sup>5</sup>Health Economics Research Group, Brunel University London, London, UK

<sup>6</sup>Department of Sports Medicine, Norwegian School of Sport Sciences, Oslo, Norway

<sup>7</sup>Medical Research Council Epidemiology Unit, University of Cambridge, Cambridge, UK

<sup>8</sup>10 Minute CBT, Devonshire Business Centre, Letchworth Garden City, UK

\*Corresponding author

**Declared competing interests of authors:** Lee David is the director of 10 Minute CBT. She helped to develop Pedometer And Consultation Evaluation-UP (PACE-UP) patient resources and training for the PACE-UP nurses and received personal fees from 10 Minute CBT during the conduct of this study.

Tess Harris is a member of the National Institute for Health Research (NIHR) Health Technology Assessment Primary Care and Community Preventative Interventions panel. Julia Fox-Rushby reports grants from the NIHR and membership of the Public Health Research Research Funding Board during the conduct of the study. Katy Morgan's salary was funded through a NIHR research methods fellowship (reference number MET-12-16), during the conduct of the study.



Published June 2018

DOI: 10.3310/hta22370

This report should be referenced as follows:

Harris T, Kerry S, Victor C, Iliffe S, Ussher M, Fox-Rushby J, *et al.* A pedometer-based walking intervention in 45- to 75-year-olds, with and without practice nurse support: the PACE-UP three-arm cluster RCT. *Health Technol Assess* 2018;**22**(37).

*Health Technology Assessment* is indexed and abstracted in *Index Medicus/MEDLINE*, *Excerpta Medica/EMBASE*, *Science Citation Index Expanded (SciSearch®)* and *Current Contents®/Clinical Medicine*.



ISSN 1366-5278 (Print)

ISSN 2046-4924 (Online)

Impact factor: 4.236

*Health Technology Assessment* is indexed in MEDLINE, CINAHL, EMBASE, The Cochrane Library and the Clarivate Analytics Science Citation Index.

This journal is a member of and subscribes to the principles of the Committee on Publication Ethics (COPE) ([www.publicationethics.org/](http://www.publicationethics.org/)).

Editorial contact: [journals.library@nhr.ac.uk](mailto:journals.library@nhr.ac.uk)

The full HTA archive is freely available to view online at [www.journalslibrary.nhr.ac.uk/hta](http://www.journalslibrary.nhr.ac.uk/hta). Print-on-demand copies can be purchased from the report pages of the NIHR Journals Library website: [www.journalslibrary.nhr.ac.uk](http://www.journalslibrary.nhr.ac.uk)

## Criteria for inclusion in the *Health Technology Assessment* journal

Reports are published in *Health Technology Assessment* (HTA) if (1) they have resulted from work for the HTA programme, and (2) they are of a sufficiently high scientific quality as assessed by the reviewers and editors.

Reviews in *Health Technology Assessment* are termed 'systematic' when the account of the search appraisal and synthesis methods (to minimise biases and random errors) would, in theory, permit the replication of the review by others.

## HTA programme

The HTA programme, part of the National Institute for Health Research (NIHR), was set up in 1993. It produces high-quality research information on the effectiveness, costs and broader impact of health technologies for those who use, manage and provide care in the NHS. 'Health technologies' are broadly defined as all interventions used to promote health, prevent and treat disease, and improve rehabilitation and long-term care.

The journal is indexed in NHS Evidence via its abstracts included in MEDLINE and its Technology Assessment Reports inform National Institute for Health and Care Excellence (NICE) guidance. HTA research is also an important source of evidence for National Screening Committee (NSC) policy decisions.

For more information about the HTA programme please visit the website: <http://www.nets.nhr.ac.uk/programmes/hta>

## This report

The research reported in this issue of the journal was funded by the HTA programme as project number 10/32/02. The contractual start date was in March 2012. The draft report began editorial review in June 2017 and was accepted for publication in November 2017. The authors have been wholly responsible for all data collection, analysis and interpretation, and for writing up their work. The HTA editors and publisher have tried to ensure the accuracy of the authors' report and would like to thank the reviewers for their constructive comments on the draft document. However, they do not accept liability for damages or losses arising from material published in this report.

This report presents independent research funded by the National Institute for Health Research (NIHR). The views and opinions expressed by authors in this publication are those of the authors and do not necessarily reflect those of the NHS, the NIHR, NETSCC, the HTA programme or the Department of Health and Social Care. If there are verbatim quotations included in this publication the views and opinions expressed by the interviewees are those of the interviewees and do not necessarily reflect those of the authors, those of the NHS, the NIHR, NETSCC, the HTA programme or the Department of Health and Social Care.

**© Queen's Printer and Controller of HMSO 2018. This work was produced by Harris *et al.* under the terms of a commissioning contract issued by the Secretary of State for Health and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science Park, Southampton SO16 7NS, UK.**

Published by the NIHR Journals Library ([www.journalslibrary.nhr.ac.uk](http://www.journalslibrary.nhr.ac.uk)), produced by Prepress Projects Ltd, Perth, Scotland ([www.prepress-projects.co.uk](http://www.prepress-projects.co.uk)).

## NIHR Journals Library Editor-in-Chief

**Professor Tom Walley** Director, NIHR Evaluation, Trials and Studies and Director of the EME Programme, UK

## NIHR Journals Library Editors

**Professor Ken Stein** Chair of HTA and EME Editorial Board and Professor of Public Health, University of Exeter Medical School, UK

**Professor Andrée Le May** Chair of NIHR Journals Library Editorial Group (HS&DR, PGfAR, PHR journals)

**Dr Martin Ashton-Key** Consultant in Public Health Medicine/Consultant Advisor, NETSCC, UK

**Professor Matthias Beck** Professor of Management, Cork University Business School, Department of Management and Marketing, University College Cork, Ireland

**Dr Tessa Crilly** Director, Crystal Blue Consulting Ltd, UK

**Dr Eugenia Cronin** Senior Scientific Advisor, Wessex Institute, UK

**Dr Peter Davidson** Director of the NIHR Dissemination Centre, University of Southampton, UK

**Ms Tara Lamont** Scientific Advisor, NETSCC, UK

**Dr Catriona McDaid** Senior Research Fellow, York Trials Unit, Department of Health Sciences, University of York, UK

**Professor William McGuire** Professor of Child Health, Hull York Medical School, University of York, UK

**Professor Geoffrey Meads** Professor of Wellbeing Research, University of Winchester, UK

**Professor John Norrie** Chair in Medical Statistics, University of Edinburgh, UK

**Professor John Powell** Consultant Clinical Adviser, National Institute for Health and Care Excellence (NICE), UK

**Professor James Raftery** Professor of Health Technology Assessment, Wessex Institute, Faculty of Medicine, University of Southampton, UK

**Dr Rob Riemsma** Reviews Manager, Kleijnen Systematic Reviews Ltd, UK

**Professor Helen Roberts** Professor of Child Health Research, UCL Great Ormond Street Institute of Child Health, UK

**Professor Jonathan Ross** Professor of Sexual Health and HIV, University Hospital Birmingham, UK

**Professor Helen Snooks** Professor of Health Services Research, Institute of Life Science, College of Medicine, Swansea University, UK

**Professor Jim Thornton** Professor of Obstetrics and Gynaecology, Faculty of Medicine and Health Sciences, University of Nottingham, UK

**Professor Martin Underwood** Director, Warwick Clinical Trials Unit, Warwick Medical School, University of Warwick, UK

Please visit the website for a list of editors: [www.journalslibrary.nihr.ac.uk/about/editors](http://www.journalslibrary.nihr.ac.uk/about/editors)

**Editorial contact:** [journals.library@nihr.ac.uk](mailto:journals.library@nihr.ac.uk)

# Abstract

## A pedometer-based walking intervention in 45- to 75-year-olds, with and without practice nurse support: the PACE-UP three-arm cluster RCT

Tess Harris,<sup>1\*</sup> Sally Kerry,<sup>2</sup> Christina Victor,<sup>3</sup> Steve Iliffe,<sup>4</sup> Michael Usher,<sup>1</sup> Julia Fox-Rushby,<sup>5</sup> Peter Whincup,<sup>1</sup> Ulf Ekelund,<sup>6,7</sup> Cheryl Furness,<sup>1</sup> Elizabeth Limb,<sup>1</sup> Nana Anokye,<sup>5</sup> Judith Ibson,<sup>1</sup> Stephen DeWilde,<sup>1</sup> Lee David,<sup>8</sup> Emma Howard,<sup>1</sup> Rebecca Dale,<sup>1</sup> Jaime Smith,<sup>1</sup> Rebecca Normansell,<sup>1</sup> Carole Beighton,<sup>1</sup> Katy Morgan,<sup>2</sup> Charlotte Wahlich,<sup>1</sup> Sabina Sanghera<sup>5</sup> and Derek Cook<sup>1</sup>

<sup>1</sup>Population Health Research Institute, St George's, University of London, London, UK

<sup>2</sup>Pragmatic Clinical Trials Unit, Queen Mary University of London, London, UK

<sup>3</sup>Gerontology and Health Services Research Unit, Brunel University London, London, UK

<sup>4</sup>Research Department of Primary Care and Population Health, University College London, London, UK

<sup>5</sup>Health Economics Research Group, Brunel University London, London, UK

<sup>6</sup>Department of Sports Medicine, Norwegian School of Sport Sciences, Oslo, Norway

<sup>7</sup>Medical Research Council Epidemiology Unit, University of Cambridge, Cambridge, UK

<sup>8</sup>10 Minute CBT, Devonshire Business Centre, Letchworth Garden City, UK

\*Corresponding author [tharris@sgul.ac.uk](mailto:tharris@sgul.ac.uk)

**Background:** Guidelines recommend walking to increase moderate to vigorous physical activity (MVPA) for health benefits.

**Objectives:** To assess the effectiveness, cost-effectiveness and acceptability of a pedometer-based walking intervention in inactive adults, delivered postally or through dedicated practice nurse physical activity (PA) consultations.

**Design:** Parallel three-arm trial, cluster randomised by household.

**Setting:** Seven London-based general practices.

**Participants:** A total of 11,015 people without PA contraindications, aged 45–75 years, randomly selected from practices, were invited. A total of 6399 people were non-responders, and 548 people self-reporting achieving PA guidelines were excluded. A total of 1023 people from 922 households were randomised to usual care ( $n = 338$ ), postal intervention ( $n = 339$ ) or nurse support ( $n = 346$ ). The recruitment rate was 10% (1023/10,467). A total of 956 participants (93%) provided outcome data.

**Interventions:** Intervention groups received pedometers, 12-week walking programmes advising participants to gradually add '3000 steps in 30 minutes' most days weekly and PA diaries. The nurse group was offered three dedicated PA consultations.

**Main outcome measures:** The primary and main secondary outcomes were changes from baseline to 12 months in average daily step counts and time in MVPA (in  $\geq 10$ -minute bouts), respectively, from 7-day accelerometry. Individual resource-use data informed the within-trial economic evaluation and the Markov

model for simulating long-term cost-effectiveness. Qualitative evaluations assessed nurse and participant views. A 3-year follow-up was conducted.

**Results:** Baseline average daily step count was 7479 [standard deviation (SD) 2671], average minutes per week in MVPA bouts was 94 minutes (SD 102 minutes) for those randomised. PA increased significantly at 12 months in both intervention groups compared with the control group, with no difference between interventions; additional steps per day were 642 steps [95% confidence interval (CI) 329 to 955 steps] for the postal group and 677 steps (95% CI 365 to 989 steps) for nurse support, and additional MVPA in bouts (minutes per week) was 33 minutes per week (95% CI 17 to 49 minutes per week) for the postal group and 35 minutes per week (95% CI 19 to 51 minutes per week) for nurse support. Intervention groups showed no increase in adverse events. Incremental cost per step was 19p and £3.61 per minute in a  $\geq 10$ -minute MVPA bout for nurse support, whereas the postal group took more steps and cost less than the control group. The postal group had a 50% chance of being cost-effective at a £20,000 per quality-adjusted life-year (QALY) threshold within 1 year and had both lower costs [–£11M (95% CI –£12M to –£10M) per 100,000 population] and more QALYs [759 QALYs gained (95% CI 400 to 1247 QALYs)] than the nurse support and control groups in the long term. Participants and nurses found the interventions acceptable and enjoyable. Three-year follow-up data showed persistent intervention effects (nurse support plus postal vs. control) on steps per day [648 steps (95% CI 272 to 1024 steps)] and MVPA bouts [26 minutes per week (95% CI 8 to 44 minutes per week)].

**Limitations:** The 10% recruitment level, with lower levels in Asian and socioeconomically deprived participants, limits the generalisability of the findings. Assessors were unmasked to the group.

**Conclusions:** A primary care pedometer-based walking intervention in 45- to 75-year-olds increased 12-month step counts by around one-tenth, and time in MVPA bouts by around one-third, with similar effects for the nurse support and postal groups, and persistent 3-year effects. The postal intervention provides cost-effective, long-term quality-of-life benefits. A primary care pedometer intervention delivered by post could help address the public health physical inactivity challenge.

**Future work:** Exploring different recruitment strategies to increase uptake. Integrating the Pedometer And Consultation Evaluation-UP (PACE-UP) trial with evolving PA monitoring technologies.

**Trial registration:** Current Controlled Trials ISRCTN98538934.

**Funding:** This project was funded by the National Institute for Health Research (NIHR) Health Technology Assessment programme and will be published in full in *Health Technology Assessment*; Vol. 22, No. 37. See the NIHR Journals Library website for further project information.

# Contents

<b>List of tables</b>	<b>xv</b>
<b>List of figures</b>	<b>xix</b>
<b>List of abbreviations</b>	<b>xxi</b>
<b>Plain English summary</b>	<b>xxiii</b>
<b>Scientific summary</b>	<b>xxv</b>
<b>Chapter 1 Introduction: why this study was needed</b>	<b>1</b>
Benefits and risks of physical activity and current physical activity guidelines	1
<i>What are the benefits of physical activity for adults and older adults?</i>	1
<i>What are the current physical activity guidelines and who is achieving them?</i>	1
<i>What are the risks from increasing physical activity?</i>	1
Strategies for increasing physical activity	2
<i>How can adults and older adults increase their physical activity levels?</i>	2
<i>Are pedometers helpful?</i>	2
<i>How do step count goals relate to physical activity recommendations?</i>	3
<i>Could accelerometers be useful in a pedometer-based walking intervention?</i>	3
<i>Are pedometers cost-effective?</i>	3
<i>What is the role of primary care in promoting physical activity?</i>	3
<i>Theoretical base, piloting and preparatory work to develop the intervention</i>	4
Rationale for research	4
<b>Chapter 2 Methods</b>	<b>7</b>
Study design	7
Study aims and objectives	7
<i>Study aims</i>	7
<i>Primary objectives (relating to the primary outcome of step counts)</i>	7
<i>Secondary objectives (relating to secondary outcomes of time in moderate to vigorous physical activity in bouts, sedentary time and cost-effectiveness)</i>	8
<i>Other objectives</i>	8
Practice and participant inclusion/exclusion criteria	8
<i>Practice inclusion criteria</i>	8
<i>Participant inclusion criteria</i>	9
<i>Participant exclusion criteria</i>	9
Recruitment of practices and participants: informed consent	9
<i>Practice recruitment</i>	9
<i>Participant recruitment</i>	9
<i>Non-responders and non-participants</i>	10
<i>Informed consent</i>	10
Changes from the published protocol	10
Interventions	10
<i>Procedure for the postal intervention group</i>	11
<i>Procedure for the nurse intervention group</i>	11
<i>Procedure for the control group</i>	12

Outcome measures	13
<i>Primary and secondary outcome measures</i>	13
<i>Ancillary outcomes</i>	15
Ascertainment of outcomes	15
<i>Accelerometry</i>	15
<i>Anthropometry</i>	15
<i>Questionnaire measures</i>	15
<i>Primary care computerised record measures</i>	16
Baseline and follow-up data collection	16
<i>Baseline data collection</i>	16
<i>Follow-up data collection</i>	16
Accelerometer data reduction	17
Adverse events and serious adverse events	17
Sample size	18
Randomisation, concealment of allocation, contamination and treatment masking	18
<i>Randomisation and concealment of allocation</i>	18
<i>Contamination</i>	19
<i>Treatment masking</i>	19
Withdrawals, losses to follow-up and missing data	19
<i>Withdrawals and losses to follow-up</i>	19
<i>Procedure for accounting for missing data</i>	19
Statistical methods	20
<i>Primary analysis</i>	20
<i>Secondary and ancillary outcome analyses</i>	20
<i>Adverse event analyses</i>	21
<i>Subgroup analyses</i>	21
<i>Sensitivity analyses</i>	21
Ethics approval and research governance	21
Management of the trial	21
Further trial follow-up at 3 years	22
<b>Chapter 3 Results</b>	<b>23</b>
Recruitment of participants	23
Baseline characteristics of the study population ( <i>Table 4</i> )	23
Losses to follow-up	23
Data completeness for accelerometry	27
Effect of the intervention on accelerometer-assessed physical activity outcomes ( <i>Table 5</i> )	27
<i>Three-month (interim) outcomes</i>	27
<i>Twelve-month (main) outcomes</i>	28
Effect of the intervention on self-reported physical activity outcomes at 12 months ( <i>Table 6</i> )	28
Effect of the intervention on other health-related outcomes ( <i>Table 7</i> )	29
Effect of the intervention on adverse events and serious adverse events ( <i>Table 8</i> )	29
Subgroup analyses ( <i>Figure 4</i> )	29
Sensitivity analyses and imputations (see <i>Appendix 2, Table 26</i> )	29
Summary of the main trial findings	32
<b>Chapter 4 Economic evaluation</b>	<b>35</b>
Introduction	35
Within-trial cost-effectiveness analysis	35
<i>Methods</i>	36
<i>Results</i>	38

Beyond-trial modelling	42
<i>Methods</i>	43
<i>Results</i>	44
Discussion	46
<i>Strengths and weaknesses</i>	47
Conclusion	47
<b>Chapter 5 Generalisability</b>	<b>49</b>
Introduction	49
Methods	49
<i>Data collection for quantitative comparisons</i>	49
<i>Comparison groups</i>	49
<i>Statistical analysis</i>	50
<i>Methods for the interview study of non-participants</i>	51
<i>Methods for analysing interviews</i>	51
Results	51
<i>Results from quantitative comparisons</i>	51
<i>Results from qualitative comparisons</i>	56
<i>Summary of the findings</i>	59
<i>Strengths and limitations</i>	59
<i>Comparisons with previous work</i>	60
<i>Implications</i>	61
Conclusions	62
<b>Chapter 6 Process evaluation</b>	<b>63</b>
Introduction	63
<i>Why is process evaluation necessary in the PACE-UP trial?</i>	63
<i>Medical Research Council's guidance on process evaluations in complex interventions</i>	63
Methods and results	66
Implementation	67
<i>Implementation process</i>	67
<i>Reach</i>	69
<i>Fidelity (content and quality)</i>	69
<i>Dose</i>	72
<i>Adaptations</i>	73
Mechanisms of impact	73
<i>Participant responsiveness</i>	73
Context	74
Association between process evaluation measures and trial outcome measures	75
<i>Nurse session attendance and physical activity outcomes</i>	75
<i>Diary return and physical activity outcomes</i>	75
<i>Pedometer use and physical activity outcomes</i>	75
Discussion	76
<i>Main findings</i>	76
<i>Strengths and limitations</i>	77
<i>Comparison with other complex intervention process evaluations</i>	78
<i>Implications of the process evaluation for the interpretation of the PACE-UP trial</i>	78
Conclusion	79
<b>Chapter 7 What did the nurses and participants think about the intervention?</b>	<b>81</b>
Introduction	81
Recruiting trial participants for the qualitative study	81
The role of nurses in the PACE-UP intervention	82

Preparing for the trial	83
Delivering and participating in the trial	83
<i>Perceived value of nurse consultations</i>	83
<i>Behaviour change techniques</i>	84
<i>Adapting the trial protocol versus fidelity</i>	85
<i>Trial materials and equipment</i>	86
<i>Nurse satisfaction</i>	86
After the trial and implementation	87
Discussion	88
<b>Chapter 8 Three-year follow-up to assess the maintenance of physical activity levels</b>	<b>89</b>
Introduction	89
Methods for quantitative physical activity evaluation	90
<i>Ethics approval and research governance</i>	90
<i>Participants eligible for the 3-year follow-up</i>	90
<i>Contacting participants</i>	90
<i>Informed consent</i>	90
<i>Data collection</i>	91
<i>Outcome measures</i>	91
<i>Accelerometer data reduction</i>	91
<i>Procedure for accounting for missing data</i>	91
<i>Statistical methods</i>	91
Methods for qualitative evaluation	92
<i>Sampling</i>	92
<i>Recruitment and informed consent</i>	92
<i>Transcribing</i>	92
<i>Interview schedule</i>	93
<i>Analysis</i>	93
Results for the quantitative physical activity evaluation	93
<i>Follow-up rate</i>	93
<i>Data completeness</i>	93
<i>Objective physical activity findings</i>	93
<i>Missing data analyses</i>	93
Results for the qualitative evaluation	96
<i>Factors affecting physical activity levels and maintenance at 3 years</i>	97
<i>The effect of the minimal intervention on physical activity levels of participants in the control group</i>	100
Discussion	101
<i>Main quantitative findings from the 3-year follow-up</i>	101
<i>Main qualitative findings from the 3-year follow-up interviews</i>	102
<b>Chapter 9 Discussion</b>	<b>103</b>
Summary of the findings	103
Strengths and limitations	104
<i>Study strengths</i>	104
<i>Study limitations</i>	104
Generalisability	105
Comparison with other studies	105
Interpretation of the results	107
Conclusions	108
<i>Implications for health care</i>	108
<i>Recommendations for research</i>	108

<b>Acknowledgements</b>	<b>109</b>
<b>References</b>	<b>113</b>
<b>Appendix 1 Methods</b>	<b>129</b>
<b>Appendix 2 Results</b>	<b>207</b>
<b>Appendix 3 Economic evaluation</b>	<b>213</b>
<b>Appendix 4 Generalisability</b>	<b>233</b>
<b>Appendix 5 Process evaluation</b>	<b>243</b>
<b>Appendix 6 Qualitative evaluation</b>	<b>257</b>
<b>Appendix 7 Three-year follow-up</b>	<b>261</b>
<b>Appendix 8 Discussion</b>	<b>273</b>



# List of tables

<b>TABLE 1</b> Components of the complex intervention for the PACE-UP trial	<b>11</b>
<b>TABLE 2</b> The PACE-UP patient handbook, and diary and BCTs included	<b>12</b>
<b>TABLE 3</b> The PACE-UP practice nurse PA consultations and BCTs included	<b>13</b>
<b>TABLE 4</b> Baseline characteristics of the 1023 randomised subjects	<b>25</b>
<b>TABLE 5</b> Primary and secondary accelerometry outcome data	<b>27</b>
<b>TABLE 6</b> Effect estimates for self-report questionnaires (IPAQ and GPPAQ) at 12 months	<b>28</b>
<b>TABLE 7</b> Effect estimates for other health-related outcomes	<b>30</b>
<b>TABLE 8</b> Adverse events	<b>31</b>
<b>TABLE 9</b> Average costs and QALYs per participant, by trial arm (£2013–14, base case, with missing values imputed)	<b>39</b>
<b>TABLE 10</b> Costs, effects and cost-effectiveness at 3 and 12 months (£2013–14; base case, adjusted for baseline differences)	<b>39</b>
<b>TABLE 11</b> Costs, effects and cost-effectiveness over a lifetime (cohort of 100,000)	<b>45</b>
<b>TABLE 12</b> Responders to the invitation letter by age, sex and IMD quintile	<b>52</b>
<b>TABLE 13</b> Completion of the baseline assessment and questionnaires in participants and non-participants who are not active on the GPPAQ, by age, sex, IMD quintile and ethnicity	<b>53</b>
<b>TABLE 14</b> Participants and non-participants who completed questionnaires and were not active on the GPPAQ: demographics and health and lifestyle factors	<b>54</b>
<b>TABLE 15</b> Summary of categories and themes: barriers to participating	<b>56</b>
<b>TABLE 16</b> Summary of the PACE-UP trial process evaluation data sources, evaluative groups and reported measures	<b>66</b>
<b>TABLE 17</b> Quality of delivery and participant responsiveness data from the nurse and patient alliance questionnaires	<b>70</b>
<b>TABLE 18</b> Fidelity: quality scores of performance for audio-recordings of nurse sessions by BCT trainer	<b>72</b>
<b>TABLE 19</b> The PACE-UP trial modelling results: relating nurse session attendance, step count diary return and pedometer use to PA outcomes	<b>76</b>

<b>TABLE 20</b> Summary means and SDs for accelerometry data at baseline, 3 months, 12 months and 3 years	<b>95</b>
<b>TABLE 21</b> Accelerometry outcome data at 3 months, 12 months and 3 years. Analysed using all available data at each follow-up. <i>N</i> = 954 at 3 months, <i>N</i> = 956 at 12 months and <i>N</i> = 681 at 3 years	<b>96</b>
<b>TABLE 22</b> Imputation analyses for the 3-year accelerometry outcomes	<b>97</b>
<b>TABLE 23</b> The number of days with $\geq 540$ minutes' accelerometer wear time by treatment group at baseline, 3 months and 12 months	<b>209</b>
<b>TABLE 24</b> Summary data for main outcome and ancillary outcome variables	<b>210</b>
<b>TABLE 25</b> Physical activity measured by self-report IPAQ and GPPAQ measurements	<b>211</b>
<b>TABLE 26</b> Sensitivity and imputation analyses for the primary outcome (step count at 12 months)	<b>212</b>
<b>TABLE 27</b> Resource use and cost components of 'set-up costs'	<b>213</b>
<b>TABLE 28</b> Components of the cost of delivering care and sources of data by trial arm	<b>215</b>
<b>TABLE 29</b> Health provider cost of health service use	<b>215</b>
<b>TABLE 30</b> Personal costs of participating in the interventions or control arms of the trial	<b>216</b>
<b>TABLE 31</b> Resource use and cost components of 'set-up cost'	<b>216</b>
<b>TABLE 32</b> Components of delivery cost of intervention (postal delivery group)	<b>219</b>
<b>TABLE 33</b> Components of delivery cost of intervention (nurse-support group)	<b>219</b>
<b>TABLE 34</b> Costs to participants of participating in interventions and PA	<b>220</b>
<b>TABLE 35</b> Health service use by trial arm with unit costs	<b>221</b>
<b>TABLE 36</b> Within-trial sensitivity analyses (at 12 months)	<b>226</b>
<b>TABLE 37</b> Parameter values for the long-term cost-effectiveness model	<b>229</b>
<b>TABLE 38</b> Implementation process: training delivered to nurses	<b>243</b>
<b>TABLE 39</b> Fidelity: content delivered in nurse intervention group sessions in accordance with nurse checklists	<b>243</b>
<b>TABLE 40</b> Nurse-support and postal intervention group PA diary return and use	<b>244</b>

<b>TABLE 41</b> Pedometer use from questionnaire data	<b>244</b>
<b>TABLE 42</b> Duration of sessions	<b>244</b>
<b>TABLE 43</b> Interview participant details	<b>259</b>



# List of figures

<b>FIGURE 1</b> A summary of the PACE-UP walking programme	<b>14</b>
<b>FIGURE 2</b> Schedule of outcome assessment measures used in the PACE-UP trial	<b>17</b>
<b>FIGURE 3</b> The PACE-UP trial CONSORT flow diagram	<b>24</b>
<b>FIGURE 4</b> Subgroup analyses	<b>32</b>
<b>FIGURE 5</b> Cost-effectiveness plane for the postal delivery group vs. the control group at 12 months	<b>41</b>
<b>FIGURE 6</b> Cost-effectiveness plane for the nurse-support group vs. the control group at 12 months	<b>42</b>
<b>FIGURE 7</b> Cost-effectiveness acceptability curve for the postal delivery and nurse-support groups (vs. the control group) at different willingness-to-pay-per-QALY thresholds	<b>42</b>
<b>FIGURE 8</b> Illustration of pathways within the long-term cost-effectiveness model	<b>43</b>
<b>FIGURE 9</b> Cost-effectiveness acceptability curve showing the probability of lifetime cost-effectiveness for the postal delivery group and the nurse-support group (vs. the control group) at different willingness-to-pay threshold levels	<b>45</b>
<b>FIGURE 10</b> Flow chart to show the recruitment process in the PACE-UP trial	<b>50</b>
<b>FIGURE 11</b> The key functions of process evaluation and the relationships between these	<b>64</b>
<b>FIGURE 12</b> Logic model for the PACE-UP (Pedometers and Consultation Evaluation – UP) PA trial	<b>65</b>
<b>FIGURE 13</b> The key functions of process evaluation and the relationships between them for the PACE-UP trial	<b>68</b>
<b>FIGURE 14</b> Behaviour change technique competency level	<b>71</b>
<b>FIGURE 15</b> The PACE-UP CONSORT flow diagram with 3-year follow-up data	<b>94</b>
<b>FIGURE 16</b> Sensitivity analyses for different values of missing steps counts	<b>98</b>
<b>FIGURE 17</b> Trial procedures and complex intervention components	<b>207</b>
<b>FIGURE 18</b> Residuals from the 12-month models for steps and weekly MVPA in $\geq 10$ -minute bouts	<b>208</b>
<b>FIGURE 19</b> Cost-effectiveness plane for nurse support vs. postal delivery at 12 months	<b>225</b>

- FIGURE 20** Cost-effectiveness acceptability curve showing the probability of within-trial cost-effectiveness for nurse support vs. postal delivery at different willingness-to-pay threshold levels 225
- FIGURE 21** Cost-effectiveness acceptability curve showing the probability of lifetime cost-effectiveness for the nurse support group compared with the postal delivery group at different willingness-to-pay threshold levels 231

## List of abbreviations

A&E	accident and emergency	MRC	Medical Research Council
AE	adverse event	MVPA	moderate to vigorous physical activity
BCT	behaviour change technique	NICE	National Institute for Health and Care Excellence
BMI	body mass index	NIHR	National Institute for Health Research
CEAC	cost-effectiveness acceptability curve	NS-SEC	National Statistics Socio-economic Classification
CHD	coronary heart disease	OR	odds ratio
CI	confidence interval	PA	physical activity
CONSORT	Consolidated Standards of Reporting Trials	PACE-LIFT	Pedometer Accelerometer Evaluation-LIFT
CVD	cardiovascular disease	PACE-UP	Pedometer And Consultation Evaluation-UP
EQ-5D	EuroQol-5 Dimensions	PAI	physical activity index
EQ-5D-3L	EuroQol-5 Dimensions, three-level version	PSA	probabilistic sensitivity analysis
EQ-5D-5L	EuroQol-5 Dimensions, five-level version	QALY	quality-adjusted life-year
GP	general practitioner	RCT	randomised controlled trial
GPPAQ	General Practice Physical Activity Questionnaire	RR	relative risk
HADS	Hospital Anxiety and Depression Scale	SAE	serious adverse event
ICER	incremental cost-effectiveness ratio	SD	standard deviation
IMD	Index of Multiple Deprivation	TMG	trial management group
IPAQ	International Physical Activity Questionnaire	TSC	Trial Steering Committee



## Plain English summary

**P**hysical inactivity is common and causes ill health. Walking briskly enough to make you warm and increase breathing and heart rate, but allow conversation, is moderate-intensity physical activity. Brisk walking for 30 minutes most days is a good way to improve health. Pedometers measure step counts and can increase physical activity levels, but few studies involving pedometers have objectively measured participants' physical activity or included long-term follow-up.

The Pedometer And Consultation Evaluation-UP (PACE-UP) trial recruited 1023 inactive 45- to 75-year-olds from seven South London practices, and randomised them to a usual physical activity (control) group or to one of two intervention groups. The postal group participants were sent a pedometer, diary and 12-week pedometer-based walking programme, advising them to gradually add in 3000 steps or a 30-minute walk on 5 or more days weekly. The nurse-support group received the same materials through practice nurse physical activity consultations. Physical activity and participant-reported 12-month outcomes were compared with the beginning of the trial, along with the costs of each trial group. A further 3-year follow-up was conducted and long-term value for money was estimated.

Both intervention groups significantly increased their walking (step counts and time in moderate-intensity physical activity) compared with controls, with no difference between nurse and postal groups. Interventions were safe and acceptable to participants and nurses. There was no effect on body size, pain or depression, but the nurse-support group participants increased their confidence in their ability to exercise. The 3-year follow-up found persistent positive effects of both interventions on physical activity levels. The postal intervention provided more value for money than the nurse-support group or the control group in the short and long term.

A primary care pedometer intervention, delivered by post or with nurse support, could provide an effective way to increase physical activity levels in adults and older adults, with the postal route offering the most value for money.



# Scientific summary

## Background

Physical activity (PA) helps adults and older adults to remain healthy, and improves physical function and emotional well-being. Inactivity is an important risk factor for mortality and leads to high health service costs. One way to achieve current national and international PA guidelines for health is by doing at least 30 minutes of moderate to vigorous physical activity (MVPA) in at least 10-minute bouts on  $\geq 5$  days weekly. However, a graded dose–response relationship exists for PA and health; therefore, for inactive people, any PA increase is valuable, as is decreasing sedentary time. Walking is the most common adult PA, and moderate-intensity walking approximates 100 steps per minute, so using a pedometer to add ‘3000 steps in 30 minutes’ onto habitual activity helps to achieve PA guidelines. Systematic reviews of pedometer-based walking interventions show significant step count increases. However, studies were mainly small, recruited volunteers and had short-term follow-up. In addition, previous pedometer studies have not rigorously evaluated their effectiveness with or without face-to-face support, and have used step counts, not MVPA, as the outcome. Programmes using personalised PA goals and behavioural strategies can achieve PA increases. Cochrane reviews have called for PA interventions to include objective PA measurement, adverse events reporting, comparisons of face-to-face interventions with remote interventions, longer follow-up and cost-effectiveness evaluations. Primary care provides an ideal context for PA interventions, allowing population-based sampling, practice nurse involvement and continuity of care. Brief PA advice in primary care is advocated; however, more primary care PA trials are required.

## Objectives

The research questions were:

1. Does a 3-month postal pedometer-based walking intervention increase PA (step count and time in MVPA in bouts) in inactive 45- to 75-year old primary care patients at 12-month follow-up?
2. Do dedicated practice nurse PA consultations provide additional benefit?

We also present cost-effectiveness analyses and effects on patient-reported outcomes, anthropometric measures and adverse events. A qualitative evaluation explored participant and practice nurse views. Longer-term follow-up was conducted at 3 years.

## Methods

### Design

A three-arm parallel-group, cluster randomised trial, comparing a 3-month pedometer-based walking intervention, by post or with nurse-support, with usual care. Randomisation was by household, allowing individuals and couples to participate, in a 1 : 1 : 1 ratio.

### Participants and setting

Recruitment was from seven ethnically and socially diverse, south London-based general practice populations, between September 2012 and October 2013. The 12-month follow-up was completed in October 2014. Eligible patients were aged 45–75 years, without contraindications to increasing MVPA. Exclusions included care home residents and those with unsuitable medical conditions. Random samples of 400 eligible households per practice were selected; this process was repeated until enough individuals were recruited. Individual invitations were posted. Those participants who reported achieving  $\geq 150$  minutes of MVPA

weekly on a validated self-report PA questionnaire were excluded. Anonymised demographic data were available through general practice records for all those invited, enabling investigation of trial recruitment inequalities. Non-participants were invited to complete a questionnaire.

### **Procedures and intervention**

Individual informed consent was obtained and baseline assessment undertaken prior to randomisation. Identical outcome assessments were conducted for all three groups. An accelerometer (GT3X+; ActiGraph LLC, Pensacola, FL, USA) was used for baseline, and 3- and 12-month masked PA assessment of step counts and time in different PA intensities. The interventions incorporated behaviour change techniques (BCTs) and included individualised step count and PA goals and the '3000 in 30' PA intensity message. The key intervention components were pedometers (SW-200 Yamax Digi-Walker; Yamasa Tokei Keiki Co. Ltd, Tokyo, Japan) to record individual step counts, a patient handbook, a PA diary (including an individual 12-week walking plan) and three individually tailored practice nurse PA (10- to 20-minute) consultations (nurse-support group only). The patient handbook and diary explained that adding 3000 steps per day (or a 30-minute walk) on  $\geq 5$  days weekly to their baseline, progressing over 12 weeks, would help to achieve PA guidelines. BCTs, including goals and planning, self-monitoring, feedback and encouraging social support, were included in the handbook, diary and nurse consultations. Control group participants were offered a pedometer, a handbook and a diary after the 12-month follow-up.

### **Outcomes**

All primary and secondary PA outcomes were assessed by 7-day accelerometry measurements. The primary outcome was change in average daily step count between baseline and 12 months. The secondary PA outcomes were changes in step counts between baseline and 3 months; changes in time spent weekly in MVPA in  $\geq 10$ -minute bouts; and time spent being sedentary between baseline and 3 and 12 months. The other secondary outcome was cost-effectiveness.

Ancillary outcomes were:

- changes in anthropometry (body mass index, waist circumference, body fat) at 12 months
- changes in patient-reported outcomes – exercise self-efficacy, anxiety, depression [as measured via the Hospital Anxiety and Depression Scale (HADS)], health-related quality of life [as measured via the EuroQol-5 Dimensions, five-level version (EQ-5D-5L)], pain and self-reported PA variables [as measured via the International Physical Activity Questionnaire (IPAQ), short form and the General Practice Physical Activity Questionnaire (GPPAQ)] at 3 and 12 months
- adverse outcomes – falls, injuries, fractures, cardiovascular events and deaths – assessed from trial monitoring procedures, 3- and 12-month questionnaires and primary care records.

### **Sample size**

A sample of 993 (331 per group) was needed to detect the 1000 steps per day difference at 12 months, comparing any two groups, with 90% power, at a  $p$ -value of 0.01, allowing for household clustering and 15% attrition.

### **Statistical analyses**

Accelerometry regression analyses were in two stages. Stage 1 estimated the average daily step count at 12 months and at baseline, derived by using the same two-level model (level 1, day within individual; level 2, individual) in which daily step counts were regressed on day order of wearing the accelerometer (from day 1 to day 7) and day of week, as fixed effects. At stage 2, the estimated 12-month average daily step count was regressed on the estimated baseline average daily step count, month of baseline accelerometry, age, sex, general practice and treatment group, effectively measuring the change in step count over 12 months. In this analysis, level 1 was individual and level 2 was household. MVPA in  $\geq 10$ -minute bouts, sedentary time, wear time and 3-month outcomes were analysed using identical approaches. The change in anthropometric and patient-reported outcomes was estimated using stage 2 models.

### Economic evaluation

Cost-effectiveness was estimated, from the NHS viewpoint, to generate the incremental cost per change in step count, minutes of MVPA in  $\geq 10$ -minute bouts and quality-adjusted life-years (QALYs). The probability of the interventions being cost-effective given different willingness-to-pay values for QALYs and incremental net benefit (difference between monetised benefit and costs of the intervention vs. the comparator) was calculated. A Markov model used the results to simulate lifetime cost-effectiveness. Deterministic and probabilistic sensitivity analyses were undertaken for short- and long-term analyses.

### Process evaluation

Data were collected contemporaneously with trial data collection, and associations between process measures and trial outcome measures were sought.

### Qualitative evaluation

Telephone interviews were conducted with nurse and postal participants, targeting some participants who had increased their PA and some who had not, to investigate their views of the intervention and the barriers to, and facilitators of, increasing PA levels. A practice nurse focus group session was conducted to understand practice nurses' experience of delivering the intervention.

### Three-year follow-up

Participant follow-up was conducted 3 years from baseline, including postal 7-day accelerometry, questionnaire and qualitative telephone interviews. The latter were carried out with randomly selected nurse and postal participants, to examine the factors affecting PA levels and maintenance of any increase in PA; and with control participants, to see the effect of the 12-month minimal intervention on PA levels.

## Results

Of the 11,015 people invited, 6399 did not respond, 548 self-reported PA guideline achievements and were excluded and 10% (1023/10,467) were randomised. Participation rates were lower in men, younger subjects, those living in deprived postcode areas and Asian patients. Black people were equally likely to participate as white people. Baseline findings for all those randomised were as follows: average steps per day, 7479 steps [standard deviation (SD) 2671 steps]; and average minutes per week in MVPA of  $\geq 10$ -minute bouts, 94 minutes (SD 102 minutes). Overall, 21% of participants (218/1023) achieved the PA guidelines of  $\geq 150$  minutes of MVPA in bouts. A total of 93% of participants (956/1023) were included in the 12-month primary analyses.

At the interim 3-month outcome, both intervention groups had increased their steps per day from baseline compared with the control group. Additional steps per day were 692 steps [95% confidence interval (CI) 363 to 1020 steps;  $p < 0.001$ ] for the postal group, and 1172 steps (95% CI 844 to 1501 steps;  $p < 0.001$ ) for the nurse-support group. The difference between intervention groups was statistically significant: 481 steps (95% CI 153 to 809 steps;  $p = 0.004$ ). MVPA findings showed a similar pattern: additional MVPA in bouts (minutes per week) was 43 minutes (95% CI 26 to 60 minutes;  $p < 0.001$ ) for the postal group, and 61 minutes (95% CI 44 to 78 minutes;  $p < 0.001$ ) for the nurse-support group; the difference between intervention groups was 18 minutes (95% CI 1 to 35 minutes;  $p = 0.04$ ). Sedentary time and accelerometer wear time were similar between groups.

For the primary outcome, both intervention groups increased their step counts from baseline to 12 months compared with control participants; additional steps per day were 642 steps (95% CI 329 to 955 steps;  $p < 0.001$ ) for the postal group, and 677 steps (95% CI 365 to 989 steps;  $p < 0.001$ ) for the nurse-support group, with no statistically significant difference between intervention groups (36 steps, 95% CI -277 to 349 steps). Time spent in MVPA in bouts showed a similar pattern: both intervention groups increased at 12 months compared with control participants. Additional MVPA in bouts (minutes per week) was 33 minutes (95% CI 17 to 49 minutes;  $p < 0.001$ ), for the postal group, and 35 minutes (95% CI 19 to

51 minutes;  $p < 0.001$ ) for the nurse-support group, with no statistically significant difference between intervention groups (2 minutes, 95% CI -14 to 17 minutes). Sedentary time and accelerometer wear time were similar between groups.

The interventions had no significant effects on anthropometric measures, anxiety, depression, health-related quality of life or pain scores. The 12-month exercise self-efficacy score was significantly higher in the nurse-support group compared with control participants. None of the following acted as an effect modifier for the intervention effect: age, sex, taking part as a couple, body mass index, disability, pain, socioeconomic group and exercise self-efficacy. Total adverse events (self-reported or from primary care records) and serious adverse events (from trial safety monitoring) were similar between groups.

### **Economic evaluation**

The incremental cost per step was £0.19 and £3.61 per minute in a  $\geq 10$ -minute MVPA bout for the nurse-support group, whereas the postal group took more steps and cost less than control participants. The postal group had a 50% chance of being cost-effective at a £20,000 per QALY threshold within 1 year, and had both lower costs (-£11M, 95% CI -£12 to -£10) and higher QALYs (759 QALYs gained, 95% CI 400 to 1247 QALYs) than the nurse-support and control groups in the long term, with an incremental net benefit of £26M per 100,000 population. Sensitivity analyses largely supported findings, except in the trial analysis, in which four alternative assumptions were made: (1) extending the perspective to participants, (2) excluding health service use, (3) using self-reported adverse events and (4) using 3-month outcome data, when control dominated postal. Long-term cost-effectiveness results were very robust.

### **Process evaluation**

A total of 256 out of 346 participants (74%) in the nurse-support group attended all three sessions, and 268 out of 339 participants (79%) in the postal group and 281 out of 346 participants (81%) in the nurse-support group returned completed step count diaries. Positive associations were seen between increases in step count and time in MVPA in bouts and between both the number of nurse sessions attended and completed step count diary return.

### **Qualitative evaluation**

Forty-three trial participants were interviewed. The intervention was acceptable and primary care was an appropriate setting. Almost all participants felt that they had benefited, irrespective of their step count change. Important facilitators included a desire for a healthy lifestyle, improved physical health, enjoying walking, having a flexible routine, appropriate external monitoring and self-monitoring and social support. Important barriers included health problems, an inflexible routine, the weather, work and other commitments. Although the postal group participants were mainly confident to increase their PA without individually tailored nurse support, two important caveats were health problems and overcoming barriers. Practice nurses enjoyed delivering the Pedometer And Consultation Evaluation-UP (PACE-UP) intervention, and believed that taking part, especially in the BCT training, enhanced the quality and delivery of support provided within routine consultations.

### **Three-year follow-up**

Of the 1023 trial participants, 681 (67%) provided adequate accelerometry outcome data. The nurse-support and postal intervention groups both showed persistent effects on the 3-year follow-up PA measures, with no difference between them; for the nurse-support group and the postal group versus the control group, additional steps per day were 648 steps (95% CI 272 to 1024 steps), and additional MVPA in  $\geq 10$ -minute bouts (minutes per week) were 26 minutes (95% CI 8 to 44 minutes). Qualitative interview findings at 3 years on factors affecting PA maintenance with intervention group participants complemented earlier qualitative findings. The pedometer was reported as 'kick-starting' regular activity and helping to maintain activity. Factors that facilitated PA level maintenance were striving to maintain good health, self-motivation, social support and good weather. Lack of time was the most frequently cited barrier; other barriers were often the reverse of facilitators, such as poor health or bad weather. Findings from the control group

participants, who were sent the pedometer and materials at 12 months, suggested that many had not used them. The persistent 3-year intervention effects, despite control participants receiving intervention materials at 12 months, suggest that other postal group factors were important (e.g. telephone contact after sending out materials and returning completed PA diaries). The postal group seemed to require this additional minimal support (not provided face to face, or by a health professional) in order to be effective.

## Conclusions

The PACE-UP pedometer-based walking intervention increased step counts by about one-tenth, and time in MVPA in bouts by about one-third, at 1 year, in predominantly inactive 45- to 75-year-old primary care patients. Nurse and postal delivery had similar effects on 12-month PA outcomes. The intervention was safe and acceptable to patients and nurses. The postal group had a 50% chance of being cost-effective at a £20,000 per QALY threshold within 1 year, and was significantly more cost-effective than nurse support and the control group in the long term, thus providing a cost-effective way of delivering long-term quality-of-life benefits. Both intervention groups had persistent positive effects on objective PA levels at 3 years, suggesting long-term benefit.

## Implications for health care

- A primary care pedometer-based walking intervention, delivered by post with minimal support, could provide an effective and cost-effective approach to addressing the public health physical inactivity challenge.
- The 3000 steps in 30 minutes neatly captures intensity and could become a useful new public health goal, particularly as many people can measure steps easily with their mobile phones.
- The PACE-UP 12-week pedometer-based walking intervention could be considered for inclusion into the NHS Health Check programme, aimed at a similar age group (of 40- to 74-year-olds) and/or the NHS Diabetes Prevention Programme.

## Recommendations for research

- The PACE-UP trial generalisability is limited by the 10% overall recruitment rate and lower recruitment in Asian and socioeconomically deprived patients. Further research into different recruitment methods is needed, as is research assessing the recruitment achievable if this programme were to be offered outside a trial setting over a more prolonged time period.
- Although overall postal outcomes were as effective as, and more cost-effective than, nurse outcomes, further research is required to understand who would benefit most from the individual tailoring offered by a nurse-supported intervention.
- There has been a recent dramatic increase in the use of wearables to monitor personal PA levels, including smartphones, wrist-worn devices, online monitoring and mobile apps. Further research into how the PACE-UP 12-week PA programme could be integrated into the use of these devices (with or without a pedometer) is needed.

## Trial registration

This trial is registered as ISRCTN98538934.

## Funding

Funding for this study was provided by the Health Technology Assessment programme of the National Institute for Health Research.

# Chapter 1 Introduction: why this study was needed

## Benefits and risks of physical activity and current physical activity guidelines

### *What are the benefits of physical activity for adults and older adults?*

Physical activity (PA) leads to reduced mortality, a reduced risk of > 20 diseases and conditions, and improved function, quality of life and emotional well-being.<sup>1</sup> Physical inactivity is the fourth leading risk factor for global mortality;<sup>2</sup> in 2008, it was estimated to have caused 9% of premature mortality and 5.3 million deaths worldwide.<sup>3</sup> Physical inactivity is also a major cost burden on health services.<sup>1,4,5</sup>

### *What are the current physical activity guidelines and who is achieving them?*

Adults and older adults are advised to be active daily and, for health benefits, should achieve at least 150 minutes (2.5 hours) weekly of at least moderate-intensity activity [moderate to vigorous PA (MVPA)] or 75 minutes of vigorous-intensity PA, or an equivalent combination, achieved in bouts of at least 10 minutes' duration.<sup>1,2</sup> Muscle-strengthening activities are also recommended on at least 2 days weekly,<sup>1,2</sup> but are not part of our intervention, which is focused on increasing walking. One effective way to achieve the aerobic PA recommendations is by undertaking 30 minutes of moderate-intensity PA on at least 5 days weekly.<sup>1,6,7</sup> Regular walking is the most common PA of adults and older adults, and walking at a moderate pace (3 miles or 5 km per hour) qualifies as moderate-intensity PA.<sup>8</sup> Time spent being sedentary for extended periods should also be minimised, as this is an independent disease risk factor,<sup>1</sup> which increases steeply with age from 45 years.<sup>9</sup> There is an increasing awareness that as a dose–response relationship exists for PA and health benefits, getting inactive people to do a little more PA is also important, rather than just relying on trying to achieve PA recommendations.<sup>10,11</sup> Emphasising that the 30 minutes can be built up from 10-minute bouts is an important message for older adults and those with disabilities, enabling them to increase their MVPA gradually. Among adults in England aged  $\geq 19$  years, 66% of men and 56% of women self-reported meeting the recommended PA levels, whereas only 58% of men and 52% of women aged 60–74 years did so.<sup>12</sup> Lower socioeconomic groups<sup>9</sup> and Indian, Pakistani, Bangladeshi and Chinese ethnic groups are significantly less likely to report meeting the recommended PA levels, whereas the activity levels of other ethnic groups (black Caribbean, black African and Irish) are similar to that of the general population.<sup>13</sup> Over one-third of adults worldwide are insufficiently active, but there is large geographical variation.<sup>10,14</sup> However, PA, including walking, is very unreliably recalled, so surveys overestimate PA levels.<sup>15</sup> Objective accelerometry found that only 5% of men and 4% of women aged 35–64 years and 5% of men and 0% of women aged  $\geq 65$  years achieved the recommended PA levels, which is a fraction of those who self-report achieving them.<sup>9</sup>

### *What are the risks from increasing physical activity?*

The risks from a sedentary lifestyle far exceed the risks from regular PA.<sup>6,16,17</sup> Moderate-intensity PA carries a low injury risk,<sup>18</sup> mainly musculoskeletal injury or falls.<sup>19</sup> Walking is very low risk, 'a near perfect exercise'.<sup>8</sup> Screening participants for contraindications before participating in light- to moderate-intensity PA programmes is no longer advocated.<sup>6,20</sup> An important safety feature of our study is that individualised goals can be set from the participant's own baseline, in line with the advice that older adults in particular should start with low-intensity PA and increase the intensity gradually: the 'start low and go slow' approach.<sup>16,17</sup> This worked well with our previous PA trial in older adults, which employed a similar approach and showed no increase in adverse events (AEs).<sup>21</sup>

## Strategies for increasing physical activity

### *How can adults and older adults increase their physical activity levels?*

A systematic review of PA interventions reported moderately positive short-term effects, but the findings were limited by mainly unreliable self-report measures in motivated volunteers.<sup>22</sup> This review has recently been updated by three complementary Cochrane reviews assessing (1) face-to-face PA interventions,<sup>23</sup> (2) remote (including postal and telephone) and web 2.0 interventions<sup>24</sup> and (3) a direct comparison of these two approaches.<sup>23</sup> Evidence supports the effectiveness of both face-to-face interventions and remote or web 2.0 interventions for promoting PA. However, the reviewers called for future studies to provide greater detail of the components of face-to-face interventions and to assess the impact on quality of life, AEs and economic data,<sup>23</sup> and to include participants from varying socioeconomic and ethnic groups.<sup>24</sup> Only one study<sup>25</sup> met the review criteria to compare face-to-face interventions with remote or web 2.0 interventions (many trials were excluded as a result of having less than 1 year's follow-up data or an inadequate control group); this study showed no effect on cardiorespiratory fitness<sup>25</sup> and there were no reported data for PA, quality of life or cost-effectiveness.<sup>23</sup> The review concluded that there was insufficient evidence to assess whether face-to-face interventions or remote and web 2.0 approaches are more effective at promoting PA, and called for more high-quality comparative studies.<sup>23</sup> None of the studies included in the reviews provided objective PA measurement.<sup>23,24</sup> Other studies have concluded that exercise programmes in diverse populations can promote short- to medium-term increases in PA when interventions are based on health behaviour theoretical constructs, individually tailored with personalised activity goals and using behavioural strategies.<sup>26,27</sup> A critical review and a best-practice statement on older people's PA interventions advised home-based rather than gym-based programmes, and behavioural strategies (e.g. goal-setting, self-monitoring, self-efficacy, support, relapse prevention training), rather than health education alone.<sup>17,27</sup> National Institute for Health and Care Excellence (NICE)'s guidance concluded that no particular behaviour change model was superior and that training should focus on generic competencies and skills, rather than on specific models.<sup>28</sup> More recent complementary NICE guidance specifically recommended that goals, planning, feedback and monitoring techniques should be included in behaviour change interventions.<sup>29</sup> Starting low, but gradually increasing to moderate intensity is promoted as best practice, with advice to incorporate interventions into the daily routine (e.g. walking).<sup>17</sup> A recent systematic review of walking interventions concluded that interventions tailored to people's needs, targeted at the most sedentary people and delivered at the level of the individual or household, can be effective, although evidence directly comparing interventions targeted at individuals, couples or households was lacking.<sup>30</sup>

### *Are pedometers helpful?*

Pedometers are small, cheap devices, worn at the hip, providing direct step count feedback. A systematic review (of 26 studies) found that pedometers increased steps per day by 2491 steps [95% confidence interval (CI) 1098 to 3885 steps] and PA levels by 27%, with significant reductions in body mass index (BMI) and blood pressure.<sup>31</sup> A second review (of 32 studies) found an average increase of 2000 steps per day.<sup>32</sup> Step count goals and diaries were key factors.<sup>31,32</sup> Several limitations were recognised: study sizes were small and long-term effects were undetermined; many studies included several components (e.g. pedometer and support), so independent effects were difficult to establish; and the inclusion of older people and men was limited.<sup>31,32</sup> Recent studies have addressed some of these limitations. A pedometer plus behaviour change intervention increased PA at 3 months, but not at 6 months, in 210 older women, with pedometers providing no additional benefit.<sup>33</sup> Two trials in high-risk groups showed sustained step count increases at 12 months.<sup>34,35</sup> A recent study of 298 older adults found a significant increase in both step counts and time in MVPA at 3 months and 12 months from a practice nurse-delivered pedometer-based walking intervention, but did not separate out pedometer- and nurse support-related effects.<sup>21</sup> NICE recently updated its advice from advising the use of pedometers only as part of research<sup>36</sup> to advising their use as part of packages, including support to set realistic goals, monitoring and feedback.<sup>37</sup>

### How do step count goals relate to physical activity recommendations?

Step count goals lead to more effective interventions, but no specific approach to goal-setting is favoured.<sup>28</sup> Goals are based on a fixed target (e.g. 10,000 steps per day)<sup>38,39</sup> or on advising incremental increases from the baseline as a percentage (5% per week,<sup>40</sup> 10% biweekly<sup>41</sup> or 20% monthly<sup>33</sup>) or on a fixed number of extra steps. Those advocating a fixed number of extra daily steps have developed step-based guidelines to fit with existing evidence-based guidelines with an emphasis on 30 minutes of MVPA on  $\geq 5$  days weekly.<sup>42</sup> Despite individual variation, moderate-intensity walking appears to be approximately equal to at least 100 steps per minute.<sup>42,43</sup> Multiplied by 30 minutes, this produces a minimum of 3000 steps per day, to be done over and above habitual activity, which is the '3000 in 30' message.<sup>43</sup> Several studies have advocated adding in 3000 steps per day on most days weekly, either from the beginning<sup>34</sup> or by increasing incrementally (initially an extra 1500 steps per day and increasing),<sup>44,45</sup> or by increasing by 500 steps per day biweekly.<sup>35</sup> Studies that advised adding 3000 steps per day from the baseline produced significant improvements in step counts at 3 months and two measured outcomes at 12 months, and showed sustained improvements in step counts,<sup>34,35</sup> waist circumference<sup>34</sup> and fasting glucose levels,<sup>35</sup> but no sustained improvements to date in MVPA levels. Although there is no evidence at present to inform a moderate-intensity cadence (steps per minute) in older adults, Tudor-Locke *et al.*<sup>46</sup> advocate using the adult cadence of 100 steps per minute in older adults (while recognising that this may be unobtainable for some individuals) and advising that the 30 minutes can be broken down into bouts of at least 10 minutes. This model was used in a primary care walking intervention in 41 older people, which found significant step count increases from baseline to week 12, which were maintained at week 24.<sup>47,48</sup>

### Could accelerometers be useful in a pedometer-based walking intervention?

Accelerometers are small activity monitors worn like pedometers, but are more expensive; however, they are able to provide a time-stamped record of PA frequency (step counts) and intensity (activity counts). They require computer analysis, function as blinded pedometers in objectively measuring baseline and outcome data, and provide objective data on time spent in different PA intensities, including time spent in MVPA and time spent being sedentary, two important public health outcomes. Pedometer studies without accelerometers have relied on self-reported measures of these outcomes. Accelerometers are valid and acceptable to adults<sup>9,49</sup> and older adults.<sup>9,21,50–53</sup> Although both instruments measure step count and are highly correlated,<sup>50</sup> pedometers usually record lower step counts, and accelerometers cannot reliably be substituted for pedometers at an individual level.<sup>54</sup> Thus, although we used the accelerometer to measure outcomes, including step count, MVPA and sedentary time, we used the blinded pedometer, worn simultaneously at baseline, to set individual step count targets.

### Are pedometers cost-effective?

There is limited knowledge on the cost-effectiveness of pedometer-based interventions in the UK. Recent systematic reviews that considered the economic outcomes of pedometer-based interventions found no evidence,<sup>55,56</sup> partly because of an insufficient number of data.<sup>57</sup> However, a recent study assessed the cost-effectiveness of giving an individualised walking programme and pedometer with or without a PA consultation alongside a community-based trial of 79 people.<sup>58</sup> The incremental cost-effectiveness ratios (ICERs) per persons achieving an additional 15,000 steps per week were £591 and £92 with and without the consultation, respectively. However, even with this highly selected sample, no data on quality of life were collected, and the impacts on long-term outcomes were not estimated.

### What is the role of primary care in promoting physical activity?

Primary care centres (general practices) in the UK provide health care and health promotion, free at the point of access, to a registered list of local patients (for many of whom PA will be of benefit), using disease registers to provide annual or more frequent chronic disease reviews via a multidisciplinary health-care team providing continuity of care. NICE guidance found that brief interventions in primary care are cost-effective, and it therefore recommends that all primary care practitioners should take the opportunity to identify inactive adults and provide advice on increasing PA levels.<sup>36</sup> New 5-yearly NHS health checks include adults aged 40–74 years and incorporate advice on increasing PA, often from primary care nurses.<sup>59</sup> Primary care nurses are effective at increasing PA, particularly walking, in this age group.<sup>60</sup> Not only can PA

advice through consultation with health professionals be individually tailored<sup>61</sup> and have more impact than other PA advice,<sup>62</sup> but this is particularly the case for older adults,<sup>63</sup> especially given the uncertainty about the effectiveness of exercise referral schemes from primary care.<sup>64</sup> Exercise-prescribing guidance in primary care reinforces the importance of follow-up to chart progress, set goals, solve problems, and identify and use social support;<sup>65</sup> this will be an important feature of the nurse PA consultations in this trial. Evaluation of the UK Step-O-Metre programme, delivering pedometers through primary care, showed self-reported PA increases, but advised investigation with a randomised controlled trial (RCT) design.<sup>44</sup> Two trials, both in older primary care patients, have assessed the effectiveness of pedometers plus primary care PA consultations; one small trial ( $n = 41$ ) showed a significant effect on step counts at 3 months, which was maintained at 6 months,<sup>47,48</sup> and the other was our recent Pedometer Accelerometer Evaluation-LIFT (PACE-LIFT) trial<sup>21</sup> ( $n = 298$ ), which showed differences in both step counts and time in MVPA in bouts of at least 10 minutes, at 3 and 12 months for the nurse intervention compared with the control group. Neither trial separated out pedometer effects from the support provided.<sup>21,47,48</sup>

### **Theoretical base, piloting and preparatory work to develop the intervention**

The pedometer-based intervention is based on work cited above,<sup>31,32</sup> showing that pedometers can increase step counts and PA intensity.<sup>31,32</sup> It extends current understanding by also including older adults and men, having a 12-month follow-up and ensuring that the pedometer and support components could be evaluated separately. The patient handbook, diary (both available on the journals library website: [www.journalslibrary.nihr.ac.uk/programmes/hta/103202/#/](http://www.journalslibrary.nihr.ac.uk/programmes/hta/103202/#/)) and practice nurse PA consultations use behaviour change techniques (BCTs; e.g. goal-setting, self-monitoring, feedback, boosting motivation, encouraging social support, addressing barriers or relapse anticipation). These techniques have been successfully used by non-specialists in primary care after brief training,<sup>66</sup> and are emphasised in the *Improving Health: Changing Behaviour: NHS Health Trainer Handbook*,<sup>67</sup> based on evidence from a range of psychological methods and intended for NHS behaviour change programmes, with local adaptation.<sup>67</sup> They also include techniques specifically recommended to be included in more recent NICE guidance (goals, planning, feedback and monitoring).<sup>29</sup> We adapted the *Improving Health: Changing Behaviour: NHS Health Trainer Handbook*<sup>67</sup> for use in this trial into Pedometer And Consultation Evaluation-UP (PACE-UP) nurse and patient handbooks, to focus specifically on PA using pedometers. The BCTs were classified in accordance with the refined taxonomy of BCTs for PA interventions by Michie *et al.*<sup>68</sup> Diary recording of pedometer step counts provides clear material for PA goal-setting, self-monitoring and feedback, and should fit well with this approach. We have adopted the approach used by others<sup>44,45</sup> of advocating adding in 3000 steps per day to an individual's baseline on most days weekly in an incremental manner, and of advising on gradually increasing PA intensity to achieve more time in MVPA, with the message that 3000 steps in 30 minutes will help people to achieve PA guidelines.<sup>43</sup> Relevant pilot and preparatory work includes observational work using pedometers and accelerometers in primary care<sup>53</sup> and a successful trial with older primary care patients developing the PA consultations and pedometer-based walking intervention (the PACE-LIFT trial; ISRCTN42122561<sup>21,69</sup>). The PACE-LIFT trial demonstrated that tailored support from practice nurse PA consultations combined with a pedometer-based walking programme (plus accelerometer feedback on PA intensity) led to an increase in both step counts and time in MVPA compared with the control group at both 3 and 12 months in 60- to 75-year-old primary care patients. The trial was limited in terms of both ethnic and socioeconomic diversity, has not yet published on sedentary time or cost-effectiveness and, as mentioned, was unable to separate out the effects of the pedometer (and accelerometer feedback) from the effects of nurse support.<sup>21</sup>

### **Rationale for research**

The PACE-UP trial aimed to fill the gaps in the current evidence base by evaluating the effect of a pedometer-based walking intervention, with and without additional nurse PA consultations in a population-based, primary care sample of inactive adults and older adults. The initial trial included follow-up to 1 year and aimed to ensure that adequate numbers of men, older adults and individuals from diverse socioeconomic and ethnic backgrounds were included. It also enabled the effectiveness of taking part as an

individual or as a couple to be estimated. The intervention used step goals and diaries, and the PA consultations and patient handbook were based on BCTs, such as those used in the *Improving Health: Changing Behaviour: NHS Health Trainer Handbook*.<sup>67</sup> To objectively test the effectiveness of the intervention on important public health outcomes, such as time spent in MVPA and time spent being sedentary, PA outcomes were assessed by accelerometry. Anonymised practice demographic data were available for all those invited to participate, enabling the investigation of inequalities in trial participation. Qualitative evaluations were also needed to explore the reasons for trial non-participation, the acceptability of the intervention to both participants and practice nurses and the barriers to, and facilitators of, the intervention. An economic evaluation was performed alongside the trial and was also used to inform long-term cost-effectiveness.



## Chapter 2 Methods

This chapter is a summary of the full study protocol for the trial as originally funded, except for the paragraph which describes changes to the published protocol. Some of the material, including the tables, has already appeared in publication,<sup>70</sup> and is reproduced here under the terms of the Creative Commons Attribution License (<http://creativecommons.org/licenses/by/2.0/>), which permits unrestricted use, distribution and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (<http://creativecommons.org/publicdomain/zero/1.0/>) applies to the data made available in this article,<sup>70</sup> unless otherwise stated. Further funding was later awarded by the National Institute for Health Research (NIHR) Health Technology Assessment programme for a 3-year follow-up of the trial cohort, the methods and results of which are described in *Chapter 8*.

### Study design

The PACE-UP walking intervention trial was a pragmatic, three-arm parallel-cluster trial (randomised by household to allow individuals and couples to participate). It was based in primary care with 45- to 75-year-old inactive adults, with a 12-month follow-up period, and compared the following three groups: control (usual PA); pedometer and written instructions by post (pedometer by post); and pedometer, written instructions and practice nurse individually tailored PA consultations (pedometer plus nurse support).

### Study aims and objectives

#### Study aims

The main hypotheses to be addressed were as follows:

1. Does a 3-month postal pedometer-based walking intervention increase PA in inactive 45- to 75-year-olds at the 12-month follow-up point?
2. Does providing practice nurse support through dedicated PA consultations provide additional benefit?

The study also aimed to assess the cost-effectiveness of both interventions, whether or not any factors modified the intervention effects and the effect of the interventions on patient-reported outcomes, anthropometric measures and primary care-recorded AEs.

#### Primary objectives (relating to the primary outcome of step counts)

In inactive adults aged 45–75 years, the primary objectives were to:

- confirm that tailored support from practice nurse PA consultations combined with a pedometer-based walking programme can promote an increase in step counts compared with the control group at 12 months (pedometer plus nurse support vs. control)
- determine whether or not the simple provision by post of pedometers plus written instructions for a pedometer-based walking programme can promote an increase in step counts compared with the control group at 12 months (pedometer by post vs. control)
- estimate the effect of tailored support from practice nurse PA consultations combined with a pedometer-based walking programme compared with the postal pedometer-based walking programme, on step counts at 12 months (pedometer plus nurse support vs. pedometer by post).

### **Secondary objectives (relating to secondary outcomes of time in moderate to vigorous physical activity in bouts, sedentary time and cost-effectiveness)**

In inactive adults aged 45–75 years, the secondary objectives were to:

- confirm that tailored support from practice nurse PA consultations combined with a pedometer-based walking programme can promote an increase in steps counts at 3 months and time spent in MVPA in  $\geq 10$ -minute bouts at 3 and 12 months, and a decrease in sedentary time at 3 and 12 months compared with control (pedometer plus nurse support vs. control)
- determine whether or not the simple provision by post of pedometers plus written instructions for a pedometer-based walking programme can promote an increase in step counts at 3 months, an increase in time spent in MVPA in  $\geq 10$ -minute bouts at 3 and 12 months and a decrease in sedentary time at 3 and 12 months compared with the control group (pedometer by post vs. control)
- estimate the effect of tailored support from practice nurse PA consultations in addition to the pedometer-based walking programme alone on step counts at 3 months, and time spent in MVPA in  $\geq 10$ -minute bouts and sedentary time at 3 and 12 months (pedometer plus nurse support vs. pedometer by post)
- determine the cost-effectiveness of these alternative approaches to increasing PA levels at both 12 months and from a lifetime perspective from the viewpoint of the NHS and participants (see *Chapter 4*).

### **Other objectives**

- To determine the effect of the interventions on anthropometric measures (BMI, waist circumference and body fat) at 12 months.
- To determine the effect of the interventions on patient-reported outcomes (self-reported PA levels, anxiety and depression score, exercise self-efficacy, quality of life, pain, AEs) and on primary care-recorded AEs at 3 months and 12 months.
- To determine whether or not age groups ( $< 60$  years vs.  $\geq 60$  years), sex, taking part as a couple, socioeconomic group, disability, pain, BMI and exercise self-efficacy modify the effect of the intervention on increasing step count at 3 months and 12 months (ethnic group was originally intended to be included as an effect modifier, but there was inadequate power for this analysis because of the low number of non-white participants; see *Changes from the published protocol*).
- To compare the age, sex, socioeconomic group and ethnicity of those taking part in the trial with those invited but not participating, and to explore the reasons for not participating (see *Chapter 5*).
- To assess the fidelity and quality of the intervention implementation over time, by the evaluation of patient diary step count goals and recorded step counts for both intervention groups at the 3-month assessment, and the number and timing of recorded practice nurse contacts for the nurse support group (see *Chapter 6*).
- To explore the intervention's acceptability to practice nurses and inactive adults, the reasons for dropout and the durability of effects, by qualitative interviews with participants after the 12-month follow-up, and a focus group with the nurses on study completion (see *Chapter 7*).

## **Practice and participant inclusion/exclusion criteria**

### **Practice inclusion criteria**

General practices were recruited through the Primary Care Research Network – Greater London. Practices were required to be in the south-west London cluster, have a practice list size of  $> 9000$ , give a commitment to participate over the duration of the study, have a practice nurse interested and with time to carry out the PA interventions and trial procedures, and have the availability of a room for the research assistant to recruit participants and carry out baseline and follow-up assessments.

### Participant inclusion criteria

Participants were patients aged 45–75 years, who were registered with one of the recruited south-west London general practices, were able to walk outside the home and had no contraindications to increasing their MVPA levels.

### Participant exclusion criteria

- Physical activity based (by screening question on invitation letter). In order to maximise the benefits of the intervention to individuals and the NHS, the trial focused on less-active adults, using a single-item validated questionnaire measure of self-reported PA as a screening question to identify them.<sup>60</sup> Those who reported achieving a minimum of 150 minutes of MVPA weekly<sup>1</sup> on their response letter were excluded (participants who, on subsequent baseline accelerometer assessment, were found to be above this PA level were not excluded, as they would be included if this intervention were to be rolled out in primary care).
- Health based [either by the Read code from primary care records or by general practitioner (GP)/practice nurse opinion, or from the telephone or face-to-face baseline assessment with the research assistant] for the following reasons:
  - housebound or living in a residential or nursing home
  - three or more falls in the previous year, or one or more falls in the previous year requiring medical attention
  - terminal illness
  - dementia or significant cognitive impairment
  - registered blind
  - new-onset chest pain, myocardial infarction, a coronary artery bypass graft or an angioplasty within the last 3 months
  - a medical or psychiatric condition that the GP (or practice nurse) considered to exclude the patient (e.g. acute systemic illness such as pneumonia, acute rheumatoid arthritis, unstable/acute heart failure, significant neurological disease/impairment, unable to move about independently, psychotic illness)
  - pregnancy.

## Recruitment of practices and participants: informed consent

### Practice recruitment

The Primary Care Research Network – Greater London identified practices that fitted the above practice inclusion criteria. Practice recruitment was challenging for a number of reasons, including difficulties in finding practices with sufficient space to accommodate a research assistant on a regular basis, finding practices with nurses willing and with sufficient time to be engaged in delivering the intervention and finding practices that were prepared to provide administrative support. The Primary Care Research Network – Greater London provided us with strong support to recruit practices. Initially, six practices were recruited, with an additional practice added half-way through to boost recruitment. This was necessary, as recruitment at that point was running at just below 10% and we were concerned that we would not achieve the target recruitment from the original six practices within 12 months. The practices were selected to include a range of sociodemographic factors and geographical circumstances based on the practice postcode Index of Multiple Deprivation<sup>71</sup> (IMD) scores (at least one practice from each quintile).

### Participant recruitment

Practice staff identified patients aged 45–74 years on their primary care electronic patient record system, and, using Read codes and local care home knowledge, excluded ineligible patients (patients were aged 45–74 years when selected, but some were aged 75 years by the time of recruitment or randomisation).

A list of potentially eligible patients was produced and ordered by household, with a unique household identifier number. An anonymised list was then used by the research team to create at least four random samples of 400 individuals at each practice. A maximum of two people per household were selected (we were aiming to select couples). If a household had two individuals, one was selected at random, and if the second individual had an age difference of  $\leq 15$  years, they were also selected; if they fell outside this age range, they were not included. If a household had more than two individuals, one was selected at random, and if there was a second individual aged within  $\leq 15$  years they were also selected; if there was not a second individual aged within  $\leq 15$  years, this became an individual household. Each sample list was examined by practice nurses or GPs to ensure trial suitability prior to invitation (see *Participant exclusion criteria*). Participants were recruited between September 2012 and October 2013, and follow-up was completed by October 2014.

### **Non-responders and non-participants**

See *Chapter 5* for more details.

### **Informed consent**

Patients were sent an invitation letter from their own practice, along with a participant information sheet and a screening question on self-reported PA. A reminder invitation was sent if no reply was received after 6 weeks. A log was kept of the response rates from each practice. The decision regarding participation in the study was entirely voluntary. Those interested in participating returned the reply slip, including a response to a single screening question about their usual PA levels. If the participant self-reported as not achieving the PA guidelines,<sup>1</sup> the research assistant arranged a baseline appointment for them and ran through the participant information sheet, and handled any questions or concerns that they had. If they were happy to proceed, they signed the study consent form; this form included consent to be contacted for qualitative interviews and consent for their general practice records for the year of the trial to be downloaded after trial follow-up was completed. Participants who had difficulty understanding, speaking or reading English were accompanied by a family member or friend during the research assistant appointment. Participants within a couple could attend together or separately.

### **Changes from the published protocol**

We planned to recruit from six general practices, but to enable target recruitment, a seventh practice was added in December 2012. Changes from protocol-planned analyses<sup>70</sup> were approved by the Trial Steering Committee (TSC), prior to analysis. We report MVPA in  $\geq 10$ -minute bouts, as this relates more closely to PA guidelines.<sup>1,2</sup> Only 20% of participants were non-white; ethnic group was therefore excluded from the subgroup analyses, as a result of low power.

### **Interventions**

*Table 1* shows the components of the intervention provided to the postal and nurse groups. *Table 2* shows the content of the patient handbook and the patient diary and the BCTs that were included in each of them, rated according to Michie *et al.*'s CALO-RE taxonomy.<sup>68</sup> *Table 3* shows the timing and session content for the three dedicated nurse PA consultations and the BCTs intended to be covered in each session. *Figure 1* provides a summary of the 12-week walking programme in terms of steps per day or time spent walking, to be added to each individual's baseline average daily steps. The training received by the practice nurses in order to deliver the interventions is described in *Chapter 6*. A figure summarising the trial procedures and complex intervention components is shown in *Appendix 1, Figure 17*.

**TABLE 1** Components of the complex intervention for the PACE-UP trial

Component	What was provided	Trial arm receiving	Additional details on components
Pedometer	Yamax Digi-Walker (Yamasa Tokei Keiki Co., Ltd, Tokyo, Japan), SW-200 model	<ul style="list-style-type: none"> <li>Postal group – pedometer posted with instructions</li> <li>Nurse-support group – pedometer given with instructions by the nurse</li> </ul>	Provided direct step count to participants. Required daily manual recording and resetting
PACE-UP handbook, 12-week walking plan and step count diary <sup>a</sup>	Handbook to support the 12-week walking programme. Individualised walking plan (see <i>Figure 1</i> ). Diary to record weekly step count and walks for 12 weeks	<ul style="list-style-type: none"> <li>Postal group – posted</li> <li>Nurse-support group – given by nurse</li> </ul>	Baseline average daily step counts (from the blinded pedometer assessment) were used to create individual targets. The 12-week walking programme gradually increased targets to achieve an additional 3000 steps per day (approximately 30 minutes of brisk walking) on $\geq 5$ days weekly. Daily step counts and target achievement were recorded in the diary. <i>Table 2</i> lists BCTs in the PACE-UP handbook and diary
Practice nurse-dedicated PA consultations	Three individually tailored consultations. Participants could be seen individually or as a couple	Nurse-support group only	Session timings, content and planned BCTs are shown in <i>Table 3</i> . Sessions reinforced the intervention defined in the diary and the handbook. The nurse consultation allowed some additional BCTs to be used and provided an opportunity to individually tailor the intervention to participants' needs

a The handbook, 12-week walking plan and step count diary are available on the NIHR Journals Library website ([www.journalslibrary.nihr.ac.uk/programmes/hta/103202/#/](http://www.journalslibrary.nihr.ac.uk/programmes/hta/103202/#/)).

This table has been adapted from Harris *et al.*<sup>70</sup> This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<http://creativecommons.org/licenses/by/2.0/>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (<http://creativecommons.org/publicdomain/zero/1.0/>) applies to the data made available in this article, unless otherwise stated.

### Procedure for the postal intervention group

The participants received (by post) a pedometer (Yamax Digi-Walker, SW-200 model; Yamasa Tokei Keiki Co., Ltd, Tokyo, Japan), instructions and a 12-week step count diary for the 12-week walking intervention (see *Figure 1*). The research assistant contacted the participant to check that the pedometer had been received and to resolve any difficulties with the equipment. At the end of the 12-month follow-up period, the postal group were offered a single practice nurse PA appointment, if they wanted it.

### Procedure for the nurse intervention group

Three dedicated PA consultations (week 1, week 5 and week 9) were arranged with the practice nurse, to individually tailor and support the 12-week pedometer-based walking programme (see *Figure 1*). At their first appointment, participants were given the same pedometer, diary and handbook that the postal group received. Participants were asked to wear a pedometer and keep a diary record of daily steps for 4 weeks between appointments, in order to review targets and goals at their next appointment. Participants were seen individually or as a couple.

**TABLE 2** The PACE-UP patient handbook, and diary and BCTs included

Component	Guide to content	<sup>a</sup> BCTs <sup>68</sup>
Patient handbook	<ul style="list-style-type: none"> <li>• Health benefits of increasing walking</li> <li>• PA guidelines</li> <li>• Moderate-intensity PA and relating it to number of steps</li> <li>• PACE-UP walking programme and step count targets</li> <li>• Review participant baseline step count</li> <li>• How to increase PA safely</li> <li>• Useful websites</li> <li>• How to keep going when the PACE-UP programme finishes</li> </ul>	1 and 2 4 7, 9 and 16 19 21 4 16, 1, 2, 26, 29 and 35
Patient diary	<ul style="list-style-type: none"> <li>• How to use the pedometer and record steps in diary</li> <li>• Frequently asked questions on the PACE-UP trial</li> <li>• Weekly recording of step count and walking in diary (weeks 1–12)</li> <li>• Achievement of targets (weeks 1–12)</li> <li>• Planning when to walk, where to walk, who to walk with</li> <li>• Week 2, tips and motivators: make walking part of your daily routine</li> <li>• Week 3, tips and motivators: remember personal benefits, what to do if you are falling behind your targets</li> <li>• Week 4, keep it up: praise and reward yourself, encouraging social support</li> <li>• Week 5, keep motivated: write down step counts, ask for support</li> <li>• Week 6, now we are moving: obstacles and solutions</li> <li>• Week 7, how to make these changes permanent – ideas for new walks, making time for walking, what gains have been made so far?</li> <li>• Week 8, maintain the gain: pacing, tips for safe exercising</li> <li>• Week 9, be busy being active: keep monitoring with the pedometer, places, people and thoughts that motivate you</li> <li>• Week 10, change does not happen in a straight line! Preparing for setbacks</li> <li>• Week 11, make it a healthy habit: building regular exercise habits, creating if-then plans</li> <li>• Week 12, I've changed: how to keep up your walking programme</li> <li>• Congratulations, you have completed the programme</li> <li>• How to keep going when the PACE-UP programme finishes</li> </ul>	16 and 21 7, 9, 19 and 26 10, 12 and 13 20 and 29 20 2, 20 and 35 12, 13 and 29 12, 16 and 29 8 38, 17 and 11 9, 21 and 35 16, 29 and 36 8 and 35 1, 2, 7 and 23 16, 20 and 29 11, 16 and 17 1, 16 and 29

a 1 provide general information on behaviour–health link; 2 provide information on consequences to the individual; 4 provide normative information about others' behaviour; 7 action-planning; 8 barrier identification; 9 set graded tasks; 10 prompt review of behavioural goals; 11 prompt review of outcome goals; 12 prompt rewards contingent on effort; 13 prompt rewards contingent on successful behaviour; 16 prompt self-monitoring of behaviour; 17 prompting self-monitoring of behavioural outcome; 19 provide feedback on performance; 20 provide information on when and where to perform the behaviour; 21 provide instructions on how to perform the behaviour; 23 teach to use prompts/cues; 26 prompt practice; 29 plan social support/social change; 35 relapse prevention/coping planning; 36 stress management/emotional control training; and 38 time management.

This table has been adapted from Harris *et al.*<sup>70</sup> This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<http://creativecommons.org/licenses/by/2.0>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (<http://creativecommons.org/publicdomain/zero/1.0/>) applies to the data made available in this article, unless otherwise stated.

### **Procedure for the control group**

The participants were advised to continue their usual activity levels and were not offered the 12-week walking intervention, but were free to participate in any other PA, just as they would if they were not enrolled in the trial. At the end of the 12-month follow-up period, the control group was offered to receive a pedometer and the PACE-UP 12-week walking programme handbook and diary, either by post or as part of a single PA practice nurse appointment, as preferred.

**TABLE 3** The PACE-UP practice nurse PA consultations and BCTs included

Sessions	Guide to session content	<sup>a</sup> BCTs <sup>68</sup>
Session 1: week 1, first steps (30 minutes)	<ul style="list-style-type: none"> <li>Review health status, current activity, health benefits of PA</li> <li>Cost–benefit analysis for increasing PA</li> <li>PA guidelines and how to increase PA safely</li> <li>Moderate-intensity PA and relating it to number of steps</li> <li>Review participant baseline step count</li> <li>Teach use of pedometer and recording walks and steps in diary</li> <li>Ideas for increasing steps</li> <li>Goal-setting – PACE-UP goals or tailored to the individual patient</li> <li>Use of rewards for effort and for achieving goals</li> <li>Summarise and check patient understanding, plan time for next meeting</li> <li>Communication strategies to overcome resistance and promote patient-led change</li> </ul>	1 and 2 2 4 and 21 19 21 and 26 20 7, 9 and 16 12 and 13 37
Session 2: week 5, continuing the changes (20 minutes)	<ul style="list-style-type: none"> <li>Review step count and walking diary</li> <li>Encourage progress in increasing walking and achieving step count goals</li> <li>Troubleshoot any problems with pedometer or diary</li> <li>Review target and agree goals for next stage</li> <li>Barriers to, and facilitators of, increasing PA, overcoming barriers, encouraging support</li> <li>Pacing and avoiding boom and bust</li> <li>Check confidence levels, build confidence to make change</li> <li>Summarise and check patient understanding, plan time for next meeting</li> <li>Communication strategies to overcome resistance and promote patient-led change</li> </ul>	10 and 19 12 and 13 8 7, 9 and 16 8 and 29 9 and 35 18, 29 and 36 37
Session 3: week 9, building lasting habits (20 minutes)	<ul style="list-style-type: none"> <li>Review step count and walking diary</li> <li>Review overall progress over the sessions</li> <li>Encourage progress in increasing walking and achieving goals</li> <li>Preparing for setbacks</li> <li>Building habits: discuss methods of maintaining lasting change, including repetition, if-then rules and support</li> <li>Setting goals: maintaining current activity or increasing further?</li> <li>Reminder regarding contact with research assistant in 3–4 weeks</li> <li>Communication strategies to overcome resistance and promote patient-led change</li> </ul>	10 and 19 11 and 17 12 and 13 35 7, 23, 29 and 35 7, 9, 16 and 26 37

<sup>a</sup> 1 provide general information on behaviour–health link; 2 provide information on consequences to individual; 4 provide normative information about others' behaviour; 7 action-planning; 8 barrier identification; 9 set graded tasks; 10 prompt review of behavioural goals; 11 prompt review of outcome goals; 12 prompt rewards contingent on effort; 13 prompt rewards contingent on successful behaviour; 16 prompt self-monitoring of behaviour; 17 prompting self-monitoring of behavioural outcome; 18 prompting focus on past success; 19 provide feedback on performance; 20 provide information on when and where to perform the behaviour; 21 provide instructions on how to perform the behaviour; 23 teach to use prompts/cues; 26 prompt practice; 29 plan social support/social change; 35 relapse prevention/coping planning; 36 stress management/emotional control training; and 37 motivational interviewing.

This table has been adapted from Harris *et al.*<sup>70</sup> This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<http://creativecommons.org/licenses/by/2.0>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (<http://creativecommons.org/publicdomain/zero/1.0/>) applies to the data made available in this article, unless otherwise stated.

## Outcome measures

### Primary and secondary outcome measures

These were selected to reflect the needs of the target population, helping adults and older adults to increase their PA, particularly through walking, and to inform UK public health policy. The primary outcome was the change in average daily step count, measured over 7 days, between baseline and 12 months, assessed

The plan is to start from where **you** are currently and to gradually increase the amount you walk over 12 weeks.



Use the **pedometer** to record the number of steps you do each day and write them in your PACE-UP diary.

Weeks of PACE-UP walking programme	Target number of steps
1-2	Add in 1500 steps on 3 or more days per week
3-4	Add in 1500 steps on 5 or more days per week
5-6	Add in 3000 steps on 3 or more days per week
7-12	Add in 3000 steps on 5 or more days per week
<p><b>Remember</b></p> <p>1500 steps equals about 15 minutes of walking &amp;</p> <p>3000 steps equals about 30 minutes of walking.</p>	

**What does this mean for you?**

**From the pedometer worn at baseline your average number of daily steps was .....**

**Your 12 week programme will be as follows:**

Add in extra steps to your baseline average of .....steps per day. Record your daily step-count on the PACE-UP diary sheets.

**First month** add in 1500 steps per day (which is about equal to a 15 minute walk), gradually increasing from 3 to 5 days per week

**Second month** add in 3000 steps per day (which is about equal to a 30 minute walk) gradually increasing from 3 to 5 days per week

**Third month** is maintenance, keep on adding in 3000 steps per day (about equal to a 30 minute walk) on at least 5 days per week.

**By the end of 12 weeks the aim is for you to be walking an extra 3000 steps most days of the week. If you can do this, your average number of daily steps should have increased to about ..... steps.**

**FIGURE 1** A summary of the PACE-UP walking programme. Adapted from Harris *et al.*<sup>70</sup> This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<http://creativecommons.org/licenses/by/2.0>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (<http://creativecommons.org/publicdomain/zero/1.0/>) applies to the data made available in this article, unless otherwise stated.

objectively by accelerometry (GT3X+; ActiGraph LLC, Pensacola, FL, USA). Secondary outcomes were as follows: changes in step counts between baseline and 3 months; changes in time spent weekly in MVPA in  $\geq 10$ -minute bouts between baseline and 3 months, and between baseline and 12 months; and time spent sedentary between baseline and 3 months, and between baseline and 12 months. All of these secondary outcomes were also assessed objectively by accelerometry. Cost-effectiveness was also a secondary outcome in our protocol [incremental cost per change in step count and per quality-adjusted life-year (QALY)]; this is presented in *Chapter 4*.

## Ancillary outcomes

- Change in self-reported PA, measured over the same 7 days as accelerometry using the short International Physical Activity Questionnaire (IPAQ)<sup>72</sup> and the General Practice Physical Activity Questionnaire [(GPPAQ)<sup>73</sup> as part of the 7-day PA questionnaire; see *Appendix 1*].
- Change in other patient-reported outcomes (from the health and lifestyle questionnaires at baseline, 3 months and 12 months; see *Appendix 1*): confidence in ability to do PA, as measured by exercise self-efficacy;<sup>74</sup> anxiety and depression, as measured by the Hospital Anxiety and Depression Scale (HADS);<sup>75</sup> perceived health status (health-related quality of life), as measured by the EuroQol-5 Dimensions, five-level version (EQ-5D-5L);<sup>76</sup> and self-reported pain, measured by two items from the Medical Outcomes Study 36-item short-form health survey.<sup>77</sup>
- Change in anthropometric measurements (weight, BMI, waist circumference, body fat; see *Ascertainment of outcomes, Anthropometry*, for measurement details).
- Adverse outcomes [falls, fractures, injuries, exacerbation of pre-existing conditions, major cardiovascular events and deaths from serious AEs (SAEs)] were collected as part of safety monitoring for the trial, by questionnaire self-report items designed by us at 3 and 12 months, and from primary care records after the 12-month follow-up period, for those giving consent.
- Health service use for those giving consent to primary care record access for the 12-month trial period, numbers of the following occurrences were collected for health economic evaluations (see *Chapter 4*): primary care consultations, accident and emergency (A&E) attendances, emergency and elective hospital admissions and outpatient referrals.

## Ascertainment of outcomes

See *Figure 2* for the schedule for outcome assessments and measures.

### Accelerometry

Participants were asked to carry on with their usual PA levels and to wear an accelerometer (GT3X+, ActiGraph LLC) on a belt over one hip, during waking hours (from rising until going to bed) for 7 days, only removing it for bathing, at baseline, 3 months and 12 months. Participants were offered the option of text messaging to remind them to wear the accelerometer each day and to return it after the 7 days. A diary was provided to record what activities were done and for how long. The monitor, belt and diary were posted back on completion. Once returned, the participants received a £10 gift voucher.

### Anthropometry

At the baseline and 12-month face-to-face assessments, the following measurements were taken: height (measured in bare feet to the nearest 0.5 cm using a stadiometer), weight (measured to the nearest 0.1 kg), body fat, bioimpedance [using the Tanita body composition analyser BC-418 MA (Tanita Corporation, Tokyo, Japan)] and waist and hip circumference (using a standard technique and tape measure with a clear plastic slider).

### Questionnaire measures

Questionnaire measures were collected using validated tools (detailed under *Outcome measures, Ancillary outcomes*), as part of self-completed questionnaires at 3 months and 12 months.

In terms of the self-reported PA in the previous week, for the IPAQ<sup>72</sup> we used the measure of MVPA (total minutes of vigorous and moderate PA weekly) and the measure of walking (total minutes of walking weekly). The GPPAQ<sup>73</sup> provides a PA index (PAI), which is calculated from a combination of PA from both work and leisure activities. Active individuals are those who self-report  $\geq 3$  hours of MVPA per week on

the PAI. However, walking is not included in the calculation of the PAI, although it is asked about in the questionnaire. Analysis of similar GPPAQ data compared with objective accelerometry in our earlier PACE-LIFT trial<sup>21</sup> demonstrated that a modified PAI, which also included walking at a brisk pace for at least 3 hours per week, improved validity and repeatability compared with the standard GPPAQ.<sup>78</sup> A modified index, GPPAQ-Walk, was therefore generated.

In addition, the following were also recorded at baseline: demographic information, based on 2011 census questions<sup>79</sup> (e.g. marital status, ethnic group, occupation, employment, household composition, home ownership); a list of common self-reported chronic conditions (e.g. heart disease, lung disease, arthritis, stroke, diabetes mellitus, depression); disability, as measured by the Townsend score;<sup>80</sup> limiting long-standing illness;<sup>79</sup> current medications; smoking; and alcohol consumption.

Several other questionnaire variables were collected at all three time periods, but were not considered to be ancillary trial outcomes in the trial protocol:<sup>70</sup> loneliness, measured by a single item;<sup>81</sup> risk of falls, measured using the Falls Risk Assessment Tool,<sup>82</sup> was assessed using a combination of both self-reported items and direct observation of the ability to rise from a chair without using arms; and self-reported usual PA, as measured by the modified Zutphen Physical Activity Questionnaire.<sup>83</sup> Data from these variables are not presented in this report.

All study groups were asked about falls, injuries, fractures, exacerbation of any pre-existing conditions and the costs of any treatments in the 3- and 12-month questionnaires. Questions on the financial costs of participating in walking and other PAs were asked in the 3- and 12-month questionnaires.

### **Primary care computerised record measures**

For participants who gave written consent, the following data were collected from their electronic primary care records, for the 12-month duration of the trial, after the 12-month follow-up:

- adverse events potentially relating to trial participation [Read codes relating to falls, fractures, injuries, cardiovascular events (myocardial infarction, coronary artery bypass graft, coronary angioplasty, transient ischaemic attack, stroke) and death]
- health service use – GP consultations, practice nurse consultations (excluding those for the trial), A&E attendances, emergency and elective hospital admissions and outpatient referrals.

These data were downloaded and pseudoanonymised before removal from the practice.

## **Baseline and follow-up data collection**

### **Baseline data collection**

At baseline, a face-to-face assessment with the research assistant occurred at the participant's general practice, and questionnaire and anthropometric data were collected (see *Ascertainment of outcomes*). Participants were then given a belt with an accelerometer (GT3X+, ActiGraph LLC) and a blinded pedometer (Yamax Digiwalker CW200) on it, and asked to wear this for 7 days. The CW200 pedometer model was used to enable the baseline target-setting of the pedometer step count, because of its 7-day memory of consecutive daily steps. However, it is bulky to wear and complicated to use, so this model was not used for the intervention.

### **Follow-up data collection**

Follow-up data collection was conducted in the same way for all trial groups (*Figure 2*): (1) 3 months (postal) after randomisation (questionnaires and accelerometry) and (2) 12 months (face to face) after the baseline assessment (questionnaires, accelerometry and anthropometry). Participants were also contacted

by the research assistant at 6 and 9 months after randomisation by telephone or e-mail to check on falls for trial safety reporting and contact details. For those in the intervention groups, a replacement pedometer or batteries were offered at each contact point, if required. The intervention groups were asked to return their 12-week step count diary following the intervention at 3 months. This was then photocopied and sent back to participants.

## Accelerometer data reduction

The accelerometer measured vertical accelerations in magnitudes from 0.05 to 2.0 g sampled at 30 Hz, then summed over a 5-second epoch time period. ActiGraph data were reduced using Actilife software (v 6.6.0; ActiGraph LLC, Pensacola, FL, USA), ignoring runs of  $\geq 60$  minutes of zero counts.<sup>70</sup> Vertical counts were used, as these are the basis of the validated step count and MVPA algorithms. The analysis summary variables used were step counts, accelerometer wear time, time spent in MVPA ( $\geq 1952$  counts per minute, equivalent to  $\geq 3$  metabolic equivalents),<sup>84</sup> time spent in  $\geq 10$ -minute MVPA bouts and time spent being sedentary ( $\leq 100$  counts per minute, equivalent to  $\leq 1.5$  metabolic equivalents).<sup>85</sup>

## Adverse events and serious adverse events

An AE was defined as any unfavourable and unintended sign, symptom, syndrome or illness that developed or worsened during the observation period of the trial. This included:

- exacerbation of a pre-existing illness
- an increase in frequency or intensity of a pre-existing condition
- a condition detected or diagnosed after the trial started (but which might have been present at baseline)
- a persistent disease or symptoms present at baseline that worsened following the start of the trial.




FIGURE 2 Schedule of outcome assessment measures used in the PACE-UP trial.

A SAE was defined as any AE occurring during the trial for any of the three groups that resulted in any of the following outcomes:

- death
- a life-threatening AE
- inpatient hospitalisation or prolongation of existing hospitalisation
- a new disability/incapacity.

All AEs were assessed for seriousness, expectedness and causality. All AEs were recorded and closely monitored until resolution or stabilisation, or until it had been shown that the study intervention was not the cause. Participants were asked to contact the trial site immediately in the event of any SAE. The chief investigator was informed immediately and determined seriousness and causality in conjunction with two other medically trained trial investigators. A SAE that was determined to be directly or possibly trial related was reported, within agreed time frames, to the TSC and the ethics committee. All SAEs were reported annually to the TSC, ethics committee and the trial sponsor.

Although it was important to record AEs contemporaneously for trial safety monitoring during the trial, there was a risk of bias in their reporting, with those having nurse contact having more opportunities for reporting falls, injuries and illnesses. For analyses and reporting, we therefore concentrated on measures for which there were fewer risks of bias between groups: (1) spontaneously reported SAEs, (2) falls, fractures and injuries from questionnaire self-report at 3 and 12 months and (3) falls, fractures, injuries, cardiovascular events (new episode of any of the following: myocardial infarction, angioplasty, coronary artery bypass, stroke, transient ischaemic attack, new-onset angina, ischaemic heart disease) and deaths from primary care records after the 12-month follow-up point.

## Sample size

A total of 217 patients in each of the three trial arms would allow a difference of 1000 steps per day to be detected between any two arms of the trial, with 90% power at the 1% significance level. However, we planned to randomise households. Assuming an intracluster correlation of 0.5 and an average household size of 1.6 eligible patients, we needed to analyse 282 patients per trial arm. Allowing for approximately 15% attrition, we needed to randomise a total of 993 patients (331 control participants, 331 participants receiving a pedometer by post and 331 participants receiving a pedometer plus nurse support). We initially planned on six practices to each recruit approximately 166 patients (approximately 55 participants to each of the three groups), but to enable target recruitment, a seventh practice was added.

We anticipated a 20% recruitment rate among eligible participants, based on other PA interventions (including with pedometers) among middle-aged and older adults in primary care, where the recruitment rate was between 17% and 35%.<sup>21,33,86-89</sup> We estimated that, even if our recruitment rate was as low as 10%, we would have enough eligible participants at practices. In fact, the recruitment rate dipped to below 10%, so a seventh practice was added.

## Randomisation, concealment of allocation, contamination and treatment masking

### *Randomisation and concealment of allocation*

Following completion of the baseline assessment (including providing accelerometry data on  $\geq 5$  complete days of  $\geq 9$  hours/540 minutes), each participant was allocated to a trial group using the King's College London clinical trials unit internet randomisation service, to ensure independence of the allocation. If participants were unable to provide at least 5 days of  $\geq 540$  minutes wear time on accelerometry, they were asked to wear the accelerometer for a further 7 days, or they were excluded if this was not possible.

Randomisation was at a household level. Randomisation of a group household took place only after both members of the household had completed the baseline assessment. Block randomisation was used within the practice with randomly sized blocks (2, 4 or 6) to ensure balance in the groups and an even nurse workload. Participants were informed by telephone which group they had been allocated to.

### Contamination

Contamination could occur between partners in a household; we minimised this by ensuring that, if two household members were recruited, they were allocated to the same group (i.e. randomisation was at a household level). Contamination would have occurred if the control group used a pedometer to increase their walking during the 12-month trial follow-up. We tried to discourage participants in the control group from buying a pedometer, by ensuring that they knew that they would receive one at the end of follow-up. A question was included in the 12-month questionnaire to ask if they had used a pedometer during the course of the trial.

### Treatment masking

Participants were randomised only after the successful return of accelerometers with 5 days' recording. It was not possible to mask participants to their intervention group. The research assistants who carried out follow-up assessments were not masked to group allocation for pragmatic reasons alone: the study was funded to support only enough researchers to carry out recruitment and follow-up simultaneously. However, the main outcome was assessed objectively through accelerometry, and the assessment of the quality of the outcome data was done blind to intervention group: days with < 9 hours of data were excluded. Weight and body fat were also assessed objectively using the Tanita scales, which provided electronic printouts of results, and other outcomes were assessed using standardised measures (e.g. patient-reported outcomes from questionnaires). The statistician carrying out the primary analyses was masked to group allocation as far as possible.

## Withdrawals, losses to follow-up and missing data

### Withdrawals and losses to follow-up

Participants could withdraw from the trial at any point. Participants who withdrew following informed consent, and prior to randomisation, were replaced with another participant. Participants who withdrew after randomisation were not replaced and were asked if they were prepared to contribute to further data collection on outcomes at 3 and 12 months. Participants were made aware that withdrawal from the trial would not affect future care and that information on those who withdrew or were lost to follow-up that had already been collected would still be used, unless consent for this was withdrawn.

### Procedure for accounting for missing data

Only days with at least 540 minutes of registered time on an accelerometer on a given day were used, which was consistent with previous work (the PACE-LIFT trial,<sup>21</sup> Trost *et al.*<sup>90</sup> and Miller *et al.*<sup>91</sup>). Participants were randomised only if they provided at least 5 such days of accelerometer data at baseline. A multilevel linear regression model was used, taking account of repeated days within individuals to estimate the baseline average daily step count for each subject, adjusted for the day of the week and the day order of wearing the accelerometer. The same approach was used to estimate the average daily step count at 3 months and 12 months. The main covariates – age, sex, practice, month of baseline accelerometry and whether or not participants were taking part as a couple – were known for all participants, and most patients had complete data for other measures. To lessen attrition bias, the primary analysis included all participants with at least 1 satisfactory day of accelerometry recording at 12 months (i.e. a wear time of  $\geq 540$  minutes). The main analysis assumed that, depending on the model covariates, outcome data were missing at random. This was likely to be true for missing data as a result of accelerometer failure, and was plausible for missing days and participants who did not return accelerometers. However, an alternative plausible assumption is that participants who failed to provide outcome data were less active. Multiple imputation was used to impute values for those with no accelerometer data at 12 months (see *Statistical*

*methods, Sensitivity analyses*). Further sensitivity analyses examined the impact of assuming that missing step counts at 12 months in the control group were equal to their baseline values and, in the two intervention groups, varied between 1500 steps lower and 1500 steps higher than their baseline values.

## Statistical methods

The analysis and reporting was in line with the Consolidated Standards of Reporting Trials (CONSORT) guidelines, with the primary analysis on an intention-to-treat basis. That is, all participants with outcome data were included, regardless of their adherence to the interventions. All participants were included in the primary analysis if they had at least 1 satisfactory day of accelerometer recording ( $\geq 540$  minutes) of registered time during a day, out of 7 days, at 12 months. The adequacy of the randomisation process to achieve balanced groups was checked by comparing participant characteristics in the three arms (e.g. sex, age, socioeconomic group, baseline PA level or BMI). Stata<sup>®</sup>, version 12 (StataCorp LP, College Station, TX, USA) was used for all analyses.

### Primary analysis

The primary outcome measure was change in average daily step count from baseline to the 12-month follow-up point measured over 7 days. However, to overcome Lord's paradox,<sup>92</sup> the analytic approach regressed 12-month outcomes on baseline measures, thus allowing for regression to the mean. Eligibility was defined on the basis of  $\geq 5$  days with  $\geq 540$  minutes' activity at baseline. If the participant was asked to wear the accelerometer for a second time, the second 7 days was used in the analysis. If there were  $> 7$  days' wear on the accelerometer, then the first 7 days were used and later readings were discarded. The primary analysis used all participants providing at least 1 day of  $\geq 540$  minutes accelerometry wear time at 12 months (i.e. a complete-case analysis).

All analyses were carried out using Stata, version 12. The *xtmixed* procedure was used for regression models. A two-stage process was used for accelerometry data. Stage 1 estimated the average daily step count at both baseline and 12 months, using a multilevel model in which daily step counts were regressed on day of the week and day order of wearing the accelerometer (from day 1 to day 7) as fixed effects, and with day within individual as the random effect (i.e. level 1 was the day within individual and level 2 was individual). In stage 2, average daily step count at 12 months was regressed on baseline average daily step count, sex, age, general practice, month of baseline accelerometry and treatment group as fixed effects, and household as the random effect, to allow for clustering at a household level (i.e. level 1 was individual and level 2 was household). This method effectively measured the change in step count from baseline to 12 months, minimising bias and maintaining power. Adjusting for baseline steps controlled for many factors that predict the number of steps in cross-sectional analyses (e.g. BMI, socioeconomic group, health status). The reference group for the intervention group comparisons was the control group. The post-estimation command *pwcompare* was used to obtain the estimates of change with 95% CIs and *p*-values for the difference in change in steps for the postal group versus the control group, the nurse-support group versus the control group and the nurse-support group versus the postal group. This last comparison provided information on whether or not the nurse intervention promoted a worthwhile increase in activity compared with a pedometer alone. It should be noted that, although this estimate can be obtained from the difference of the first two estimates, *pwcompare* also provided 95% CIs for this comparison. Checks were carried out to confirm that the distribution of residuals from the regression model for change in steps was normally distributed.

### Secondary and ancillary outcome analyses

Secondary PA outcome measures from accelerometry were total weekly minutes of MVPA in  $\geq 10$ -minute bouts, average daily sedentary time at 12 months and steps, MVPA in bouts and sedentary time at 3 months. These data were processed and analysed in the same way as described for the step counts (see *Primary analysis*). MVPA was highly positively correlated with step counts and sedentary time was negatively correlated with step counts.

Other ancillary outcomes were changes in exercise self-efficacy, anxiety, depression, perceived health status (health-related quality of life, as measured using the EQ-5D-5L), self-reported pain, anthropometric measures (weight, BMI, waist circumference, body fat) and self-reported PA from the IPPAQ and GPAQ questionnaires. Changes in these outcomes from baseline to 3 and 12 months were analysed using identical models to stage 2, as described in *Primary analysis* (i.e. level 1 was individual and level 2 was household).

### Adverse event analyses

The number of participants who suffered an AE between 0 and 3 months or between 0 and 12 months (a spontaneously reported SAE or a systematically reported SAE from the 3- or 12-month questionnaire, or a SAE collected from the primary care record data) was compared between groups using exact tests for categorical tables.

### Subgroup analyses

Sex, age groups (< 60 years or  $\geq$  60 years), taking part as a couple, socioeconomic subgroups, BMI, disability, pain and exercise self-efficacy were examined as potential effect modifiers by adding interaction terms to the regression model for the primary outcome, which was changes in step counts at 12 months.

### Sensitivity analyses

Sensitivity analyses were carried out for the primary outcome (change in step counts from baseline to 12 months). The effects of using different criteria for defining satisfactory wear at 12 months were examined as follows: (1) at least 5 days of  $\geq$  540 minutes' wear time, (2)  $\geq$  1 day of  $\geq$  600 minutes' wear time and (3)  $\geq$  5 days of  $\geq$  600 minutes' wear time. The effect of adjusting for change in wear time between baseline and 12 months was also examined.

Additional sensitivity analyses assessed whether participants lost to follow-up or who failed to provide a single adequate day's recording might have introduced bias. This was first done by assuming that outcome data were missing at random, depending on the model covariates, using the Stata procedure *mi impute*. The first model used the standard model covariates to impute missing step counts at 12 months (treatment group, baseline steps, sex, age, general practice, month of baseline accelerometry and household as a random effect) and the second model added in the National Statistics Socio-economic Classification (NS-SEC), self-reported pain and fat mass as additional covariates. Further analyses explored the possible impact of outcomes not being missing at random, using the following assumptions: among those with missing data in the control group, the change in mean steps from baseline to 12 months was 0, and among those with missing data in each of the intervention groups, the change in mean steps from baseline to 12 months was -1500, 0 or +1500.

## Ethics approval and research governance

Ethics approval was granted for the trial from London, Hampstead Research Ethics Committee (reference number 12/LO/0219). The NHS Research and Development approval was granted by the Clinical Commissioning Groups in south-west London, through the Primary Care Research Network, to cover all the practice sites.

## Management of the trial

The trial progress, including recruitment, safety, finance and data management, was reviewed regularly by the trial management group (TMG). This was made up of the chief investigator, two trial investigators, the trial statistician and the trial manager. The TMG met on a monthly basis. All of the trial investigators met as a group (the trial investigator group) on a biannual basis, and the TSC met prior to participant recruitment, and then annually or biannually as necessary. Minutes were kept of all TMG, trial investigator

group and TSC meetings. The TSC included a patient advisor and more details of their role in terms of patient and public involvement are given in *Appendix 1*.

### **Further trial follow-up at 3 years**

After the initial trial results were analysed, funding was obtained to follow up the trial cohort at 3 years. Details of the methods and results for this further follow-up are given in *Chapter 8*.

## Chapter 3 Results

The main results from the PACE-UP trial are published,<sup>93</sup> and are reproduced here under the terms of the Creative Commons Attribution License (CC BY 4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided that the original author and source are credited.

### Recruitment of participants

The CONSORT diagram of participant flow (*Figure 3*) shows that of the 11,015 people invited to participate, 6399 did not respond and 548 were excluded as a result of self-reported PA guideline achievement; therefore, 1023 out of 10,467 (10%) were randomised.

### Baseline characteristics of the study population (*Table 4*)


Participants recruited to the trial were evenly spread across the age groups. Just over one-third of those recruited were men, around two-thirds were married and around one-fifth took part in the trial as a couple. The majority were in full- or part-time employment, mostly in high-level manual, administrative or professional jobs, with a minority in intermediate or routine and manual occupations. About 80% of those recruited were of white ethnicity, around 10% were black/African/Caribbean or black British and approximately 7% were Asian or Asian British. In terms of health factors, just under 10% were current smokers, around 80% reported their health as being good or very good, the majority had one or more chronic disease and some self-reported pain, around 60% reported no current disability, around 10% had a high depression score, around 20% had a high anxiety score, and around two-thirds of participants were overweight or obese. Recruitment occurred throughout all four seasons, but was slightly higher in summer and slightly lower in winter. All of these factors were well balanced between the three randomised groups.

In terms of objectively measured baseline PA levels, the nurse-support group had a slightly higher baseline-adjusted average daily step count [7653 steps, standard deviation (SD) 2826 steps] and minutes spent weekly in MVPA in bouts of  $\geq 10$  minutes (105 minutes, SD 116 minutes) than the postal group (7402 steps, SD 2476 steps; 92 minutes, SD 90 minutes) and the control group (7379 steps, SD 2696 steps; 84 minutes, SD 97 minutes). A higher proportion of the nurse-support group participants were achieving the guidelines of  $\geq 150$  minutes per week of MVPA in bouts of  $\geq 10$  minutes (26%, 89/346) than participants in the postal group (20%, 68/339) and those in the control group (18%, 61/338). The three groups were similar in terms of average daily sedentary time, at around 10 hours per day.

In terms of self-reported PA levels the patterns were different, with the control group reporting the highest number of weekly minutes of MVPA on the IPAQ, not including walking; however, the nurse-support group reported higher levels of MVPA if walking was included. A slightly higher proportion of participants in the control group than those in the intervention groups reported being active on the GPPAQ PAI, both excluding and including walking.

### Losses to follow-up

*Figure 3* shows the losses to follow-up. Of the 1023 people randomised, 32 (3%) withdrew and eight (1%) were unable to be contacted at 12 months. In total, 956 out of 1023 participants (93%) provided at least 1 day of 540 minutes' wear time accelerometer data and were included in the 12-month primary analyses.



**FIGURE 3** The PACE-UP trial CONSORT flow diagram. Adapted from Harris *et al.*<sup>93</sup> This is an open access article distributed in accordance with the terms of the Creative Commons Attribution (CC BY 4.0) license, which permits others to distribute, remix, adapt and build upon this work, provided the original work is properly cited. See: <http://creativecommons.org/licenses/by/4.0>.

TABLE 4 Baseline characteristics of the 1023 randomised subjects

Characteristic	Trial arm		
	Control (N = 338)	Postal (N = 339)	Nurse (N = 346)
Age (years) at randomisation, <i>n</i> (%)			
45–54	101 (30)	118 (35)	121 (35)
55–64	138 (41)	125 (37)	124 (36)
65–75	99 (29)	96 (28)	101 (29)
Sex (male), <i>n</i> (%)	115 (34)	124 (37)	128 (37)
Marital status (married), <i>n</i> (%)	213 (64)	215 (65)	230 (68)
Randomised as a couple, <sup>a</sup> <i>n</i> (%)	66 (20)	68 (20)	73 (21)
Employment status, <sup>79</sup> <i>n</i> (%)			
In full- or part-time employment	190 (57)	193 (59)	190 (56)
Retired	102 (31)	96 (29)	101 (30)
Other	39 (12)	39 (12)	50 (15)
NS-SEC (current or previous job), <sup>79</sup> <i>n</i> (%)			
High-level managerial, administrative, professional	199 (62)	191 (60)	184 (56)
Intermediate occupations	70 (22)	85 (27)	95 (29)
Routine and manual occupations	51 (16)	44 (14)	52 (16)
Ethnicity, <sup>79</sup> <i>n</i> (%)			
White	253 (78)	270 (83)	267 (80)
Black/African/Caribbean/black British	30 (9)	31 (10)	40 (12)
Asian/Asian British	26 (8)	20 (6)	22 (7)
Other	15 (5)	4 (1)	6 (2)
Current smoker, <i>n</i> (%)	27 (8)	29 (9)	26 (8)
General health: <sup>79</sup> very good or good, <i>n</i> (%)	265 (80)	277 (84)	277 (82)
Chronic diseases, <i>n</i> (%)			
None	129 (39)	135 (41)	117 (35)
One or two	183 (55)	171 (51)	188 (55)
≥ 3	21 (6)	27 (8)	34 (10)
Presence of self-reported pain, <sup>77</sup> <i>n</i> (%)	220 (66)	236 (71)	234 (70)
Limiting long-standing illness, <sup>79</sup> <i>n</i> (%)	76 (23)	73 (22)	74 (22)
Townsend disability score, <sup>80</sup> <i>n</i> (%)			
None (0)	190 (57)	196 (59)	210 (62)
Slight or some disability (1–6)	127 (38)	130 (39)	124 (36)
Appreciable or severe disability (7–18)	15 (5)	8 (2)	7 (2)
HADS depression score: <sup>75</sup> borderline or high, <i>n</i> (%)	36 (11)	33 (10)	42 (12)
HADS anxiety score: <sup>75</sup> borderline or high, <i>n</i> (%)	65 (19)	64 (19)	71 (21)
Low self-efficacy score, <sup>74</sup> <i>n</i> (%)	102 (31)	96 (29)	117 (35)

continued

**TABLE 4** Baseline characteristics of the 1023 randomised subjects (*continued*)

Characteristic	Trial arm		
	Control (N = 338)	Postal (N = 339)	Nurse (N = 346)
Month of baseline measure, n (%)			
March–May	80 (24)	75 (22)	76 (22)
June–August	105 (31)	106 (31)	110 (32)
September–November	88 (26)	82 (24)	92 (27)
December–February	65 (19)	76 (22)	68 (20)
Physical characteristics			
Overweight/obese: BMI of $\geq 25$ kg/m <sup>2</sup> , n (%)	227 (67)	221 (65)	233 (67)
Fat mass (kg), mean (SD)	26 (10)	27 (11)	26 (11)
Waist circumference (cm), mean (SD)	93 (14)	94 (14)	93 (13)
PA data			
Accelerometry			
Adjusted baseline step count per day, mean (SD)	7379 (2696)	7402 (2476)	7653 (2826)
Total weekly minutes of MVPA in $\geq 10$ -minute bouts, mean (SD)	84 (97)	92 (90)	105 (116)
Average daily sedentary time (minutes), mean (SD)	613 (68)	614 (71)	619 (78)
Average daily wear time (minutes), mean (SD)	789 (73)	787 (78)	797 (84)
150 minutes of MVPA in $\geq 10$ -minute bouts (yes), n %	61 (18)	68 (20)	89 (26)
IPAQ score <sup>72</sup>			
IPAQ MVPA score: total weekly minutes of MVPA in $\geq 10$ -minute bouts (N = 909), mean (SD)	197 (314)	147 (256)	172 (279)
IPAQ walking score: total weekly minutes of walking in $\geq 10$ -minute bouts (N = 888), mean (SD)	333 (333)	330 (338)	312 (277)
150 weekly minutes of IPAQ MVPA score (N = 909): yes, n (%)	110 (37)	91 (30)	109 (35)
150 weekly minutes of IPAQ walking score (N = 888): yes, n (%)	193 (65)	190 (66)	208 (69)
GPPAQ score, <sup>73</sup> n (%)			
PAI score (N = 973)			
Inactive	159 (49)	153 (48)	156 (47)
Moderately inactive	69 (21)	66 (21)	83 (25)
Moderately active	50 (16)	63 (20)	60 (18)
Active	44 (14)	36 (11)	34 (10)
PAI score, including walking (GPPAQ walking score; N = 973)			
Inactive	129 (40)	134 (42)	133 (40)
Moderately inactive	57 (18)	56 (18)	63 (19)
Moderately active	43 (13)	49 (15)	47 (14)
Active	93 (29)	79 (25)	90 (27)

SD, standard deviation.

a Two and one participants in the postal and nurse groups, respectively, were randomised and took part in the trial as a couple, although their partner was excluded before randomisation because of a lack of wear time.

Adapted from Harris *et al.*<sup>93</sup> This is an open access article distributed in accordance with the terms of the Creative Commons Attribution (CC BY 4.0) license, which permits others to distribute, remix, adapt and build upon this work, provided the original work is properly cited. See: <http://creativecommons.org/licenses/by/4.0>.

## Data completeness for accelerometry

Accelerometer wear time was similar between the groups at baseline, the 3-month follow-up point and the 12-month follow-up point (see *Tables 4 and 5*). Over 90% of all groups provided  $\geq 5$  days of  $\geq 540$  minutes' wear time at 12 months (see *Appendix 2, Table 23*).

## Effect of the intervention on accelerometer-assessed physical activity outcomes (*Table 5*)

### Three-month (interim) outcomes

There were significant differences for the change in average daily step counts from baseline to 3 months between intervention groups and the control group: additional step counts (steps per day) were 692 steps (95% CI 363 to 1020 steps;  $p < 0.001$ ) for the postal group and 1173 steps (95% CI 844 to 1501 steps;  $p < 0.001$ ) for the nurse-support group, and the difference between the intervention groups was statistically significant (481 steps, 95% CI 153 to 809 steps;  $p = 0.004$ ). Findings for the change in time in MVPA levels showed a similar pattern: additional MVPA in bouts of  $\geq 10$  minutes (minutes per week) was 43 minutes (95% CI 26 to 60 minutes;  $p < 0.001$ ) for the postal group and 61 minutes (95% CI 44 to 78 minutes;  $p < 0.001$ ) for the nurse-support group, and the difference between intervention groups was 18 minutes (95% CI 1 to 35 minutes;  $p = 0.04$ ). There was no difference between the groups for the change in sedentary time. Summary data for the 3-month PA outcomes are shown in *Appendix 2, Table 24*.

**TABLE 5** Primary and secondary accelerometry outcome data

Outcome	Comparison between trial arms					
	Postal vs. control		Nurse support vs. control		Nurse support vs. postal	
	Effect (95% CI)	<i>p</i> -value	Effect (95% CI)	<i>p</i> -value	Effect (95% CI)	<i>p</i> -value
Daily step count						
3 months	692 (363 to 1020)	< 0.001	1173 (844 to 1501)	< 0.001	481 (153 to 809)	0.004
12 months	642 (329 to 955)	< 0.001	677 (365 to 989)	< 0.001	36 (-277 to 349)	0.82
Total weekly minutes of MVPA in $\geq 10$ -minute bouts						
3 months	43 (26 to 60)	< 0.001	61 (44 to 78)	< 0.001	18 (1 to 35)	0.04
12 months	33 (17 to 49)	< 0.001	35 (19 to 51)	< 0.001	2 (-14 to 17)	0.83
Daily sedentary time (minutes)						
3 months	-2 (-12 to 7)	0.59	-7 (-16 to 3)	0.16	-4 (-13 to 5)	0.38
12 months	1 (-8 to 10)	0.83	-0.2 (-9 to 9)	0.96	-1 (-10 to 8)	0.79
Daily wear time (minutes)						
3 months	2 (-8 to 12)	0.69	4 (-6 to 14)	0.40	2 (-8 to 12)	0.65
12 months	9 (-1 to 19)	0.08	9 (-0.8 to 19)	0.07	0.3 (-10 to 10)	0.96

### Notes

Accelerometry data were available in the control, postal and nurse groups for 318, 317 and 319 participants at 3 months, respectively, and for 323, 312 and 321 at 12 months, respectively.

All models include practice, sex, age at randomisation and month of baseline accelerometry as fixed effects and household as a random effect in a multilevel model.

The *xtmixed* command in Stata was used, followed by the post-estimation command *pwcompare*, to generate the pairwise estimates of effect and their CIs.

Adapted from Harris *et al.*<sup>93</sup> This is an open access article distributed in accordance with the terms of the Creative Commons Attribution (CC BY 4.0) license, which permits others to distribute, remix, adapt and build upon this work, provided the original work is properly cited. See: <http://creativecommons.org/licenses/by/4.0>.

### Twelve-month (main) outcomes

Both intervention groups increased their step counts between baseline and 12 months compared with the control group: additional step counts (steps per day) were 642 steps (95% CI 329 to 955 steps;  $p < 0.001$ ) for the postal group and 677 steps (95% CI 365 to 989 steps;  $p < 0.001$ ) for the nurse-support group, with no statistically significant difference between intervention groups (36 steps, 95% CI -277 to 349 steps;  $p = 0.82$ ). Time spent in MVPA in bouts showed a similar pattern, that is, both intervention groups increased at 12 months compared with the control group: additional MVPA in bouts (minutes per week) was 33 minutes (95% CI 17 to 49 minutes;  $p < 0.001$ ) for the postal group and 35 minutes (95% CI 19 to 51 minutes;  $p < 0.001$ ) for the nurse-support group, with no statistically significant difference between the two intervention groups (2 minutes, 95% CI -14 to 17 minutes;  $p = 0.83$ ). Again, there was no difference between the groups for the change in sedentary time. Summary data for the 12-month PA outcomes are shown in *Appendix 2, Table 24*.

Residuals from the 12-month models for steps and weekly MVPA in  $\geq 10$ -minute bouts were plotted, and the distribution of residuals from both models was normally distributed (see *Appendix 2, Figure 18*).

### Effect of the intervention on self-reported physical activity outcomes at 12 months (Table 6)

At 12 months, the IPAQ weekly minutes of MVPA (not including walking) did not show any effect of the intervention for either intervention group compared with the control group. However, weekly minutes of walking from the IPAQ at 12 months compared with baseline showed significant increases for both groups compared with controls: 69 minutes (95% CI 19 to 119 minutes) in the postal group and 55 minutes (95% CI 5 to 105 minutes) in the nurse-support group; there was no difference between the intervention groups (-14 minutes, 95% CI -64 to 37 minutes). This was also reflected in the odds ratio (OR) for achieving  $\geq 150$  minutes of activity in a week, conditional on the baseline state, which was not significant for IPAQ MVPA for either intervention group, but was for IPAQ walking (postal group vs. control group: OR 2.1 minutes, 95% CI 1.3 to 3.3 minutes; nurse-support group vs. control group: OR 1.7 minutes,

**TABLE 6** Effect estimates for self-report questionnaires (IPAQ and GPPAQ) at 12 months

Questionnaire outcome	Comparison between trial arms					
	Postal vs. control		Nurse support vs. control		Nurse support vs. postal	
	Effect (95% CI)	<i>p</i> -value	Effect (95% CI)	<i>p</i> -value	Effect (95% CI)	<i>p</i> -value
<b>IPAQ<sup>72</sup></b>						
Change in weekly minutes of activity						
Vigorous and moderate activity ( <i>n</i> = 775)	-10 (-58 to 38)	0.67	-32 (-80 to 16)	0.19	-22 (-70 to 27)	0.38
Walking ( <i>n</i> = 750)	69 (19 to 119)	0.01	55 (5 to 105)	0.03	-14 (-64 to 37)	0.59
OR for achieving $\geq 150$ minutes of activity in a week at follow-up, conditional on baseline state						
Vigorous and moderate activity ( <i>n</i> = 775)	1.0 (0.5 to 2.0)	0.99	0.6 (0.3 to 1.3)	0.18	0.6 (0.3 to 1.3)	0.19
Walking ( <i>n</i> = 750)	2.1 (1.3 to 3.3)	0.001	1.7 (1.1 to 2.6)	0.01	0.8 (0.5 to 1.3)	0.41
<b>GPPAQ<sup>73</sup></b>						
OR for being active at follow-up, conditional on baseline state						
PAI ( <i>n</i> = 892)	1.2 (0.7 to 2.1)	0.46	0.9 (0.5 to 1.6)	0.80	0.8 (0.4 to 1.3)	0.32
PAI, including walking ( <i>n</i> = 892)	1.1 (0.6 to 1.8)	0.81	0.9 (0.5 to 1.5)	0.64	0.8 (0.5 to 1.4)	0.48

95% CI 1.1 to 2.6 minutes); there was no difference between the intervention groups (OR 0.8 minutes, 95% CI 0.5 to 1.3 minutes).

For the GPPAQ, the OR for being active at the 12-month follow-up, conditional on the baseline state, did not show a significant effect for either of the intervention groups compared with the control group, whether or not walking was included in the GPPAQ PAI.

Summary data for the effect of the intervention on the IPAQ and the GPPAQ are given in *Appendix 2, Table 25*.

### Effect of the intervention on other health-related outcomes (*Table 7*)

Fat mass was slightly reduced at 12 months in both intervention groups, but this did not differ significantly from the control group. There was no change in BMI or waist circumference between baseline and 12 months. The interventions had no significant effects on anxiety, depression, quality of life (EQ-5D-5L) or pain scores at either 3 months or 12 months. The exercise self-efficacy score significantly increased in both intervention groups at 3 months compared with the control group, and there was a greater effect in the nurse-support group than in the postal group. By 12 months, the self-efficacy score was significantly higher in the nurse group than in the control group, and the postal group was intermediate between, but not significantly different from, either of the other groups.

### Effect of the intervention on adverse events and serious adverse events (*Table 8*)

The number of total AEs did not differ between the groups at either 3 months or 12 months, whether using higher numbers of events self-reported from the patient questionnaire (falls, fractures, sprains or injuries) or lower numbers of events from primary care records (any AE – cardiovascular, fracture, sprains/injuries, falls or pain from back or lower limb). There was also no between-group difference in trial SAEs reported for safety monitoring. Self-reported falls were lower in the nurse-support group at 12 months (43/318, 14%) than in the postal group (57/310, 18%) or the control group (71/318, 22%;  $p = 0.02$ ). Falls reported in primary care records over 12 months were fewer in number, but also in the same direction, although the differences were non-significant ( $p = 0.13$ ). Primary care-recorded cardiovascular events over 0–12 months were lower in the nurse-support group (2/340, 0.6%) and the postal group (1/331, 0.3%) than in the control group (8/334, 2.4%;  $p = 0.04$ ).

### Subgroup analyses (*Figure 4*)

There was no evidence of effect modification on the change in step count at 12 months for either of the intervention groups versus the control group for any of the following: age, sex, taking part as a couple, BMI, disability, pain, socioeconomic group and exercise self-efficacy.

### Sensitivity analyses and imputations (see *Appendix 2, Table 26*)

The sensitivity analyses on the primary outcome measure (change in average daily step count at 12 months), restricted to those with  $\geq 600$  minutes' daily wear time, increased the effect size for both intervention groups versus the control group, but did not change the interpretation (both intervention groups had a significant effect compared with the control group, but there was no significant difference between the interventions). Similarly, imputations with both missing-at-random and missing-not-at-random assumptions made some difference to the effect sizes for both interventions compared with the control group and with each other, but, again, made no difference to the overall interpretation.

TABLE 7 Effect estimates for other health-related outcomes

Health-related outcome	Comparison between trial arms					
	Postal vs. control		Nurse support vs. control		Nurse support vs. postal	
	Effect (95% CI)	p-value	Effect (95% CI)	p-value	Effect (95% CI)	p-value
BMI (kg/m <sup>2</sup> )						
12 months	-0.1 (-0.3 to 0.1)	0.24	-0.03 (-0.2 to 0.1)	0.71	0.07 (-0.1 to 0.3)	0.42
Fat mass (kg)						
12 months	-0.4 (-0.8 to 0.07)	0.10	-0.2 (-0.7 to 0.2)	0.30	0.1 (-0.3 to 0.6)	0.54
Waist circumference (cm)						
12 months	-0.04 (-0.8 to 0.7)	0.92	0.08 (-0.6 to 0.8)	0.23	0.1 (-0.6 to 0.8)	0.74
HADS anxiety score <sup>75</sup>						
3 months	-0.3 (-0.7 to 0.1)	0.13	-0.3 (-0.7 to 0.1)	0.16	0.01 (-0.4 to 0.4)	0.94
12 months	-0.2 (-0.6 to 0.2)	0.28	-0.2 (-0.6 to 0.2)	0.28	0.0006 (-0.4 to 0.4)	1.00
HADS depression score <sup>75</sup>						
3 months	-0.2 (-0.6 to 0.1)	0.12	-0.2 (-0.5 to 0.1)	0.19	0.04 (-0.3 to 0.3)	0.82
12 months	-0.1 (-0.5 to 0.2)	0.44	-0.02 (-0.4 to 0.3)	0.91	0.1 (-0.2 to 0.5)	0.51
EQ-5D-5L score <sup>76</sup>						
3 months	-0.005 (-0.02 to 0.01)	0.60	-0.01 (-0.03 to 0.01)	0.26	-0.006 (-0.03 to 0.01)	0.54
12 months	-0.01 (-0.03 to 0.01)	0.30	-0.01 (-0.03 to 0.01)	0.23	-0.002 (-0.02 to 0.02)	0.87
Exercise self-efficacy score <sup>74</sup>						
3 months	1.1 (0.2 to 2.0)	0.01	2.3 (1.4 to 3.2)	< 0.001	1.2 (0.3 to 2.1)	0.01
12 months	0.6 (-0.3 to 1.6)	0.20	1.2 (0.3 to 2.2)	0.01	0.6 (-0.4 to 1.5)	0.22
Self-reported pain score						
3 months	0.05 (-0.06 to 0.17)	0.37	0.05 (-0.07 to 0.16)	0.42	-0.004 (-0.12 to 0.11)	0.94
12 months	0.05 (-0.06 to 0.17)	0.35	0.02 (-0.10 to 0.13)	0.76	-0.04 (-0.15 to 0.08)	0.53

**Notes**

At baseline, data were available for all participants for BMI and waist circumference, and for 335, 337 and 346 participants in the control, postal and nurse-support groups, respectively, for fat mass.

At 12 months, data were available in the control, postal and nurse-support groups for 323, 314 and 321 participants, respectively, for BMI and waist circumference, and for 319, 308 and 320, respectively, for fat mass.

Questionnaire data were available for varying numbers of participants at baseline, 3 months and 12 months.

All models include practice, sex, age at randomisation and month of baseline accelerometry as fixed effects and household as a random effect in a multilevel model.

Adapted from Harris *et al.*<sup>93</sup> This is an open access article distributed in accordance with the terms of the Creative Commons Attribution (CC BY 4.0) license, which permits others to distribute, remix, adapt and build upon this work, provided the original work is properly cited. See: <http://creativecommons.org/licenses/by/4.0>.

TABLE 8 Adverse events

AEs	Time frame in each trial arm							
	0–3 months				0–12 months			
	Control, n (%)	Postal, n (%)	Nurse support, n (%)	p-value <sup>a</sup>	Control, n (%)	Postal, n (%)	Nurse support, n (%)	p-value <sup>a</sup>
<b>AEs reported on the questionnaire</b>	<b>(N = 931)</b>				<b>(N = 946)</b>			
Fall, fracture, sprain or injury	59/313 (19)	70/310 (23)	65/308 (21)	0.51	113/318 (36)	99/310 (32)	96/318 (30)	0.34
Fall	25 (8)	24 (8)	24 (8)	0.99	71 (22)	57 (18)	43 (14)	0.02
Fracture	3 (1)	3 (1)	7 (2)	0.28	15 (5)	10 (3)	11 (3)	0.57
Sprain or injury	49 (16)	54 (17)	47 (15)	0.74	66 (21)	68 (22)	63 (20)	0.81
	<b>(N = 911)</b>				<b>(N = 924)</b>			
Deterioration in health problems already present since the start of the study	33/311 (11)	30/303 (10)	39/297 (13)	0.42	68/313 (22)	67/300 (22)	65/311 (21)	0.91
<b>AEs from primary care records<sup>b</sup></b>	<b>(N = 1005)</b>				<b>(N = 1005)</b>			
Any AE	29/334 (8.7)	23/331 (7.0)	20/340 (5.9)	0.36	85/334 (25.5)	75/331 (22.7)	77/340 (22.7)	0.62
Cardiovascular <sup>c</sup>	2 (0.6)	0	1 (0.3)	0.55	8 (2.4)	1 (0.3)	2 (0.6)	0.04
Fracture	4 (1.2)	2 (0.6)	2 (0.6)	0.68	11 (3.3)	4 (1.2)	4 (1.2)	0.11
Sprain/injury	2 (0.6)	1 (0.3)	2 (0.6)	1.00	8 (2.4)	4 (1.2)	5 (1.5)	0.51
Fall	0	0	0		8 (2.4)	4 (1.2)	2 (0.6)	0.13
Pain (back or lower limb)	23 (6.9)	20 (6.0)	16 (4.7)	0.48	65 (19.5)	65 (19.6)	70 (20.6)	0.93
<b>SAE spontaneously reported<sup>d</sup></b>	<b>(N = 1023)</b>				<b>(N = 1023)</b>			
SAE	3/338 (0.9)	1/339 (0.3)	3/346 (0.9)	0.65	10/338 (3.0)	5/339 (1.5)	11/346 (3.2)	0.30


a Chi-squared tests or Fisher exact tests were carried out to assess the statistical significance of the overall differences between the three groups.

b A total of 1005 participants gave permission at randomisation for their primary care records to be accessed and downloaded.

c Cardiovascular events recorded in primary care records included a new episode of any of the following: myocardial infarction, coronary artery bypass graft, angioplasty, ischaemic heart disease, angina, transient ischaemic attack and stroke.

d Information on spontaneously reported SAEs was collected for the entire cohort (i.e.  $n = 1023$ ). SAEs were recorded for safety purposes contemporaneously in the trial, and included the following: deaths, hospital admission and new-onset disability. All of the SAEs reported during the 0- to 12-month trial follow-up were emergency hospital admissions.


Adapted from Harris *et al.*<sup>93</sup> This is an open access article distributed in accordance with the terms of the Creative Commons Attribution (CC BY 4.0) license, which permits others to distribute, remix, adapt and build upon this work, provided the original work is properly cited. See: <http://creativecommons.org/licenses/by/4.0>.



**FIGURE 4** Subgroup analyses. (a) Postal group and control group; and (b) nurse-support group and control group. (continued)

## Summary of the main trial findings

Overall, 10% (1023/10,467) of those invited participated in the trial, and we had primary outcome data on 93% (956/1023) of participants at 12 months. Although the nurse-supported intervention had a greater effect on objective PA outcomes at 3 months, by the main 12-month outcome, both the postal and nurse-supported pedometer interventions significantly increased step counts by around 10%, and time in MVPA in bouts by around one-third compared with the control group, with no statistically significant difference between the interventions. There was no significant effect of the interventions on sedentary time or anthropometric measures. In terms of the effects on self-reported PA levels, the IPAQ MVPA questions did not show any intervention effect, but both the nurse-supported intervention and the postal intervention showed a significant effect on the IPAQ walking question. The GPPAQ score did not show an intervention effect, even when walking was included in the score. The interventions had no effect on most other patient-reported outcomes, except that exercise self-efficacy was increased in both intervention



**FIGURE 4** Subgroup analyses. (a) Postal group and control group; and (b) nurse-support group and control group.

groups at 3 months, and in the nurse-support group at 12 months, compared with the control group. AEs were not increased by the interventions; some individual AEs were lower in the intervention groups, but this was based on small numbers of events. No important subgroup effects were demonstrated, and the sensitivity analyses and imputations did not change the interpretation of the trial results.

The following chapters present the results relating to other aspects of the trial: the economic evaluation (see *Chapter 4*), generalisability and representativeness (see *Chapter 5*), the process evaluation (see *Chapter 6*), the qualitative evaluation (see *Chapter 7*) and the 3-year trial follow-up (see *Chapter 8*). *Chapter 9* discusses the trial findings in detail.



# Chapter 4 Economic evaluation

## Introduction

Evidence on the short- and long-term cost-effectiveness of pedometer-based interventions could support the development of policy and practice encouraging increased PA. Calls for evidence on 'what works' have been made, in both primary and secondary prevention policy documents, along with appeals to link interventions to clear health outcomes and ensure that resources are used most efficiently.<sup>94,95</sup>

To date, only one published estimate of the cost-effectiveness of pedometer programmes for the UK was based on primary evidence.<sup>58</sup> A small ( $n = 79$ ), highly selected (80% of women from one GP practice in Glasgow) sample was used. A 'maximal' pedometer-based walking programme, which included two 30-minute consultations (based on the transtheoretical model of behaviour change), was compared with a waiting list control group, which was asked to wait for 12 weeks, after which the group members received a 'minimal' walking programme, which included a pedometer and two 5-minute slots of brief advice.<sup>45,96</sup> Compared with the 12-week waiting list control group, it cost an additional £92 per person to achieve an additional eight people meeting the target of 15,000 steps per day over a 12-week period. Comparing the maximal walking programme with the minimal walking programme, it cost a further £591 for one additional person to achieve the same target. No data were collected on QALYs, and long-term cost-effectiveness was not modelled.

Elsewhere, in Australia, New Zealand and the Netherlands, evidence on the benefits of pedometer-based interventions for primary prevention has been assessed for community-based adults with low PA levels.<sup>97–99</sup> Interventions such as pedometer prescriptions and pedometer-based telephone coaching were compared with time-based activity prescriptions or usual practice. Evidence suggests that pedometers may be cost-effective in the long term, but estimates vary widely (from being cost-saving and having fewer disability-adjusted life-years in Australia in the long term to €11,110 per QALY gained). The generalisability of results to other contexts has also not been considered.<sup>100</sup>

This chapter examines the short- and long-term cost-effectiveness, from the NHS perspective, of alternative pedometer-based walking programmes to increase PA levels using PA outcomes for comparison with other PA programmes and QALYs to aid decision-making beyond PA programmes. The interventions are compared against usual practice, in inactive adults aged 45–75 years from south London, and are as described in *Chapter 2*:

1. provision, by post, of pedometers with written instructions
2. pedometers provided with tailored support from a practice nurse.

This chapter is structured into two sections: (1) a within-trial analysis with a time horizon of 1 year, and (2) beyond-trial modelling that takes a lifetime perspective. In each section, the methods and results are presented. This is followed by a discussion of the findings in the context of the strengths and weaknesses of the study, as well as current literature.

## Within-trial cost-effectiveness analysis

The population, interventions and comparator are identical to *Chapter 2*. Harris *et al.*<sup>70</sup> set out the protocol for methods, including for the economic evaluation. This section covers methods used to measure, value and aggregate costs and outcomes, the treatment of missing data and methods of assessing cost-effectiveness.

## Methods

### Identification, measurement, valuation and aggregation of cost

To identify NHS resource use, meetings with the trial team established 'who did what, to whom and how often',<sup>101</sup> accounting for events that are likely to have high unit costs, be frequent or differ between trial arms, and excluding research-focused costs. NHS resources identified for collection included:

- Set-up of service (e.g. design, setting up the intervention in GP practices and staff training, but excluding trial set-up; see *Appendix 3, Table 27*).
- Delivery of service, including, for example, pedometers, post/telephone services, handbooks and staff time; all costs fell within months 0–3, except research assistant contacts with participants (4–12 months; see *Appendix 3, Table 28*).
- Health service use in primary care (GP and nurse consultations, excluding nurse PA consultations undertaken as part of the trial) and secondary care (hospital admissions, A&E, outpatients), as changes could occur from treating AEs and changes in lifestyle (see *Appendix 3, Table 29*); the health service data were available on the 1005 out of 1023 randomised participants who gave written informed consent for their primary care data to be downloaded. Of these, 956 participants (323 in the control group, 312 in the postal group and 321 in the nurse-support group) also had 12-month outcome data and, therefore, were included in the health economic analyses relating to health service use.

Resource use was measured using administrative/trial management records, electronic diaries and interviews of the trial manager and the principal investigator. Participant-level health service use (e.g. GP visits, referrals) was collected through a one-time download of GP records, for those who gave explicit consent for this, at the end of the trial (see *Appendix 3, Tables 27–29*).

NHS resources were valued using national costs<sup>102,103</sup> (see *Appendix 3, Tables 27–33*) to increase generalisability. Where national unit costs were not available, local unit costs from St George's Hospital, London, were used. All costs were expressed in 2013–14 pounds sterling, inflated to the same base year when appropriate, using the Hospital and Community Health Service inflation index.<sup>103</sup> As the study covers 1 year, costs and outcomes were not discounted. All resources and costs were collected at, or apportioned to, the trial participant level. The total cost per participant was the sum of each resource use multiplied by the relevant unit cost over 0–3 and 4–12 months, with costs censored at 12 months.

To support a sensitivity analysis of an alternative wider viewpoint that included participants, as participation can be affected by economic barriers, three types of costs borne by participants were collected: participation in the intervention (e.g. time and money spent accessing the intervention for months 0–3; see *Appendix 3, Table 30*), money shown to contribute to the costs of 'walking' and other PA (e.g. membership/event fees, shoes/clothing, food/drink)<sup>104</sup> and money spent as a result of falls/fractures/sprains/injuries. These data were collected for months 1–3 using participant-completed questionnaires at 3 months and for months 10–12 using the participant-completed questionnaires at 12 months (see *Appendix 1*). As the data for months 10–12 were follow-up data beyond the intervention, costs from months 10–12 were multiplied by three (to approximate annual costs when added to the cost from months 1–3) and added to the costs from months 1–3 for an annual participant cost.

### Measurement, valuation and aggregation of outcomes

The economic analysis uses indicators of PA outcomes. The use of cost per additional step aids comparison of inputs with directly intended and objectively measured outputs, which the trial was specifically powered to detect, and which therefore relates the economics to the main trial outcome. As objectively measured weekly minutes of MVPA in bouts of  $\geq 10$  minutes were statistically significantly different, have important health impacts, provide a second point of comparison to other studies and link directly to the longer-term model, these were also included as an additional outcome measure for assessing cost-effectiveness.

To facilitate the comparison of the PACE-UP trial with other health interventions using the quality-of-life measure recommended for evaluating health interventions in England, participants also completed the EQ-5D-5L questionnaire at baseline, 3 and 12 months. The EQ-5D-5L, rather than the EQ-5D-3L (EuroQol-5 Dimensions, three-level version), was selected as the EQ-5D-3L is known to suffer from 'ceiling effects' and the five-level version was expected to be more sensitive to differences in health among healthier people and, therefore, less subject to suffer from ceiling effects. This has been subsequently shown to be the case in England, especially for older populations, and, therefore, the EQ-5D-5L has been recommended for use in general population surveys (despite the ceiling effects of dimensions ranging from 58–90%).<sup>105</sup> Utility weights were assigned at each time point, based on an interim scoring 'cross-walk' function<sup>106</sup> linked to the standard UK-based weights.<sup>107</sup> EuroQol-5 Dimensions (EQ-5D) utilities were converted to QALYs over the trial period using the 'area under the curve' method.<sup>108</sup>

## Methods of analysis

### *Missing data*

Data were investigated for patterns of missingness.<sup>109</sup> Mean imputation was used when the proportion of missing data was  $\leq 5\%$ .<sup>110,111</sup> Missing EQ-5D-5L data were replaced using an index, rather than domain imputation, as the sample size was  $> 500$ .<sup>112</sup> Multiple imputation by chained equations was fitted to replace item non-response. In line with Rubin's rules<sup>113</sup> and other recommendations,<sup>114,115</sup> the point estimate for imputations was derived by averaging estimates of the imputed data based on results from five imputations. The point estimate for categorical data was rounded up to the nearest decimal point. The imputation model included variables used in the main model for the analysis, while also including the predictors of missingness. The dependent variable was included in the imputation model to ensure that the imputed values have the same relationship to the dependent variable as the observed values.<sup>116</sup>

### *Incremental cost-effectiveness analyses*

Incremental cost-effectiveness analyses were based on multiple regression models to adjust for variations not accounted for by randomisation, and to provide more robust estimates. Generalised linear models (GLMs) were fitted separately for costs and QALYs,<sup>117</sup> accounting for the cluster effect (identified as household identifier) via clustered standard errors.<sup>118</sup> Models used for step count and MVPA have been described in *Chapter 2*. The cost models used the Poisson distribution and the QALY models used the binomial 1 family, equivalent to beta regression.<sup>119</sup> Although the generalised linear models do not account for the correlation between costs and QALYs, the efficiency loss (i.e. higher standard errors) will be minimal, as the inclusion of the cluster effect provides robust standard errors and mitigates the effects of potential inaccuracies in the family distribution used. The choice of distributional family rested on the modified Park test<sup>120</sup> and the comparison of observed and predicted values. Covariates included the baseline level (for QALY-based models), as recommended,<sup>116</sup> practice and variables found to be correlates of PA-related outcomes – that is, demography (age, sex, ethnicity, marital status, education, employment, socioeconomic status, cohabitation), health (number of disease conditions) and other lifestyle behaviours (smoking and alcohol intake).<sup>121</sup> Reduced models were generated using Wald tests to examine the joint significance of variables found to be insignificant in the base model. Significance levels were set at 5%.

To provide more precise estimates of uncertainty, the 'margins method' was used to generate sample means for trial arms and incremental point estimates for costs and QALYs.<sup>116,122</sup> A different standard error and calculated CIs<sup>123</sup> accounted for the cluster design.

### *Sensitivity analyses*

To reflect the stochastic uncertainty surrounding the mean incremental cost-effectiveness, cost-effectiveness planes and cost-effectiveness acceptability curves (CEACs) were constructed using 2000 non-parametric samples from the base-case estimates. Bootstrapping used a new unique identifier for the clusters in addition to the original cluster identifier (household ID).<sup>116</sup>

Deterministic sensitivity analyses performed included:

- all randomised participants (not only those who provided accelerometry data)
- varying exclusion of costs of health service use beyond the immediate intervention
- a method of accounting for AEs
- only spontaneously self-reported SAEs
- only GP data relating to AEs; these were predefined by GP investigators and collaborators (TH, SI, SDW, JI) as possibly being related to increased walking, and included musculoskeletal events (falls requiring medical attention, fractures, sprains or injuries, pain in back or lower limb) and cardiovascular events [myocardial infarction, coronary artery bypass graft, angioplasty, stroke, transient ischaemic attack or new-onset ischaemic heart disease (angina)]
- a perspective of analysis (i.e. NHS with or without users)
- variation in the length of the life of a pedometer (between 1 and 4 years)
- scenario combinations (excluding all health service use costs, and including participant costs related to participation in PA and interventions, except the health service use cost borne by participants), to ensure that the long-run model could use evidence of 'worst-case' findings.

## Results

Table 9 summarises the data on costs, EQ-5D-5L utility scores and quality of life (see Appendix 3, Tables 31–35). At 3 months, the average cost per participant was highest in the nurse group (£249), followed by the postal group (£122) and the control group (£107). The mean cost and distribution is affected considerably by the inclusion of health service use, which resulted in the control group costing £36 more per participant than the postal group and £12 more than the nurse-support group. QALYs varied marginally, with the gap being the greatest between the control and postal groups at +0.002. At 12 months, the average cost per participant was highest in the nurse group (£603), followed by the control group (£461) and the postal group (£375). The inclusion of health service use resulted in the control group costing £86 more per participant than the postal group, but £142 less than the nurse-support group. QALYs were marginally higher in the postal group (0.843 QALYs) than in the control group (0.837 QALYs) and the nurse-support group (0.836 QALYs) group.

The main results (Table 10), which are adjusted for baseline differences, show that, at 3 months, the cost of the nurse-support group was statistically significantly higher than that of the control group (£135, 95% CI £99 to £171), whereas this was not the case for the postal group (£15, 95% CI –£15 to £45). Table 10 also shows that there was a statistically significant increase in daily steps and minutes of MVPA in  $\geq 10$ -minute bouts for the intervention groups compared with the control group. The ICER per additional minute of MVPA in  $\geq 10$ -minute bouts was £0.35 for the postal group and £2.21 for the nurse-support group, compared with the control group. However, both intervention groups accrued slightly fewer QALYs than the control group (postal group: –0.0005 QALYs; nurse-support group –0.0004 QALYs), although this difference was not statistically significant. Nevertheless, it contributed to the dominance (lower costs and more QALYs) of the control group compared with both intervention groups at 3 months.

Comparing the two interventions at 3 months (see Table 10) shows that the nurse group achieved 481 more steps (95% CI 153 to 809 steps) and 18 more minutes of MVPA (95% CI 1 to 35 minutes) per person than the postal group, at a statistically significant additional cost of £120 (95% CI £95 to £146). The estimated cost per additional step and additional MVPA minute (in bouts of  $\geq 10$  minutes) was £0.25 and £6.67, respectively. The nurse-support group had slightly fewer QALYs, although this was not significantly different (0.0004 QALYs, 95% CI –0.0026 to 0.0018 QALYs); however, it contributed to the nurse-support group being dominated (higher costs and fewer QALYs) by the postal group.

The main results at 12 months (see Table 10) were somewhat different from those at 3 months. Although the mean costs were lower for the postal group (–£91, 95% CI –£213 to £33) and higher for the nurse-support group (£126, 95% CI –£37 to £290) than the control group, neither was statistically

**TABLE 9** Average costs and QALYs per participant, by trial arm (£2013–14, base case, with missing values imputed)

Cost and quality of life (EQ-5D-5L)	Trial arm, mean (SD)		
	Control	Postal	Nurse support
<b>0–3 months</b>	<b>(N = 318)</b>	<b>(N = 317)</b>	<b>(N = 319)</b>
<i>Costs (£)</i>			
Total cost	107 (254)	122 (107)	249 (215)
Set-up cost	0 (0)	45 (0)	105 (0)
Delivery of intervention	0 (0)	7 (0)	50 (18)
Health service use	107 (254)	71 (107)	95 (214)
<i>Quality of life</i>			
EQ-5D-5L scores at baseline	0.839 (0.14)	0.853 (0.12)	0.851 (0.12)
EQ-5D-5L scores at 3 months	0.844 (0.14)	0.848 (0.14)	0.841 (0.14)
QALYs, 0–3 months	0.194 (0.03)	0.196 (0.03)	0.195 (0.03)
<b>0–12 months</b>	<b>(N = 323)</b>	<b>(N = 312)</b>	<b>(N = 321)</b>
<i>Costs (£)</i>			
Total cost	461 (916)	375(611)	603 (987)
Set-up cost	0 (0)	45 (0)	105 (0)
Delivery of intervention	0 (0)	10 (0)	52 (18)
Health service use	461 (916)	320 (611)	447 (987)
<i>Quality of life</i>			
EQ-5D-5L scores at baseline	0.837 (0.14)	0.850 (0.12)	0.849 (0.13)
EQ-5D-5L scores at 3 months	0.840 (0.14)	0.847 (0.13)	0.837 (0.14)
EQ-5D-5L scores at 12 months	0.833 (0.15)	0.836 (0.13)	0.831 (0.14)
QALYs, 0–12 months	0.837 (0.13)	0.843 (0.11)	0.836 (0.13)

**TABLE 10** Costs, effects and cost-effectiveness at 3 and 12 months (£2013–14; base case, adjusted for baseline differences)

Cost, effects or cost-effectiveness	Trial arm, mean (95% CI)			Nurse support vs. postal delivery, mean (95% CI)
	Control	Postal delivery <sup>a</sup>	Nurse support <sup>a</sup>	
<b>Costs and effects over 3 months</b>				
Total cost per participant (£)	108 (80 to 136)	123 (111 to 135)	244 (221 to 266)	–
Incremental cost (£)	–	15 (–15 to 45)	135 (99 to 171)	120 (95 to 146)
Total QALYs per participant	0.1957 (0.1936 to 0.1978)	0.1952 (0.1930 to 0.1974)	0.1948 (0.1926 to 0.1970)	–
Incremental <sup>b</sup> QALYs	–	–0.0005 (–0.0027 to 0.0016)	–0.0009 (–0.0031 to 0.0012)	–0.0004 (–0.0026 to 0.0018)

continued

**TABLE 10** Costs, effects and cost-effectiveness at 3 and 12 months (£2013–14; base case, adjusted for baseline differences) (*continued*)

Cost, effects or cost-effectiveness	Trial arm, mean (95% CI)			Nurse support vs. postal delivery, mean (95% CI)
	Control	Postal delivery <sup>a</sup>	Nurse support <sup>a</sup>	
Incremental daily steps	–	692 (363 to 1020)	1172 (844 to 1501)	481 (153 to 809)
Incremental weekly minutes of MVPA in bouts of ≥ 10 minutes	–	43 (26 to 60)	61 (44 to 78)	18 (1 to 35)
<b>Costs and effects over 12 months</b>				
Total cost per participant (£)	467 (365 to 569)	376 (307 to 445)	593 (473 to 714)	–
Incremental cost (£)	–	–91 (–215 to 33)	126 (–37 to 290)	217 (81 to 354)
Total QALYs per participant	0.842 (0.832 to 0.853)	0.838 (0.827 to 0.849)	0.836 (0.824 to 0.847)	–
Incremental QALYs	–	–0.004 (–0.017 to 0.009)	–0.007 (–0.020 to 0.007)	–0.002 (–0.016 to 0.011)
Incremental daily steps	–	642 (329 to 955)	677 (365 to 989)	36 (–227 to 349)
Incremental weekly minutes of MVPA in bouts of ≥ 10 minutes	–	33 (17 to 49)	35 (19 to 51)	2 (–14 to 17)
<b>ICER<sup>a</sup> at 3 months</b>				
Cost per additional QALY (£)	–	<i>Postal delivery dominated by control</i>	<i>Nurse support dominated by control</i>	<i>Nurse support dominated by postal delivery</i>
Cost per additional step count (£)	–	0.02	0.12	£0.25
Cost per additional minute of MVPA in a bout of ≥ 10 minutes (£)	0.35	0.35	2.21	£6.67
<b>ICER<sup>a</sup> at 12 months</b>				
Cost per additional QALY (£)	–	<i>Postal delivery is less costly but has fewer QALYs. £21,162 saved per QALY lost</i>	<i>Nurse support dominated by control</i>	<i>Nurse support dominated by post</i>
Cost per additional step count (£)	–	<i>Postal delivery dominates control</i>	0.19	6.03
Cost per additional minute of MVPA in a bout of ≥ 10 minutes (£)	–	<i>Postal delivery dominates control</i>	3.61	109.00


<sup>a</sup> For incremental analyses, the comparisons are postal delivery vs. control and nurse support vs. control.

significantly different. However, the increase in the cost of moving from postal delivery to nurse-support delivery was statistically significantly higher (£217, 95% CI £81 to £354). Although both interventions were associated with a statistically significant increase in both step count and weekly minutes of MVPA in ≥ 10-minute MVPA bouts compared with the control group, the difference between intervention groups was not statistically different at 12 months. The postal group took more steps on average (+ 642 steps)


and cost less on average (–£91) than the control group, and dominated the control group in terms of the PA outcomes. Compared with the control group, the nurse-support group cost an additional £0.19 per step and £3.61 per additional minute of MVPA in bouts of  $\geq 10$  minutes. None of the small decrements in QALYs at each incremental comparison (–0.0009 QALYs for the postal group vs. the control group, –0.0007 QALYs for the nurse-support group vs. the control group and –0.0004 QALYs for the nurse-support group vs. the postal group) was statistically significantly different. Compared with the control group, the postal group had fewer QALYs (although this was not statistically significantly different) and lower costs (also not statistically significantly different). However, the magnitude of the cost-savings is such that they outweigh the forgone QALYs at a threshold of £20,000 per QALY, and would be considered cost-effective. Using QALYs, the nurse-support group is dominated by both the control group and the postal group.

Comparing the two interventions at 12 months (see *Table 10*) shows that the estimated cost per additional step and additional MVPA minute was £6 and £109, respectively, and that, in terms of QALYs, the nurse-support group was still dominated by the postal delivery group.


The cost-effectiveness planes (*Figures 5 and 6*; see also *Appendix 3, Figure 19*) broadly confirm the findings that the postal delivery group had a strong likelihood of lower costs, but also fewer QALYs, and that the nurse-support group tended to have fewer QALYs and higher costs than the control group. However, different levels of uncertainty surround these mean estimates, as reflected in the CEACs (*Figure 7*; see also *Appendix 3, Figure 20*). At £20,000 per QALY, the postal delivery group has a 50% chance of being cost-effective compared with the control group, which falls to 42% at £30,000 per QALY. This is because, as the willingness-to-pay threshold increases (and, therefore, the higher the value that is placed on forgone QALYs), the value of QALYs lost begins to outweigh the cost-savings (see *Figure 9*). This is reflected in the CEAC, on which the probability moves towards zero. The nurse-support group had only a 5.5% chance of being cost-effective compared with the control group at a willingness-to-pay threshold to gain, or give up, a QALY of £20,000, and this fell to 4.9% when compared with the postal delivery group.



**FIGURE 5** Cost-effectiveness plane for the postal delivery group vs. the control group at 12 months.



**FIGURE 6** Cost-effectiveness plane for the nurse-support group vs. the control group at 12 months.



**FIGURE 7** Cost-effectiveness acceptability curve for the postal delivery and nurse-support groups (vs. the control group) at different willingness-to-pay-per-QALY thresholds.

The deterministic sensitivity analyses (see *Appendix 3, Table 36*) show that, with the exceptions of (1) using health service use including only self-reported serious adverse effects, (2) excluding all health service costs, (3) changing perspective (including all participant costs) and (4) the worst-case 'combined scenario', the sensitivity analyses produced results that were consistent with the base-case findings. For the exceptions, the postal delivery group was dominated by the usual-care control group at 12 months.


## Beyond-trial modelling

Systematic reviews have indicated the positive influence that PA has on primary prevention for a range of conditions, including coronary heart disease (CHD), stroke, type 2 diabetes mellitus and cancers,<sup>124–128</sup> and, more recently, for improving cognition in older adults.<sup>129</sup> Carlson *et al.*<sup>5</sup> have separately shown that increasing amounts of leisure time PA is associated with decreasing health expenditure. Therefore, by reducing the risk of disease, increased PA can increase future QALYs, as well as lower future costs. The next section provides the methods used to estimate the long-term cost-effectiveness of the PACE-UP trial.

## Methods

An existing Markov model,<sup>130</sup> designed to assess the cost-effectiveness of PA interventions, was used. This model has evolved from assessing the cost-effectiveness analysis of exercise referral schemes<sup>131–133</sup> to brief interventions<sup>129</sup> and beyond.<sup>134</sup> It has been used by NICE to update national guidance (PH44 on brief interventions, PH2 on exercise referral schemes guidance)<sup>36,135</sup> and is the basis for the NICE Return on Investment Tool<sup>136</sup> used by local authorities.

The model is driven by evidence of the impact that PA interventions have on the proportion of people meeting the recommended PA levels, short-term quality-of-life gains (associated with meeting the recommended PA levels) and the impact of PA on future rates of CHD, stroke and type 2 diabetes mellitus. *Figure 8* shows the pathways within the model. In the original Markov model,<sup>129</sup> a cohort of 100,000 33-year-old people were followed in annual cycles over their lifetime. At the end of the first year of the model, the cohort would be either 'active' (doing 150 minutes of MVPA per week) or 'inactive', and could have had one of three events (non-fatal CHD, non-fatal stroke, type 2 diabetes mellitus), remain event free (i.e. without CHD, stroke or diabetes mellitus) or die, either from cardiovascular disease (CVD) or from non-CVD-related causes. Active individuals have a better life expectancy and quality of life, attributable to lower risks of developing CHD, stroke and type 2 diabetes mellitus. People who become active in the first year (irrespective of the trial arm) accrue a one-off utility gain associated with achieving the recommended level of PA. QALYs reflect the health outcomes from a reduced risk of disease. A discount rate of 3.5% per annum is used for costs and QALYs, as recommended by NICE, and the analysis is conducted from a NHS perspective. Full details of the model are provided in *Appendix 3* and elsewhere.<sup>130</sup>



**FIGURE 8** Illustration of pathways within the long-term cost-effectiveness model.<sup>130</sup>

The model by Anokye *et al.*<sup>130</sup> was adapted for use in five ways:

1. The population begins with the mean age of the trial population (i.e. 59 years rather than 33 years) and was followed to 88 years (average life expectancy at 59 years in the UK).<sup>137</sup> This change was also reflected in the age-specific estimates used.
2. The intervention was either pedometer plus nurse support or a posted pedometer.
3. Within-trial costs were used, with a second year of annuitised values added for the intervention arms (£5.03 per person for the postal delivery group and £4.14 per person for the nurse-support group – the number of pedometers to the postal delivery group was relatively higher as a result of more replacements), as the trial analysis had assumed pedometers lasted 2 years.
4. Effectiveness estimates from the PACE-UP trial were used as follows: the probability of moving from an inactive to an active state was based on estimated relative risks (RRs) for achieving 150 minutes of MVPA in  $\geq 10$ -minute bouts over 7 days at 12 months. RRs of achieving  $\geq 150$  minutes of MVPA in  $\geq 10$ -minute bouts at 12 months were estimated from ORs using the formula  $OR / [(1 - P_{ref}) + (P_{ref} \times OR)]$ , in which  $P_{ref}$  is the proportion of all subjects achieving 150 minutes of MVPA in  $\geq 10$ -minute bouts at baseline (i.e.  $218/1023 = 0.21$ ). The OR was derived from a logistic regression model in which achieving 150 minutes of MVPA in bouts of  $\geq 10$  minutes at 12 months was regressed on baseline minutes of MVPA in bouts of  $\geq 10$  minutes, month of baseline accelerometry, age, sex, general practice and treatment group, with household as a cluster.
5. The short-term psychological benefits associated with achieving 150 minutes of MVPA per week used trial data; incremental EQ-5D-5L scores (at 12 months) for active people were regressed, via beta regression, on EQ-5D-5L scores at baseline, ethnicity, education, employment status, intervention group, practice and disability.

Other parameters were informed by estimates from the original model. Cost and utility estimates for disease conditions were originally sourced from literature reviews of economic evaluations conducted for NICE on CVD and diabetes mellitus.<sup>5</sup> Estimates for the health impacts of PA were taken from national/international evidence-based guidance on PA and health, such as the US *Physical Activity Guidelines Advisory Committee Report, 2008*.<sup>138</sup> *Appendix 3, Table 37* details all parameter values.

The probabilistic sensitivity analysis (PSA) addressed the uncertainties around all parameters in the model (except for baseline mortality, as the mortality census data have little uncertainty). A total of 10,000 Monte Carlo simulations were used to generate stable estimates. Given that the within-trial sensitivity analysis showed the decisional influence of some assumptions, a deterministic sensitivity analysis using the lifetime model explored two alternative, conservative scenarios:

- Scenario 1 – combined exclusion of all health service use costs during the trial period (year 1 of the model), with no short-term QALY gain associated with achieving the recommended level of PA. This was considered as a result of the uncertainty around short-term changes to health service use, and because previous studies found the exclusion of short-term QALY gain associated with being physically active to the recommended level to be decisional.<sup>5,129</sup>
- Scenario 2 – scenario 1 plus user costs related to participation in PA and the interventions. This combination represented a ‘worst-case’ scenario in the trial. Although this perspective is not one adopted by NICE, it represents the most conservative scenario based on this evidence.

## Results


*Table 11* shows that the postal delivery group dominated both usual practice and the nurse-support group, as the lifetime costs were lower and the number of QALYs was greater. The stochastic uncertainty associated with the mean ICER (*Appendix 3, Figure 21*) indicates that these findings are robust, as there is a 100% likelihood, at a willingness-to-pay threshold of £20,000 per QALY, that the postal delivery group is cost-effective compared with the control group and with the nurse-support group (*Figure 9*). This is consistent with the net monetary benefit estimates, which show that, although we can be 95% confident

**TABLE 11** Costs, effects and cost-effectiveness over a lifetime (cohort of 100,000)

Costs, effects and cost-effectiveness	Trial arm, mean (95% CI)			
	Control	Postal delivery <sup>a</sup>	Nurse support <sup>a</sup>	Nurse support vs. postal delivery
<b>Cost</b>				
Lifetime total cost (£M) <sup>b</sup>	340 (307 to 371)	329 (296 to 361)	351 (318 to 384)	–
Lifetime incremental cost (£M)	–	–11 (–12 to –10)	11 (10 to 12)	22 (21 to 23)
<b>QALYs</b>				
Lifetime total QALYs (million)	1.07 (0.88 to 1.30)	1.07 (0.88 to 1.30)	1.07 (0.89 to 1.30)	–
Lifetime incremental QALYs	–	759 (400 to 1247)	671 (346 to 1071)	–108 (–223 to –10)
Lifetime ICER for QALYs (£)	–	Postal delivery dominates control	16,368	Postal delivery dominates nurse support
Lifetime incremental net monetary benefit (£M, @ £20,000 per QALY)	–	26 (18 to 36)	2 (–5 to 11)	–24 (–27 to –21)

a For the incremental analyses, the comparisons are postal delivery vs. control and nurse support vs. control.

b £46.7M, £37.6M and £59.3M of the total costs are attributed to the costs of the control, postal delivery and nurse-supported interventions, respectively, estimated from the within-trial analysis.

**FIGURE 9** Cost-effectiveness acceptability curve showing the probability of lifetime cost-effectiveness for the postal delivery group and the nurse-support group (vs. the control group) at different willingness-to-pay threshold levels.

that the postal delivery group is better than the control group and the nurse-support group, we cannot be 95% confident that the nurse-support group is better than the control group.

The results for scenario 1 of the sensitivity analyses for the 100,000 cohort were as follows:

- postal delivery group versus control group – postal delivery moved from a dominant position to being a more expensive option (+£4M) with greater QALY gains (+609 QALYs) and an ICER of £6100
- nurse-support group versus control group – the ICER increased from £16,000 to £26,000 (+£14M, +538 QALYs)
- nurse-support versus postal delivery group – the nurse-support group remained dominated by the postal delivery group (+£10M, –87 QALYs).

For scenario 2, the sensitivity analyses for the 100,000 cohort showed the following:

- postal delivery group versus control group – the postal delivery group moved from a dominant position to being more expensive (+£16M) with greater QALY gains (+609 QALYs) and an ICER of £26,600
- nurse-support group versus control group – the ICER increased from £16,000 to £25,400 (+£13.7M; +538 QALYs)
- nurse-support group versus postal delivery group – the nurse-support group moved from a dominated position to a cost-effective position (–£2M, –87 QALYs).

## Discussion

The within-trial analysis shows that, at 3 months, compared with the control group, both interventions cost something to achieve increases in PA. Compared with the control group, the postal delivery group cost an additional £0.02 per additional step gained to an average of + 692 steps per day, which was a cheaper buy than the nurse-support group (at £0.12 per additional step). However, the nurse-support group achieved more steps on average, and the additional 448 steps were achieved at an incremental cost of £0.25 per step. Although this pattern of results was replicated for additional minutes of MVPA (in bouts of 10 minutes), the results for QALYs were very different as both intervention groups were dominated by the control group (i.e. the control group cost less and had more QALYs).

The main results at 12 months were different, leaning more favourably towards the postal intervention. Compared with the control group, the postal delivery group achieved statistically significantly better PA outcomes, and did so at a lower cost. This was much better than the results for the nurse-support group, and the insignificant difference in PA outcomes between the nurse-support and postal delivery groups at 12 months implied very high costs per additional step (£6.00). The analysis of the costs per QALY confirmed that the nurse-support group was not a cost-effective alternative. It also showed that, although the postal delivery group has fewer QALYs (although not statistically different) and lower costs (with costs saved higher than £20,000 per QALY), the postal delivery group could be considered to be cost-effective. Assuming a value of £20,000 per QALY, there was a 50% probability that the postal delivery group was cost-effective compared with the control group, and a 5% probability that the nurse-support group was cost-effective compared with the control group or the postal delivery group at 1 year. The sensitivity analyses did not change the conclusions, except in three cases (using self-reported SAEs, excluding health service use, but including all participant costs), when the postal delivery group was dominated by the usual-care control group.

The lack of evidence on effectiveness in terms of quality-of-life outcomes is not necessarily evidence of no effect, as the trial was not powered to detect a change in quality of life. The results indicate a lot of variation around the change in QALYs (95% CI –0.017 to 0.009 QALYs) and we are aware of some ceiling effects at baseline (98% self-care, 83% usual activities, 79% mobility, 73% anxiety, 43% pain). Although this might contribute to raising questions about the relevance of general quality-of-life measures for capturing the quality-of-life impacts of public health interventions within the first year, it also serves to highlight the importance of capturing the QALY impact of public health interventions on disease avoidance in longer-term economic models. Cost-per-QALY results from short-term public health trials have the potential to mislead decision-makers on the efficiency of investments in the context of changes that lead to longer-term reductions in the risk of disease.

A lifetime cost-effectiveness model characterised the long-term impact of PA interventions on CHD, stroke and type 2 diabetes mellitus.<sup>129</sup> This showed that the postal delivery group would dominate both the control group and the nurse-support groups, as quality-of-life gains (759 QALYs, 95%CI 400 to 1247 QALYs) add to increased cost-savings (–£11M, 95% CI –£12M to –£10M), resulting in an incremental net monetary benefit of £26M (95% CI £18M to £36M) for a 100,000 cohort. There was a 100% likelihood that the postal intervention was cost-effective compared with the control group and the nurse-support

group. The conservatively framed deterministic scenario analyses showed that excluding both the short-term reduction in health service use and the utility gain seen in the trial would not alter the main conclusion that the postal delivery group would be an extremely cost-effective intervention (ICER of £6100 per QALY). Even taking the unusual step of including participant costs did not raise the ICER beyond a threshold value of £30,000 per QALY.

### Strengths and weaknesses

To our knowledge, this is the first published study of short- and long-term costs and effects of a pedometer intervention. Its strengths are the use of detailed individual-level cost and effectiveness data from a well-designed population-based RCT, which had nearly complete (93.4%) follow-up data to 1 year, to estimate the cost per QALY at 1 year, and also to input into a lifetime model of cost-effectiveness. It also included both provider and user perspectives in costing service provision and participation, which allowed the impact of perspective to be investigated, and which provides a basis for further investigation of the role of cost in its association with participation in PA. The estimates of uncertainty extended commonly used techniques to account for increased precision in the context of clustered data. The sensitivity analysis pushed both the short- and long-term analyses to very conservative outcomes given the trial data and, therefore, provides a good indication of the robustness of findings based on the current evidence.

The weakness of the within-trial cost-effectiveness study connects to the cost of health service use over the period of the trial; no information was available on the severity or procedures used for hospital admissions, or cause of admission to the A&E department. We relied on the principal investigator's 'best guess' or 'nearest appropriate code' (while blind to the treatment group) and on averaging across elective/non-elective admissions and we therefore explored alternative assumptions in our sensitivity analyses. There was considerable variation in costs in each trial arm, and the trial was not powered to detect a difference. Data were also not collected on costs to participants for months 4–9, and the last 3 months were multiplied to represent the missing data. These may have over- or underestimated participant costs and, if significantly underestimated, could be decisionally important. With respect to the long-term modelling, the model assumes that people would revert to PA patterns observed in long-term cohort studies. This estimate could be improved with longer-term trial data. All the challenges set out in previous work<sup>130</sup> are also relevant here (e.g. some diseases, such as cancer and AEs, are not accounted for, which could lead to either over- or under-estimation of cost-effectiveness).

The study feeds into an area sparse of primary data<sup>139,140</sup> populated only by small studies.<sup>95,96</sup> Leung *et al.*<sup>97</sup> showed a 95% likelihood that pedometers would be a cost-effective addition to green prescriptions (in New Zealand) at 12 months, which is much higher than the 50% likelihood that we found. Our study also provides long-term estimates based on the population-level primary data for comparison with the larger body of cost-effectiveness estimates<sup>134</sup> from decision models.<sup>97,98,141,142</sup> Some have identified cost-savings and an improved quality of life at a population level from pedometers in the long term.<sup>98,137</sup> Others<sup>97,138</sup> have indicated high probabilities that pedometers will be cost-effective in the long term, with Brennan *et al.*<sup>142</sup> indicating that, even with long-term support at £25 per year (for monitoring and support), ICERs fell well below £10,000 per QALY gained. Our study provides further support to indicate that pedometer-based programmes are a cost-effective method of improving health.

### Conclusion

A range of sensitivity analyses of both short- and long-term cost-effectiveness confirmed the view that postal delivery of pedometer interventions to people aged 45–75 years through primary care has a high chance of being cost-effective in the long term and has a 50% likelihood of being cost-effective, through resource-savings from changes in health service use, within 1 year. Further research is needed to ascertain the level of maintenance of PA beyond 1 year and the impact of PA on quality of life and general health service use in both the short term and long term.



# Chapter 5 Generalisability

## Introduction

Although the numbers of adults achieving the recommended PA levels are generally low,<sup>9</sup> there are marked differences between groups, with lower PA levels in women, older people and those from socioeconomically deprived areas and of Asian ethnicity.<sup>9,143</sup> Walking interventions aiming to increase PA levels ideally need to try to ensure that these groups are well represented. When participation rates are low,<sup>144–146</sup> there may be systematic differences between those who participate and those who do not, but to whom the intervention could reasonably be applied. Failure to include certain groups of people for whom PA levels are lower may lead to the implementation of interventions that are likely to increase health inequalities. When there are differences between participants and non-participants, exploring the reasons for non-participation using a qualitative approach can be instructive.

The population-based sampling frame used in this study provided an opportunity to assess whether or not there were differences in terms of age, sex, ethnicity and area-level deprivation between general practice patients who replied to the invitation letter compared with those who did not. We also compared the health, lifestyle, education and social factors of those who agreed to participate in the trial with those who agreed to complete a questionnaire, but who did not wish to participate (see *Appendix 4* for the non-participant questionnaire). These findings are now published.<sup>147</sup> Qualitative interviews with a sample of this latter group allowed us to investigate the reasons for non-participation in the trial, and these findings are also published.<sup>148</sup>

## Methods


### *Data collection for quantitative comparisons*

The sex, age and IMD score of all those invited were collected from general practice records. The IMD score is an anonymised measure of deprivation based on postcode.<sup>71</sup> To avoid the possibility of individuals being identified, aggregated practice-recorded ethnicity was exported from the practice in 10-year age bands for all batches where everyone was mailed, less exclusions ( $n = 10,155$ ). Those not wanting to participate in the trial were asked in their invitation letter if they were willing to complete a shortened version of the trial baseline questionnaire, including questions on demographics, health, PA levels and a question on reasons for not participating. The following categories were offered, based on previous research, with space to add other reasons for trial non-participation: (1) I do not have time, (2) I cannot increase my PA, (3) I am not interested in increasing my PA, (4) I am already very physically active, (5) I am not interested in research and (6) I do not want to be put in a group by chance.

### *Comparison groups*

Individuals whose invitation letters were 'returned to sender' were excluded from the analyses before calculating response rates. 'Responders' are defined as those who replied to the invitation letter, regardless of whether or not they wanted to take part. Individuals could respond by post, e-mail or telephone. 'Participants' are those who completed the baseline assessment, although not all were randomised as some provided inadequate accelerometry data. 'Non-participants' are those who completed a questionnaire but did not wish to participate in the trial (*Figure 10*).

As the PACE-UP trial targeted inactive adults, participants who attended a baseline appointment were selected on the basis of their low PA levels. Non-participants were not selected in this way. In order to minimise selection bias, the quantitative analysis of participants and non-participants was therefore restricted to those categorised as 'not active' according to a self-reported primary care PA questionnaire, the GPPAQ,<sup>73</sup> which was the only PA measure available for both groups.



**FIGURE 10** Flow chart to show the recruitment process in the PACE-UP trial. All percentages are out of all of those whose age and sex were matched with GP records ( $n = 10,927$ ).

### Statistical analysis

Age- and sex-standardised rates were used to compare IMD quintiles for responders. Similarly, sex-standardised rates were used to compare age groups and age-standardised rates were used to compare sexes. The full population of invitees was used as a standard population throughout. No further analysis on non-responders was possible because they did not provide any questionnaire data on ethnicity or other factors.

Practice ethnicity data were available in 10-year age bands for 10,155 invitees, which was effectively a random sample of the 11,015 people invited to participate. The proportion of patients belonging to each ethnicity category within each age band and within each practice was calculated, and the number of invitees in each ethnicity in each practice and age band was estimated. Overall, 1903 invitees had ethnicity recorded as 'unknown'. These are assumed to be missing at random in the main results, but sensitivity analyses were performed assuming that these were all white people or all non-white people. Age-standardised participation rates for not-active participants and non-participants completing questionnaires were calculated, assuming that invitees gave the same ethnicity on the questionnaire as was recorded in their practice records. Participation rates by age, sex and IMD score were calculated for not-active participants versus not-active non-participants completing questionnaires, as in the analysis of responders.

Not-active participants and non-participants completing the questionnaire were compared for additional demographic and social characteristics, and health and lifestyle factors, using logistic regression. All data came from the questionnaires. Models were adjusted for clustering by practice and household, by including fixed effects for practice and using robust standard errors for household.

### **Methods for the interview study of non-participants**

This is fully described elsewhere.<sup>148</sup> Non-participants completing the questionnaire were asked if they could be contacted to discuss their reasons in more detail. A purposive sample of those willing to be contacted was selected to provide men and women of varying ages, ethnicities and employment status from the initial six participating practices. To maximise participation, we used focused telephone interviews; permission was gained for interviews to be audio-recorded. The topic guide was developed from the literature, from the previous PACE-LIFT trial qualitative evaluation<sup>21,149</sup> and discussions between the authors, and is published<sup>148</sup> and provided in *Appendix 4*. Approximately 30 interviews were planned, with recruitment continuing until no new themes were identified and a demographically balanced sample had been achieved. Open questions were asked about what influenced their decision not to participate and their opinions on the trial information received. Responses given on the completed questionnaires were used as a starting point to further explore their reasons. They were asked general questions about the perception of the trial design and were invited to make any final comments.

### **Methods for analysing interviews**

Audio-recordings were transcribed verbatim and checked for accuracy. After 10 interviews, researchers (Rebecca Holmes, TH and CV) read the transcripts and discussed the interviews. The interview technique was then modified slightly to ensure that interviewees understood the trial randomisation process, as several participants had appeared not to understand the question about whether or not being put in a group by chance had influenced their decision not to participate. On completion of the interviewing, the transcripts were read and re-read for familiarisation by the researchers, who assigned codes (RN and TH), before a thematic framework was produced.<sup>150</sup> Coding discrepancies between researchers were resolved by discussion. The framework produced was informed both by a priori issues, mostly related to trial design, and by emerging themes. Themes were refined further by discussion between authors (Rebecca Holmes, TH, RN and CV), and broader categories, encompassing several subthemes, were generated. Reasons for declining given by all non-participants were also compared with those given at interview, to put our findings in a wider context and assess the generalisability to all of those actively declining.

## **Results**

### **Results from quantitative comparisons**

Of the 12,625 individuals selected for screening (see *Figure 10*), 1421 (11.3%) were excluded by practice staff and 189 (1.5%) had invitation letters that were returned, as they had moved away; both of these groups were classified as 'not invited'. In the 44 households where one person refused the invitation and the other did not respond, it was impossible to match the response to individual invitees within the household, so age and sex are unknown. These 88 people have been excluded from further analyses.

Of the remaining 10,927, 4572 (42%) responded to the invitation letter, mainly by post, and 1150 (11%) completed the baseline assessments.

Of all invitees, 5229 (48%) were aged 45–54 years. Although all quintiles of deprivation were represented, only 7% were in the most deprived quintile. Response rates were higher in older people, women and those living in less deprived areas (*Table 12*). As individual ethnicity was available only for the participants and non-participants who completed a questionnaire, it was not possible to estimate response rates by ethnicity for all responders.

Although the GPPAQ was not used to assess PA levels for trial inclusion, it was the only PA measure available for both participants and non-participants. A total of 118 participants and 388 non-participants were classified as active by the GPPAQ, and 134 people did not complete the GPPAQ. These people were excluded from further analysis, leaving 924 participants and 715 non-participants.

Similar to the response rates, participation rates were higher in older people, women and those living in less deprived areas. (*Table 13*). Ethnicity was extracted from the practice for 10,155 invitees. Of these, 5991 were recorded as white (59%), 893 (9%) were recorded as Asian or British Asian and 915 (9%) were recorded as black Caribbean, black British or black African. A total of 1903 (18.7%) were recorded as 'unknown'. The percentage of people with 'unknown' ethnicity varied by practice from 3% to 48%. *Table 13* shows the estimated number in each ethnicity category for all 10,927 invitees, assuming that those for whom ethnicity was recorded as 'unknown' and those for whom we were not able to collect ethnicity have the same ethnicity distribution as the group with known ethnicity.

**TABLE 12** Responders to the invitation letter by age, sex and IMD quintile

Characteristic	All invitees ( <i>N</i> = 10,927), <i>n</i> (%)	Responders to the invitation ( <i>N</i> = 4572)		
		<i>n</i>	Standardised percentage response <sup>a</sup> (95% CI)	Ratio of response rates (95% CI)
Age (years)				
45–54	5229 (47.8)	1698	33.4 (32.1 to 34.7)	0.57 (0.54 to 0.60)
55–64	3367 (30.8)	1535	46.2 (44.5 to 47.9)	0.79 (0.76 to 0.84)
65–75	2331 (21.3)	1339	57.8 (55.8 to 59.8)	1.00
Sex				
Female	5604 (51.3)	2638	46.7 (45.4 to 48.0)	1.00
Male	5323 (48.7)	1934	36.8 (35.5 to 38.1)	0.80 (0.76 to 0.84)
IMD national quintile <sup>b</sup>				
1 (most deprived)	712 (6.8)	207	29.5 (26.2 to 32.8)	0.55 (0.50 to 0.61)
2	2768 (26.4)	995	36.1 (34.4 to 37.9)	0.67 (0.63 to 0.72)
3	2960 (28.2)	1242	41.2 (39.8 to 43.2)	0.77 (0.73 to 0.82)
4	2328 (22.2)	1060	45.6 (43.6 to 47.5)	0.85 (0.80 to 0.90)
5 (least deprived)	1711 (16.3)	914	53.4 (51.4 to 56.0)	1.00

a Age percentages were standardised for sex, sex percentages were standardised for age, and IMD percentages were standardised for age and sex. Percentages are of all those invited.

b A total of 448 people are missing IMD quintile, primarily because of certain postcode areas not being included in the look-up table.

**TABLE 13** Completion of the baseline assessment and questionnaires in participants and non-participants who are not active on the GPPAQ, by age, sex, IMD quintile and ethnicity

Characteristic	All invitees ( <i>N</i> = 10,927), <i>n</i>	Participants ( <i>N</i> = 9241) <sup>a</sup>			Non-participants ( <i>N</i> = 7152) <sup>b</sup>		
		<i>n</i>	Standardised completion rate <sup>c</sup> (95% CI)	Ratio of completion rates (95% CI)	<i>n</i>	Standardised completion rate <sup>c</sup> (95% CI)	Ratio of completion rates (95% CI)
Age (years)							
45–54	5229	331	6.4 (5.7 to 7.1)	0.60 (0.51 to 0.71)	231	4.6 (4.0 to 5.1)	0.41 (0.34 to 0.49)
55–64	3367	342	10.1 (9.1 to 11.1)	0.94 (0.81 to 1.10)	213	6.3 (5.5 to 7.1)	0.56 (0.47 to 0.67)
65–74	2331	251	10.8 (9.4 to 11.9)	1.0	264	11.2 (10.0 to 12.6)	1.00
Sex							
Female	5604	597	10.6 (9.8 to 11.4)	1.0	408	7.2 (6.5 to 7.9)	1.00
Male	5323	327	6.2 (5.6 to 6.9)	0.59 (0.52 to 0.67)	308	5.9 (5.2 to 6.5)	0.82 (0.71 to 0.94)
IMD national quintile <sup>d</sup>							
1 (most deprived)	712	40	5.5 (3.8 to 7.2)	0.52 (0.39 to 0.70)	31	4.5 (3.0 to 6.0)	0.51 (0.37 to 0.70)
2	2768	183	6.7 (5.7 to 7.6)	0.63 (0.52 to 0.78)	128	4.6 (3.8 to 5.4)	0.52 (0.41 to 0.66)
3	2960	288	9.6 (8.6 to 10.7)	0.92 (0.77 to 1.10)	213	7.1 (6.2 to 8.0)	0.80 (0.65 to 0.98)
4	2328	206	8.8 (7.7 to 10.0)	0.84 (0.69 to 1.02)	172	7.4 (6.3 to 8.4)	0.83 (0.67 to 1.03)
5 (least deprived)	1711	179	10.5 (9.1 to 11.9)	1.0	150	8.9 (7.5 to 10.2)	1.00
Ethnicity							
White	81,295 <sup>e</sup>	709	8.7 (8.1 to 9.3)	1.0	638	7.9 (7.3 to 8.4)	1.00
Asian	11,315 <sup>e</sup>	61	5.4 (4.1 to 6.7)	0.62 (0.50 to 0.76)	27	2.4 (1.5 to 3.3)	0.31 (0.24 to 0.38)
Black	10,845 <sup>e</sup>	90	8.5 (6.7 to 10.2)	0.97 (0.79 to 1.20)	20	1.9 (1.1 to 2.8)	0.24 (0.19 to 0.31)
Other	5835 <sup>e</sup>	22	3.8 (2.2 to 5.4)	0.44 (0.33 to 0.59)	20	3.9 (2.2 to 5.6)	0.59 (0.36 to 0.68)

a Participants completed the baseline health and lifestyle questionnaire and the baseline assessment.

b Non-participants completed the non-participant questionnaire.

c Age percentages were standardised for sex, sex and ethnicity percentages were standardised for age, and IMD percentages were standardised for age and sex. Percentages are of all those invited.

d A total of 448 people are missing IMD quintile data, primarily because of certain postcode areas not being included in the look-up table.

e Number of invitees estimated from practice summary data.

Of the white invitees, 709 (8.7%) agreed to participate in the trial and were not active, and a further 638 (7.9%) completed a non-participant questionnaire and were not active. Both Asian and black invitees had very low non-participant questionnaire completion (2.4% and 1.9%), but black invitees were as willing to participate as white invitees (8.5% vs. 8.7%), whereas only 5.4% of Asian invitees participated. The sensitivity analyses assuming that all ethnicities recorded as 'unknown' were white or non-white people showed similar results, and the same patterns were also seen in practices with nearly complete ethnicity coding.

Those providing questionnaire data were more likely to be working part-time, married or living with a partner, and less likely to have finished their education aged  $\leq 16$  years (*Table 14*). Participation was associated with recent primary care contact and with some degree of health problems (general health, long-standing illness and comorbidities), although those more severely affected were less likely to participate (see *Table 14*). This is consistent with the EQ-5D-5L (health-related quality-of-life) domains, whereby participants were more likely to have problems with pain and mobility, but less likely to have problems with self-care, which is likely to indicate greater disability. Forty-five per cent of the sample gave insufficient time ( $n = 327$ ) or already being physically active ( $n = 325$ ) as reasons for non-participation, even though those classified on the GPPAQ as active were excluded from this analysis. Less commonly, 152 (21%) people answered that they could not or were not interested in ( $n = 122$ , 17%) increasing their PA. Randomisation was cited as a reason for non-participation only by 88 respondents (12%).

**TABLE 14** Participants and non-participants who completed questionnaires and were not active on the GPPAQ: demographics and health and lifestyle factors

Variables	Participants with baseline information ( $N = 924$ ), <sup>a</sup> $n$ (%)	Non-participants who completed a questionnaire ( $N = 715$ ), <sup>a</sup> $n$ (%)	OR for participation adjusted for clustering (95% CI) <sup>b</sup>	OR for participation adjusted for clustering, age and sex (95% CI)
<b>Demographic factors</b>				
Invited as a couple	393 (42.3)	314 (43.9)	0.98 (0.79 to 1.21)	0.99 (0.79 to 1.23)
Married/living together as a couple	595 (65.8)	439 (62.5)	1.20 (0.96 to 1.49)	1.25 (1.01 to 1.56)*
<i>Age (years) finished full-time education</i>				
$\leq 16$	238 (26.4)	246 (35.6)	0.64 (0.49 to 0.83)	0.67 (0.51 to 0.87)
17 or 18	204 (22.6)	122 (16.2)	1.39 (1.10 to 1.76)	1.23 (0.93 to 1.64)
$\geq 19$	334 (48.3)	334 (48.3)	1.0**	1.0**
<i>Employment status</i>				
Full-time	334 (37.1)	248 (35.4)	1.0***	1.0**
Part-time	175 (19.4)	83 (11.8)	1.60 (1.17 to 2.19)	1.57 (1.13 to 2.18)
Retired	274 (30.4)	269 (38.4)	0.77 (0.60 to 0.99)	0.87 (0.63 to 1.21)
Other	118 (13.1)	101 (14.4)	0.87 (0.64 to 1.19)	0.85 (0.62 to 1.17)
<b>Residential status</b>				
Home owner	734 (82.7)	587 (84.2)	0.92 (0.69 to 1.23)	0.91 (0.68 to 1.21)
<b>Health and lifestyle factors</b>				
Contact with GP or nurse in the last 3 months	591 (65.4)	409 (59.3)	1.31 (1.61 to 1.06)*	1.34 (1.09 to 1.65)**
Current smoker	74 (8.4)	62 (9.0)	0.90 (0.63 to 1.29)	0.87 (0.60 to 1.24)

**TABLE 14** Participants and non-participants who completed questionnaires and were not active on the GPPAQ: demographics and health and lifestyle factors (*continued*)

Variables	Participants with baseline information (N = 924), <sup>a</sup> n (%)	Non-participants who completed a questionnaire (N = 715), <sup>a</sup> n (%)	OR for participation adjusted for clustering (95% CI) <sup>b</sup>	OR for participation adjusted for clustering, age and sex (95% CI)
<i>General health level</i>				
Very good/good	727 (81.0)	579 (84.0)	1.0*	1.0*
Fair	154 (17.2)	88 (12.8)	1.34 (1.01 to 1.79)	1.40 (1.05 to 1.86)
Poor/very poor	16 (1.8)	22 (3.1)	0.54 (0.28 to 1.04)	0.56 (0.29 to 1.09)
<i>Limiting long-standing illness</i>				
Yes, a lot	24 (2.7)	46 (6.7)	0.40 (0.24 to 0.66)	0.41 (0.24 to 0.70)
Yes, a little	194 (21.7)	113 (16.4)	1.35 (1.04 to 1.77)	1.40 (1.07 to 1.84)
No	678 (75.7)	528 (76.9)	1.0***	1.0***
One or more comorbidities	568 (58.6)	401 (41.4)	1.23 (1.01 to 1.51)*	1.29(1.05 to 1.59)*
One or more different medications taken per day	517 (57.6)	384 (55.5)	1.07 (0.87 to 1.31)	1.17 (0.95 to 1.46)
<i>EQ-5D measurements</i>				
Mobility – some problems	202 (22.4)	122 (17.4)	1.36 (1.05 to 1.76)*	1.44 (1.10 to 1.87)**
Self-care – some problems	23 (2.6)	31 (4.4)	0.53 (0.30 to 0.93)*	0.56 (0.32 to 0.99)*
Usual activities – some problems	163 (18.3)	121 (17.2)	1.06 (0.81 to 1.38)	1.09 (0.83 to 1.43)
Pain/discomfort – some problems	522 (58.0)	326 (46.4)	1.61 (1.31 to 1.97)***	1.62 (1.32 to 2.00)***
Anxiety/depression some problems	247 (27.8)	169 (24.0)	1.20 (0.96 to 1.52)	1.19 (0.94 to 1.50)
<i>Health factors relating to exercise</i>				
Balance problems	106 (11.7)	64 (9.3)	1.26 (0.91 to 1.76)	1.27 (0.90 to 1.78)
One or more falls in the past year	157 (17.5)	123 (18.0)	0.97 (0.74 to 1.26)	0.98 (0.75 to 1.27)
Brisk/fast walking pace	256 (27.9)	342 (48.2)	0.42 (0.34 to 0.51)***	0.39 (0.32 to 0.49)***
Someone to walk with				
Sometimes/often/always	791 (87.2)	600 (84.2)	1.25 (0.93 to 1.69)	1.20 (0.88 to 1.63)
* $p < 0.05$ , ** $p < 0.01$ , *** $p < 0.001$ , from the Wald test $p$ -value for the inclusion of the variable in the logistic model, used to assess the significance of inclusion of categorical variables with more than two categories.				
<sup>a</sup> Total number in each group. Some questions have missing data.				
<sup>b</sup> ORs are from models with fixed effects for practice and robust standard errors for clustering by household.				

### Results from qualitative comparisons

Fifty-five trial non-participants were telephoned from March to July 2013: 21 could not be contacted and four declined to be interviewed. Thirty trial non-participants representing the six initial participating practices were interviewed. Data saturation was achieved prior to completing 30 interviews, but we continued to 30 to ensure a more ethnically diverse sample. The demographic details of interviewees and their main reasons for non-participation are published.<sup>141</sup> Those interviewed were not selected on the basis of inactivity, and a slightly higher percentage (67%; 20/30) reported being too active as a reason for non-participation compared with those who were included in the main quantitative analysis.

Most interviewees gave one primary reason for declining participation, consistent across sex, ethnicity and age groups. The majority ( $n = 18$ ) said that they were too active either because they felt that their activity exceeded the trial's target levels or because others would benefit more. Less frequently cited main reasons included existing medical problems ( $n = 4$ ), travel from home ( $n = 3$ ), work/other commitments ( $n = 3$ ), concerns about potential equipment problems ( $n = 1$ ) and reluctance to be randomised ( $n = 1$ ). To further understand the reasons for non-participation, we categorised the emerging themes into three domains: internal, external and trial related. Short quotations illustrating all of these reasons are shown in *Table 15* and more detailed quotations are given in our published paper.<sup>148</sup>

**TABLE 15** Summary of categories and themes: barriers to participating

Category	Subcategory	Theme	Quotations with non-participant (NP) number
Internal	Already active	Personal activity	<i>I tend to walk quite a lot anyway, so I didn't think a pedometer would probably be likely to increase my walking at all really.</i> NP12
		Work activity	<i>I actually work as a postman, so I do a hell of a lot of walking . . . and that was basically the reason that I didn't think I'd need to actually join the programme.</i> NP06
	Medical problems	Stroke	<i>I had the stroke in '94. So that limited my walking.</i> NP07
		Pain	<i>If I walk for more than half an hour at a time, I get incredibly stiff and painful.</i> NP16
		Heart condition	<i>I'm always at the hospital seeing a cardiologist.</i> NP18
		Multiple medical problems	<i>I don't need anything else going on to do with health . . . I certainly would have thought . . . that they would have thought, oh, she would not want to do this because she's got lots of other problems.</i> NP18
	No wish to increase activity	Not interested/does not like PA	<i>And I do not really like running . . . and I certainly will not join a gym. I hate exercising.</i> NP02
		Already doing enough	<i>No, I think I do enough. I'm fine with what I do.</i> NP17
	Not interested in walking	'More interesting than walking'	<i>Cycling's nice, swimming . . . any form of recreation thing, like ice skating or horse riding or bicycle riding, anything like that . . . Walking's quite boring.</i> NP02
		Team sport	<i>Well, it would be hard for you to organise team sports I should think wouldn't it? I mean I used to play badminton quite a lot which I enjoyed.</i> NP19

TABLE 15 Summary of categories and themes: barriers to participating (continued)

Category	Subcategory	Theme	Quotations with non-participant (NP) number
		Running	<i>If anybody's doing research into people who have had heart attacks and then trying to get back into running, that I'd be extremely interested in.</i> NP24
	Not the right person	For younger people	<i>You get to a stage in your life and you think, that's it . . . I'm relaxing now. I exercise my mind instead.</i> NP02
		For lonely people	<i>These sort of things people take them up if they are lonely and I'm not lonely.</i> NP18
		For overweight people	<i>Unless you were a really fat person, which I'm not.</i> NP18
	Altruism		<i>. . . an opportunity for someone else, you know, that it may be more useful to.</i> NP13
External	Work commitments		<i>It's bad enough trying to get . . . a day off for a normal appointment.</i> NP02
			<i>I just did not think I'd have time . . . because I know how important walking is, and I love walking, and if I have an hour or two free, I would prefer to walk than talk to the nurse.</i> NP21
		Travel difficulties	<i>If I had time, I'd love to be part of your research and go to the surgery and all the rest of it, but I think, actually . . . the awkwardness of the journey . . .</i> NP22
	Other commitments	Travel from home	<i>I'm going away so much, I could not really tie myself down to anything like that.</i> NP01
		Caring for family member	<i>I'm a carer for my father. I think most of it is just being there.</i> NP04
		Chores/'life'	<i>I've got grandchildren. I've got a husband. I like to do my gardening. I've got a four bedroom house to keep clean. I feel my load is more than enough to keep me going.</i> NP08
	Advice from others		<i>I did mention it to my daughter actually and she said that sounds crazy! She said it's not for me, so I did not go any further.</i> NP07
Trial related	Length of programme		<i>It does sound a bit on the lengthy side does not it really . . . some people could be put off by that.</i> NP10
	Trial material	Too long	<i>. . . there was a lot to read. Bullet points are good. Just make it simple.</i> NP19
		Aimed at older people	<i>I just remember thinking, actually, I do not think I'm in that age group yet. It kind of seemed to be geared to people who really were in their 70s and over.</i> NP09

continued

TABLE 15 Summary of categories and themes: barriers to participating (continued)

Category	Subcategory	Theme	Quotations with non-participant (NP) number
	Equipment problems	Pedometer/accelerometer	<i>Well I mean I have actually used a pedometer but I would not sort of particularly want to do it for a week.</i> NP09
	Randomisation	Did not like concept	<i>I think if you're doing research then you should be able to choose . . . within reason . . . what club you're willing to join really.</i> NP13
Did not want to be in nurse-support group		<i>. . . I could probably commit to the other two groups, but possibly not to the nurse support.</i> NP09	
Did not want to be in the control group		<i>Well . . . I could not see the point of being in a group that did nothing.</i> NP04	
Venue	Fitness-related venue better	<i>If you're going to do a fitness programme, you should do it in a fitness venue.</i> NP04	
	Does not like the GP surgery	<i>I have to go there when I'm not well. I certainly am not going to go to the surgery when I'm well.</i> NP18	
Walking environment	Boring	<i>Walking's quite boring. Unless you're walking somewhere on an outing somewhere, you know, in the country or something, seaside. You should have more trips.</i> NP02	
	Wrong season	<i>As the weather gets better, then I might go for a walk in the evening . . . it was really due to the seasons as well.</i> NP28	
Preferred group		<i>I think you get more encouragement if you are in a group.</i> NP05	
Trial design		<i>. . . that is not something I wanted to be part of I think I'd have found it incredibly boring.</i> NP18	

Adapted from Normansell *et al.*<sup>148</sup> This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (<http://creativecommons.org/licenses/by/4.0/>), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (<http://creativecommons.org/publicdomain/zero/1.0/>) applies to the data made available in this article, unless otherwise stated.

Internal reasons for non-participation included already being active, medical problems (pain, heart conditions, stroke and multimorbidity), no wish to increase activity, no interest in walking, feeling incorrectly 'targeted' and altruistic reasons. The dominant reason in this category was a belief in already being sufficiently active. When explored in more depth, it seemed that, on self-report, many were achieving, with some significantly exceeding, the recommendations. This is supported by the finding that non-participants were found to be more active on the GPPAQ. Of those citing medical reasons, it was less clear whether or not these problems constituted a definite contraindication, especially as those with predefined medical conditions contraindicating an increase in walking should have been excluded. A small number of people suggested that they did not enjoy PA, were not interested in walking or suggested a different activity or a team sport.

The external theme related to factors 'external' to the potential participant, including work and other commitments, travel problems, being a carer and advice from others. Work and work-related travel were frequently given as reasons for not participating and many feared that they could not commit to the trial. Family and home life commitments were also important barriers to increasing activity, including being a full-time carer for family members. We were interested in finding out whether or not advice from friends or family affected the decision not to participate. Very few interviewees discussed participation; for those who did, it did not influence their decision, except for one interviewee whose daughter strongly agreed that she should decline.

Reasons related to trial design included programme length, trial material, equipment problems, being randomised, the venue, the walking environment, the nurse interaction and the overall trial design. For some interviewees, the trial duration, at 3 months, was too long and it was difficult to commit for this period. One interviewee reported a previous negative experience with pedometers as her primary reason for declining. Several felt that not being able to choose their allocated group was a disadvantage. Two interviewees expressed concern about the trial promoting walking as an exercise, because the local walking environment was 'boring', and another stated that it was 'the wrong season' for walking outdoors; however, most interviewees thought that walking was an appropriate and inclusive activity. Some expressed interest in a group intervention rather than one to one with a nurse, feeling that this would improve motivation and sociability; however, others felt that interacting directly with a nurse was preferable to being in a group. Most interviewees approved of the choice of their GP surgery as the location for a PA intervention, describing their surgery as 'lovely', 'pleasant', 'convenient' and 'appropriate'. Many interviewees expressed a positive attitude towards PA and research, and regretted not being able to participate.

### Summary of the findings

The PACE-UP trial recruited 11% of patients aged 45–75 years who were invited by post from their registered general practice, although not all were randomised because of failure to provide adequate accelerometry data. Those not replying were younger and more likely to be male and from deprived postcode areas. Asian patients were less likely to participate. Participation was associated with mild or moderate health impairment, although those with more severe problems were less likely to participate. Not having enough time and being already physically active were the most common reasons for non-participation, even among patients who were classified as not active. Interview findings supported the questionnaire findings and gave more detail about the reasons behind the lack of time (work, travel, family, caring commitments, etc.) and the type of health impairments that stopped people from taking part. Despite not wanting to participate, almost all interviewees were positive about the trial, aware of the benefits of PA and the importance of research, and supported primary care as a venue for such programmes. The design of the trial and intervention was not stated as a key reason for declining to participate.

### Strengths and limitations

The PACE-UP trial is a large trial recruiting from a clearly defined invited population, based on GP lists, enabling us to assess the potential reach of the intervention in terms of age, sex and deprivation. Our estimate of 11% participation may underestimate the true rate, particularly in areas of high mobility where patients may have moved away and not informed the practice, inflating the number of patients counted as invited. Although based on limited data, the PACE-UP trial offers a rare opportunity to examine demographic differences between participants and non-participants. We were able to estimate participation within different ethnicities using pooled data. However, we were not able to match at an individual level and some participants may have categorised themselves in a different ethnic group to that on the GP register. Ethnicity was also poorly recorded in some practices and we needed to make assumptions about whether or not those with 'unknown' ethnicity were similar to those with recorded ethnicity. In a sensitivity analysis, even under extreme assumptions, the difference between Asian and black ethnic groups persisted. The trial excluded individuals who self-reported being active, but the non-participants were not selected in this way. Our quantitative analysis attempted to mitigate this difference by restricting analysis to all those who self-reported as not being active. However, some residual bias may remain.

The interview study represents an innovative attempt to systematically explore the reasons for non-participation with a purposive sample of those who were invited but declined. Our aim was to further understand the perceived barriers to participation to enhance recruitment to future trials and exercise programmes. We were also able to explore non-participants' perception of the trial design and research in general. This sample spanned six out of seven of the practices involved and included both sexes, a range of ages, ethnicities, employment and educational backgrounds. The telephone interviews allowed in-depth exploration of the barriers to participation not possible from a questionnaire alone and allowed us to compare the interview findings with the non-participant questionnaire responses. The main limitation of the interview study is that this was based on a self-selected group of people who both returned the non-participant questionnaire and agreed to be interviewed. It is possible that some of our sample would have been excluded in any case on the basis of their pre-existing activity levels and, therefore, their decision to decline may have been entirely appropriate. In addition, despite our attempt to sample interviewees from non-white British backgrounds, these groups were under-represented when compared with the ethnic diversity of the population invited.

### Comparisons with previous work

A systematic review of 47 studies of walking interventions<sup>151</sup> showed that recruitment methods and participation rates were poorly reported. Of 25 RCTs, participation rates could be calculated for only five. We recruited by post to reduce the burden on practice staff and to obtain response rate data. Postal invitations are used in primary care for other preventative activities, making this a pragmatic approach.<sup>152</sup> Other walking intervention trials using postal invitations in primary care<sup>33,48,144,153</sup> had similar response rates of 10–20%; those with higher rates (37% and 39%)<sup>154,155</sup> recruited individuals who were older and more frequent attenders in primary care, and invited individuals in the primary care consultation, as well as by post. Our previous trial<sup>21</sup> used similar recruitment strategies to the PACE-UP trial, but, unlike other trials, included active people. This trial had a recruitment rate of 30%, but was conducted among older people in an affluent setting with few non-white residents.

Non-responders were followed up with one reminder letter, but because of data protection constraints we were unable to contact patients by telephone. Although only 1% of invitation letters were returned to sender, this may underestimate those who did not receive the letter as we did not use registered post. A previous London study using registered post found that 26% of letters were not delivered.<sup>156</sup> Our findings of greater participation in women,<sup>157,158</sup> older people<sup>158</sup> and those in affluent areas<sup>157</sup> are supported by other studies. Attwood *et al.*<sup>158</sup> found no association with deprivation or ethnicity, but this trial was based in an area of high deprivation with few non-white patients. Among Asian patients, our response rate was similar to postal invitations in the PODOSA (Prevention of Diabetes and Obesity in South Asians) trial (5.2%), in which community-based approaches,<sup>159</sup> through partnership with local South Asian groups, were found to be more effective. Wilbur *et al.*<sup>160</sup> found that social networking was the most effective method for recruiting African American women from low-income areas.

The finding that declining participation in this PA trial was attributable to interviewees considering themselves to be already sufficiently active is in line with other literature.<sup>157,161–163</sup> Importantly, objective measurement of PA reveals that most people overestimate their activity levels,<sup>9</sup> and that their assessment of their personal activity levels is likely to be influenced by a social context.<sup>161</sup> However, this interview series allowed activity levels to be explored in more detail and revealed that, at least on self-report, this was a relatively active cohort for some of whom the trial may not have been appropriate.

Our finding that participation was associated with some degree of health problems, but that severe impairment reduced participation, is more nuanced than previous work, which has suggested that declining participation in PA programmes or trials is attributable to medical problems, including pain,<sup>157,161,162,164</sup> particularly in studies with older participants.<sup>165</sup> Lack of time because of work and other commitments has also been identified as an important barrier,<sup>157,161–163,166,167</sup> particularly in younger and middle-aged participants.<sup>165</sup> A lack of interest in PA has also been reported in the literature,<sup>157,161–163,166</sup> but travel away from home has not been reported prominently. This may reflect the high proportion of our interviewees still in full- or part-time work and the seasonal migration of the diverse south-west London population.

## Implications

Guidelines published by NICE<sup>36</sup> concluded that more research was needed to determine which interventions are effective and cost-effective in increasing activity levels among lower socioeconomic and high-risk groups, and that there is little evidence on differential effects of interventions. In our trial, those groups for which more evidence is required tended to be those with the lowest recruitment rates, such as Asians and those in more deprived areas.<sup>143</sup> It has been suggested<sup>168</sup> that specific cultural groups may respond better to interventions directly targeted at their needs, rather than to universal interventions. Reasons for non-participation were often related to individuals not wanting to increase activity or feeling that they were sufficiently active. It is likely that such resistance will similarly apply to any intervention roll-out and may apply more widely to other public health interventions. Low participation rates mean that policy-makers should be cautious about the intervention's potential reach and the possibility that it could increase activity inequalities, but these are not a reason not to implement an intervention shown to be effective in 11%<sup>93</sup> of the population. We were successful in recruiting older people, women and those with comorbidities or some degree of health limitation. These groups have lower PA levels and are likely to benefit more from increased PA. However, those with more severe disability, people who have had falls and those with a fear of falling were not over-represented, indicating a rational choice by individuals.

Only 12% of non-participants cited randomisation as a factor for not participating, whereas 45% cited time constraints. The nurse intervention required three additional visits to the practice on top of the three data collection visits, which may deter working people or those with child-care and other commitments. However, the PACE-UP trial showed that both the nurse-support and postal delivery groups performed similarly at the main 12-month outcome.<sup>93</sup> An intervention offering pedometers with brief advice, without the need to provide research data, may be more acceptable.

Both the PACE-LIFT and the PACE-UP trials recruited to target, achieved follow-up rates of over 90% and demonstrated that the interventions were effective in increasing PA levels.<sup>21,93</sup> However, considerably more research effort was required (e.g. more contacts from research assistants) per randomised participant in the PACE-UP trial than in the PACE-LIFT trial, resulting from a lower uptake rate. In spite of the effort, we still had limited power to investigate ethnic and socioeconomic subgroups. Trials with greater reach are likely to be more expensive in terms of recruitment, and gains in generalisability need to be balanced with greater costs. Our findings have important implications for those planning PA trials, as well as for those commissioning community PA programmes. As the cohort we interviewed appeared to be relatively physically active, it may be necessary to tailor some interventions to maintaining, rather than increasing, activity; this may also be important to mitigate the decrease in PA levels that often occurs with ageing. Equally, education about the levels of activity that optimise health gain may prevent potential participants from declining because of overestimation of their actual levels of activity. Measurements using pedometers or accelerometers provide an easy approach to validating PA levels.

Lack of time was an important barrier, so it may be helpful to reiterate that activity can be broken up into 10-minute bouts throughout the day (this can also help those individuals limited by pain or disability). Tailoring interventions to an individual's travel and work commitments and for their specific health problems may also increase uptake. Promotional material should be inclusive and explicitly state that pre-existing medical conditions do not necessarily prevent participation and dispel myths about the risks of moderate-intensity exercise. Information about the value of PA, particularly walking, for many different health conditions<sup>1</sup> should be emphasised in the invitation to participate. RCTs inevitably involve randomisation, but emphasising that, in some trials (including the PACE-UP trial), the control group can receive the intervention after the trial may help recruitment. Most interviewees felt that primary care was an appropriate, convenient location for delivering a walking-based PA intervention, indicating that further primary care-based trials and programmes are likely to be well received.

## Conclusions

Participation in an effective PA trial among adults and older adults in a socially and ethnically diverse population was only 11%, with lower rates in more deprived and Asian subgroups, limiting the trial's ability to investigate differential effects in these important subgroups. Trials with greater reach are likely to be more expensive in terms of recruitment, and gains in generalisability need to be balanced with greater costs. Differential uptake of interventions found to be successful in trials may increase inequalities in PA levels and should be monitored.

# Chapter 6 Process evaluation

## Introduction

### *Why is process evaluation necessary in the PACE-UP trial?*

The PACE-UP RCT is a complex intervention comprising multiple interacting components (pedometer, handbook, diary, practice nurse PA consultations and BCTs – as part of both written materials and consultations). Although the RCT design is able to establish the effectiveness of the intervention (see *Chapter 3*), it does not provide information on how it works, or whether or not there are contextual factors that could be associated with variation in outcome in different settings.<sup>169</sup> Conducting a process evaluation of the PACE-UP trial enables a detailed examination of the mechanisms of change by gaining an understanding of how the intervention was delivered and received and how this may have affected the variation in outcomes. The process evaluation investigates the relationship between the fidelity and quality of implementation, the context of the intervention and the main trial outcomes. The evaluation also helps to draw conclusions on the replicability and generalisability of the intervention. The main findings from the process evaluation are published<sup>170</sup> and are reproduced here under the terms of the Creative Commons Attribution License (<http://creativecommons.org/licenses/by/4.0>).

### *Medical Research Council's guidance on process evaluations in complex interventions*


In 2014, the Medical Research Council (MRC) published new guidance for process evaluations of complex interventions.<sup>169</sup> The guidance draws on the experiences of researchers and wider stakeholders who have conducted process evaluations within trials of complex public health interventions. We have used the guidance to provide the framework for the process evaluation of the PACE-UP trial. Process evaluation is accomplished through investigating aspects such as *implementation, mechanisms of impact* and *context*, and the relations between these, as described in *Figure 11*.

Implementation refers to the structures, resources and methods through which delivery is realised, and comprises the following factors: *implementation process, reach, fidelity, dose* and *adaptations*. The implementation process describes *how* the delivery is achieved, through training, support, resources, etc. Reach refers to coverage and the degree to which the intervention is delivered to those for whom it was intended, that is, *who* receives the intervention. The other aspects of implementation are related to *what* is delivered. Fidelity is the degree to which the intervention was delivered as intended (content) and includes assessment of the quality of the intervention. Dose denotes the quantity of the intervention implemented. Adaptations are participant and implementer adjustments, which may impede or strengthen the intervention and which arise in response to the intervention itself.


*Mechanisms of impact* refer to how the intervention activities and participants' responses to them cause change and adaptations.

*Context* refers to external factors which may influence, and be influenced by, implementation mechanisms and outcomes.

The first stage of designing the process evaluation was to describe the intervention and to clarify casual assumptions, which was accomplished through the use of a logic model, shown in *Figure 12*.



**FIGURE 11** The key functions of process evaluation and the relationships between these. Green boxes represent the components of process evaluation, which are informed by the causal assumptions of the intervention, and inform the interpretation of outcomes. Adapted from Moore *et al.*<sup>169</sup> This is an Open Access article distributed in accordance with the terms of the Creative Commons Attribution (CC BY 4.0) license, which permits others to distribute, remix, adapt and build upon this work, for commercial use, provided the original work is properly cited. See: <http://creativecommons.org/licenses/by/4.0/>.



**FIGURE 12** Logic model for the PACE-UP (Pedometers and Consultation Evaluation – UP) PA trial.

## Methods and results

The PACE-UP trial process evaluation was conducted alongside the effectiveness evaluation, included both qualitative and quantitative components and was undertaken by the same team that carried out the effectiveness evaluation.

In accordance with the MRC guidance, the methods were selected through following the key functions model (see *Figure 11*) and are summarised in *Table 16*, which details the process evaluation components, the data sources, the trial group to which they refer and the measures used. The nurse-supported intervention was the most complex to deliver as it involved eight nurses from seven practices delivering three consultations over a 3-month period. Most of the process evaluation was therefore designed to evaluate the nurse-supported intervention group. When process evaluation occurred for other groups, this is clearly described.

**TABLE 16** Summary of the PACE-UP trial process evaluation data sources, evaluative groups and reported measures

Process evaluation component	Data source	Trial groups evaluated	Measures
<b>Implementation</b>			
Implementation process <i>How was it delivered?</i>	Training: <ul style="list-style-type: none"> <li>Nurse training day agendas</li> <li>BCT trainer telephone feedback records (generated from audio-recordings of nurse intervention sessions)</li> <li>Trial administrative records</li> </ul> Resources: <ul style="list-style-type: none"> <li>Trial administrative records (see <i>Chapter 4</i>)</li> </ul>	Nurse-support group	Time spent on training activities
Reach <i>Who was it delivered to?</i>	<ul style="list-style-type: none"> <li>Trial recruitment records (see <i>Chapter 2</i>)</li> <li>Data collection on non-responders and non-participants, including non-participant interviews (see <i>Chapter 5</i>)</li> </ul>	All groups and non-participants	<ul style="list-style-type: none"> <li>Recruitment frequencies and percentages</li> <li>Qualitative themes and subthemes from non-participant interviews</li> </ul>
Fidelity (content and quality) <i>What was delivered?</i>	<ul style="list-style-type: none"> <li>Nurse session checklists (see <i>Appendix 5</i>)</li> <li>Patient alliance questionnaire (see <i>Appendix 5</i>)</li> <li>Nurse alliance questionnaire (see <i>Appendix 5</i>)</li> <li>BCT trainer feedback sheets (generated from audio-recordings of nurse intervention sessions)</li> <li>PA diaries</li> <li>Participant interviews and nurse-support focus groups and interviews (see <i>Chapter 7</i>)</li> <li>Pedometer use questionnaire (see <i>Appendix 5</i>)</li> </ul>	Nurse-support group	<ul style="list-style-type: none"> <li>Content – number of items delivered (mean and SD)</li> <li>Quality of delivery (frequencies and percentages)</li> <li>BCT competency scores, measures of quality of delivery (mean, SD and range)</li> </ul>
Dose <i>What was delivered?</i>	<ul style="list-style-type: none"> <li>Nurse session checklists (see <i>Appendix 5</i>)</li> <li>Audio-recordings of nurse intervention sessions (used to generate BCT trainer feedback sheets)</li> </ul>	Nurse-support group	<ul style="list-style-type: none"> <li>Completed diary return and weekly target achievement (frequencies and percentages)</li> <li>Participant and nurse quotations, qualitative themes and subthemes</li> <li>Pedometer use (frequencies and percentages)</li> <li>Sessions attended (frequencies and percentages)</li> <li>Consultation durations (mean SDs, medians and interquartile ranges)</li> </ul>

**TABLE 16** Summary of the PACE-UP trial process evaluation data sources, evaluative groups and reported measures (*continued*)

Process evaluation component	Data source	Trial groups evaluated	Measures
Adaptations	<ul style="list-style-type: none"> <li>Nurse training session records</li> <li>PA diaries</li> </ul>	Nurse-support group	<ul style="list-style-type: none"> <li>Comments made by nurses</li> <li>Alteration of targets (frequencies and percentages)</li> </ul>
<i>What was delivered?</i>	<ul style="list-style-type: none"> <li>Participant interviews and nurse focus groups and interviews (see <i>Chapter 7</i>)</li> </ul>	Nurse-support and postal delivery groups	<ul style="list-style-type: none"> <li>Participant and nurse quotations</li> </ul>
<b>Mechanisms of impact</b>			
Participant responsiveness	<ul style="list-style-type: none"> <li>Patient alliance questionnaire (see <i>Appendix 5</i>)</li> <li>Nurse alliance questionnaire (see <i>Appendix 5</i>)</li> <li>Participant interviews and nurse focus groups and interviews (see <i>Chapter 7</i>)</li> </ul>	Nurse-support group	<ul style="list-style-type: none"> <li>Measures of responsiveness (frequencies and percentages)</li> <li>Participant and nurse quotations</li> </ul>
		Nurse-support and postal delivery groups	Qualitative themes and subthemes
<b>Context</b>			
Contextual factors	Nurse training session records	Nurse-support group	<ul style="list-style-type: none"> <li>Comments made by nurses</li> <li>Qualitative themes and subthemes</li> <li>Participant and nurse quotations</li> </ul>
	Participant interviews and nurse focus groups and interviews (see <i>Chapter 7</i> )	Nurse-support and postal delivery groups	

To reduce duplication, and for ease of reading, the methods and results for each aspect of the process evaluation are presented together. The main results are summarised in a further key functions model after all of the results have been presented (*Figure 13*). Several aspects of the process evaluation are dealt with appropriately in other chapters of this report, such as reach in *Chapter 5* and participant responsiveness in *Chapter 7*. They are referred to in *Table 16* for completeness and the relevant chapter in which the methods and results for this aspect are presented are clearly shown.


We have selected three quantitative aspects of the process evaluation to relate directly to PA outcome measurements at 12 months (change in step counts and change in time in MVPA in bouts): the number of nurse appointments attended whether or not completed step count diaries were returned by participants at 3 months in the nurse-support and postal delivery groups, and the use of pedometers in the nurse-support and postal delivery groups during the 12-week intervention. These analyses relating process to outcome measures are described at the end of *Methods and results*.

## Implementation

### Implementation process

#### Training

Nurses delivering the intervention were provided with training in PA guidance (1 hour and 25 minutes), trial protocols (4 hours), safety reporting (1 hour and 10 minutes) and BCTs (9 hours and 25 minutes) across the duration of the trial (see *Appendix 5, Table 38*). Data on nurse training were obtained from training-day agendas and BCT trainer telephone feedback records and trial administrative records. The total training time was approximately 16 hours; most of this was allocated to delivering BCTs as the active ingredient in the intervention.



**FIGURE 13** The key functions of process evaluation and the relationships between them for the PACE-UP trial. Green boxes represent components of process evaluation, which are informed by the causal assumptions of the intervention and inform the interpretation of outcomes. Adapted from Moore *et al.*<sup>169</sup> This is an Open Access article distributed in accordance with the terms of the Creative Commons Attribution (CC BY 4.0) license, which permits others to distribute, remix, adapt and build upon this work, for commercial use, provided the original work is properly cited. See: <http://creativecommons.org/licenses/by/4.0/>.

## Resources

Resources for the trial include the trial materials [patient handbooks and diaries, see the NIHR Journals Library website: [www.journalslibrary.nihr.ac.uk/programmes/hta/103202/#/](http://www.journalslibrary.nihr.ac.uk/programmes/hta/103202/#/) (accessed 25 May 2018)], trial equipment (pedometers and accelerometers) and payment of nurse time and room hire. These are all fully costed in *Chapter 4* and are not further commented on in this chapter.

## Reach

The overall trial recruitment rate was 10% (1023/10,467). Details on how practices and participants were selected and recruited is described in *Chapter 2*. The methods for assessing trial representativeness and generalisability, by comparison of non-responders, non-participants and participants, and by interviews of non-participants, are described in *Chapter 5*.

## Fidelity (content and quality)

### Content

#### Nurse sessions

Nurse session attendance and session content delivered was recorded by the nurses after each session (see *Appendix 5*). There were 11 compulsory items to be covered in session 1 and six items to be covered in sessions 2 and 3. The level of nurse session attendance was high; approximately three-quarters of participants attended all three sessions ( $n = 255/346$ ; 74%). Adherence to content delivered was high in all sessions; the mean number of items delivered in each session was 11 (range 10–11) and six (range 5–6) in sessions 2 and 3, respectively. Of those participants who attended session 3, most reported still using the pedometer and diary ( $n = 258/263$ ; 98%) (*Appendix 5, Table 39*).

#### Physical activity diaries

Physical activity diaries (see *Appendix 5, Table 40*) returned by participants after the intervention provided data on the achievement of weekly walking targets for the intervention groups. Eighty per cent of participants ( $n = 549$ ) returned completed diaries; there was similar return across both groups. One-third of participants in the nurse-support group altered their step count targets (89/346; 32%) and the majority were decreased ( $n = 80$ ). In comparison, just four participants in the postal delivery group altered their step count targets and all were decreased. The relationship between diary return at 3 months and the trial outcome measures was explored (see the association between the process evaluation measures and the trial outcomes at the end of *Methods and results*).

#### Pedometer use

All participants were asked about their pedometer use during the 12-week intervention period (see *Appendix 5, Table 41*). During the 12-week intervention, a high proportion of both the postal delivery and nurse-support groups reported using their pedometer either every day or most days: 238 out of 294 (81%) in the postal delivery group and 269 out of 303 (89%) in the nurse-support group. The relationships between pedometer use during the intervention and the trial PA outcomes at 3 and 12 months were explored for both intervention groups (see the association between the process evaluation measures and the trial outcomes at the end of *Methods and results*).

## Quality

### Nurse and patient alliance questionnaire

Following the intervention, both the nurse and the participant independently completed a 12-item nurse and patient alliance questionnaire (see *Appendix 5*) covering different intervention aspects (e.g. working together and goal-setting, number of appointments). The questionnaires were developed by BCT trainers and trial investigators, and questions 1–11 were adapted from the Working Alliance Inventory,<sup>171,172</sup> which is a validated alliance measure used in cognitive-behavioural therapy-based studies, and the Outcome Rating Scale.<sup>173</sup> Item 12 was added to specifically ask about the number of PACE-UP trial appointments.

The questionnaire was posted to the participant and returned to the researcher, so that the nurse was blind to participant responses. Three directly comparable items (questions 1, 3 and 4) from both the patient questionnaire and the nurse questionnaire provided data on the quality of intervention delivery (Table 17). Seven directly comparable items directly relate to participant responsiveness (questions 5, 6, 8, 9, 10, 11 and 12). Two items (questions 2 and 7) were discounted as they did not relate to quality of participant responsiveness.

The questionnaires were completed by 295 out of 346 participants (85%) in the nurse-supported intervention group and by the nurses for 251 out of 346 nurse-support group participants (73%).

There was strong agreement between the participant and nurse results for all of the items relating to quality and 80% or more of both nurses and participants agreed or strongly agreed with all of these statements, suggesting high quality of delivery.

**TABLE 17** Quality of delivery and participant responsiveness data from the nurse and patient alliance questionnaires

Delivery and responsiveness	Questionnaire					
	Patient alliance			Nurse alliance		
	<i>N</i>	'Agree' or 'strongly agree', <i>n</i> (%)	Missing items	<i>N</i>	'Agree' or 'strongly agree', <i>n</i> (%)	Missing items
<b>Quality of delivery</b>						
Q1: the patient and I worked together on setting goals that were important to the patient	287	231 (80)	8	250	221 (88)	1
Q3: the patient felt heard, understood and respected	287	259 (90)	8	249	234 (94)	2
Q4: in our meetings together, the patient discussed everything they wanted to discuss	285	267 (94)	10	249	234 (94)	2
<b>Participant responsiveness</b>						
Q5: the patient understands how to make lasting changes in activity levels	289	259 (90)	6	249	215 (86)	2
Q6: the approach to making change suited the patient	287	247 (86)	8	249	182 (73)	2
Q8: the patient feels confident to continue to make positive changes in PA on their own	288	238 (83)	7	246	191 (78)	5
Q9: the patient feels confident about overcoming obstacles to increasing activity levels in the future	257	169 (66)	38	190	124 (65)	70
Q10: the pedometer used in the PACE-UP study was helpful to the patient	288	260 (90)	7	246	209 (85)	5
Q11: the diary used in the PACE-UP study was helpful to the patient	284	229 (81)	11	247	203 (83)	4
Q12: the number of appointments with the PA nurse was just right . . .	278	232 (83)	17	241	178 (74)	10
<b>Notes</b>						
Missing items were excluded from the percentage calculations.						
Q9 on the nurse alliance questionnaire was printed blank on the Likert scale for answers, so a high number of responses were missing.						

The following are some examples of participant and nurse comments relating to quality from the questionnaires:

*Nurse was encouraging, supportive. Encouraged me to set goals that were achievable for me and not to put too much pressure on myself.*

*Female, aged 47 years, nurse-support group*

*My nurse was lovely and encouraged me all the way through, even when some days I couldn't do what I needed, we discussed alternatives. My nurse was a diamond. Thanks to PACE-UP and the nurse my walking has really improved.*

*Female, aged 47 years, nurse-support group*

*Client pleased with programme. Learning curve. Would recommend to others.*

*Practice nurse*

*Enjoyed patient, good discussions and understanding around increasing exercise.*

*Practice nurse*

### Audio-recordings from nurse sessions

Nurses were asked to audio-record a sample of their sessions so that these could be listened to by the BCT trainer and rated according to their skill in six different communication skill competencies. Ratings were made by the BCT trainer against a primary care consultation rating scale (range 0–6) in six domains (Figure 14) and used for both fidelity (quality) evaluation and supervision purposes. The rating scale used was developed from the Cognitive Behavioural Therapy Techniques for Palliative Care Practitioners Rating Scale<sup>174</sup> and the Department of Health and Social Care's *The Ten Essential Shared Capabilities – A Framework for the Whole of the Mental Health Workforce*.<sup>175</sup> The nurses were each asked to provide three audio-recorded sessions, one each for sessions 1, 2 and 3. They were asked to try to ensure that one of the recorded sessions was from a session where a couple were seen together. The mean scores and ranges for all nurses are shown across all domains in Table 18.

The range of scores illustrates that even the lowest ratings were competent, and the highest scores were expert, across all six competencies. The lowest scoring competency was given for empowering explanations (mean score 4.7), whereas all the other competencies had mean scores above 5, demonstrating proficiency, with very good features.

Competence level	Examples
Incompetent } 0	Absence of feature, or highly inappropriate performance
	1 Inappropriate performance, major problems evident
Novice } 2	Evidence of competence, but numerous problems and lack of consistency
Advanced beginner } 3	Competent, but some problems and/or inconsistencies
Competent } 4	Good features, but minor problems or inconsistencies
Proficient } 5	Very good features, minimal problems and/or inconsistencies
Expert } 6	Excellent performance, or very good even in the face of patient difficulties

FIGURE 14 Behaviour change technique competency level.

**TABLE 18** Fidelity: quality scores of performance for audio-recordings of nurse sessions by BCT trainer

Scores	Communication skill competency					
	1. Framing, pacing, focus and use of time	2. Empowering explanations	3. Collaboration and active listening; interpersonal effectiveness	4. Setting goals, agreeing actions and motivational techniques	5. Feedback, reviewing and summarising	6. Building self-efficacy
Average (mean) score	5.3	4.7	5.0	5.2	5.3	5.2
Range of scores	3–6	3–6	4–6	4–6	5–6	4–6

### Qualitative perspective

Semistructured individual interviews with participants and focus groups with nurses provided a qualitative perspective of the intervention, including the quality of delivery; this is presented in detail in *Chapter 7*. Overall, the nurses and participants described the intervention in a positive manner, as highlighted by the following quotations:

*... they kept saying how well I was doing, and all this sort of thing, so it made me want to continue. I think it was ... a part motivation, yes, because I knew I had to face somebody and I didn't want to fail.*

*Female, aged 63 years, nurse-support group*

*... if you had, in your drawer, you had like a set ... a package, programme, you could do, and if through the NHS Health Check you identified someone who was suitable, you could then discuss it with them and say, 'Would this be something you'd be wanting to look at? ... and go from there.*

*Practice nurse*

### Dose

For the purpose of the PACE-UP trial, the dose delivered to the postal delivery group was fixed, as they all received the same handbook, diary and pedometer. The dose could vary for the nurse group according to the number of sessions attended and the length of each of the sessions. Nurses were required to complete checklists at the end of each session (see *Appendix 5, Table 39*), providing details on attendance and the duration of sessions. The duration of sessions was also captured from the audio-recorded sample of intervention sessions; this allowed a comparison with session durations calculated from nurse checklists. Overall, three-quarters of participants in the nurse-support group attended all three sessions. Ninety-five per cent of participants (330/346) attended session 1, 86% (296/346) attended session 2 and 76% (263/346) attended session 3. The relationship between the number of sessions attended and trial PA outcomes was also explored (see the association between process evaluation measures and trial outcomes at the end of *Methods and results*).

Trial protocols detailed the following approximate duration of each nurse intervention session: 30 minutes for session 1 and 20 minutes each for sessions 2 and 3. A summary of nurse intervention session durations from nurse self-report and audio-recordings is available in *Appendix 5, Table 42* (19 recordings, relating to 22 participants, as some were couples). There was good agreement between the planned protocol session length and the nurse self-report durations: mean of 30 minutes (SD 4 minutes) for session 1, mean of 24 minutes (SD 3 minutes) for session 2 and mean of 22 minutes (SD 4 minutes) for session 3. The duration of consultations from audio-recordings was based on much smaller numbers ( $n = 22$  participants) but had a shorter mean duration: mean of 21 minutes (SD 6 minutes) for session 1, mean of 21 minutes (SD 7 minutes) for session 2 and mean of 14 minutes (SD 5 minutes) for session 3.

## Adaptations

Details of nurse and participant adaptations made to the intervention were provided from nurse training session records. There were many examples presented relating to step count target adaptation and tailoring the intervention to individual circumstances. Adjustments were made to the intervention to accommodate religious observances, such as Ramadan and Christmas. Step count targets were adapted to be more achievable to reflect participants' reduced energy/activity levels in advance of holidays, when there were expected to be reductions or increases in PA, during periods of participant illness and pain and in response to changing weather conditions. Nurses also explained the need for flexibility with participants who experienced difficulties with equipment use; for example, a small number of participants who did not like using the pedometer were advised to use time to measure their walking, rather than measuring step count (e.g. extra walks of 10–15 minutes per day, rather than an extra 1000–1500 steps per day). At the second training session, it became clear that the nurses did not find the optional handouts provided for use in consultations to supplement the patient handbook helpful and, as a consequence, were not using them. From these discussions, it was decided that these materials would be discontinued. Another adaptation revealed by the nurses was adapting targets and advice for participants taking part as a couple, particularly if they had very different PA levels and targets; this sometimes related to one individual of the couple having health problems that had an impact on mobility. Nurses adapted the intervention to encourage both participants to meet their targets, often encouraging a mixture of walking together and walking apart to achieve this.

Physical activity diaries also provided data on adaptations to the prescribed intervention through alterations of participants' walking targets (see *Appendix 5, Table 40*). Few participants in the postal intervention group altered their targets in the diary (1%; 4/339), whereas 32% (89/346) of the nurse-supported intervention group altered their walking targets, mainly by decreasing the target [29% (80/346)].

Additional details of nurse and participant adaptations to the intervention by both intervention groups, obtained as part of the qualitative evaluations of the trial, are presented in *Chapter 7*. Some examples are given here.

The nurse quotations below illustrate the flexibility in intervention delivery during Ramadan and also during bad weather:

*... they couldn't walk or increase on their walking at that time because they hadn't eaten and then they weren't feeling too good, and all that, so we did it a different way then, and what I did with them was we relaxed it and then I said to them, when Ramadan's over, we made the appointment so that their actual trial went on a bit longer.*

*Practice nurse*

*... if the weather was bad, or it was cold, or there were obstacles that got in the way ... they would do things like, you know ... activities indoors where they could not always go outside.*

*Practice nurse*

## Mechanisms of impact

### Participant responsiveness

Seven items reflecting participant responsiveness were identified in both the patient alliance questionnaire and the nurse alliance questionnaire (see *Table 17*). There was a good degree of consistency between participant and nurse responses for all of the items relating to participant responsiveness and high levels of agreement with all of the statements. For example, 90% of participants said that the pedometer was helpful and 83% said that the number of nurse appointments was just right, suggesting that there was a good level of participant responsiveness to the intervention.

Some examples of both participant and nurse comments relating to participant responsiveness from the alliance questionnaires are shown below:

*PACE-UP has changed my life. I use the car less when I go about. Although I drive to work I park about 1 km away from work, then walk all the way to and from.*

*Female, aged 47 years, nurse-support group*

*Wearing the pedometer really raised my awareness of how far I walked each day. I will continue to use it.*

*Female, aged 68 years, nurse-support group*

*Positive, liked study book. Was a very reflective/honest person regarding his exercise. Positives/negatives easily identified by patient.*

*Practice nurse*

*Patient has own excel monitor of readings/pedometer count. Also converts to miles daily.*

*Practice nurse*

Information about participant responsiveness also came from the qualitative evaluations of participants from both the postal delivery and the nurse groups (from individual interviews) and from practice nurses (from a focus group and individual interviews), and is presented in *Chapter 7*.

The following quotations from the qualitative evaluation illustrate participant responsiveness and engagement from a nurse and participant perspective:

*... the only other thing I'd say about the diary is that the people that really liked filling it in found it a really good motivator. When they came to the last appointment, they wanted another one.*

*Practice nurse*

*There's nothing like the fact that you know you're going to meeting someone and talk about it to make you do it, you know, ... It's basically the routine of being checked up on by someone else ...*

*Male, aged 61 years, nurse-support group*

*... well having something which counts the steps makes one conscious of it and filling out a little booklet every day, likewise, it just creates some personal pressure.*

*Male, aged 59 years, postal delivery group*

## Context

Comments made by nurses during training sessions relevant to contextual factors were noted down. There was overlap with the factors mentioned in the section on adaptation of the intervention, as contextual factors often required the nurses to consider adapting the intervention or targets after discussion with participants. Examples of contextual factors mentioned are as follows: the difficulty of walking in bad weather, the effect of taking part in the intervention as a couple, health issues that required a slower, more gradual approach and undertaking the intervention during Ramadan or Christmas.

How contextual factors may have affected (and been affected by) the implementation, such as season, environment, health status, employment and social and religious factors, were explored as part of the qualitative evaluation of participants (from individual interviews) and nurse perspectives (from focus group and individual interviews), and are described more fully in *Chapter 7*. The following factors were described: season/weather (problems with rain or snow and ice), environment (ease of walking in parks, more difficult in built-up areas), health issues (examples both of pain getting worse with walking and of walking improving

pain), employment (retired people saying they have increased time for walking, some occupations providing the opportunity for walking or at least walking to work), religious factors (difficulty with walking during Ramadan when fasting and having low energy levels) and social factors (walking with family/grandchildren, etc. or not having anyone to walk with). This last factor is illustrated by the following quotation taken from the qualitative evaluation:

*... it's something I want to keep up, because I just felt that it was such a benefit, and even the kids would come out with me sometimes.*

*Nurse-support group participant*

## Association between process evaluation measures and trial outcome measures

Although the trial was powered only for analysis of the difference in outcome measures between the three groups, and not for exploration of the effect of process evaluation measures, we felt that it was interesting to explore if there was any relationship between adherence to the intervention and the change in outcomes. We have focused on three quantitative measures of process evaluation in relation to the PA outcome measures at 3 months and 12 months (changes in average daily step count and weekly time in MVPA in bouts). The three measures were all to do with the implementation of the intervention:

1. Dose – nurse session attendance (0, 1, 2 or 3 sessions attended; nurse-support group).
2. Fidelity – return of completed diaries after the 3-month intervention (yes/no; postal delivery and nurse-support groups).
3. Fidelity – pedometer use – how often did you wear the pedometer? Every day or most days (yes/no; postal delivery and nurse-support groups) during the 12-week intervention (0–3 months).

All measures described were considered as independent variables in the models, with (1) change in average daily step count and (2) change in total weekly MVPA in bouts as outcomes. All analyses were adjusted for age, sex, practice, month of baseline accelerometry, household identifier (to account for clustering by household) and trial group (as in the main trial analyses; see *Chapter 2*). *Table 19* shows the results of the models.

### *Nurse session attendance and physical activity outcomes*

In the nurse group at 3 months and 12 months there was a positive association between the number of sessions attended and the PA outcomes. Participants attending all three sessions increased their step count and their time in MVPA in bouts at 3 and 12 months by significantly more than those attending between 0 and 2 sessions.

### *Diary return and physical activity outcomes*

In the postal delivery group, there was a strong positive association between returning a diary and on both change in steps and MVPA in bouts at both 3 and 12 months compared with those in the postal delivery group, who did not return a diary. In the nurse-support group, there was a positive association between returning the diary and on change in step count and MVPA at 3 months, compared with those in the nurse-support group who did not return a diary. However, by 12 months, there was no significant association for either PA outcome of returning a diary within the nurse-support group.

### *Pedometer use and physical activity outcomes*

In the postal delivery group, reported use of a pedometer every day or most days during the 12-week intervention period was associated with a significant change in step count at 3 months and 12 months, and with change in MVPA at 3 months (borderline effect at 12 months).

**TABLE 19** The PACE-UP trial modelling results: relating nurse session attendance, step count diary return and pedometer use to PA outcomes

Intervention components	PA outcome							
	Daily step count				Total weekly minutes of MVPA in ≥ 10-minute bouts			
	3 months		12 months		3 months		12 months	
	Effect (95% CI)	p-value	Effect (95% CI)	p-value	Effect (95% CI)	p-value	Effect (95% CI)	p-value
Nurse session attendance								
Attended all three nurse sessions: yes vs. no	1197 (627 to 1766)	<0.001	605 (74 to 1137)	0.03	74 (45 to 103)	<0.001	30 (3 to 57)	0.03
Diary returned								
Postal delivery group: yes vs. no	1458 (854 to 2061)	<0.001	1114 (538 to 1689)	<0.001	64 (33 to 94)	<0.001	47 (17 to 75)	0.002
Nurse-support group: yes vs. no	873 (190 to 1555)	0.01	323 (-278 to 925)	0.29	50 (15 to 85)	<0.001	3 (-27 to 33)	0.89
Pedometer use every day or most days during the 12-week intervention								
Postal delivery group: yes vs. no	1029 (383 to 1675)	<0.001	606 (22 to 1190)	0.04	40 (6 to 73)	0.02	26 (-2 to 55)	0.07
Nurse-support group: yes vs. no	337 (-525 to 1198)	0.44	394 (-321 to 1109)	0.28	24 (-20 to 68)	0.28	10 (-25 to 45)	0.58

**Notes**

All models include practice, sex, age at randomisation and month of baseline accelerometry as fixed effects and household as a random effect in a multilevel mode.

Within the nurse-support group, there were no significant associations between regular pedometer use during the 12-week intervention and change in step count or MVPA at 3 months and 12 months. This lack of significant effect could be explained by the very small numbers of participants in the nurse-support group who reported not having used a pedometer regularly during the 12-week intervention ( $n = 34$ ; 11%).

Overall, the analysis of the association between process measures and PA trial outcomes exhibits a clear pattern of positive associations (i.e. increased nurse appointments, diary return and pedometer use were associated with increased objective PA levels). This provides clear evidence of the engagement with the trial process and outcomes, but cannot be interpreted as causality.

**Discussion**

**Main findings**

Figure 13 summarises the key findings from the PACE-UP trial process evaluation, which followed the MRC guidance for process evaluation of complex interventions.<sup>169</sup> We gathered a number of positive data on implementation, suggesting good-quality intervention delivery and adherence to the protocol, despite the low reach of the trial. Nurse training was an important element of the trial, with nurses receiving approximately 16 hours of training, predominantly around delivery of BCTs. We demonstrated good

coverage of the proposed session content by the nurses and also good-quality delivery, with the audio-recording of nurse sessions demonstrating high levels of competency in communication skills. High-quality delivery was also reflected in comments from participants who felt heard, understood and respected. Three-quarters of the nurse group attended all three PA consultations, and around 80% of both the nurse-support and the postal delivery groups engaged with the self-monitoring aspects of the trial and returned completed step count diaries at 3 months. In terms of the mechanisms of impact, we demonstrated high levels of participant responsiveness. Context was important and factors affecting the implementation of the walking intervention were suggested by nurses and participants from both intervention arms, and included the effects of weather, the environment, health issues, pain, employment, observance of religious events and social factors. The nurses worked with participants to help them to make adaptations, either to the intervention or their individual targets, or to encourage participants to come up with solutions when possible, when there were contextual challenges. Several process evaluation measures (number of nurse sessions attended, return of a completed diary and regular pedometer use) showed significant associations with PA outcomes at 3 and 12 months.

## Strengths and limitations

### Strengths

Despite the PACE-UP trial process evaluation having been designed before the publication of the MRC guidance,<sup>169</sup> we were able to use the data that we collected and fit them into the framework, which has provided a useful structure for reporting process evaluation findings. We have a number of different data sources that reflect three different perspectives in the trial: participant, practitioner and observer. This provided a broader picture of the process than many studies have reported and allowed comparison of results from different methods (e.g. for consultation duration). We tried to reduce the burden of participant measurement, trial costs and duplication of effort, by collecting as many routine trial data as we could for the evaluation (from administrative records, nurse training records, nurse checklists, nurse audio-recordings from supervision sessions, etc.), but we supplemented this with data collected specifically for the evaluation (e.g. the nurse and patient alliance questionnaires or the 12-month pedometer use questionnaire). We have used a mixed-methods approach to the process evaluation, as recommended, combining quantitative data from key process variables from all participants with in-depth qualitative data from purposively selected samples.<sup>169</sup> The qualitative element is described in full in *Chapter 7*; however, we have used relevant quotations in this chapter to illustrate the quality of delivery, adaptations, participant responsiveness and context, and these have provided a voice to participants and nurses and added a richness and depth to the evaluation. The data were collected longitudinally and contemporaneously throughout the trial, which is seen to be the most complete and accurate method of data collection, and also allows any change in intervention delivery over the course of the trial to be detected.<sup>169</sup> The data are comprehensive, with a high response rate and completeness of data sources, strengthening the robustness of the findings. The process evaluation analysis was conducted before the outcome analysis to avoid a biased interpretation of the process data. Only the final analyses examining the effects of process evaluation variables on outcome data were carried out following the main outcome analyses.

### Limitations

The process evaluation was conducted by the trial team while the trial was ongoing. This allowed efficient data collection in a contemporaneous manner, but could have led to bias in evaluation. We tried to minimise the bias by using objective instruments when possible (e.g. nurse and patient alliance questionnaires, 12-month pedometer use questionnaires, return of patient diaries). In addition, the qualitative evaluation was led by Christina Victor, who was not involved in the day-to-day trial conduct. Some process measures were not filled out by everyone (patient alliance questionnaire: 85% completion; nurse alliance questionnaire: 73% completion); this could have led to a more positive assessment of statements, if those who felt negatively about the programme did not reply. Nurses could have selected more positive consultations to audio-record, inflating the BCT competency levels, although they were encouraged to record cases as they occurred. Not all of the nurses submitted audio-recorded consultations with couples, meaning that we were unable to look separately at the quality of these consultations. The content delivery for the nurse consultations was evaluated

from checklists filled out by the nurses because they may have overestimated what they had achieved. We tried to compensate for this by collecting additional data from both the participant and observer perspective to help to corroborate these data; both participant and observer data suggested a high degree of quality in the consultations. The consultation durations were shorter from observer data than from self-report, but data on observed consultations were based on a much smaller sample. The study was not powered to look at the effects of adherence to different aspects of the protocol on trial outcomes; we therefore have reduced power for these analyses, which limits the interpretation of the findings, which cannot be taken to be casual.

### **Comparison with other complex intervention process evaluations**

A number of studies have examined intervention implementation fidelity, with a large variety of process structures and methods; therefore, it is difficult to draw direct comparisons. Process evaluations have become increasingly important, but the purposes and design of studies have been mixed. Many process evaluations are completed independently of trial data collection and are observations of a random subsample of participants or practitioners.<sup>176,177</sup> The process evaluation of the PACE-UP intervention provides both participant and nurse perspectives and identifies a link between contextual factors and adaptations in intervention delivery and acceptance. The study allowed us to look at both perceived and observed behaviour change in the nurse intervention delivery and participant responsiveness; this is unlike many other studies, which have tended to focus on only one perspective, which is most often the person delivering the intervention.<sup>176,178-181</sup> Nurse comments collected at training, individual session checklists and nurse and participant comments from the qualitative work illustrate the intervention delivery and adaptations in context. The intervention was designed to bring about change at an individual level when delivered in a primary care environment; we have observed that context influences the delivery and implementation of the intervention through adaptation. This is similar to findings from other PA and dietary complex intervention studies with process evaluation.<sup>182,183</sup> Specifically, Fitzgerald *et al.*<sup>182</sup> identified that negotiation and flexibility play an integral role in overcoming the barriers and resistance to change in a dietary intervention. Previous studies have collected data at an organisational or practice level;<sup>176,181</sup> there are few studies that have captured the evaluation of behaviour change at an individual level and from two perspectives. A previous study that did look at both patient and practitioner perspectives, however, reported much greater variations in dose and adherence to protocols than seen in the PACE-UP trial, therefore making it difficult to establish which elements of the intervention were effective.<sup>184</sup> Berendsen *et al.*<sup>184</sup> reported that many health-care professionals deviated from the protocol of a lifestyle intervention to accommodate individuals and reduce fallout, which was associated with increased patient satisfaction for the intervention sessions. This perhaps suggests that adaptations and tailoring of an intervention have a strong influence on retention, adherence and, possibly, effectiveness in lifestyle and behaviour change interventions. The PACE-UP intervention allowed nurses to adapt the sessions as necessary to each individual, while maintaining the key deliverables in each nurse-led session; although we have not looked at the effect of adaptation on retention, we have seen that dose (nurse session attendance) was associated with effectiveness of the intervention. This, in turn, promotes the consideration of building adaptations and flexibility into intervention design. Our finding of an association between the return of a completed step count diary and a change in PA outcomes is consistent with the findings of a systematic review,<sup>31</sup> which suggested that the use of a step count diary was common to many successful pedometer interventions.

### **Implications of the process evaluation for the interpretation of the PACE-UP trial**

We have demonstrated that the PACE-UP trial had good adherence to the protocol, the intervention was acceptable and was rated positively by both the nurse-support group participants and the postal delivery group participants, and both groups engaged in self-monitoring using the pedometer and step count diary. It is not possible to infer causality directly from the process evaluation data, but the high level of engagement with pedometers and diaries by both intervention groups suggests that these were important factors in helping people to make the PA changes observed. This is supported by the associations demonstrated between increased PA levels and the following process measures: number of consultations attended, return of a completed step count diary and pedometer use. The careful description and documentation of the trial processes, the collection of additional data for the process evaluation and the publication of the resources used as appendices mean that our intervention and process evaluation would

be easy for others to replicate, from training through delivery, to follow-up and evaluation. Use of the MRC framework gave a logical and coherent structure for reporting,<sup>169</sup> which is also easy for others to follow. The PACE-UP trial had a positive and significant effect on PA outcomes, but had this not been the case, the positive process evaluation with high levels of fidelity would have enabled us to have confidence that any negative trial effect would not have been because of poor trial implementation. The trial demonstrated a stronger effect on the main PA outcomes and on exercise self-efficacy at 3 months in the nurse-support group than in the postal delivery group, although the effects on PA outcomes were similar between the groups at 12 months (self-efficacy remained higher at 12 months in the nurse-support group). The process evaluation demonstrated that the nurses were delivering BCTs in their PA consultations in accordance with the protocol and with high levels of competence (in addition to the BCTs provided in the handbook and diary for both groups). This suggests that the nurse-delivered BCT elements of the intervention have strong short-term effects on PA levels (and, possibly, longer-term effects on self-efficacy). The possible effects on longer-term maintenance are examined in *Chapter 8*. The implications of the low reach of the trial for generalisability and the public health impact have been discussed in *Chapter 5* and will be considered further in the main discussion in *Chapter 9*. The process evaluation demonstrated important contextual factors that had an impact on participants' ability to engage with a walking intervention; these should be considered in any future roll-out of the programme, particularly regarding how the programme may need adaptations to be made in these circumstances.

## Conclusion

The PACE-UP trial process evaluation demonstrated that the trial was well delivered by the trial team and well received by participants. The MRC framework was a useful vehicle for reporting the evaluation. An association between adherence to the trial protocol and main trial PA outcomes has been demonstrated. Important contextual factors were shown that may need adaptations to be considered in any roll-out of the intervention.



# Chapter 7 What did the nurses and participants think about the intervention?

## Introduction

It is important, within the delivery of a behaviour change intervention trial, to understand the experiences of those involved in the delivery and receipt of the intervention. In order to address these important issues, two qualitative studies were embedded within the trial protocol. In these studies, we sought to gain insights into two important issues: (1) the views and experiences of the nurses delivering the intervention and (2) the experiences of trial participants. Summaries of the nurses' perspectives on the trial<sup>185</sup> and the participants' evaluation of the trial in helping them to increase their levels of PA<sup>162</sup> have been published and are reproduced here under the terms of the Creative Commons Attribution 4.0 International License (<http://creativecommons.org/licenses/by/4.0>). In this chapter, we focus upon the perceptions of the nurses and participants of the trial; some of the quotations have been published previously in the publications detailed above.

It is of fundamental importance to understand the perspectives of both those involved in the delivery of the intervention and those who received the intervention. In *Chapter 6*, we provided a comprehensive process evaluation of the trial which described, in detail, the training and support given to the trial nurses. In *Chapter 6*, we also addressed issues related to the fidelity of the trial delivery by the nurses. In this chapter, we focus on the nurses' perspective on their experience of participating in the trial, with a view to understanding how we can better plan and deliver primary care-based trials and then implement them more widely. There is an extensive literature that examines adherence to behaviour change interventions in adults and which establishes the barriers to, and facilitators of, for example, increasing PA. For example, Picorelli *et al.*,<sup>186</sup> focusing on older adults, reported that adherence to exercise interventions was associated with key demographic factors (higher socioeconomic status and not living alone), health status (fewer health conditions, taking fewer medications and better self-rated health) and psychological factors (fewer depressive symptoms).<sup>186</sup> For trial participants, a novel part of our qualitative study addressed a related, but much less well researched, issue of trying to understand why the intervention did, or did not, work as a means of evaluating the individual elements of the intervention in facilitating behaviour change.

## Recruiting trial participants for the qualitative study

At initial recruitment into the trial, participants were asked for consent to participate in follow-up telephone interviews, such as those included in this aspect of the study. The trial statistician prepared a spreadsheet of all participants who had completed the 12-month follow-up in January 2014 and who had given consent to be approached to participate in the telephone interviews (this list was updated in March 2014). We purposely recruited participants who had, and had not, increased their PA levels from both nurse-supported and pedometer-only intervention groups. We defined an increase as  $\geq 200$  steps per day; anyone who either did not achieve this or decreased their PA was defined as a non-improver. This gave us four interview groups: (1) nurse support/increase, (2) nurse support/no increase, (3) postal delivery/increase and (4) postal delivery/no increase. We also ensured that we sampled participants with a range of ages, from both sexes and from all six of the initial participating practices. As noted in *Chapter 2*, a novel feature of our trial was the option for participants to take part as a couple and we wanted to ensure their inclusion in our qualitative study. We purposely targeted potential participants from demographic groups under-represented in our main sample (e.g. ethnic minority community participants) to ensure that we explored the widest range of views possible.

Between February and April 2014, we identified 96 trial participants who had been selected on the basis of the criteria described above. We made contact with 44 of these participants, of whom only one declined to be interviewed. We were unable to make contact after three attempts with the remaining 52 participants, who had been initially identified as potential participants. The 43 participants we recruited broadly approximated to the demographic parameters specified, with 20 participants in the 45- to 59-year-old age group, 29 participants being female, 21 participants in the nurse-supported intervention group and 23 participants who did not increase their step counts. We interviewed seven participants who took part as a couple, but we did not interview both partners. In terms of ethnicity, 29 were white British and a further five were from other white ethnicity groups, with nine participants from black and Asian ethnic minority groups. *Appendix 6, Table 43* shows the demographic and step count details of individual participants.

We used a semistructured interview guide tailored for each group to reflect the nature of the interventions and the classification of participants as improvers/non-improvers.<sup>162</sup> The 43 interviews completed ranged in duration from 9 to 44 minutes, with an average (mean) duration of 21 minutes. Interviews were recorded and transcribed verbatim. Full details of the analysis strategy for our qualitative interviews is provided elsewhere,<sup>162</sup> but are briefly summarised here. All transcripts were read by four authors (RN, JS, CV and TH), codes were assigned independently and discrepancies were resolved by discussion. Codes were grouped into themes, which were further refined by discussion to produce broader themes, encompassing several subthemes. Theoretically informed BCTs were an important element of the trial and we were interested in understanding which of these had been of most use to participants. We performed an additional analysis of the data to specifically draw out themes relevant to these techniques. We have reported the reasons for trial non-participation and the barriers to, and facilitators of, increasing PA elsewhere.<sup>148,162</sup> We have noted elsewhere that, although we defined our groups by the quantitative increase in walking, responses from participants did not demonstrate this distinction. In this, and in our previous qualitative evaluation from the PACE-LIFT study,<sup>149</sup> almost all participants interviewed felt that they had benefited from the trials, even if this had not been manifested by an increase in their step count. In this chapter, we focus on what participants told us about their motivation for participating in the trial, their experiences of the various components of the trial and the longer-term impact of trial participation.

## The role of nurses in the PACE-UP intervention

As described in detail in *Chapter 6*, the trial intervention was delivered by eight nurses across seven practices. They delivered three PA consultations to participants in their arm of the trial. These took place in weeks 1, 5 and 9 of the 12-week pedometer-based walking programme. Participants developed an individualised PA plan with the practice nurses, based around their current level of activity, with the goal of increasing both step count and time spent in MVPA. The nurses provided each participant with an individual PA diary, including step count targets for the 12 weeks, based on their own baseline PA measures, but this could be tailored further in the nurse PA consultations through joint discussions between nurse and participant. Five PACE-UP trial nurses participated in a focus group that was led by two of the research team (CB and CV); additionally, two nurses were interviewed individually by Rebecca Normansell (who also attended the focus group) and one further nurse was not available to participate in this phase of the research. A further focus group was also carried out with nurses involved in the previous PACE-LIFT trial of a pedometer-based walking intervention with older people.<sup>21</sup> The focus groups lasted for, on average, 106 minutes and the individual interviews lasted for 50 minutes. The published evaluation of nurse experiences of the interventions includes data from both trials.<sup>185</sup> In this chapter, we have limited the results presented to those from the PACE-UP trial nurses. A semistructured interview guide was used to elicit the nurses' views on their participation in the trial (see *Appendix 6*). The interviews/focus groups were audio-recorded and transcribed verbatim. Full details of the methods used are available elsewhere,<sup>185</sup> but are briefly summarised here. Coding the transcript themes was guided by thematic analysis for both the group and individual interviews, and areas of disagreement were discussed to ensure a consensus. Researchers were mindful that group interviews reflect a generalised understanding, whereas individual interviews provide more personal views. However, similar interpretations and themes emerged from both types of interview, and referral

to field notes throughout the process enhanced the trustworthiness of the findings through data triangulation.<sup>185</sup>

In the rest of this chapter, we combine the perspectives of both the nurses and the trial participants to provide an overview of their experiences of being part of the PACE-UP trial. We present our results in terms of the three key phases of the intervention: preparing for the trial, delivering or receiving the intervention and after the trial/implementation.

## Preparing for the trial

A key theme that emerged from our work with the nurses was the importance of the pre-trial training programme. As documented in *Chapter 6*, before the trial was implemented the nurses received training in the BCTs that underpinned the intervention. Support was then ongoing once the trial had started. Although these were experienced practice nurses, we could not presume detailed familiarity with all of the techniques that our study involved. An additional and important feature of the training was the importance of trial fidelity. One unique element of our trial was the delivery to couples. This is not a familiar service delivery model for our nurses and so it was one area where we provided specific support/training. As comprehensively demonstrated in *Chapter 6*, the consensus from our nurses was that they felt appropriately trained and prepared to deliver the intervention as per the protocol: 'all the training was really excellent' (PACE-UP nurse, focus group).

For participants, the key pre-trial activity focused upon the decision to participate. This is described in detail in *Chapter 5*, in which we discuss the recruitment and participation rates. In *Chapter 5*, and in Normansell *et al.*,<sup>148</sup> we present both the sociodemographic profile of participants and examine why individuals opted not to participate in the trial. Although we have details of the sociodemographic profiles of those who take part in PA trials, we have less information on what motivated participants to take part in the trial. This was not explicitly explored in our interview, as the focus was on the trial and its impact on levels of PA. However, some participants talked explicitly about their reasons for taking part in the trial. Key individually based motivations to participate were concerns about weight and helping to manage existing long-term conditions (especially diabetes mellitus). Others noted the commitment they were making in signing up for the intervention, even though they were not aware of which group they were in when they agreed to participate in the trial: 'Well I must admit, when I first signed up for it, I was thinking what I have done to commit myself to this for quite a long time' (ID30).

## Delivering and participating in the trial

Our focus in this chapter is on the experiences of participating in the trial, rather than on the outcomes or the factors that facilitated changes in PA. Our trial had three arms: usual care ( $n = 338$ ), postal pedometer intervention ( $n = 339$ ) and nurse-supported pedometer intervention ( $n = 346$ ). Of our 43 interviewees, 21 were in the nurse-supported intervention group and 22 were in the postal delivery group. We first consider the experiences of participants who were in the nurse-support group and compare these with the postal delivery group in terms of how they perceived their engagement with the trial.

### Perceived value of nurse consultations

The nurse-led consultations were well accepted by the participants in that part of the trial, with 74% (255/346) attending all three sessions. Overall, those who were allocated to the nurse-supported intervention arm were very happy with their meetings with the nurse, as illustrated thus:

*Yes, the nurse was very helpful . . . it was really good for me.*

ID12

Conversely, those who had not been in the nurse-support group were, overall, confident that they did not need the support of the nurse:

*I think I was happy doing it on my own. I don't think . . . I mean it was very . . . it was very easy to follow your instructions and what you wanted us to do and so I don't think meeting a nurse . . .*

ID13

*No, I don't think it [visiting the nurse] would have been useful really.*

ID17

Some were sceptical of what advice the nurse could give:

*No, not really. What would she say, walk a bit quicker, eat a bit less? It's common sense, I knew in the first place.*

ID23

*I know what I should be doing.*

ID8

Others were confident in their own internal motivation:

*I think if I've agreed to do something, then I will try and achieve that target, whether somebody tells me face to face or by post, so I think it's dependent on the individuals maybe, individual choice.*

ID38

There were two key caveats to the confidence of the postal delivery group in increasing their PA without the support of a nurse. These were existing health problems and overcoming barriers. Several participants in the postal delivery group observed that if they had had a long-standing health problem, they may have preferred the security and support of the nurse, as illustrated in this comment:

*If I did have health problems, I may have wanted to see a nurse, and say, look, I've been doing this and I've had an ache and a pain here, shall I stop or . . . you know, if it was that situation, and I think yes, you might need to speak to someone you know who could advise you medically, but I didn't need it.*

ID13

In addition, some participants in the postal delivery group thought that being able to see the nurse might have helped them to overcome the difficulties and challenges they experienced when trying to increase their PA, for example:

*I would have found that better [to see a nurse] because, if I'd have talked to her about the steps, she might have been able to umm introduce something else . . . [participant was concerned that the target step count was unachievable]. I think if I'd have been seeing the nurse regularly then, during that summer, umm, we would have found another way I feel, you know.*

ID19

### **Behaviour change techniques**

Our intervention included over 20 distinct behaviour change activities, as defined by Michie *et al.*,<sup>68</sup> embedded within the PACE-UP trial handbook and diary (received by both the postal delivery group and the nurse-support group) and, additionally, within the protocol for the nurse consultations. Reference to these specific BCTs were then extracted from the interview transcripts to determine what elements of behaviour change were viewed as being most helpful by the participants.<sup>162</sup> There were 152 examples of these factors in our interviews: 54 in the postal delivery group and 98 in the nurse-support group. With the exception of self-monitoring, the BCTs were more frequently noted in the nurse-support group

compared with the postal delivery group. The elements of Michie *et al.*'s<sup>68</sup> typology that were especially evident in our participants' comments were (1) the provision of information, (2) monitoring and feedback and (3) strategies for relapse prevention/overcoming challenges. Rewards, an important element of the typology, were not seen as being of great importance by our participants. Both of our intervention groups appreciated receiving information about the link between behaviour and health. However, a key and important type of information provided, especially in the nurse-support group, was specifically tailored and personalised information about how, where and when to increase walking, for example:

*She gave me a printout of umm . . . some . . . walks that you could do, group walks and things like that.*  
ID18

In terms of monitoring and feedback, nurses played an important role for their group, as exemplified by comments such as the following:

*She was very encouraging.*  
ID39

*Oh I felt really happy [with the nurse] and she was very happy too with me and I did really like my nurses, yes. That was one of my reasons because, each week I go, I ask her if they think I am doing well, am doing well, yes [laughs].*  
ID12

Importantly, the nurses were seen to provide motivation and encouragement when the 'novelty' of the intervention was waning and participants were at risk of lapsing, for example:

*I think there was a point where they sort of said, you know, don't give up now, or something like that, you know, at the point where . . . the novelty might have worn off . . .*  
ID35

The postal delivery group largely felt that they could self-monitor their activity:

*I felt like it was enough to know [the step count] . . . I think it was fine, just to sort of keep . . . I was very good about filling the diary in and it was sort of for me that was enough to keep me going really.*  
ID43

### **Adapting the trial protocol versus fidelity**

Given that this was a trial, it was essential that the nurses delivered the intervention as per the protocol; therefore, before the trial started, we provided extensive training to the nurses and emphasised the importance of adherence to the prescribed protocol:

*The equipment was excellent, the pedometers, the accelerometers, excellent, excellent, excellent.*

However, given that the trial ran over 12 months, pragmatic adaptations were made by the nurses (in consultation with the team) in response to the specific circumstances of participants, for example, working around holiday periods (e.g. Christmas) or periods of religious observance, such as Ramadan:

*. . . forget about the 2 months around Christmas . . . you can't get appointments and they don't want to wear it [pedometer].*

This serves to remind us that delivering behaviour change interventions in real-world practice requires 'fine tuning' in the delivery to reflect the complexity of people's daily lives. We assessed fidelity by audio-recording a minimum of three consultations for each nurse, as described in detail in *Chapter 6*. However, this also enabled us to provide specific feedback to the nurses on their use of the BCTs employed. This was universally

welcomed and improved their practice during the trial, but also provided them with enhanced skills to take into practice beyond and after the trial:

*I actually changed my practice from thereon, so yes, it was exceptionally helpful.*

### **Trial materials and equipment**

Both nurses and participants remarked on the materials that supported the trial, namely a pedometer, a PA diary and a series of optional handouts, as described in *Chapter 2*. From the participants' perspective, each element of the trial had both advantages and disadvantages. However, the focus of the comments about equipment from the participants' perspective was upon the accuracy (or otherwise) of the pedometer. Typical of the more critical comments of the pedometer was:

*That day we went for a really long walk round the common, I was really disappointed when I come back, it didn't seem to register very many steps. I've obviously done a lot more than . . . registered about ,000 or something, well walked around the whole of Tooting, is a bit more than that I think.*

ID7

There were fewer comments about the diary, which was seen as being motivating:

*I was very good about filling the diary in and it was sort of for me that was enough to keep me going really.*

ID43

However, for others it was chore:

*Like I say, it is an effort, it's umm . . . you have to know what you are in for, and then really maintain it. I had to record it every day, yes, you are busy, sometimes you are out and you go for dinner and then you come home and then you had a few drinks and you can't remember what day it is.*

ID1

*Actually writing down the activities and things, it . . . after about the first day, I got bored with that.*

ID3

### **Nurse satisfaction**

One feature of the trial noted by the nurses (but not the participants) was the time that they had to devote to the PA consultations compared with their normal activities, as this comment illustrates:

*You know, we don't have any protected time for health promotion . . . the health promotion is the add-on. It's giving us the time, because we don't have the time.*

From the nurses' perspective, this engagement provided considerable job satisfaction in seeing their participants embrace change and become more physically active. A feature not experienced prior to the trial by most of the nurses was delivering the intervention to couples rather than individuals. This presented a unique challenge for some of the nurses as, in normal practice, it is unusual to be working with two patients simultaneously. Sometimes the dynamic worked well:

*. . . most couples, they enjoy doing it together because they'd go . . . they could go out walking together and, even if it was through the winter, at least if they were both going, they had each other . . . they use to encourage each other. So if one didn't want to go the other one would encourage them and they'd make sure they went.*

At other times, the problems encountered were a significant barrier:

*I'm not actually overly sure how couples worked. I don't know if I had, I don't know if it caused more issues sometimes, in the fact with the pedometers, because they got so focused sometimes on the fact that their pedometers didn't match up.*

## After the trial and implementation

All participants felt that they had benefited, regardless of changes in their objective PA levels, and had developed skills in terms of embedding PA in their daily lives and routines and by developing strategies to overcome challenges when they arose:

*Yes, everyone in my house now, we don't drive to the shops, we all walk to the shops . . . it was easier for me just to jump in to the car, now I have to think twice, do I really have to?*

ID21

*Yes, setting my own targets and now . . . well, it's something that I've got used to now and I'm determined to keep it up.*

ID11

All of our nurses were very positive about how participation in the trial had developed and enhanced their knowledge and skills, which they were applying across a wide range of routine lifestyle consultations, not just related to PA, but also for smoking cessation, weight loss management and the prevention of chronic diseases. From the perspective of primary care and the nurses specifically, participation in the trial generated a legacy and the project was, in a small way, able to support the development of expertise in primary care of the use of BCTs and in working with patients in different ways (e.g. couples).

Our intervention was an individual as opposed to a group-based intervention. Some participants firmly believed that this was most appropriate:

*If it involved each person reporting back on their success or failure at meeting the previous targets, it might be a bit awkward in a group possibly.*

ID2

However, others identified the potential benefits of a group intervention:

*When you are with other people, and then you see the same problems they are facing, some of them might come up with other ideas . . . you can form a team, support network.*

ID21

Ultimately, this suggests that we need a repertoire of interventions that mesh with the circumstances and preferences of the different populations.

There was virtually uniform support for the location of the trial within a primary care context, with many participants recognising the convenience of getting to their GP surgery:

*. . . you wouldn't want someone to have to travel and people know how to get to their doctors don't they?*

ID 29

*Yes, that was good, because obviously it was very near home so it was ideal.*

ID15

From the nurses' perspective, although acknowledging that the intervention would be beneficial to their patients, they observed that within the time constraints of routine practice, they would not be able to replicate the full intervention as it stood within a routine nurse consultation. The nurses made suggestions for modifying the intervention to focus on the pedometer and printed materials for use opportunistically within 'normal' practice and, perhaps, to be available on prescription. The suggestion that health advisors, or a related role, could deliver the intervention that we evaluated was not supported by our nurses.

## Discussion

From this phase of our study, several key points arise. Almost without exception, both the nurses and the participants enjoyed taking part in the study and felt that it had provided them with important and enduring benefits. For the nurses, these benefits were couched in terms of new skills that they could transfer into their routine practice. For participants, there was an increase in their awareness of the benefits of walking as a means of enhancing health by increasing PA. Among our intervention groups, this perceived benefit was articulated irrespective of the objective changes in PA.

For nurses and intervention group participants, a key feature of the trial was the preparatory work before the intervention started. This was especially important for the practices who participated and the nurses. We opted to deliver this trial in 'ordinary' general practice settings to test out the potential of the intervention to be implemented in routine primary care settings. Participants and nurses alike felt that primary care is the appropriate setting from which to run such interventions. However, the nurses provided a caveat to this with comments about the constraints of time within 'real-world' primary care. Prior to the implementation of the intervention, the research team and our behaviour change experts worked extensively with the practices and nurses and provided training in the intervention, feedback on the delivery of the intervention and support across the trial to the nurses delivering the intervention. One example of a challenge with which some nurses needed support was in working with couples. This is not something that usually occurs within their general working regime and support from the research team in dealing with these challenges was important.

The nurses were supported to adapt how materials were introduced and used within the consultations to make these materials relevant to the participant and thereby personalise the intervention more. This is a key challenge in effectively delivering standardised interventions, in both trial settings and every day primary care – how to ensure the consistency of information provision and support, while also making it relevant to individuals. Empowering nurses, and other primary care staff, to make 'patient-centred' adaptations to standard behaviour change programmes is likely to result in improved outcomes. This links to the important issue of tailoring support to make changes in health behaviours to match the circumstances and preferences of individuals. Thus, support needs to be appropriate to external factors, such as seasons or the time of year, or key events in peoples' lives, such as retirement, but also reflect individual circumstances such as preferences for group or individual activities and the relevance of written or other types of digital materials and current health problems. Our study has included two types of intervention that offered varying levels of support, both of which generated increased levels of PA. A key challenge for future studies is to determine which groups would benefit from the 'minimal support' pedometer by post-type intervention, and those for whom the more intense nurse-led intervention is the most appropriate.

# Chapter 8 Three-year follow-up to assess the maintenance of physical activity levels

## Introduction

The PACE-UP analyses showed positive effects on 12-month PA levels (see *Chapter 3*). We wanted to see if this effect was maintained at 3 years, as this has important implications for the NHS; specifically, would any future pedometer programme require a 'top-up' after 12 months? Our interventions led to an extra 33–35 minutes weekly of MVPA in bouts (an increase of about one-third from baseline) in a predominantly inactive cohort. Delivery via three nurse PA consultations had the same effect on 12-month outcomes as the simpler, cheaper postal delivery. These are exciting findings, as they show that a low-cost postal pedometer intervention increases PA levels in sedentary adults and older adults. However, it is vital to know whether 12-month effects persist at 3 years or if a further intervention boost is needed. We therefore successfully applied for additional funding from NIHR's Health Technology Assessment programme to follow-up the trial cohort at 3 years (2 years after the previous 12-month follow-up) with both quantitative and qualitative evaluations. Both the qualitative<sup>187</sup> and the quantitative findings<sup>188</sup> have been published and are reproduced here under the terms of the Creative Commons Attribution License (<http://creativecommons.org/licenses/by/4.0>).

To date, little is known about the long-term sustainability of PA interventions. A meta-analysis of interventions (including pedometers) to increase PA levels in 55- to 70-year-olds included only four trials with data beyond 12 months (all self-reported). They found a limited evidence base beyond 12 months, and called for more trials with a longer follow-up period and objective PA measures.<sup>26</sup> These findings were supported by a Cochrane systematic review<sup>23</sup> and recent NICE guidance on PA interventions.<sup>29</sup> The ProAct 65 + trial<sup>189</sup> of a PA intervention found that between-group differences persisted at 2 years post intervention, but only for self-reported PA.

As well as a lack of long-term objective PA data after interventions, there is also a lack of qualitative evidence on maintenance. A literature review suggested that PA disengagement usually occurs 6 months after an intervention has ended, but called for more research to distinguish the factors that lead to successful and unsuccessful PA maintenance.<sup>190</sup> A very small primary care study followed up participants 6 months after a pedometer-based intervention, and found some useful insights to explain how this pedometer intervention worked and how it may be developed,<sup>44</sup> but further qualitative studies on longer-term effects are lacking.

The PACE-UP trial 3-year follow-up provides evidence on objective PA levels, 2 years after the 12-month follow-up. After the 12-month follow-up, 212 out of 322 controls (66%) received a pedometer, handbook and diary by post. They had no further input (unlike the original postal delivery group, who were telephoned by a research assistant 1 week after being sent the pedometer, to check that it had arrived, and who were asked to return their completed PA diaries for review at 3 months). The control participants being sent the pedometer by post mimics what would happen if this simple, pragmatic intervention were to be rolled out by post through routine primary care, without any further input. As described in our protocol,<sup>70</sup> a further 64 out of 322 control participants (20%) attended a single nurse appointment after the main trial, in which they were given a pedometer, diary and handbook, but, again, received no further contact. The other intervention groups received no further intervention after the 12-month follow-up [apart from a small number of the postal delivery group, 50/312 (16%), who had a single nurse PA appointment].

Anthropometric measures did not show differences at 12 months; therefore, data on these were not collected at the 3-year follow-up. Therefore, our follow-up study focused on establishing evidence of effectiveness at 3 years in objective PA measures and had the following objectives:

- to investigate if the original nurse-support and postal delivery groups showed any persistent intervention effect (change in step count and time in MVPA in bouts) at 3 years, compared with the baseline levels
- to investigate if there were any differences between the original nurse-support and postal delivery groups in their change in objective PA levels (step count and time in MVPA in bouts) between baseline and 3 years
- to investigate if the simple postal pedometer intervention at 12 months increased objective PA levels (step count and time in MVPA in bouts) in the control group compared with baseline.

We also felt that it was important to explore how participants in the nurse-support and postal delivery groups felt about the interventions in terms of maintenance of any increase in PA levels, and what factors might help to encourage this further or to overcome barriers they had to increasing or maintaining their PA levels. Furthermore, we were interested in how the initial control group felt about the minimal intervention that they received. Our qualitative evaluation therefore had the following objectives:

1. qualitative evaluation of both the nurse-support and postal delivery intervention groups to look at factors affecting PA levels and maintenance of any increase in PA levels at 3 years
2. qualitative evaluation of the control group to see the effect of the minimal intervention on PA levels.

## Methods for quantitative physical activity evaluation

The 3-year follow-up focused on collecting the objective PA accelerometry data and other questionnaire-based self-reported outcomes by post to minimise data collection costs. To allow for seasonal variation in PA levels, the baseline, 12-month and 3-year outcomes needed to be assessed in the same calendar month; therefore, follow-up ran from October 2015 to November 2016.

### *Ethics approval and research governance*

Ethics approval for the 3-year follow-up was granted to the trial from London, Hampstead Research Ethics Committee (reference number 12/LO/0219). NHS local research and development approval was granted to cover all of the practice sites.

### *Participants eligible for the 3-year follow-up*

All trial participants who had not withdrawn from the trial were eligible to be followed up, even if they had not provided 3- or 12-month follow-up data. Lists of eligible participants were organised by practice and practices were asked to check whether any participants had died, moved away or developed a terminal illness or dementia since trial participation. These patients were then excluded.

### *Contacting participants*

Eligible participants were contacted with a letter explaining the trial 3-year follow-up. A participant information sheet, consent form and a Freepost return envelope were also included, as was information on the main 12-month trial results. The letter explained that a research assistant would contact the participants by telephone in around 1 week's time to discuss the 3-year follow-up. If they were happy to take part without further discussion, they were invited to post back the signed consent form.

### *Informed consent*

The research assistant contacted participants by telephone approximately 1 week after sending out the letter about the 3-year follow-up to discuss any questions they might have after reading the participant information sheet. Part of the consent form included consent to contact participants for an interview to

discuss their current PA levels in more detail. If the participants were happy to proceed with the 3-year follow-up, they signed and dated the informed consent sheet and returned the top copy to us.

### Data collection

Once the informed consent for follow-up was agreed, the research assistant arranged a time to post out the accelerometer (GT3X+) to participants to measure their current usual PA levels for 1 week. Instructions about how to wear the accelerometer were included (on a belt, over one hip) and participants were asked to wear it for 7 consecutive days, from getting up until going to bed, as they had done previously. A diary was also provided to record what activities were done and for how long. They were also sent a health and lifestyle questionnaire to complete (see *Appendix 7*; this was similar to that completed previously) and a short questionnaire about self-reported PA levels to complete (the 7-day PA questionnaire used previously) after they had finished wearing the accelerometer. They were provided with a Freepost return envelope to send the accelerometer and both questionnaires back. If the accelerometer did not record at least 5 days with at least 540 minutes per day, participants were asked to rewear it for a further week. The set of recordings with the greatest number of days with at least 540 minutes per day was included in the analysis. Once accelerometers with adequate data were received, participants were posted out a £10 gift voucher.

### Outcome measures

The main outcome measures (all accelerometry) used to evaluate the 3-year follow-up were as follows:

1. change in average daily step count, measured over 7 days between baseline and 3 years
2. change in time spent weekly in MVPA in  $\geq 10$ -minute bouts between baseline and 3 years
3. change in time spent sedentary weekly between baseline and 3 years.

Although patient-reported outcome measures were collected from the health and lifestyle questionnaire (e.g. depression,<sup>75</sup> anxiety,<sup>75</sup> quality of life,<sup>76</sup> self-efficacy,<sup>74</sup> pain,<sup>77</sup> disability<sup>80</sup>) and from the 7-day PA questionnaire (IPAQ<sup>72</sup> and GPPAQ<sup>73</sup>), these have not been assessed further as part of this report.

### Accelerometer data reduction

ActiGraph data were reduced, as described previously in *Chapter 2*, for the main trial. Analysis summary variables were also identical to those used in the main trial, described fully in *Chapter 2*.

### Procedure for accounting for missing data

Only days with at least 540 minutes of registered time on the accelerometer on a given day were used. The main analysis of effect included all subjects with at least 1 satisfactory day of recording at 3 years.

### Statistical methods

Statistical methods for the analysis of the 3-year follow-up are largely as described in *Chapter 2* for the primary analysis at 12 months. Average daily step count at 3 years was computed from a random-effects model, allowing for day of the week and day order of wearing the accelerometer as fixed effects and participant as a random effect. The average daily step count at 3 years was then regressed on average daily step count at baseline with treatment group, age, sex, practice and month of baseline accelerometry as fixed effects and household as a random effect, in a multilevel model. The same analyses were carried out for MVPA in  $\geq 10$ -minute bouts and daily minutes of sedentary time.

The primary analyses used the 681 participants who provided accelerometry data at 3 years. Sensitivity analyses were carried out to assess the effect of missingness:

1. Multiple imputation methods were used to impute outcome data for those missing at 3 years, assuming that outcomes were missing at random, conditional on variables in the model. We used the Stata procedure *mi impute*.

- Missing-not-at-random analyses were used when it was assumed that changes in the control group from baseline to 3 years were missing at random, but the change in each of the intervention groups was  $\pm 500$  and  $\pm 1000$  steps from their missing-at-random estimate.

For this analysis, we used a mean score method,<sup>191</sup> which has been implemented in a Stata module, *rctmiss*, available from Statistical Software Components at <https://ideas.repec.org/s/boc/bocode.html> (accessed 25 May 2018).

## Methods for qualitative evaluation

### Sampling

Participants consented to be contacted for a telephone interview at the same time as they consented to take part in the 3-year follow-up. In February 2016, the research assistant produced three lists of participants who had already provided 3-year accelerometry data and who had given consent to be interviewed (one list for each arm of the trial – nurse support, postal delivery, control). The trial statistician randomly sorted these three lists ready for the qualitative researchers to start approaching participants for interviews. The interviewers were blinded to participants' previous and current PA levels.

One of the aims of the qualitative evaluation was to explore the success, or otherwise, of the minimalist intervention provided to the control group after the main trial; therefore, the following participants were excluded from this qualitative evaluation:

- control group participants who had attended a nurse consultation after the main trial
- control group participants who opted not to receive the postal pedometer after the main trial.

At 12 months, participants in the postal delivery group were also offered a nurse consultation. Again, those who attended the nurse consultation were excluded from the sampling procedure, so that all those sampled from the postal delivery group had received just the postal intervention.

The aim was to interview approximately 15–20 people from each arm of the trial (45–60 people in total), but continuing further if required, until saturation was reached. As two researchers (CB and CW) were interviewing participants, they met regularly to discuss the sampling, interview schedule and any emerging themes. Interviews were conducted until saturation of new information was reached. By looking at the participants' demographic information it was possible to ensure that the study group included both males and females and also represented a range of different ages and ethnicities, to ensure that a wide range of views were explored.

### Recruitment and informed consent

Participants were initially contacted via e-mail to arrange an appropriate time to contact them for a telephone interview. Participants without an e-mail address were called and the interview was either conducted then or arranged for later. To assess response, a detailed record was kept of when each participant was contacted, including information on who agreed, who refused and who could not be contacted. Charlotte Wahlich and Carole Beighton conducted the guided interviews with participants using a topic guide (see *Appendix 7*). Before the interview commenced, the participants were reminded of their initial consent to be approached for an interview; if the participants were happy to go ahead, their consent was then sought for the interview to be audio-recorded. Once the recording had started, the qualitative researchers stated the participant's ID number to ensure confidentiality and anonymity in the subsequent transcript. On interview completion, the participants were offered a £10 high-street gift voucher to thank them for their time.

### Transcribing

Interviews were promptly transcribed verbatim by an external source. Once the transcripts were received back, they were double-checked against each audio-recording by the qualitative researchers. Transcripts were also circulated to the research team to ensure consistency between the interviewers and to help assess when theme saturation had been reached.

### Interview schedule

The interview schedules were developed through discussions with Tess Harris, Charlotte Wahlich, Carole Beighton, Christina Victor and Rebecca Normansell. Slightly different questions were used for participants in the intervention groups (postal delivery and nurse support) and participants in the control group (see *Appendix 7*). For those in the intervention groups, the aim was to explore participants' views about PA maintenance and whether or not a 'top-up' intervention was required, whereas for those in the control group, the aim was to explore their views about the minimalist intervention. The interview schedules were revised slightly during data collection to ensure that the questions were clear and to include additional questions to gain a better understanding of the participants' experiences.

### Analysis

All verbatim transcripts were read repeatedly by Charlotte Wahlich and Carole Beighton. Initial line-by-line coding was conducted independently to assign conceptual ideas to important episodes within the data. Through discussion with Rebecca Normansell, Tess Harris and Christina Victor, any discrepancies were resolved; this helped to ensure that the interpretation and categorisation of the data were valid. After further discussions between Charlotte Wahlich and Carole Beighton, these codes were then refined and grouped into emergent and anticipated themes.

## Results for the quantitative physical activity evaluation

### Follow-up rate

Of the 1023 original trial participants, 32 had withdrawn by the end of the 12-month follow-up, a further two had died between the 12-month and the 3-year follow-up and one was excluded by their practice for health reasons. Therefore, we approached 988 participants and 681 provided adequate accelerometry data ( $\geq 1$  day with  $\geq 540$  minutes wear time) for analysis, giving a 3-year follow-up rate of 69% (681/988). However, in relation to the initial trial participants providing 3-year outcome data, the 3-year follow-up rate was 681 out of 1023 (67%). The CONSORT flow diagram with 3-year follow-up data is shown in *Figure 15*, by randomised group.

### Data completeness

*Table 20* shows that 92% of participants (625/681) overall provided  $\geq 5$  days of accelerometry data at 3 years (88% of control participants, 94% of postal delivery participants and 93% of nurse-support group participants).

### Objective physical activity findings

*Table 20* shows the summary measures for all three groups at each time point and *Table 21* shows the estimates of effect for the different groups. For the main trial outcome of steps per day, both intervention groups were still doing more than the original trial control group: 627 steps (95% CI 198 to 1056 steps) in the postal delivery group and 670 steps (95% CI 237 to 1102 steps) in the nurse-support group. The nurse-support and postal delivery groups combined did 648 steps per day (95% CI 272 to 1024 steps). The pattern was similar for the total weekly MVPA in bouts (minutes per week): 28 minutes (95% CI 7 to 49 minutes) in the postal delivery group and 24 minutes (95% CI 3 to 45 minutes) in the nurse-support group. The nurse-support and postal delivery groups combined did 26 minutes (95% CI 8 to 44 minutes). There was no difference between the groups at 3 years for sedentary time or daily wear time.

### Missing data analyses

Imputation analyses (see *Table 22*) presents the results for missing at random, using imputations based on the different assumptions detailed in the methods section. The imputation analyses show that making adjustments for missing values has only a small effect on the primary outcome, that is, the step count estimate, and does not change the interpretation.




FIGURE 15 The PACE-UP CONSORT flow diagram with 3-year follow-up data.

**TABLE 20** Summary means and SDs for accelerometry data at baseline, 3 months, 12 months and 3 years

Accelerometry data	Randomised group											
	Control				Postal delivery				Nurse-support			
	Baseline	3 months	12 months	3 years	Baseline	3 months	12 months	3 years	Baseline	3 months	12 months	3 years
Number of participants	338	318	323	214	339	317	312	236	346	319	321	231
Number of participants with ≥ 5 days wear (%)	338 (100)	286 (90)	300 (93)	188 (88)	339 (100)	282 (89)	287 (92)	222 (94)	346 (100)	296 (93)	302 (94)	215 (93)
Daily step count, mean (SD)	7379 (2696)	7327 (2688)	7246 (2671)	7281 (2721)	7402 (2476)	8086 (3014)	8010 (2922)	7896 (2853)	7653 (2826)	8707 (3206)	8131 (3228)	8131 (3410)
Total weekly minutes of MVPA in ≥ 10-minute bouts, mean (SD)	84 (97)	87 (101)	89 (94)	94 (102)	92 (90)	136 (125)	129 (124)	132 (124)	105 (116)	164 (154)	138 (141)	138 (161)
Daily sedentary time (minutes), mean (SD)	613 (68)	614 (70)	616 (72)	615(71)	614 (71)	614 (74)	617 (71)	617 (75)	619 (78)	613 (77)	620 (79)	620 (69)
Daily wear time (minutes), mean (SD)	789 (73)	795 (78)	791 (76)	789 (78)	787 (78)	798 (84)	800 (80)	798 (86)	797 (84)	805 (85)	807 (89)	805 (81)

**Note**

Accelerometry data are adjusted for day of the week and day order of wearing the accelerometer as fixed effects and participant as a random effect in a multilevel model.

**TABLE 21** Accelerometry outcome data at 3 months, 12 months and 3 years. Analysed using all available data at each follow-up. *N* = 954 at 3 months, *N* = 956 at 12 months and *N* = 681 at 3 years

Outcome	Comparison of change from baseline between randomised groups					
	Postal delivery vs. control		Nurse support vs. control		Nurse support and postal delivery vs. control	
	Effect (95% CI)	<i>p</i> -value	Effect (95% CI)	<i>p</i> -value	Effect (95% CI)	<i>p</i> -value
Daily step count						
3 months	692 (363 to 1020)	< 0.001	1173 (844 to 1501)	< 0.001	–	
12 months	642 (329 to 955)	< 0.001	677 (365 to 989)	< 0.001	660 (389 to 930)	< 0.001
3 years	627 (198 to 1056)	0.004	670 (237 to 1102)	0.002	648 (272 to 1024)	< 0.001
Total weekly minutes of MVPA in ≥ 10-minute bouts						
3 months	43 (26 to 60)	< 0.001	61 (44 to 78)	< 0.001	–	
12 months	33 (17 to 49)	< 0.001	35 (19 to 51)	< 0.001	34 (20 to 48)	< 0.001
3 years	28 (7 to 49)	0.009	24 (3 to 45)	0.026	26 (8 to 44)	0.006
Daily sedentary time (minutes)						
3 months	–2 (–12 to 7)	0.59	–7 (–16 to 3)	0.16	–	
12 months	1 (–8 to 10)	0.82	0 (–9 to 9)	0.96	0 (–7 to 8)	0.92
3 years	–1 (–12 to 11)	0.90	–2 (–14 to 9)	0.69	–1 (–11 to 8)	0.77
Daily wear time (minutes)						
3 months	2 (–8 to 12)	0.69	4 (–6 to 14)	0.39	–	
12 months	9 (–1 to 19)	0.08	9 (–1 to 19)	0.07	9 (0 to 18)	0.04
3 years	8 (–5 to 20)	0.23	7 (–6 to 19)	0.32	7 (–4 to 18)	0.21

**Notes**

All models include treatment group, practice, sex, age at randomisation and month of baseline accelerometry as fixed effects and household as a random effect in a multilevel model. The *xtmixed* command in Stata version 12 was used, followed by the postestimation command *pwcompare* to generate the pairwise estimates of effect and their CIs (see Table 22).

The missing-not-at-random analyses make a bigger impact, but only when we assume that there is a strong differential departure between the non-random effects in the control and treatment groups (solid lines in Figure 16). Even then, it is only when we assume that the missing data in the treatment groups are 1000 steps below their missing-not-at-random values, while the values in the control group are at their missing-not-at-random values, that the treatment effects become non-significant; even then, the CI is still largely positive.

**Results for the qualitative evaluation**

Between March and April 2016, 105 participants were randomly selected, 96 were contacted and all agreed to participate. Telephone interviews were arranged and undertaken with 60 participants (20 from each trial arm). Fifty-two participants were white and eight were non-white. Interviews lasted between 4 and 22 minutes (median 10 minutes). One participant who had difficulty hearing was e-mailed the questions to complete. In the quotations that follow, ID3Y\_ refers to the participant’s ID number, F/M refers to the participant’s sex, the number following this refers to their age and N, P or C refers to whether the participant is in the nurse-support group, the postal delivery group or the control group, respectively.

TABLE 22 Imputation analyses for the 3-year accelerometry outcomes

Missing at random imputation analyses	N	Randomised group(s) vs. randomised group					
		Postal delivery vs. control		Nurse support vs. control		Nurse support and postal delivery vs. control	
		Effect (95% CI)	p-value	Effect (95% CI)	p-value	Effect (95% CI)	p-value
All participants with follow-up data	681	627 (198 to 1056)	0.004	670 (237 to 1102)	0.002	648 (272 to 1024)	< 0.001
Imputed using treatment group, baseline steps, sex, age, practice, month of baseline accelerometry	1023	597 (174 to 1020)	0.006	679 (268 to 1089)	0.001	649 (295 to 1003)	< 0.001
Imputed using treatment group, baseline steps, sex, age, practice, month baseline accelerometry, NS-SEC, baseline self-reported pain and baseline body fat mass <sup>a</sup>	996	634 (211 to 1057)	0.003	735 (293 to 1178)	0.001	637 (239 to 1034)	0.002
Imputed using treatment group, baseline steps, sex, age, practice, month baseline accelerometry and 12-month steps <sup>b</sup>	965	625 (217 to 1033)	0.003	683 (270 to 1095)	0.001	655 (305 to 1005)	< 0.001

a Baseline data for NS-SEC or self-reported pain or body fat mass were missing for 27 participants and imputations were not available for these 27 participants when including these variables as predictors.

b Twelve-month steps were missing for 58 participants and imputations were not available for these 58 participants when including 12-month steps as a predictors.

### Factors affecting physical activity levels and maintenance at 3 years

A key theme that emerged from our interviews was the impact that the PACE-UP trial had on participants. Most participants, regardless of what group they were in, reported an increased awareness of PA. Participants described an increased understanding about the importance of PA for health, as well as an awareness about the amount of PA required to meet their daily step count target:

*It's made me more aware of the need to actually commit to doing some exercise a day, just strolling around the house, and going to the shops occasionally doesn't really make much difference. It doesn't meet the sort of threshold that you need to reach to ensure that you lead a healthy lifestyle.*

ID3Y27M56P

Participants felt that taking part in the PACE-UP trial and using a pedometer had 'kick-started' regular activity:


*It was the PACE-UP trial that helped get me started and I think that did make a huge difference to me.*

ID3Y47F51N

Participants highlighted different barriers to, and facilitators of, being able to stay physically active in the longer term. These barriers and facilitators were often the opposite of each other; for example, some participants saw good weather as a motivator to engage in PA, whereas others saw bad weather as a barrier to being physically active. Other important facilitators and barriers included health, self-motivation, ageing and social support. These factors were considered to be important by participants, regardless of which group they were in. For some participants, they felt that engaging in regular PA helped them to manage their health condition:

*The more active I am, the better the arthritis is.*

ID3Y25F60P



**FIGURE 16** Sensitivity analyses for different values of missing step counts. (a) Postal delivery group vs. control group; (b) nurse-support group vs. control group; and (c) postal delivery and nurse-support groups combined vs. control group. The figures show how different values for the missing step counts changes the treatment effects. The starting point where all missing step counts are replaced by ‘missing-at-random’ estimates in each group is represented by the zero difference estimate. Estimates in the different groups are then altered differentially over a range of scenarios. Control group – missing step counts are the same as the 3-year missing-at-random estimates. Treatment groups – missing step counts are 500 or 1000 steps lower than the 3-year missing-at-random estimates. Control group – missing step counts are 500 or 1000 steps higher than the 3-year missing-at-random estimates. Treatment group – missing step counts are the same as the 3-year missing-at-random estimates. Missing step counts are 500 or 1000 steps lower or higher than the 3-year missing-at-random estimates in all control and treatment groups (see White<sup>191</sup> for methods). The vertical lines are the 95% CIs for the estimated treatment effects. The treatment effect becomes statistically not significant when the CI crosses the horizontal line at zero.

Conversely, others felt that having a health condition was a contraindication to PA:

*I've got an ongoing problem where I get pain, so there's no way I'm going to be going out walking if I don't have to.*

ID3Y24F61P

Self-motivation was seen to be an important determinant to PA:

*I think it's got to come from inside.*

ID3Y19F62C

Some participants attributed the PACE-UP trial to providing them with this motivation:

*Before the PACE-UP trial, I had no incentive. And that really did help me. That put me/gave me the first steps as it were, got me on the right track.*

ID3Y47F51N

On the other hand, a few participants felt that since the PACE-UP trial had ended, their PA levels had decreased as a result of a lack of self-motivation:

*I'm not covering anything like what I was covering when I was on the programme, but I don't know how . . . to put myself in that mind set . . .*

ID3Y55M68N

Some participants chose to engage in PA as a way to stay young and slow down the ageing process:

*I've got nieces and a nephew . . . I need to be active to keep up with them because they are young. I just need to keep up with everyone else really. I don't want to slow down and become old. Unfortunately, I'm not really motivated by anything else.*

605027F65N

Other participants felt that their age had become a barrier to PA and were less likely to do as much as they did when they were younger:

*If anything I'm getting a bit older and I'm beginning to find it a little bit more of a strain.*

ID3Y42F59N

Many participants spoke about the importance of having friends and family to motivate them to participate in PA. Support from, and accountability to, family and friends were therefore seen as common facilitators of PA:

*Maybe my motivation is not only my health, but having somebody to do it with . . . to maybe be paired up with somebody who was like-minded . . . if I've promised/only promised myself, then I might find excuses not to do it.*

ID3Y50F63N

Lack of social support meant that some participants did not engage in PA:

*I haven't got anyone to walk with.*

ID3Y37F67P

Lack of time was the most frequently cited barrier to maintaining PA. Unlike the other factors previously mentioned, 'having time' to engage in PA was not mentioned as a facilitator. The reasons for a lack of

time included having 'family responsibilities' (looking after children, caring for older relatives), 'work commitments' or simply being 'too busy':

*I've got plenty of things that encourage me, it's just the time I find because I work full time, I just find it difficult to come home, sort of prepare meals, go to the gym, go for a walk . . . I don't think I need any more actual motivation, I just need a bit more time!*

ID3Y43F54N

Some participants spoke about strategies they adopted to overcome the barrier of lack of time, either by incorporating PA into their daily routine or by building up their daily PA in short bouts of activity:

*I walk up the escalators to get my little bit of exercise.*

ID3Y15M62C

*As opposed to the mind set of, oh, I've got to do an hour in the gym. Actually 10 minutes solid walking somewhere, several times a day, actually builds stuff up.*

ID3Y56F68N

At the end of the interview, participants were asked for their views on what additional support could be provided to aid PA maintenance. Participants were offered examples to comment on, which included regular text messages, online resources, annual nurse appointments and walking groups. Participants had varying preferences over which additional resources they would find the most beneficial. Although some participants liked the idea of a regular text message or 'jolly little reminders' (ID3Y47F51N) encouraging PA, others felt that these would be 'too intrusive' (ID3Y27M56P). Similarly, some participants liked the idea of having PA resources online to 'open at their own time' (ID3Y9F62C), whereas others felt that obtaining this information online would require 'a more proactive' (ID3Y47F51N) approach. On the whole, walking groups and nurse appointments were considered to be favourable. Some participants felt that walking groups would provide 'more motivation to go out' (ID3Y17M68C) and a regular nurse or other appointment would provide 'external accountability' (ID3Y52M66N).

As well as providing feedback on suggested possible resources, we proposed that participants also come up with additional suggestions. These suggestions included holistic appointments with a nurse to discuss both diet and PA, and more opportunities for older people:

*There is not much for people over 60, there's no real places that are easy on the doorstep.*

ID3Y2F64C

One participant spoke about being afraid to increase their PA levels, as they were unsure of whether or not it was safe. This participant sought more guidance around riskless ways to increase PA levels:

*I'm doing quite well with what I'm doing, so what's the point of sort of having a risk of a heart attack or something like that, suddenly break in to a stride and start running, so maybe a bit of guidance on what's going to happen to you if you do step up your exercise plan.*

ID3Y23M67P

### **The effect of the minimal intervention on physical activity levels of participants in the control group**

Of the 20 control group participants interviewed, 17 received the pedometer, handbook and diary after 12 months. Thirteen of these participants reported using these resources when they first received them; however, at 3 years, only four participants were continuing to monitor their steps [two with a pedometer, one with a Fitbit (Fitbit, San Francisco, CA, USA) and one with a mobile phone].

Although most of the control group participants who were interviewed felt that the PACE-UP trial had not increased their PA levels, they still stated that the PACE-UP trial had increased their awareness:

*It's made me aware that I do not do as much as I should be doing.*

ID3Y20F66C

Some, however, did talk about changes they had made to their daily lives as a result of their increased awareness:

*I'm more likely to walk to work now, rather than going on the bus.*

ID3Y11M54C

For those who did not utilise the pedometer, some reported difficulties in using it:

*I could not work the pedometer . . . could not get it going.*

ID3Y9F63C

A few others who used the pedometer stated that discontinued use was either because it had a negative impact on them psychologically or because they had fallen out of the habit of using it regularly:

*It's quite distressing to see how little I do.*

ID3Y1M58C

*. . . there are lots of other things [that] intrude and you tend to slip back to old patterns.*

ID3Y5F68C

There was also a suggestion that, as well as the pedometer, you needed to have someone to report back to:

*It always needs to have someone keeping you aware I think.*

ID3Y5F68C

## Discussion

### **Main quantitative findings from the 3-year follow-up**

We followed up just over two-thirds of the original trial cohort with accelerometry outcome data at 3 years (and over 90% provided  $\geq 5$  days of data). Compared with baseline, those in the original nurse-support and postal delivery groups were still doing significantly more steps per day and weekly time in MVPA in bouts at 3 years than the control group. There were no significant differences in outcomes between the postal delivery and nurse-supported intervention groups (as was also the case at 12 months), and there were no significant differences between the three groups in terms of wear time or sedentary time. Our sensitivity analyses looking at the potential impact of missing outcome data at 3 years suggest that it is highly unlikely that missing data have substantially biased our results. Fairly extreme departures from the missing-at-random analyses were needed to result in non-significant effects and, even then, the 95% confidence limits were largely positive. This suggests that the trial interventions had a persistent effect on objectively measured PA levels at 3 years, with no difference between intervention groups. The fact that the minimal intervention given to the control group at 12 months was not effective at increasing the participants' PA levels suggests that the additional support given to the original trial postal intervention group (with a follow-up telephone call after 1 week and encouragement to return the completed PA diary after 3 months) was an important component of this group's success. Both the follow-up telephone call and the encouragement to return the completed PA diaries after the intervention were not part of the intended intervention package, but, rather, were research measures as part of the process evaluation to

ensure fidelity of the intervention delivery. However, this minimal support, which was not provided face to face or by a health-care professional, seems to have been important to the success of the postal intervention. The original trial postal delivery group also received the postal pedometer intervention when they had just been recruited to the PA trial, when motivation may have been higher, and they had step count targets set for them based on their baseline blinded pedometer use, whereas those receiving the materials at 12 months needed to wear the pedometer again for 1 week to set their target step count. These factors may also have been important to the success of the trial postal intervention group.

### ***Main qualitative findings from the 3-year follow-up interviews***

A key finding was that most participants discussed their increased awareness of PA, irrespective of which group they were in and regardless of whether or not they thought that the PACE-UP trial had actually increased their PA levels. Key barriers to, and facilitators of, maintaining PA were reported that were often the inverse of one another and included health, weather, self-motivation, ageing and social support. Lack of time was the most frequently cited barrier. Some participants were able to overcome lack of time by incorporating PA into their daily routine or by breaking PA down into smaller, more manageable bouts throughout the day. Participants gave us mixed feedback on how useful they thought text messages and online resources would be to help to inform future interventions to increase and maintain PA, but walking groups and nurse or other appointments to provide external accountability were broadly welcomed. Additional suggestions provided included more holistic appointments with a nurse and more opportunities for PA for older people. Participants had differing opinions over the resources they would find most beneficial, emphasising the importance of individual tailoring of some aspects of PA interventions. Only a few of the control group participants interviewed were continuing to use the pedometer provided at 12 months. Some participants were not sure how it worked, and others felt that, as well as using the pedometer, it was important to have someone to report back to. This highlights the importance of the extra contact that participants in the postal delivery group received as part of the main trial: a follow-up telephone call to check that they knew how to work the device and encouragement to send back their completed PA diaries with step count recordings after the 12-week programme.

Further discussion of the strengths and weaknesses of both the quantitative and qualitative approaches, and the implications of the findings for health care and future research, are detailed in *Chapter 9*.

# Chapter 9 Discussion

## Summary of the findings

The PACE-UP trial demonstrated that both the postal delivery and the nurse-supported pedometer interventions, based on trying to gradually add in '3000 steps in 30 minutes' on most days, increased objectively assessed PA (step counts by around one-tenth and MVPA in bouts by around one-third) among predominantly inactive 45- to 75-year-olds at 12 months. Although the nurse-led delivery had a greater effect than the postal delivery at 3 months, by 12 months this difference was not sustained. The interventions had no effect on sedentary time, anthropometry or other outcomes and did not increase AEs. No effect modification was demonstrated (by age, sex, taking part as a couple, self-efficacy, disability, socioeconomic status, pain or BMI). Questionnaire-based outcome measures tended to support the conclusions of accelerometer measures, but only if walking was an explicit part of the questionnaire. Thus, the IPAQ MVPA question did not show any intervention effect, but the IPAQ walking question showed a significant effect of both the nurse-supported and the postal delivery interventions with no difference between the interventions, although with less precision than the accelerometry data.

Both interventions were well accepted and the trial had high fidelity; three-quarters of the nurse group attended all three sessions and around 80% of both the postal delivery and the nurse-support groups returned completed step count diaries. Increase in step count was positively associated with both nurse session attendance and completed diary return.

Incremental cost per step was £0.19 and £3.61 per minute in a  $\geq 10$ -minute MVPA bout for the nurse-support group, whereas the postal delivery group took more steps and cost less than the control group. The postal delivery group had a 50% chance of being cost-effective at a £20,000 per QALY threshold within 1 year. The QALY-based conclusion changed to the control group dominating the postal delivery group when four alternative assumptions were made (using the 3-month outcome data, extending the perspective to participants, excluding health service use and using self-reports of AEs), although this was not the case for cost-effectiveness ratios based on step count and MVPA. The postal delivery group was significantly more cost-effective than both the nurse-support group and the control group in the long term and this finding was robust to changes in assumptions.

Nurses and intervention group participants described the intervention in a positive way and confirmed that primary care was an appropriate setting. Nurses believed that participating in the trial, especially in the BCT training, enhanced the quality and delivery of the advice and support they provided within routine consultations. Participants described important facilitators of increasing PA, including the desire for a healthy lifestyle, improved physical health, enjoyment of walking in the local environment, having a flexible routine, appropriate self-monitoring and external monitoring and support from others. Important barriers included physical health problems, having an inflexible routine, work and other commitments and poor weather. Several BCTs were highlighted as having an important impact, including self-monitoring and review of goals and outcomes, planning social support/change and relapse prevention. Although most participants in the postal delivery group were confident in increasing their PA without nurse support, two key caveats were existing health problems and overcoming barriers.

The follow-up of over two-thirds of the trial cohort at 3 years demonstrated persistent increases in both step count and time in MVPA for the nurse-support and postal delivery groups compared with the control group, with no difference between intervention groups. The postal intervention given to the control group at 12 months, with no follow-up telephone call after 1 week and no requirement to post back the diary to be reviewed after 3 months, was not effective at increasing participants' PA levels. This suggests that these 'minimal support' components of the postal delivery intervention, which were not face to face or not

provided by a health-care professional, may have been important to its success. Qualitative evaluation found that most participants felt that the PACE-UP trial had increased their awareness of the importance of PA, irrespective of their intervention group and whether or not they felt that their PA had actually increased. Many of the barriers to, and facilitators of, PA maintenance were the inverse of each other and most were similar to those found to be important for increasing PA during the actual trial (health conditions, weather, ageing, social support, time). Participants varied in the resources that they would find most beneficial to help them maintain their PA levels, emphasising the importance of individual tailoring of some aspects of PA interventions.

The PACE-UP trial was novel in clearly separating out the effects of pedometer provision and nurse support in a general population sample of adults and older adults and in demonstrating the effects on both step counts and MVPA in bouts, thus making the outcome assessment relevant to current national and international PA guidelines.

## Strengths and limitations

### Study strengths

The PACE-UP study had many important strengths. It was large and population based with primary care sampling, allowing response and any bias in response to be assessed, rather than relying on recruiting volunteers. It was designed to have household randomisation, which allowed two members of a couple to take part together if they wished to, enabling a comparison of individual and couple effects. It had three trial arms, allowing the separation of nurse support and pedometer/handbook/diary effects. The intervention was pragmatic, using practice nurses who worked in the practices to deliver the nurse PA consultations, rather than external researchers or exercise specialists. There was a very good uptake rate of nurse appointments and return of completed step count diaries, showing participant engagement with the interventions. The main PA outcomes were objectively measured and were relevant to the PA guidelines. AEs were measured in a number of ways to minimise bias, both self-reported from questionnaires and objectively from primary care records. The trial achieved a follow-up rate of over 90% with complete primary outcome data. The trial also included embedded process, qualitative and economic evaluations, with the economic evaluations using trial results in a simulation of long-term cost-effectiveness. An extended 3-year follow-up allowed maintenance of any intervention effects beyond 12 months to be studied.

### Study limitations

There were also some important study limitations. The 10% recruitment into the trial is considered in detail below, in *Generalisability*. At the baseline assessment, 218 out of 1023 participants (21%) achieved the PA guideline targets based on their accelerometry. These participants were not excluded from the trial because if the intervention were to be rolled out in primary care, self-reported PA levels would define participation. Our nurse-supported intervention group had slightly higher baseline PA levels; however, the trial results were not biased, as analyses were based on individual change, controlling for baseline PA level. It was impossible to mask participants and nurses to the intervention group and, pragmatically, research assistants recruited and followed up the same participants, so were unmasked to group at the outcome assessment. However, all the primary and secondary PA outcomes were assessed objectively by accelerometry. It is possible that participants might have tried harder with their PA when monitored, but this would also have affected control participants and would be reduced by using a 7-day protocol for data collection.<sup>31</sup> In addition, our intervention groups increased their MVPA in bouts of  $\geq 10$  minutes, implying that participants made changes suggested by the programme. Despite recruiting to target and having excellent follow-up, our CIs for the difference between intervention groups cannot rule out a small 12-month difference. Interpretation of our 3-year follow-up findings was potentially limited by the fact that two-thirds of the control group participants received a pedometer, handbook and diary, and 20% of them also received a single nurse appointment after their 12-month follow-up. However, any contamination appears to be minimal, as there was no evidence of a change in the control group and the intervention estimates at 3 years were very similar to those at 12 months. These findings are of potential importance as, in combination, they suggest that the minimal contact with the

postal delivery group after participants were sent their pedometer packs (telephone contact after 1 week and encouragement to return their completed step count diaries at 3 months) was important in stimulating an effect. Timing may have been important too; as the control group was offered the intervention 12 months after the participants had initially expressed an interest in participating in the trial, they would have had to have worn the pedometer to measure their step count and set targets, whereas the trial postal delivery group had targets set based on wearing a blinded pedometer at baseline. These added factors may have also been important to the success of the trial postal delivery intervention group.

## Generalisability

Overall, only 10% of people invited to participate in the trial ended up being recruited and randomised. This is similar to other primary care PA trials,<sup>33,192</sup> but lower than the 30% that we achieved in our recent older adult PA trial.<sup>21</sup> However, 10% of a population sample is still a useful percentage to participate in a public health intervention, and this trial shows the potential of primary care to contribute to PA public health goals, particularly within an urban context. As well as monitoring overall recruitment, using primary care as a sampling framework allowed us to look for any selection bias in recruitment to the trial. Primary care record comparisons showed that participation rates were significantly lower in men, in those aged < 55 years, in those who were living in the most socioeconomically deprived quintile and among Asian rather than white or black ethnic groups. Despite selecting practices from deprived, ethnically diverse areas, few participants were from lower socioeconomic and ethnic minority groups, limiting both the subgroup analysis power and the generalisability to more diverse populations. Failure to include socioeconomically deprived or ethnic minority groups, in which PA levels were lower, could also increase health inequalities. In a RCT of an intervention, it is not possible to separate out reluctance to participate in the intervention from reluctance to participate in the trial itself, with requirements for informed consent, randomisation and rigorous follow-up and evaluation. If the intervention were to be rolled out in routine primary care, uptake could be higher and less prone to selection bias. Handing out the intervention materials (pedometer, handbook and diary) in primary care consultations in which advice to increase low PA levels is already being offered may also increase the intervention's reach (e.g. in relevant chronic disease consultations, or as part of NHS Health Checks, which cover a similar age group and aim to reduce cardiovascular risk<sup>59</sup>). The intervention could also be a valuable addition to diabetes mellitus prevention strategies, such as the NHS Diabetes Prevention Programme, whereby primary care is being used to identify patients at a high risk of developing diabetes mellitus, many of whom are inactive<sup>193</sup> and with higher proportions from ethnic minority groups. Using the PACE-UP trial intervention in these ways would need further evaluation and monitoring, but this may have the potential to improve generalisability and either decrease, or at least not increase, inequalities.

## Comparison with other studies

We believe that this is the largest population-based trial of a pedometer-based walking intervention with 12-month follow-up findings and the only pedometer trial with objective PA data on time in MVPA, which is relevant to PA guidelines at 3 years. The results are consistent with, and extend, our findings in 60- to 75-year-olds that were achieved in the smaller PACE-LIFT trial<sup>21</sup> and also support the recent change in NICE guidance to promoting pedometers as part of packages including support to set realistic goals, monitoring and feedback.<sup>37</sup> The intervention used in the PACE-LIFT trial also included pedometer feedback, use of a step count diary and practice nurse PA consultations based around BCTs. However, the PACE-LIFT trial intervention comprised four longer practice nurse consultations, which also included individual accelerometer feedback on PA intensity. The PACE-LIFT trial was a two-arm trial with only a single intervention arm, and was therefore unable to separate out PA monitor effects from those of the nurse-support group. Despite including a much less intense intervention, the PACE-UP trial has delivered similar levels of effect at both 3 and 12 months in PA outcomes and, furthermore, has shown what can be achieved via a postal route. It is also reassuring that our interventions did not increase sedentary time, given its potential harm,<sup>194,195</sup> as compensation can sometimes occur. The absolute step count increase

achieved in the PACE-UP trial was modest compared with that reported in systematic reviews.<sup>26,31,32</sup> However, most trials with 12-month data have been based on small numbers and recruited either volunteers<sup>196</sup> or high-risk groups,<sup>35</sup> or reported only self-reported PA data;<sup>97</sup> all of these factors are likely to lead to larger effect sizes. Although PA guidelines focus on time in MVPA in bouts, not on step counts, the systematic reviews presented no data on this important outcome.<sup>26,31,32</sup> The PACE-UP trial results confirm the PACE-LIFT trial findings,<sup>21</sup> with significant 12-month increases in MVPA in bouts. Based on the '3000 in 30' formula, 33–35 extra minutes of MVPA per week in bouts corresponds to approximately 500 extra steps per day. Thus, approximately three-quarters of the extra steps achieved in the PACE-UP trial (650–700 per day) contributed to an increase in MVPA in bouts. We believe that our trial is the first to show that the '3000-in-30' message<sup>43</sup> can lead to an approximately one-third increase in weekly MVPA in bouts at 12 months, as was achieved across both intervention groups. The '3000 steps in 30 minutes' formula neatly captures intensity<sup>43</sup> and could become an important new public health goal, particularly as many people now have the ability to measure steps easily with their mobile phones. Based on a systematic review, which has quantified the strength of association between walking and the risk of developing CHD,<sup>197</sup> the increase of 33 minutes per week in the postal delivery group in our study at 12 months, if sustained, would be expected to reduce the risk of CHD by approximately 4.5% (95% CI 3% to 6%; see *Appendix 8* for details). A cohort study that has related pedometer-measured steps to mortality<sup>198</sup> has similarly allowed us to estimate that a sustained increase of 642 steps per day would be expected to lead to a decrease in all-cause mortality of approximately 4% (95% CI 1% to 7%; see *Appendix 8* for details). Recalculating these estimates for the effect estimates in the postal delivery group at 3 years makes little difference, with the resultant decreases being 4% (95% CI 3% to 5%) for CHD and 4% (95% CI 1% to 5%) for total mortality.

Most pedometer-based interventions have not separated out the effects of the pedometer itself from the effects of the additional support provided.<sup>21,24,31</sup> The Healthy Steps trial<sup>97</sup> showed that pedometers achieved an additional effect compared with a primary care green prescription, but the PA outcomes presented were based on self-report. The PACE-UP trial demonstrates that although the nurse intervention group had a significantly greater effect on both step counts and time in MVPA at 3 months, by 12 months both the nurse-supported and postal delivery interventions still had a significant effect, but with no evidence of a difference between them. This stronger effect during the period of contact with the nurse, which was not sustainable in the longer term, has also been shown in other interventions with health professionals.<sup>199</sup> Both the nurse-support and postal delivery groups received a pedometer, diary and handbook as part of the PACE-UP trial package; therefore, it is not possible to know how much the individual components contributed. A systematic review suggested that step count diaries were common to successful pedometer interventions,<sup>31</sup> and approximately 80% of both of our intervention groups returned completed step count diaries. In addition, our process evaluation showed that returning a completed diary was significantly associated with an increase in step counts for both of the intervention groups. Qualitative findings also confirmed that participants from both groups valued the handbook and diary, as well as the pedometer.<sup>162</sup> Control group participants provided with the pedometer, diary and handbook by post at 12 months did not significantly increase their PA levels; however, they were not asked to return completed step count diaries after 3 months, which may have contributed to the lack of effect of the materials in this group.

We found no effect of the interventions on anthropometric measures, such as BMI or fat mass; this is consistent with other similar studies.<sup>21,196</sup> Our interventions also did not affect anxiety or depression scores, which is consistent with other primary care pedometer-based interventions, suggesting either no effect or insensitivity of these measures to change, particularly when levels are in the normal range for most people.<sup>21,33</sup> Although a few participants mentioned that they had negative effects from overdoing walking, most intervention participants talked about feeling fitter, sleeping better, improved mood, having more energy, less pain and keeping more active into older age.<sup>162</sup> There is currently a lack of data comparing individual, couple or household participation in walking studies.<sup>21,30</sup> Household sampling allowed us to investigate this in the PACE-UP trial, but, unfortunately, only 20% of the participants took part in the study as a couple; therefore, we had reduced power for our subgroup analysis, which showed no effect of taking part as a couple, similar to the findings in our PACE-LIFT trial.<sup>21</sup>

The self-efficacy differences that we demonstrated between both intervention groups and the control group at 3 months and between the nurse-support group and control group participants at 12 months are consistent with the positive relationship between changing self-efficacy and PA behaviour that others have reported.<sup>200</sup> The BCTs most associated with self-efficacy and successful PA outcomes are goal- and action-planning, prompting self-monitoring and feedback and planning of social support/change.<sup>200</sup> All of these BCTs were specifically recommended in recent guidance<sup>29</sup> and were included in our study in written materials for both intervention groups and as a focus of nurse PA consultations.<sup>70</sup> Our qualitative interviews found that more BCT comments were made by the nurse support group than by the postal delivery group, apart from around self-monitoring.<sup>162</sup> Increased self-efficacy has also been shown to be important for long-term PA adherence;<sup>201</sup> however, we found no difference in 3-year PA maintenance between intervention groups, despite the nurse-support group having a higher level of self-efficacy than the postal group at 12 months.

Walking is a safe intervention, which is indicated in many chronic diseases,<sup>1,8</sup> although empirical data on the safety of walking interventions are limited.<sup>24</sup> A large trial based on 40- to 74-year-old women, which encouraged a single 30-minute brisk walk 5 days weekly, reported increased falls and injuries.<sup>60</sup> Our findings in the PACE-UP trial, showing no increase in AEs, builds on similar evidence from the PACE-LIFT trial,<sup>21</sup> using both self-reported and objective primary care data, and highlights the potential importance of building up MVPA gradually, particularly in older adults, those who are inactive or those who have comorbidities.<sup>1,11</sup> The suggestion of a protective effect of the interventions in the PACE-UP trial on both falls and cardiovascular events at 12 months is plausible, but not definitive, as it is based on only a small number of events.

We demonstrated a persistent intervention effect at 3 years, in terms of both step counts and time in MVPA in bouts. This adds to the limited evidence from the systematic review by Hobbs *et al.*,<sup>26</sup> who found only two trials with objective PA measurement data beyond 12 months in this age group. One trial reported a significant intervention effect on step counts at 18 months, but suffered high attrition bias,<sup>202</sup> and another trial found no effect at the 24-month follow-up on either step count or accelerometry-assessed vector magnitude.<sup>203</sup> Recent NICE guidance<sup>29</sup> and a Cochrane systematic review<sup>23</sup> also called for PA interventions with a longer follow-up period and objective PA measures. Our qualitative evaluations at 3 years also add to the limited evidence base on factors that lead to successful and unsuccessful PA maintenance<sup>190</sup> and suggest that many of the factors that were important barriers to, or facilitators of, increasing PA levels in the original trial (e.g. health conditions, weather, ageing, social support, time) are still important when considering maintenance. This provides support for the credibility of our work and suggests that barriers and facilitators may be similar for both PA adoption and maintenance.<sup>204</sup> Our findings support others in suggesting that future interventions should focus on techniques to transform PA barriers into facilitators, for example by demonstrating the value of PA for many chronic health conditions, as well as safe ways in which individuals can increase their PA levels to change the presence of chronic health conditions from inhibiting to promoting PA as people age.<sup>157,205,206</sup>

Our results on cost-effectiveness provide new evidence in a research area that reflects a dearth of primary evidence.<sup>139,140</sup> The evidence that the postal intervention has a 50% chance, and the nurse intervention a 5% chance, of being cost-effective within 12 months is new. Although lower than the 95% likelihood of green prescriptions being cost-effective in New Zealand at 12 months,<sup>97</sup> it is still a reasonably high percentage for a behaviour change intervention to achieve at 12 months. The expectation that the postal intervention is most cost-effective over a lifetime is very strong and is comparable to other findings from models.<sup>141,142</sup>

## Interpretation of the results

Primary care patients aged 45–75 years can achieve important increases in their PA levels using a 12-week pedometer-based walking intervention, including handbooks and PA diaries (available at

[www.journalslibrary.nihr.ac.uk/programmes/hta/103202/#/](http://www.journalslibrary.nihr.ac.uk/programmes/hta/103202/#/)), delivered either by post with minimal support or through practice nurse PA consultations, with both methods achieving similar 12-month effects. An important part of the intervention was to try and gradually add in 3000 steps in 30 minutes most days weekly. The persistent effect at 3 years suggests a long-term beneficial effect. This is a safe intervention that is acceptable to patients and nurses. The postal delivery group was significantly more cost-effective than the nurse-support and control groups in the long term, thus providing a cost-effective way of delivering long-term quality-of-life benefits. The lack of an increase in PA levels at 3 years in the control group, which received a simple postal intervention without further contact after the 12-month follow-up, suggests that contacting participants after posting the intervention components to them and encouraging the return of PA diaries may be important factors for success for the postal intervention route, but this minimal support does not need to be face to face or provided by a health-care professional.

## Conclusions

### *Implications for health care*

- A primary care pedometer-based walking intervention, delivered by post with minimal support, could provide an effective and cost-effective approach to addressing the public health physical inactivity challenge.
- The '3000 steps in 30 minutes' formula neatly captures intensity and could become a useful new public health goal, particularly as many people can measure steps easily with their mobile phones.
- The PACE-UP 12-week pedometer-based walking intervention could be considered for inclusion into the NHS Health Check programme, aimed at a similar age group (40- to 74-year-olds), and/or the NHS Diabetes Prevention Programme.

### *Recommendations for research*

- The PACE-UP trial generalisability is limited by the 10% overall recruitment rate and a lower recruitment rate in Asian and socioeconomically deprived patients. Further research into different recruitment methods is needed, as is research assessing the recruitment rate achievable if this programme were offered outside a trial setting over a more prolonged time period.
- Although the overall postal intervention outcomes were as effective and more cost-effective than the nurse-supported intervention outcomes, further research is required to understand who would benefit most from the individual tailoring offered by a nurse-supported intervention.
- There has been a recent dramatic increase in the use of wearables to monitor personal PA levels, including through smartphones, wrist-worn devices, online monitoring and mobile apps. Further research into how the PACE-UP 12-week PA programme could be integrated into the use of these devices (with/without a pedometer) is needed.

# Acknowledgements

All the authors would like to pay tribute to Dr Sunil Shah, who was one of the trial investigators and helped to conceive the idea for the trial, and was involved in its planning, delivery and evaluation until his death in September 2015.

We are grateful to the south-west London general practices, their practice nurses who supported this study and all of the patients from these practices who participated: Upper Tooting Road Practice, Tooting; Chatfield Practice, Battersea; Wrythe Green Surgery, Carshalton; Francis Grove Surgery, Wimbledon; Putneymead Group Medical Practice, Putney; Heathfield Practice, Putney; and Cricket Green Medical Practice, Mitcham.

We would like to thank our supportive TSC: Professor Sarah Lewis (chairperson), Professor Paul Little (GP representative) and Mr Bob Laventure (patient and public involvement representative).

We would also like to provide our grateful thanks to the following people for their input in the study: Dr Iain Carey, who helped with processing the downloaded general practice data; Debbie Brewin, who helped with practice nurse training and handbook and diary content; and Becca Homes, who conducted the non-participant interviews.

## Contributions of authors

**Tess Harris** (GP and Professor of Primary Care Research) conceived the idea for the study with the other study co-investigators; led the protocol development and the funding application; co-designed the behaviour change intervention, the patient handbook and the patient diary; supervised the running of the trial; contributed to the analysis and led the drafting of the report.

**Sally Kerry** (Reader in Medical Statistics) helped to conceive the idea for the study, participated in the study design and the development of the research protocol and the funding application, sat on the TMG, wrote the statistics analysis plan, performed the quantitative analyses and contributed to the drafting of the report.

**Christina Victor** (Professor of Gerontology and Health Services Research) helped to conceive the idea for the study, developed the research protocol and funding application, helped with the questionnaire development, led on the qualitative aspects of the study and contributed to the drafting of the report.

**Steve Iliffe** (GP and Professor of Primary Care for Older People) helped to conceive the idea for the study, developed the research protocol and funding application, advised on the trial safety aspects, helped with the questionnaire development and contributed to the drafting of the report.

**Michael Ussher** (Professor of Behavioural Medicine) helped to conceive the idea for the study, developed the research protocol and funding application, co-designed the behaviour change intervention, co-designed and helped to carry out the nurse training, advised on the questionnaire development and contributed to the drafting of the report.

**Julia Fox-Rushby** (Professor of Health Economics) developed the research protocol and funding application, designed the health economics procedures and data collection tools, supervised the health economics data collection, analysis and reporting and contributed to the drafting of the report.

**Peter Whincup** (Professor of Cardiovascular Epidemiology) helped to conceive the idea for the study, developed the research protocol and funding application, helped with the questionnaire development, advised on the anthropometric assessment and contributed to the drafting of the report.

**Ulf Ekelund** (Professor of Physical Activity Epidemiology) helped to conceive the idea for the study, developed the research protocol and funding application, advised on PA measurement, reporting and analysis and contributed to the drafting of the report.

**Cheryl Furness** (Trial Manager) provided the day-to-day overall management of the trial, sat on the TMG, co-designed and carried out the nurse training, co-ordinated the recruitment of practices and participants, took responsibility for data management, led on the process evaluation and contributed to the drafting of the report.

**Elizabeth Limb** (Study Statistician) sat on the TMG, helped to write the statistics analysis plan, arranged the random sampling of households, performed the quantitative analyses, prepared the tables and flow diagrams and contributed to the drafting of the report.

**Nana Anokye** (Health Economist) designed the health economics procedures and data collection tools, carried out the health economics analyses, prepared the tables and appendices relating to the health economics results and contributed to the drafting of the report.

**Judith Ibison** (GP and Senior Lecturer in Primary Care) helped with the recruitment of practices, recruitment of research staff, downloading of data in practices, questionnaire development and planning of the intervention delivery and contributed to the drafting of the report.

**Stephen DeWilde** (GP and Senior Lecturer in Primary Care) helped with the recruitment of practices, advising on GP searches, downloading of data in practices, interpretation of GP data and contributed to the drafting of the report.

**Lee David** (GP and Director of 10 Minute CBT) co-designed the behaviour change intervention, co-designed the patient handbook and diary, advised on the nurse and patient feedback forms, co-designed the nurse training, led on the behaviour change aspects of training, provided feedback to the nurses on BCT delivery and contributed to the drafting of the report.

**Emma Howard** (Research Assistant) was involved in compiling patient information and data collection packs, conducted recruitment and follow-up of participants (including informed consent, randomisation and data collection), collated and analysed data for the process evaluation and contributed to the drafting of the report.

**Rebecca Dale** (Research Assistant) was involved in compiling patient information and data collection packs, conducted recruitment and follow-up of participants (including informed consent, randomisation and data collection) and contributed to the drafting of the report.

**Jaime Smith** (Research Assistant) recruited and followed up participants (including informed consent, randomisation and data collection), carried out qualitative interviews with the intervention group participants, undertook the qualitative analyses and contributed to the drafting of the report.

**Rebecca Normansell** (GP and Deputy Coordinating Editor of the Cochrane Airways Group) carried out qualitative interviews with the intervention group participants and practice nurses, undertook the qualitative analyses and contributed to the drafting of the report.

**Carole Beighton** (Senior Lecturer in Nursing) conducted a focus group with the practice nurses, carried out qualitative interviews with participants as part of the 3-year follow-up, undertook the qualitative analyses and contributed to the drafting of the report.

**Katy Morgan** (Statistician) carried out analyses relating to the generalisability and representativeness of the sample and contributed to the drafting of the report.

**Charlotte Wahlich** (Research Assistant) contacted participants for the 3-year follow-up (including informed consent and data collection), carried out the qualitative interviews with participants as part of the 3-year follow-up, undertook the qualitative analyses and contributed to the drafting of the report.

**Sabina Sanghera** (Health Economist) carried out the economic analyses relating to the health services use data and contributed to the drafting of the report.

**Derek Cook** (Professor of Epidemiology) helped to conceive the idea for the study; participated in the study design, development of the research protocol and the funding application; sat on the TMG; wrote the statistical analysis plan; performed the quantitative analyses and contributed to the drafting of the report.

## Publications

Harris T, Kerry SM, Victor CR, Shah SM, Iliffe S, Ussher M, *et al.* PACE-UP (Pedometer And Consultation Evaluation – UP) – a pedometer-based walking intervention with and without practice nurse support in primary care patients aged 45-75 years: study protocol for a randomised controlled trial. *Trials* 2013;**14**:418.

Normansell R, Smith J, Victor C, Cook DG, Kerry S, Iliffe S, *et al.* Numbers are not the whole story: a qualitative exploration of barriers and facilitators to increased physical activity in a primary care based walking intervention. *BMC Public Health* 2014;**14**:1272.

Beighton C, Victor C, Normansell R, Cook D, Kerry S, Iliffe S, *et al.* 'It's not just about walking . . . it's the practice nurse that makes it work': a qualitative exploration of the views of practice nurses delivering complex physical activity interventions in primary care. *BMC Public Health* 2015;**15**:1236.

Normansell R, Holmes R, Victor C, Cook DG, Kerry S, Iliffe S, *et al.* Exploring non-participation in primary care physical activity interventions: PACE-UP trial interview findings. *BMC Trials* 2016;**17**:178.

Harris T, Kerry SM, Limb ES, Victor CR, Iliffe S, Ussher M, *et al.* Effect of a primary care walking intervention with and without nurse support on physical activity levels in 45- to 75-year-olds: the Pedometer And Consultation Evaluation (PACE-UP) cluster randomised clinical trial. *PLOS Med* 2017;**14**:e1002210.

Wahlich C, Beighton C, Victor C, Normansell R, Cook D, Kerry S, *et al.* 'You started something . . . then I continued by myself': a qualitative study of physical activity maintenance. *Prim Health Care Res Dev* 2017;**18**:574–90.

Furness C, Howard E, Limb E, Cook DG, Kerry S, Wahlich C, *et al.* Relating process evaluation measures to complex intervention outcomes: findings from the PACE-UP primary care pedometer-based walking trial. *Trials* 2018;**19**:58.

Harris T, Kerry SM, Limb ES, Furness C, Wahlich C, Victor CR, *et al.* Physical activity levels in adults and older adults 3-4 years after pedometer-based walking interventions: Long-term follow-up of participants from two randomised controlled trials in UK primary care. *PLOS Med* 2018;**15**:e1002526.

Kerry SM, Morgan KE, Limb E, Cook DG, Furness C, Carey I, *et al.* Interpreting population reach of a large, successful physical activity trial delivered through primary care. *BMC Public Health* 2018;**18**:170.

## Data sharing statement

Anonymised individual patient data may be available for the trial effectiveness and cost-effectiveness analyses. These will be stored in a secure data repository at St George's, University of London. All queries and requests should be submitted to the corresponding author for initial consideration.

## Patient data

This work uses data provided by patients and collected by the NHS as part of their care and support. Using patient data is vital to improve health and care for everyone. There is huge potential to make better use of information from people's patient records, to understand more about disease, develop new treatments, monitor safety, and plan NHS services. Patient data should be kept safe and secure, to protect everyone's privacy, and it's important that there are safeguards to make sure that it is stored and used responsibly. Everyone should be able to find out about how patient data are used. #datasaveslives You can find out more about the background to this citation here: <https://understandingpatientdata.org.uk/data-citation>.

## References

1. Department of Health and Social Care. *Start Active, Stay Active: A Report on Physical Activity for Health from the Four Home Countries' Chief Medical Officers*. London: Department of Health and Social Care; 2011.
2. World Health Organization. *Global Recommendations on Physical Activity for Health*. Geneva: World Health Organization; 2010.
3. Lee IM, Shiroma EJ, Lobelo F, Puska P, Blair SN, Katzmarzyk PT, Lancet Physical Activity Series Working Group. Effect of physical inactivity on major non-communicable diseases worldwide: an analysis of burden of disease and life expectancy. *Lancet* 2012;**380**:219–29. [https://doi.org/10.1016/S0140-6736\(12\)61031-9](https://doi.org/10.1016/S0140-6736(12)61031-9)
4. Oldridge NB. Economic burden of physical inactivity: healthcare costs associated with cardiovascular disease. *Eur J Cardiovasc Prev Rehabil* 2008;**15**:130–9. <https://doi.org/10.1097/HJR.0b013e3282f19d42>
5. Carlson SA, Fulton JE, Pratt M, Yang Z, Adams EK. Inadequate physical activity and health care expenditures in the United States. *Prog Cardiovasc Dis* 2015;**57**:315–23. <https://doi.org/10.1016/j.pcad.2014.08.002>
6. Garber CE, Blissmer B, Deschenes MR, Franklin BA, Lamonte MJ, Lee IM, *et al*. Quantity and quality of exercise for developing and maintaining cardiorespiratory, musculoskeletal, and neuromotor fitness in apparently healthy adults: guidance for prescribing exercise. *Med Sci Sports Exerc* 2011;**43**:1334–59. <https://doi.org/10.1249/MSS.0b013e32818213febf>
7. O'Donovan G, Blazeovich AJ, Boreham C, Cooper AR, Crank H, Ekelund U, *et al*. The ABC of Physical Activity for Health: a consensus statement from the British Association of Sport and Exercise Sciences. *J Sports Sci* 2010;**28**:573–91. <https://doi.org/10.1080/02640411003671212>
8. Morris JN, Hardman AE. Walking to health. *Sports Med* 1997;**23**:306–32. <https://doi.org/10.2165/00007256-199723050-00004>
9. NHS Digital. *Health Survey for England – 2008: Physical Activity and Fitness*. London: NHS Digital; 2009.
10. de Souto Barreto P. Global health agenda on non-communicable diseases: has WHO set a smart goal for physical activity? *BMJ* 2015;**350**:h23. <https://doi.org/10.1136/bmj.h23>
11. Sparling PB, Howard BJ, Dunstan DW, Owen N. Recommendations for physical activity in older adults. *BMJ* 2015;**350**:h100. <https://doi.org/10.1136/bmj.h100>
12. NHS Digital. *Health Survey for England – 2012*. London: NHS Digital; 2013.
13. National Centre for Social Research. *Health Survey for England – 2004*. London: Department of Health; 2005.
14. World Health Organization. *Global Health Observatory Data Repository*. URL: [www.who.int/gho/ncd/risk\\_factors/physical\\_activity\\_text/en/](http://www.who.int/gho/ncd/risk_factors/physical_activity_text/en/) (accessed 25 May 2018).
15. Tudor-Locke CE, Myers AM. Challenges and opportunities for measuring physical activity in sedentary adults. *Sports Med* 2001;**31**:91–100. <https://doi.org/10.2165/00007256-200131020-00002>
16. Morey MC, Sullivan RJ. Medical assessment for health advocacy and practical strategies for exercise initiation. *Am J Prev Med* 2003;**25**(Suppl. 3):204–8. [https://doi.org/10.1016/S0749-3797\(03\)00180-6](https://doi.org/10.1016/S0749-3797(03)00180-6)

17. Cress ME, Buchner DM, Prohaska T, Rimmer J, Brown M, Macera C, *et al.* Best practices for physical activity programs and behavior counseling in older adult populations. *J Aging Phys Act* 2005;**13**:61–74. <https://doi.org/10.1123/japa.13.1.61>
18. Thompson PD, Buchner D, Pina IL, Balady GJ, Williams MA, Marcus BH, *et al.* Exercise and physical activity in the prevention and treatment of atherosclerotic cardiovascular disease: a statement from the Council on Clinical Cardiology (Subcommittee on Exercise, Rehabilitation, and Prevention) and the Council on Nutrition, Physical Activity, and Metabolism (Subcommittee on Physical Activity). *Circulation* 2003;**107**:3109–16. <https://doi.org/10.1161/01.CIR.0000075572.40158.77>
19. Hootman JM, Macera CA, Ainsworth BE, Martin M, Addy CL, Blair SN. Association among physical activity level, cardiorespiratory fitness, and risk of musculoskeletal injury. *Am J Epidemiol* 2001;**154**:251–8. <https://doi.org/10.1093/aje/154.3.251>
20. Ory M, Resnick B, Jordan PJ, Coday M, Riebe D, Ewing Garber C, *et al.* Screening, safety, and adverse events in physical activity interventions: collaborative experiences from the behavior change consortium. *Ann Behav Med* 2005;**29**:20–8. [https://doi.org/10.1207/s15324796abm2902s\\_5](https://doi.org/10.1207/s15324796abm2902s_5)
21. Harris T, Kerry SM, Victor CR, Ekelund U, Woodcock A, Iliffe S, *et al.* A primary care nurse-delivered walking intervention in older adults: PACE (pedometer accelerometer consultation evaluation)-Lift cluster randomised controlled trial. *PLOS Med* 2015;**12**:e1001783. <https://doi.org/10.1371/journal.pmed.1001783>
22. Hillsdon M, Foster C, Thorogood M. Interventions for promoting physical activity. *Cochrane Database Syst Rev* 2005;**1**:CD003180. <https://doi.org/10.1002/14651858.CD003180.pub2>
23. Richards J, Thorogood M, Hillsdon M, Foster C. Face-to-face versus remote and web 2.0 interventions for promoting physical activity. *Cochrane Database Syst Rev* 2013;**9**:CD010393. <https://doi.org/10.1002/14651858.CD010393.pub2>
24. Foster C, Richards J, Thorogood M, Hillsdon M. Remote and web 2.0 interventions for promoting physical activity [published online ahead of print September 30 2013]. *Cochrane Database Syst Rev* 2013. <https://doi.org/10.1002/14651858.CD010395.pub2>
25. King AC, Haskell WL, Taylor CB, Kraemer HC, DeBusk RF. Group- vs home-based exercise training in healthy older men and women. A community-based clinical trial. *JAMA* 1991;**266**:1535–42. <https://doi.org/10.1001/jama.1991.03470110081037>
26. Hobbs N, Godfrey A, Lara J, Errington L, Meyer TD, Rochester L, *et al.* Are behavioral interventions effective in increasing physical activity at 12 to 36 months in adults aged 55 to 70 years? A systematic review and meta-analysis. *BMC Med* 2013;**11**:75. <https://doi.org/10.1186/1741-7015-11-75>
27. King AC, Rejeski WJ, Buchner DM. Physical activity interventions targeting older adults. A critical review and recommendations. *Am J Prev Med* 1998;**15**:316–33. [https://doi.org/10.1016/S0749-3797\(98\)00085-3](https://doi.org/10.1016/S0749-3797(98)00085-3)
28. Richards D. Behaviour change guidance. *Evid Based Dent* 2007;**8**:98–100. <https://doi.org/10.1038/sj.ebd.6400520>
29. NICE. *Behaviour Change: Individual Approaches*. London: NICE; 2014.
30. Ogilvie D, Foster CE, Rothnie H, Cavill N, Hamilton V, Fitzsimons CF, *et al.* Interventions to promote walking: systematic review. *BMJ* 2007;**334**:1204. <https://doi.org/10.1136/bmj.39198.722720.BE>
31. Bravata DM, Smith-Spangler C, Sundaram V, Gienger AL, Lin N, Lewis R, *et al.* Using pedometers to increase physical activity and improve health: a systematic review. *JAMA* 2007;**298**:2296–304. <https://doi.org/10.1001/jama.298.19.2296>

32. Kang M, Marshall SJ, Barreira TV, Lee JO. Effect of pedometer-based physical activity interventions: a meta-analysis. *Res Q Exerc Sport* 2009;**80**:648–55. <https://doi.org/10.1080/02701367.2009.10599604>
33. McMurdo ME, Sugden J, Argo I, Boyle P, Johnston DW, Sniehotta FF, Donnan PT. Do pedometers increase physical activity in sedentary older women? A randomized controlled trial. *J Am Geriatr Soc* 2010;**58**:2099–106. <https://doi.org/10.1111/j.1532-5415.2010.03127.x>
34. Houle J, Doyon O, Vadeboncoeur N, Turbide G, Diaz A, Poirier P. Innovative program to increase physical activity following an acute coronary syndrome: randomized controlled trial. *Patient Educ Couns* 2011;**85**:e237–44. <https://doi.org/10.1016/j.pec.2011.03.018>
35. Yates T, Davies M, Gorely T, Bull F, Khunti K. Effectiveness of a pragmatic education program designed to promote walking activity in individuals with impaired glucose tolerance: a randomized controlled trial. *Diabetes Care* 2009;**32**:1404–10. <https://doi.org/10.2337/dc09-0130>
36. NICE. *Four Commonly Used Methods to Increase Physical Activity: Brief Interventions in Primary Care, Exercise Referral Schemes, Pedometers and Community Based Exercise Programmes for Walking and Cycling*. London: NICE; 2006.
37. NICE. *Walking and Cycling. Local Measures to Promote Walking and Cycling as Forms of Travel or Recreation*. London: NICE; 2012.
38. Schneider PL, Bassett DR, Thompson DL, Pronk NP, Bielak KM. Effects of a 10,000 steps per day goal in overweight adults. *Am J Health Promot* 2006;**21**:85–9. <https://doi.org/10.4278/0890-1171-21.2.85>
39. Lindberg R. Active living: on the road with the 10,000 Steps program. *J Am Diet Assoc* 2000;**100**:878–9. [https://doi.org/10.1016/S0002-8223\(00\)00251-0](https://doi.org/10.1016/S0002-8223(00)00251-0)
40. Croteau KA, Richeson NE, Farmer BC, Jones DB. Effect of a pedometer-based intervention on daily step counts of community-dwelling older adults. *Res Q Exerc Sport* 2007;**78**:401–6. <https://doi.org/10.1080/02701367.2007.10599439>
41. Prochaska JJ, Hall SM, Humfleet G, Munoz RF, Reus V, Gorecki J, Hu D. Physical activity as a strategy for maintaining tobacco abstinence: a randomized trial. *Prev Med* 2008;**47**:215–20. <https://doi.org/10.1016/j.ypmed.2008.05.006>
42. Tudor-Locke C, Craig CL, Brown WJ, Clemes SA, De Cocker K, Giles-Corti B, *et al*. How many steps/day are enough? For adults. *Int J Behav Nutr Phys Act* 2011;**8**:79. <https://doi.org/10.1186/1479-5868-8-79>
43. Marshall SJ, Levy SS, Tudor-Locke CE, Kolkhorst FW, Wooten KM, Ji M, *et al*. Translating physical activity recommendations into a pedometer-based step goal: 3000 steps in 30 minutes. *Am J Prev Med* 2009;**36**:410–15. <https://doi.org/10.1016/j.amepre.2009.01.021>
44. McKay J, Wright A, Lowry R, Steele K, Ryde G, Mutrie N. Walking on prescription: the utility of a pedometer pack for increasing physical activity in primary care. *Patient Educ Couns* 2009;**76**:71–6. <https://doi.org/10.1016/j.pec.2008.11.004>
45. Baker G, Gray SR, Wright A, Fitzsimons C, Nimmo M, Lowry R, *et al*. The effect of a pedometer-based community walking intervention 'Walking for Wellbeing in the West' on physical activity levels and health outcomes: a 12-week randomized controlled trial. *Int J Behav Nutr Phys Act* 2008;**5**:44. <https://doi.org/10.1186/1479-5868-5-44>
46. Tudor-Locke C, Craig CL, Aoyagi Y, Bell RC, Croteau KA, De Bourdeaudhuij I, *et al*. How many steps/day are enough? For older adults and special populations. *Int J Behav Nutr Phys Act* 2011;**8**:80. <https://doi.org/10.1186/1479-5868-8-80>

47. Macmillan F, Fitzsimons C, Black K, Granat MH, Grant MP, Grealy M, *et al.* West End Walkers 65+: a randomised controlled trial of a primary care-based walking intervention for older adults: study rationale and design. *BMC Public Health* 2011;**11**:120. <https://doi.org/10.1186/1471-2458-11-120>
48. Mutrie N, Doolin O, Fitzsimons CF, Grant PM, Granat M, Grealy M, *et al.* Increasing older adults' walking through primary care: results of a pilot randomized controlled trial. *Fam Pract* 2012;**29**:633–42. <https://doi.org/10.1093/fampra/cms038>
49. Ekelund U, Tingström P, Kamwendo K, Krantz M, Nylander E, Sjöström M, Bergdahl B. The validity of the Computer Science and Applications activity monitor for use in coronary artery disease patients during level walking. *Clin Physiol Funct Imaging* 2002;**22**:248–53. <https://doi.org/10.1046/j.1475-097X.2002.00426.x>
50. Harris TJ, Owen CG, Victor CR, Adams R, Ekelund U, Cook DG. A comparison of questionnaire, accelerometer, and pedometer: measures in older people. *Med Sci Sports Exerc* 2009;**41**:1392–402. <https://doi.org/10.1249/MSS.0b013e31819b3533>
51. Davis MG, Fox KR. Physical activity patterns assessed by accelerometry in older people. *Eur J Appl Physiol* 2007;**100**:581–9. <https://doi.org/10.1007/s00421-006-0320-8>
52. Jefferis BJ, Sartini C, Lee IM, Choi M, Amuzu A, Gutierrez C, *et al.* Adherence to physical activity guidelines in older adults, using objectively measured physical activity in a population-based study. *BMC Public Health* 2014;**14**:382. <https://doi.org/10.1186/1471-2458-14-382>
53. Harris TJ, Owen CG, Victor CR, Adams R, Cook DG. What factors are associated with physical activity in older people, assessed objectively by accelerometry? *Br J Sports Med* 2009;**43**:442–50. <https://doi.org/10.1136/bjism.2008.048033>
54. Tudor-Locke C, Ainsworth BE, Thompson RW, Matthews CE. Comparison of pedometer and accelerometer measures of free-living physical activity. *Med Sci Sports Exerc* 2002;**34**:2045–51. <https://doi.org/10.1097/00005768-200212000-00027>
55. NICE Public Health Collaborating Centre. *A Rapid Review of the Effectiveness of Pedometer Interventions to Promote Physical Activity in Adults*. London: NICE; 2006.
56. Talib H, Sabirin J. *Pedometer and Accelerometer in Assessing Physical Activity Among Children and Adolescents*. Kuala Lumpur, Malaysia: Health Technology Assessment Unit; 2007.
57. NICE. *Modelling the Cost-effectiveness of Physical Activity Interventions*. London: NICE; 2006.
58. Shaw R, Fenwick E, Baker G, McAdam C, Fitzsimons C, Mutrie N. 'Pedometers cost buttons': the feasibility of implementing a pedometer based walking programme within the community. *BMC Public Health* 2011;**11**:200. <https://doi.org/10.1186/1471-2458-11-200>
59. Health Checks Programme NHS. *Putting Prevention First: NHS Health Checks: Vascular Risk Assessment and Management Best Practice Guidelines*. London: NHS; 2009.
60. Lawton BA, Rose SB, Elley CR, Dowell AC, Fenton A, Moyes SA. Exercise on prescription for women aged 40–74 recruited through primary care: two year randomised controlled trial. *BMJ* 2008;**337**:a2509. <https://doi.org/10.1136/bmj.a2509>
61. Brawley LR, Rejeski WJ, King AC. Promoting physical activity for older adults: the challenges for changing behavior. *Am J Prev Med* 2003;**25**(Suppl. 3):172–83. [https://doi.org/10.1016/S0749-3797\(03\)00182-X](https://doi.org/10.1016/S0749-3797(03)00182-X)
62. Tai SS, Gould M, Iliffe S. Promoting healthy exercise among older people in general practice: issues in designing and evaluating therapeutic interventions. *Br J Gen Pract* 1997;**47**:119–22.

63. Goodman C, Davies S, Tai SS, Dinan S, Iliffe S. Promoting older peoples' participation in activity, whose responsibility? A case study of the response of health, local government and voluntary organizations. *J Interprof Care* 2007;**21**:515–28. <https://doi.org/10.1080/13561820701637204>
64. Pavey TG, Taylor AH, Fox KR, Hillsdon M, Anokye N, Campbell JL, *et al.* Effect of exercise referral schemes in primary care on physical activity and improving health outcomes: systematic review and meta-analysis. *BMJ* 2011;**343**:d6462. <https://doi.org/10.1136/bmj.d6462>
65. Khan KM, Weiler R, Blair SN. Prescribing exercise in primary care. *BMJ* 2011;**343**:d4141. <https://doi.org/10.1136/bmj.d4141>
66. David L. *Using CBT in General Practice. The 10 Minute Consultation*. Bloxham, Oxfordshire: Scion; 2006.
67. British Psychological Society. *Improving Health: Changing Behaviour: NHS Health Trainer Handbook*. London: Department of Health and Social Care; 2008.
68. Michie S, Ashford S, Sniehotta FF, Dombrowski SU, Bishop A, French DP. A refined taxonomy of behaviour change techniques to help people change their physical activity and healthy eating behaviours: the CALO-RE taxonomy. *Psychol Health* 2011;**26**:1479–98. <https://doi.org/10.1080/08870446.2010.540664>
69. Harris T, Kerry S, Victor C, Ekelund U, Woodcock A, Iliffe S, *et al.* Randomised controlled trial of a complex intervention by primary care nurses to increase walking in patients aged 60–74 years: protocol of the PACE-Lift (Pedometer Accelerometer Consultation Evaluation - Lift) trial. *BMC Public Health* 2013;**13**:5. <https://doi.org/10.1186/1471-2458-13-5>
70. Harris T, Kerry SM, Victor CR, Shah SM, Iliffe S, Ussher M, *et al.* PACE-UP (Pedometer and consultation evaluation – UP) – a pedometer-based walking intervention with and without practice nurse support in primary care patients aged 45-75 years: study protocol for a randomised controlled trial. *Trials* 2013;**14**:418. <https://doi.org/10.1186/1745-6215-14-418>
71. Department for Communities and Local Government. *English Indices of Deprivation 2010: Guidance Document*. London: Department for Communities and Local Government; 2011.
72. Booth M. Assessment of physical activity: an international perspective. *Res Q Exerc Sport* 2000;**71**(Suppl. 2):114–20. <https://doi.org/10.1080/02701367.2000.11082794>
73. Physical Activity Policy Unit, Department of Health and Social Care. *The General Practice Physical Activity Questionnaire (GPPAQ)*. London: Department of Health and Social Care; 2009.
74. Jette AM, Rooks D, Lachman M, Lin TH, Levenson C, Heislein D, *et al.* Home-based resistance training: predictors of participation and adherence. *Gerontologist* 1998;**38**:412–21. <https://doi.org/10.1093/geront/38.4.412>
75. Zigmond AS, Snaith RP. The Hospital Anxiety and Depression Scale. *Acta Psychiatr Scand* 1983;**67**:361–70. <https://doi.org/10.1111/j.1600-0447.1983.tb09716.x>
76. Brooks R. EuroQol: the current state of play. *Health Policy* 1996;**37**:53–72. [https://doi.org/10.1016/0168-8510\(96\)00822-6](https://doi.org/10.1016/0168-8510(96)00822-6)
77. Ware JE, Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. *Med Care* 1992;**30**:473–83. <https://doi.org/10.1097/00005650-199206000-00002>
78. Ahmad S, Harris T, Limb E, Kerry S, Victor C, Ekelund U, *et al.* Evaluation of reliability and validity of the General Practice Physical Activity Questionnaire (GPPAQ) in 60-74 year old primary care patients. *BMC Fam Pract* 2015;**16**:113. <https://doi.org/10.1186/s12875-015-0324-8>
79. Office for National Statistics. *The English and Welsh 2011 Census*. Newport: Office for National Statistics; 2012.

80. McGee MA, Johnson AL, Kay DW. The description of activities of daily living in five centres in England and Wales. Medical Research Council Cognitive Function and Ageing Study. *Age Ageing* 1998;**27**:605–13. <https://doi.org/10.1093/ageing/27.5.605>
81. Tunstall J. *Old and Alone*. London: Routledge and Kegan; 1957.
82. Nandy S, Parsons S, Cryer C, Underwood M, Rashbrook E, Carter Y, *et al*. Development and preliminary examination of the predictive validity of the Falls Risk Assessment Tool (FRAT) for use in primary care. *J Public Health* 2004;**26**:138–43. <https://doi.org/10.1093/pubmed/fdh132>
83. Caspersen CJ, Bloemberg BP, Saris WH, Merritt RK, Kromhout D. The prevalence of selected physical activities and their relation with coronary heart disease risk factors in elderly men: the Zutphen Study, 1985. *Am J Epidemiol* 1991;**133**:1078–92. <https://doi.org/10.1093/oxfordjournals.aje.a115821>
84. Freedson PS, Melanson E, Sirard J. Calibration of the Computer Science and Applications, Inc. accelerometer. *Med Sci Sports Exerc* 1998;**30**:777–81. <https://doi.org/10.1097/00005768-199805000-00021>
85. Matthews CE, Chen KY, Freedson PS, Buchowski MS, Beech BM, Pate RR, Troiano RP. Amount of time spent in sedentary behaviors in the United States, 2003–2004. *Am J Epidemiol* 2008;**167**:875–81. <https://doi.org/10.1093/aje/kwm390>
86. Little P, Dorward M, Gralton S, Hammerton L, Pillinger J, White P, *et al*. A randomised controlled trial of three pragmatic approaches to initiate increased physical activity in sedentary patients with risk factors for cardiovascular disease. *Br J Gen Pract* 2004;**54**:189–95.
87. Stevens W, Hillsdon M, Thorogood M, McArdle D. Cost-effectiveness of a primary care based physical activity intervention in 45–74 year old men and women: a randomised controlled trial. *Br J Sports Med* 1998;**32**:236–41. <https://doi.org/10.1136/bjbm.32.3.236>
88. Munro JF, Nicholl JP, Brazier JE, Davey R, Cochrane T. Cost effectiveness of a community based exercise programme in over 65 year olds: cluster randomised trial. *J Epidemiol Community Health* 2004;**58**:1004–10. <https://doi.org/10.1136/jech.2003.014225>
89. Sugden JA, Sniehotta FF, Donnan PT, Boyle P, Johnston DW, McMurdo ME. The feasibility of using pedometers and brief advice to increase activity in sedentary older women – a pilot study. *BMC Health Serv Res* 2008;**8**:169. <https://doi.org/10.1186/1472-6963-8-169>
90. Trost SG, McIver KL, Pate RR. Conducting accelerometer-based activity assessments in field-based research. *Med Sci Sports Exerc* 2005;**37**(Suppl. 11):531–43. <https://doi.org/10.1249/01.mss.0000185657.86065.98>
91. Miller GD, Jakicic JM, Rejeski WJ, Whit-Glover MC, Lang W, Walkup MP, Hodges ML. Effect of varying accelerometry criteria on physical activity: the look ahead study. *Obesity* 2013;**21**:32–44. <https://doi.org/10.1002/oby.20234>
92. Senn S. Change from baseline and analysis of covariance revisited. *Stat Med* 2006;**25**:4334–44. <https://doi.org/10.1002/sim.2682>
93. Harris T, Kerry SM, Limb ES, Victor CR, Iliffe S, Ussher M, *et al*. Effect of a primary care walking intervention with and without nurse support on physical activity levels in 45- to 75-year-olds: the Pedometer And Consultation Evaluation (PACE-UP) cluster randomised clinical trial. *PLOS Med* 2017;**14**:e1002210. <https://doi.org/10.1371/journal.pmed.1002210>
94. Department of Health and Social Care. *Healthy Lives, Healthy People: Our Strategy for Public Health in England*. London: Department of Health and Social Care; 2010.
95. Department of Health and Social Care. *Improving Outcomes: A Strategy for Cancer*. London: Department of Health and Social Care; 2011.

96. Fitzsimons CF, Baker G, Wright A, Nimmo MA, Ward Thompson C, Lowry R, *et al.* The 'Walking for Wellbeing in the West' randomised controlled trial of a pedometer-based walking programme in combination with physical activity consultation with 12 month follow-up: rationale and study design. *BMC Public Health* 2008;**8**:259. <https://doi.org/10.1186/1471-2458-8-259>
97. Leung W, Ashton T, Kolt GS, Schofield GM, Garrett N, Kerse N, Patel A. Cost-effectiveness of pedometer-based versus time-based Green Prescriptions: the Healthy Steps Study. *Aust J Prim Health* 2012;**18**:204–11. <https://doi.org/10.1071/PY11028>
98. Over EA, Wendel-Vos GW, van den Berg M, Reenen HH, Tariq L, Hoogenveen RT, van Baal PH. Cost-effectiveness of counseling and pedometer use to increase physical activity in the Netherlands: a modeling study. *Cost Eff Resour Alloc* 2012;**10**:13. <https://doi.org/10.1186/1478-7547-10-13>
99. Cobiac LJ, Vos T, Barendregt JJ. Cost-effectiveness of interventions to promote physical activity: a modelling study. *PLOS Med* 2009;**6**:e1000110. <https://doi.org/10.1371/journal.pmed.1000110>
100. Vijay GC, Wilson ECF, Suhrcke M, Hardeman W, Sutton S. Are brief interventions to increase physical activity cost-effective? *Br J Sports Med* 2016;**50**:408–17. <https://doi.org/10.1136/bjsports-2015-094655>
101. Drummond M SM, Klaxton K, Stoddart G, Torrance G, editors. *Methods for the Economic Evaluation of Health Care Programmes*. 4th edn. Oxford: Oxford University Press; 2015.
102. Department of Health and Social Care. *NHS Reference Costs 2014–15*. London: Department of Health and Social Care; 2014.
103. Curtis LA. *Unit Costs of Health and Social Care 2014*. Canterbury: PSSRU, University of Kent; 2014.
104. Anokye NK, Pokhrel S, Fox-Rushby J. Economic analysis of participation in physical activity in England: implications for health policy. *Int J Behav Nutr Phys Act* 2014;**11**:117. <https://doi.org/10.1186/s12966-014-0117-9>
105. Feng Y, Devlin N, Herdman M. Assessing the health of the general population in England: how do the three- and five-level versions of EQ-5D compare? *Health Qual Life Outcomes* 2015;**13**:171. <https://doi.org/10.1186/s12955-015-0356-8>
106. Rabin R, Oemar M, Oppe M, Janssen B, Herdman M. *EQ-5D-5L User Guide: Basic Information on How to Use the EQ-5D-5L Instrument*. Rotterdam: EuroQol Group; 2011.
107. Dolan P. Modeling valuations for EuroQol health states. *Med Care* 1997;**35**:1095–108. <https://doi.org/10.1097/00005650-199711000-00002>
108. Lydick E, Epstein RS, Himmelberger D, White CJ. Area under the curve: a metric for patient subjective responses in episodic diseases. *Qual Life Res* 1995;**4**:41–5. <https://doi.org/10.1007/BF00434382>
109. Briggs A, Clark T, Wolstenholme J, Clarke P. Missing... presumed at random: cost-analysis of incomplete data. *Health Econ* 2003;**12**:377–92. <https://doi.org/10.1002/hec.766>
110. Schafer JL. Multiple imputation: a primer. *Stat Methods Med Res* 1999;**8**:3–15. <https://doi.org/10.1177/096228029900800102>
111. Bennett DA. How can I deal with missing data in my study? *Aust N Z J Public Health* 2001;**25**:464–9. <https://doi.org/10.1111/j.1467-842X.2001.tb00294.x>
112. Simons CL, Rivero-Arias O, Yu LM, Simon J. Multiple imputation to deal with missing EQ-5D-3L data: should we impute individual domains or the actual index? *Qual Life Res* 2015;**24**:805–15. <https://doi.org/10.1007/s11136-014-0837-y>

113. Rubin D. *Multiple Imputation for Nonresponse in Surveys United States of America*. Hoboken, NJ: John Wiley & Sons; 1987. <https://doi.org/10.1002/9780470316696>
114. Allison PD. Multiple imputation for missing data: a cautionary tale. *Sociol Method Res* 2000;**28**:301–9. <https://doi.org/10.1177/0049124100028003003>
115. Carpenter JR, Kenward MG. MAR Methods for Quantitative Data. In Carpenter JR, Kenward MG, editors. *Missing Data In Randomised Controlled Trials: A Practical Guide*. Birmingham: Health Technology Assessment Methodology Programme; 2007. pp. 51–72.
116. Sterne JA, White IR, Carlin JB, Spratt M, Royston P, Kenward MG, *et al*. Multiple imputation for missing data in epidemiological and clinical research: potential and pitfalls. *BMJ* 2009;**338**:b2393. <https://doi.org/10.1136/bmj.b2393>
117. Glick HA, Doshi JA, Sonnad SS, Polsky D. *Economic Evaluation in Clinical Trials*. 2nd edn. Oxford: Oxford University Press; 2015.
118. Vu T, Harris A, Duncan G, Sussman G. Cost-effectiveness of multidisciplinary wound care in nursing homes: a pseudo-randomized pragmatic cluster trial. *Fam Pract* 2007;**24**:372–9. <https://doi.org/10.1093/fampra/cmm024>
119. Basu A, Manca A. Regression estimators for generic health-related quality of life and quality-adjusted life years. *Med Decis Making* 2012;**32**:56–69. <https://doi.org/10.1177/0272989X11416988>
120. Manning WG, Mullahy J. Estimating log models: to transform or not to transform? *J Health Econ* 2001;**20**:461–94. [https://doi.org/10.1016/S0167-6296\(01\)00086-8](https://doi.org/10.1016/S0167-6296(01)00086-8)
121. Smith L, Gardner B, Fisher A, Hamer M. Patterns and correlates of physical activity behaviour over 10 years in older adults: prospective analyses from the English Longitudinal Study of Ageing. *BMJ Open* 2015;**5**:e007423. <https://doi.org/10.1136/bmjopen-2014-007423>
122. Henderson C, Knapp M, Fernández JL, Beecham J, Hirani SP, Cartwright M, *et al*. Cost effectiveness of telehealth for patients with long term conditions (Whole Systems Demonstrator telehealth questionnaire study): nested economic evaluation in a pragmatic, cluster randomised controlled trial. *BMJ* 2013;**346**:f1035. <https://doi.org/10.1136/bmj.f1035>
123. Graubard BI, Korn EL. Analyzing health surveys for cancer-related objectives. *J Natl Cancer Inst* 1999;**91**:1005–16. <https://doi.org/10.1093/jnci/91.12.1005>
124. Reiner M, Niermann C, Jekauc D, Woll A. Long-term health benefits of physical activity – a systematic review of longitudinal studies. *BMC Public Health* 2013;**13**:813. <https://doi.org/10.1186/1471-2458-13-813>
125. Sattelmair J, Pertman J, Ding EL, Kohl HW, Haskell W, Lee IM. Dose response between physical activity and risk of coronary heart disease: a meta-analysis. *Circulation* 2011;**124**:789–95. <https://doi.org/10.1161/CIRCULATIONAHA.110.010710>
126. Jeon CY, Lokken RP, Hu FB, van Dam RM. Physical activity of moderate intensity and risk of type 2 diabetes: a systematic review. *Diabetes Care* 2007;**30**:744–52. <https://doi.org/10.2337/dc06-1842>
127. Warburton DE, Nicol CW, Bredin SS. Health benefits of physical activity: the evidence. *CMAJ* 2006;**174**:801–9. <https://doi.org/10.1503/cmaj.051351>
128. Lee CD, Folsom AR, Blair SN. Physical activity and stroke risk: a meta-analysis. *Stroke* 2003;**34**:2475–81. <https://doi.org/10.1161/01.STR.0000091843.02517.9D>
129. Olanrewaju O, Kelly S, Cowan A, Brayne C, LaFortune L. Physical activity in community dwelling older people: a systematic review of reviews of interventions and context. *PLOS ONE* 2016;**11**:e0168614. <https://doi.org/10.1371/journal.pone.0168614>

130. Anokye NK, Lord J, Fox-Rushby J. Is brief advice in primary care a cost-effective way to promote physical activity? *Br J Sports Med* 2014;**48**:202–6. <https://doi.org/10.1136/bjsports-2013-092897>
131. Campbell F, Holmes M, Everson-Hock E, Davis S, Buckley Woods H, Anokye N, *et al.* A systematic review and economic evaluation of exercise referral schemes in primary care: a short report. *Health Technol Assess* 2015;**19**(60). <https://doi.org/10.3310/hta19600>
132. Pavey TG, Anokye N, Taylor AH, Trueman P, Moxham T, Fox KR, *et al.* The clinical effectiveness and cost-effectiveness of exercise referral schemes: a systematic review and economic evaluation. *Health Technol Assess* 2011;**15**(44). <https://doi.org/10.3310/hta15440>
133. Anokye NK, Trueman P, Green C, Pavey TG, Hillsdon M, Taylor RS. The cost-effectiveness of exercise referral schemes. *BMC Public Health* 2011;**11**:954. <https://doi.org/10.1186/1471-2458-11-954>
134. Anokye N, Anagnostou A, Lord J, Vali Y, Taylor S, Foster C, *et al.* *An Individual-level Simulation Model for Assessing Physical Activity Interventions*. European Public Health Conference, Vienna, 2016.
135. NICE. *Physical Activity: Brief Advice for Adults in Primary Care*. Public health guideline [PH44]. London: NICE; 2013.
136. Matrix. *Estimating Return on Investment for Interventions and Strategies to Increase Physical Activity-Technical Report*. London: NICE; 2014.
137. Office for National Statistics. *Life Expectancy*. 2015. URL: <http://visual.ons.gov.uk/how-long-will-my-pension-need-to-last/> (accessed 27 November 2017).
138. Physical Activity Guidelines Advisory Committee. *Physical Activity Guidelines Advisory Committee Report, 2008*. Washington, DC: Department of Health and Human Services; 2008.
139. Laine J, Kuvaja-Köllner V, Pietilä E, Koivuneva M, Valtonen H, Kankaanpää E. Cost-effectiveness of population-level physical activity interventions: a systematic review. *Am J Health Promot* 2014;**29**:71–80. <https://doi.org/10.4278/ajhp.131210-LIT-622>
140. Garrett S, Elley CR, Rose SB, O’Dea D, Lawton BA, Dowell AC. Are physical activity interventions in primary care and the community cost-effective? A systematic review of the evidence. *Br J Gen Pract* 2011;**61**:e125–33. <https://doi.org/10.3399/bjgp11X561249>
141. De Smedt D, De Cocker K, Annemans L, De Bourdeaudhuij I, Cardon G. A cost-effectiveness study of the community-based intervention ‘10 000 Steps Ghent’. *Public Health Nutr* 2012;**15**:442–51. <https://doi.org/10.1017/S1368980011001716>
142. Brennan A, Blake L, Hill-McManus D, Payne N, Buckley Woods H, Blank L. *Walking and Cycling: Local Measures to Promote Walking and Cycling As Forms of Travel or Recreation: Health Economic and Modelling Report*. London: NICE; 2012.
143. NHS Digital. *Health Survey for England – 2004: The Health of Ethnic Minorities, Headline Results*. London: NHS Digital; 2006.
144. Lamb SE, Bartlett HP, Ashley A, Bird W. Can lay-led walking programmes increase physical activity in middle aged adults? A randomised controlled trial. *J Epidemiol Community Health* 2002;**56**:246–52. <https://doi.org/10.1136/jech.56.4.246>
145. Copeland RJ, Horspool K, Humphreys L, Scott E, Booster trial team. Recruiting to a large-scale physical activity randomised controlled trial - experiences with the gift of hindsight. *Trials* 2016;**17**:104. <https://doi.org/10.1186/s13063-016-1229-0>
146. Caperchione CM, Duncan M, Kolt GS, Vandelanotte C, Rosenkranz RR, Maeder A, *et al.* Examining an Australian physical activity and nutrition intervention using RE-AIM. *Health Promot Int* 2016;**31**:450–8. <https://doi.org/10.1093/heapro/dav005>

147. Kerry SM, Morgan KE, Limb E, Cook DG, Furness C, Carey I, *et al.* Interpreting population reach of a large, successful physical activity trial delivered through primary care. *BMC Public Health* 2018;**18**:170. <https://doi.org/10.1186/s12889-018-5034-4>
148. Normansell R, Holmes R, Victor C, Cook DG, Kerry S, Iliffe S, *et al.* Exploring non-participation in primary care physical activity interventions: PACE-UP trial interview findings. *Trials* 2016;**17**:178. <https://doi.org/10.1186/s13063-016-1299-z>
149. Victor CR, Rogers A, Woodcock A, Beighton C, Cook DG, Kerry SM, *et al.* What factors support older people to increase their physical activity levels? An exploratory analysis of the experiences of PACE-Lift trial participants. *Arch Gerontol Geriatr* 2016;**67**:1–6. <https://doi.org/10.1016/j.archger.2016.06.006>
150. Ritchie J, Spencer L. Qualitative Data Analysis for Applied Policy Research. In Bryman AB, Burgess RG, editors. *Analysing Qualitative Data*. London: Routledge; 1994. pp. 173–95. [https://doi.org/10.4324/9780203413081\\_chapter\\_9](https://doi.org/10.4324/9780203413081_chapter_9)
151. Foster CE, Brennan G, Matthews A, McAdam C, Fitzsimons C, Mutrie N. Recruiting participants to walking intervention studies: a systematic review. *Int J Behav Nutr Phys Act* 2011;**8**:137. <https://doi.org/10.1186/1479-5868-8-137>
152. Loudon K, Treweek S, Sullivan F, Donnan P, Thorpe KE, Zwarenstein M. The PRECIS-2 tool: designing trials that are fit for purpose. *BMJ* 2015;**350**:h2147. <https://doi.org/10.1136/bmj.h2147>
153. Warner ET, Glasgow RE, Emmons KM, Bennett GG, Askew S, Rosner B, Colditz GA. Recruitment and retention of participants in a pragmatic randomized intervention trial at three community health clinics: results and lessons learnt. *BMC Public Health* 2013;**13**:192. <https://doi.org/10.1186/1471-2458-13-192>
154. Dubbert PM, Cooper KM, Kirchner KA, Meydrech EF, Bilbrew D. Effects of nurse counseling on walking for exercise in elderly primary care patients. *J Gerontol A Biol Sci Med Sci* 2002;**57**:M733–40. <https://doi.org/10.1093/gerona/57.11.M733>
155. Dubbert PM, Morey MC, Kirchner KA, Meydrech EF, Grothe K. Counseling for home-based walking and strength exercise in older primary care patients. *Arch Intern Med* 2008;**168**:979–86. <https://doi.org/10.1001/archinte.168.9.979>
156. Cappuccio FP, Cook DG, Atkinson RW, Wicks PD. The Wandsworth Heart and Stroke Study. A population-based survey of cardiovascular risk factors in different ethnic groups. Methods and baseline findings. *Nutr Metab Cardiovasc Dis* 1998;**8**:371–85.
157. Rogers A, Harris T, Victor C, Woodcock A, Limb E, Kerry S, *et al.* Which older people decline participation in a primary care trial of physical activity and why: insights from a mixed methods approach. *BMC Geriatr* 2014;**14**:46. <https://doi.org/10.1186/1471-2318-14-46>
158. Attwood S, Morton K, Sutton S. Exploring equity in uptake of the NHS Health Check and a nested physical activity intervention trial. *J Public Health (Oxf)* 2016;**38**:560–8. <https://doi.org/10.1093/pubmed/fdv070>
159. Douglas A, Bhopal RS, Bhopal R, Forbes JF, Gill JM, Lawton J, *et al.* Recruiting South Asians to a lifestyle intervention trial: experiences and lessons from PODOSA (Prevention of Diabetes & Obesity in South Asians). *Trials* 2011;**12**:220. <https://doi.org/10.1186/1745-6215-12-220>
160. Wilbur J, Buchholz SW, Ingram DM, Braun LT, Johnson TJ, Fogg L, *et al.* Effectiveness, efficiency, duration, and costs of recruiting for an African American women's lifestyle physical activity program. *Res Nurs Health* 2013;**36**:487–99. <https://doi.org/10.1002/nur.21550>
161. Crombie IK, Irvine L, Williams B, McGinnis AR, Slane PW, Alder EM, *et al.* Why older people do not participate in leisure time physical activity: a survey of activity levels, beliefs and deterrents. *Age Ageing* 2004;**33**:287–92. <https://doi.org/10.1093/ageing/afh089>

162. Normansell R, Smith J, Victor C, Cook DG, Kerry S, Iliffe S, *et al*. Numbers are not the whole story: a qualitative exploration of barriers and facilitators to increased physical activity in a primary care based walking intervention. *BMC Public Health* 2014;**14**:1272. <https://doi.org/10.1186/1471-2458-14-1272>
163. Chinn DJ, White M, Howel D, Harland JO, Drinkwater CK. Factors associated with non-participation in a physical activity promotion trial. *Public Health* 2006;**120**:309–19. <https://doi.org/10.1016/j.puhe.2005.11.003>
164. Costello E, Kafchinski M, Vrazel J, Sullivan P. Motivators, barriers, and beliefs regarding physical activity in an older adult population. *J Geriatr Phys Ther* 2011;**34**:138–47. <https://doi.org/10.1519/JPT.0b013e31820e0e71>
165. Cohen-Mansfield J, Marx MS, Guralnik JM. Motivators and barriers to exercise in an older community dwelling population. *J Ageing Phys Act* 2003;**11**:242–53. <https://doi.org/10.1123/japa.11.2.242>
166. Justine M, Azizan A, Hassan V, Salleh Z, Manaf H. Barriers to participation in physical activity and exercise among middle-aged and elderly individuals. *Singapore Med J* 2013;**54**:581–6. <https://doi.org/10.11622/smedj.2013203>
167. Booth ML, Bauman A, Owen N, Gore CJ. Physical activity preferences, preferred sources of assistance, and perceived barriers to increased activity among physically inactive Australians. *Prev Med* 1997;**26**:131–7. <https://doi.org/10.1006/pmed.1996.9982>
168. Bock C, Jarczok MN, Litaker D. Community-based efforts to promote physical activity: a systematic review of interventions considering mode of delivery, study quality and population subgroups. *J Sci Med Sport* 2014;**17**:276–82. <https://doi.org/10.1016/j.jsams.2013.04.009>
169. Moore GF, Audrey S, Barker M, Bond L, Bonell C, Hardeman W, *et al*. Process evaluation of complex interventions: Medical Research Council guidance. *BMJ* 2015;**350**:h1258. <https://doi.org/10.1136/bmj.h1258>
170. Furness C, Howard E, Limb E, Cook DG, Kerry S, Wahlich C, *et al*. Relating process evaluation measures to complex intervention outcomes: findings from the PACE-UP primary care pedometer-based walking trial. *Trials* 2018;**19**:58. <https://doi.org/10.1186/s13063-017-2428-z>
171. Horvath AO, Greenberg LS. Development and validation of the working alliance inventory. *J Couns Psychol* 1989;**36**:223–33. <https://doi.org/10.1037/0022-0167.36.2.223>
172. Andrusyna TP, Tang TZ, DeRubeis RJ, Luborsky L. The factor structure of the working alliance inventory in cognitive-behavioral therapy. *J Psychother Pract Res* 2001;**10**:173–8.
173. Low DC, Miller SD, Squire B. *The Outcome Rating Scale (ORS) and Session Rating Scales (SRS): Feedback Informed Treatment in Child and Adolescent Mental Health Services (CAMHS)*. 2012. URL: [www.aft.org.uk/SpringboardWebApp/userfiles/aft/file/Events/2012/David%20Low%20paper%20for%20CYP-IAPT.pdf](http://www.aft.org.uk/SpringboardWebApp/userfiles/aft/file/Events/2012/David%20Low%20paper%20for%20CYP-IAPT.pdf) (accessed 18 June 2018).
174. Mannix KA, Blackburn IM, Garland A, Gracie J, Moorey S, Reid B, *et al*. Effectiveness of brief training in cognitive behaviour therapy techniques for palliative care practitioners. *Palliat Med* 2006;**20**:579–84. <https://doi.org/10.1177/0269216306071058>
175. Hope R. *The Ten Essential Shared Capabilities – A Framework for the Whole of the Mental Health Workforce*. London: Department of Health and Social Care; 2004. <https://doi.org/10.1037/e543012011-001>
176. Ramsay CR, Thomas RE, Croal BL, Grimshaw JM, Eccles MP. Using the theory of planned behaviour as a process evaluation tool in randomised trials of knowledge translation strategies: a case study from UK primary care. *Implement Sci* 2010;**5**:71. <https://doi.org/10.1186/1748-5908-5-71>

177. Clarke DJ, Godfrey M, Hawkins R, Sadler E, Harding G, Forster A, *et al.* Implementing a training intervention to support caregivers after stroke: a process evaluation examining the initiation and embedding of programme change. *Implement Sci* 2013;**8**:96. <https://doi.org/10.1186/1748-5908-8-96>
178. Tomasone JR, Martin Ginis KA, Estabrooks PA, Domenicucci L. Changing minds, changing lives from the top down: an investigation of the dissemination and adoption of a Canada-wide educational intervention to enhance health care professionals' intentions to prescribe physical activity. *Int J Behav Med* 2015;**22**:336–44. <https://doi.org/10.1007/s12529-014-9414-6>
179. Tomasone JR, Arbour-Nicitopoulos KP, Pila E, Lamontagne ME, Cummings I, Latimer-Cheung AE, Routhier F. Exploring end user adoption and maintenance of a telephone-based physical activity counseling service for individuals with physical disabilities using the theoretical domains framework. *Disabil Rehabil* 2017;**39**:1332–40. <https://doi.org/10.1080/09638288.2016.1193231>
180. Hasson H, Blomberg S, Dunér A. Fidelity and moderating factors in complex interventions: a case study of a continuum of care program for frail elderly people in health and social care. *Implement Sci* 2012;**7**:23. <https://doi.org/10.1186/1748-5908-7-23>
181. Grimshaw JM, Zwarenstein M, Tetroe JM, Godin G, Graham ID, Lemyre L, *et al.* Looking inside the black box: a theory-based process evaluation alongside a randomised controlled trial of printed educational materials (the Ontario printed educational message, OPEM) to improve referral and prescribing practices in primary care in Ontario, Canada. *Implement Sci* 2007;**2**:38. <https://doi.org/10.1186/1748-5908-2-38>
182. Fitzgerald TM, Williams PA, Dodge JA, Quinn M, Heminger CL, Moultrie R, *et al.* Program implementation approaches to build and sustain health care coordination for type 2 diabetes. *Health Promot Pract* 2017;**18**:306–13. <https://doi.org/10.1177/1524839916643705>
183. Campbell-Scherer DL, Asselin J, Osunlana AM, Fielding S, Anderson R, Rueda-Clausen CF, *et al.* Implementation and evaluation of the 5As framework of obesity management in primary care: design of the 5As Team (5AsT) randomized control trial. *Implement Sci* 2014;**9**:78. <https://doi.org/10.1186/1748-5908-9-78>
184. Berendsen BA, Kremers SP, Savelberg HH, Schaper NC, Hendriks MR. The implementation and sustainability of a combined lifestyle intervention in primary care: mixed method process evaluation. *BMC Fam Pract* 2015;**16**:37. <https://doi.org/10.1186/s12875-015-0254-5>
185. Beighton C, Victor C, Normansell R, Cook D, Kerry S, Liffie S, *et al.* 'It's not just about walking . . . it's the practice nurse that makes it work': a qualitative exploration of the views of practice nurses delivering complex physical activity interventions in primary care. *BMC Public Health* 2015;**15**:1236. <https://doi.org/10.1186/s12889-015-2568-6>
186. Picorelli AM, Pereira LS, Pereira DS, Felício D, Sherrington C. Adherence to exercise programs for older people is influenced by program characteristics and personal factors: a systematic review. *J Physiother* 2014;**60**:151–6. <https://doi.org/10.1016/j.jphys.2014.06.012>
187. Wahlich C, Beighton C, Victor C, Normansell R, Cook D, Kerry S, *et al.* 'You started something . . . then I continued by myself': a qualitative study of physical activity maintenance. *Prim Health Care Res Dev* 2017;**18**:574–90. <https://doi.org/10.1017/S1463423617000433>
188. Harris T, Kerry SM, Limb ES, Furness C, Wahlich C, Victor CR, *et al.* Physical activity levels in adults and older adults 3-4 years after pedometer-based walking interventions: long-term follow-up of participants from two randomised controlled trials in UK primary care. *PLOS Med* 2018;**15**:e1002526. <https://doi.org/10.1371/journal.pmed.1002526>

189. Iliffe S, Kendrick D, Morris R, Masud T, Gage H, Skelton D, *et al.* Multicentre cluster randomised trial comparing a community group exercise programme and home-based exercise with usual care for people aged 65 years and over in primary care. *Health Technol Assess* 2014;**18**(49). <https://doi.org/10.3310/hta18490>
190. Marcus BH, Dubbert PM, Forsyth LH, McKenzie TL, Stone EJ, Dunn AL, Blair SN. Physical activity behavior change: issues in adoption and maintenance. *Health Psychol* 2000;**19**:32–41. <https://doi.org/10.1037/0278-6133.19.Suppl1.32>
191. White IR, Carpenter J, Horton N. *A Mean Score Method for Sensitivity Analysis to Departures from the Missing at Random Assumption in Randomised Trials*. Statistica Sinica; 2017. URL: [www.stat.sinica.edu.tw/statistica/](http://www.stat.sinica.edu.tw/statistica/) (accessed 25 May 2018).
192. Tully MA, Cupples ME, Chan WS, McGlade K, Young IS. Brisk walking, fitness, and cardiovascular risk: a randomized controlled trial in primary care. *Prev Med* 2005;**41**:622–8. <https://doi.org/10.1016/j.ypmed.2004.11.030>
193. NHS England Public Health England Diabetes UK. *Healthier You: NHS Diabetes Prevention Programme (NHS DPP)*. 2015. URL: [www.england.nhs.uk/ourwork/qual-clin-lead/action-for-diabetes/diabetes-prevention](http://www.england.nhs.uk/ourwork/qual-clin-lead/action-for-diabetes/diabetes-prevention) (accessed 27 November 2017).
194. Chau JY, Grunseit AC, Chey T, Stamatakis E, Brown WJ, Matthews CE, *et al.* Daily sitting time and all-cause mortality: a meta-analysis. *PLOS ONE* 2013;**8**:e80000. <https://doi.org/10.1371/journal.pone.0080000>
195. Biswas A, Oh PI, Faulkner GE, Bajaj RR, Silver MA, Mitchell MS, Alter DA. Sedentary time and its association with risk for disease incidence, mortality, and hospitalization in adults: a systematic review and meta-analysis. *Ann Intern Med* 2015;**162**:123–32. <https://doi.org/10.7326/M14-1651>
196. Fitzsimons CF, Baker G, Gray SR, Nimmo MA, Mutrie N, Scottish Physical Activity Research Collaboration (SPARColl). Does physical activity counselling enhance the effects of a pedometer-based intervention over the long-term: 12-month findings from the Walking for Wellbeing in the west study. *BMC Public Health* 2012;**12**:206. <https://doi.org/10.1186/1471-2458-12-206>
197. Zheng H, Orsini N, Amin J, Wolk A, Nguyen VT, Ehrlich F. Quantifying the dose-response of walking in reducing coronary heart disease risk: meta-analysis. *Eur J Epidemiol* 2009;**24**:181–92. <https://doi.org/10.1007/s10654-009-9328-9>
198. Dwyer T, Pezic A, Sun C, Cochrane J, Venn A, Srikanth V, *et al.* Objectively measured daily steps and subsequent long term all-cause mortality: the tasped prospective cohort study. *PLOS ONE* 2015;**10**:e0141274. <https://doi.org/10.1371/journal.pone.0141274>
199. Marcus BH, Lewis BA, Hogan J, King TK, Albrecht AE, Bock B, *et al.* The efficacy of moderate-intensity exercise as an aid for smoking cessation in women: a randomized controlled trial. *Nicotine Tob Res* 2005;**7**:871–80. <https://doi.org/10.1080/14622200500266056>
200. Ashford S, Edmunds J, French DP. What is the best way to change self-efficacy to promote lifestyle and recreational physical activity? A systematic review with meta-analysis. *Br J Health Psychol* 2010;**15**:265–88. <https://doi.org/10.1348/135910709X461752>
201. Cox KL, Flicker L, Almeida OP, Xiao J, Greenop KR, Hendriks J, *et al.* The FABS trial: a randomised control trial of the effects of a 6-month physical activity intervention on adherence and long-term physical activity and self-efficacy in older adults with memory complaints. *Prev Med* 2013;**57**:824–30. <https://doi.org/10.1016/j.ypmed.2013.09.010>
202. Kuller LH, Kinzel LS, Pettee KK, Kriska AM, Simkin-Silverman LR, Conroy MB, *et al.* Lifestyle intervention and coronary heart disease risk factor changes over 18 months in postmenopausal women: the Women On the Move through Activity and Nutrition (WOMAN study) clinical trial. *J Womens Health* 2006;**15**:962–74. <https://doi.org/10.1089/jwh.2006.15.962>

203. Opdenacker J, Boen F, Coorevits N, Delecluse C. Effectiveness of a lifestyle intervention and a structured exercise intervention in older adults. *Prev Med* 2008;**46**:518–24. <https://doi.org/10.1016/j.ypmed.2008.02.017>
204. Tulloch H, Sweet SN, Fortier M, Capstick G, Kenny GP, Sigal RJ. Exercise facilitators and barriers from adoption to maintenance in the diabetes aerobic and resistance exercise trial. *Can J Diabetes* 2013;**37**:367–74. <https://doi.org/10.1016/j.jcjd.2013.09.002>
205. Kaewthummanukul T, Brown KC. Determinants of employee participation in physical activity: critical review of the literature. *AAOHN J* 2006;**54**:249–61. <https://doi.org/10.1177/216507990605400602>
206. Sharma M, Sargent L, Stacy R. Predictors of leisure-time physical activity among African American women. *Am J Health Behav* 2005;**29**:352–9. <https://doi.org/10.5993/AJHB.29.4.7>
207. Office for National Statistics (ONS). *Annual survey of hours and earnings*. ONS Digital; 2015. URL: [www.ons.gov.uk/employmentandlabourmarket/peopleinwork/earningsandworkinghours/bulletins/annualsurveyofhoursandearnings/2015provisionalresults](http://www.ons.gov.uk/employmentandlabourmarket/peopleinwork/earningsandworkinghours/bulletins/annualsurveyofhoursandearnings/2015provisionalresults) (accessed November 2015).
208. Sharples L, Glover M, Bennett M, Jordan J, Clutterbuck-James A, Davies M, *et al.* TOMADO: a crossover randomised controlled trial of oral mandibular advancement devices for obstructive sleep apnoea-hypopnoea. *Health Technol Assess* 2014;**18**(67). <https://doi.org/10.3310/hta18670>
209. Gillett M, Dallosso HM, Dixon S, Brennan A, Carey ME, Campbell MJ, *et al.* Delivering the diabetes education and self-management for ongoing and newly diagnosed (DESMOND) programme for people with newly diagnosed type 2 diabetes: cost effectiveness analysis. *BMJ* 2010;**341**:c4093. <https://doi.org/10.1136/bmj.c4093>
210. Richardson G, Kennedy A, Reeves D, Bower P, Lee V, Middleton E, *et al.* A Cost effectiveness of the Expert Participants Programme (EPP) for participants with chronic conditions. *J Epidemiol and Community Health* 2008;**62**:361–367. <https://doi.org/10.1136/jech.2006.057430>
211. Hu G, Qiao Q, Silventoinen K, Eriksson JG, Jousilahti P, Lindström J, *et al.* Occupational, commuting, and leisure-time physical activity in relation to risk for Type 2 diabetes in middle-aged Finnish men and women. *Diabetologia* 2003;**46**:322–9. <https://doi.org/10.1007/s00125-003-1031-x>
212. Hu G, Sarti C, Jousilahti P, Silventoinen K, Barengo NC, Tuomilehto J. Leisure time, occupational, and commuting physical activity and the risk of stroke. *Stroke* 2005;**36**:1994–9. <https://doi.org/10.1161/01.STR.0000177868.89946.0c>
213. Hu G, Jousilahti P, Borodulin K, Barengo NC, Lakka TA, Nissinen A, Tuomilehto J. Occupational, commuting and leisure-time physical activity in relation to coronary heart disease among middle-aged Finnish men and women. *Atherosclerosis* 2007;**194**:490–7. <https://doi.org/10.1016/j.atherosclerosis.2006.08.051>
214. Briggs AS, Sculpher MJ, Claxton K. *Decision Modelling for Health Economic Evaluation*. Oxford: Oxford University Press; 2006.
215. Hu G, Jousilahti P, Antikainen R, Tuomilehto J. Occupational, commuting, and leisure-time physical activity in relation to cardiovascular mortality among Finnish subjects with hypertension. *Am J Hypertens* 2007;**20**:1242–50. <https://doi.org/10.1016/j.amjhyper.2007.07.015>
216. Preis SR, Pencina MJ, Hwang SJ, D'Agostino RB, Savage PJ, Levy D, Fox CS. Trends in cardiovascular disease risk factors in individuals with and without diabetes mellitus in the Framingham Heart Study. *Circulation* 2009;**120**:212–20. <https://doi.org/10.1161/CIRCULATIONAHA.108.846519>
217. Ward SL, Lloyd Jones M, Pandor A, Holmes M, Ara R, Ryan A. *et al.* A systematic review and economic evaluation of statins for the prevention of coronary. *Health Technol Assess* 2007;**11**(14).

218. National Clinical Guideline Centre (UK). *Hypertension: The Clinical Management of Primary Hypertension in Adults: Update of Clinical Guidelines 18 and 34*. NICE Clinical Guidelines. London: NICE; 2011.
219. Jamrozik K. Estimate of deaths attributable to passive smoking among UK adults: database analysis. *BMJ* 2005;**330**:812. <https://doi.org/10.1136/bmj.38370.496632.8F>
220. Brønnum-Hansen H, Davidsen M, Thorvaldsen P, Danish MONICA Study Group. Long-term survival and causes of death after stroke. *Stroke* 2001;**32**:2131–6. <https://doi.org/10.1161/hs0901.094253>
221. Preis SR, Hwang SJ, Coady S, Pencina MJ, D'Agostino RB Sr, Savage PJ, *et al*. Trends in all-cause and cardiovascular disease mortality among women and men with and without diabetes mellitus in the Framingham Heart Study, 1950 to 2005. *Circulation* 2009;**119**:1728–35. <https://doi.org/10.1161/CIRCULATIONAHA.108.829176>
222. Ward S, Lloyd Jones M, Pandor A, Holmes M, Ara R, Ryan A, *et al*. *Statins for the prevention of coronary events. Technology assessment report commissioned by the HTA programme on behalf of The National Institute for Clinical Excellence*. London: NICE; 2005.
223. National Clinical Guideline Centre (NCGC). *Hypertension: the clinical management of primary hypertension in adults. Clinical guideline: methods, evidence and recommendations*. London: NICE; 2011.
224. Gonzalez ELM, Johansson S, Wallander MA. Trends in the prevalence and incidence of diabetes in the UK, 1996–2005. *J Epidemiol Community Health* 2009;**63**:332–6. <https://doi.org/10.1136/jech.2008.080382>
225. Department for Health and Social Care. *Health Survey for England – 2011, Health, Social Care and Lifestyles*. London: Department for Health and Social Care; 2012.



## Appendix 1 Methods

# PACE-UP study

## *Health and lifestyle survey*

---

Study IDNO \_\_\_\_\_

Thank you for filling in this questionnaire.

It will take you about 15-20 minutes to complete.

Please feel free to write comments by any question.

All information will be kept strictly confidential.

Please enter your date of birth    \_\_\_\_ / \_\_\_\_ / \_\_\_\_

Please enter today's date        \_\_\_\_ / \_\_\_\_ / \_\_\_\_

Thank you

## Section A - Some general questions about your health

Please put a tick in the box next to the most appropriate answer for each question.



**How is your health in general?**

- |           |                          |
|-----------|--------------------------|
| Very good | <input type="checkbox"/> |
| Good      | <input type="checkbox"/> |
| Fair      | <input type="checkbox"/> |
| Poor      | <input type="checkbox"/> |
| Very poor | <input type="checkbox"/> |

**Are your day-to-day activities limited because of a health problem or disability which has lasted, or is expected to last, at least 12 months? (Include problems related to old age.)**

- |                       |                          |
|-----------------------|--------------------------|
| Yes, limited a lot    | <input type="checkbox"/> |
| Yes, limited a little | <input type="checkbox"/> |
| No                    | <input type="checkbox"/> |

**3 How much physical or bodily pain have you had in the past 4 weeks?**

- |                       |                          |
|-----------------------|--------------------------|
| None                  | <input type="checkbox"/> |
| Very mild or mild     | <input type="checkbox"/> |
| Moderate              | <input type="checkbox"/> |
| Severe or very severe | <input type="checkbox"/> |

**4 In the past four weeks, how much did pain interfere with your normal activities?**

- |                          |                          |
|--------------------------|--------------------------|
| Not at all               | <input type="checkbox"/> |
| A little bit             | <input type="checkbox"/> |
| Moderately               | <input type="checkbox"/> |
| Quite a bit or extremely | <input type="checkbox"/> |

## Section B - specific questions about your health

Have you **ever** been told by a doctor or nurse that you have any of these conditions?  
(Please tick **all** that apply to you)

YES

- Angina .....
- A heart attack .....
- Other heart problems.....
- Stroke.....
- High blood pressure.....
- Chronic bronchitis.....
- Asthma .....
- Diabetes.....
- Arthritis .....
- Cancer (apart from skin cancer) .....
- Depression.....
- Parkinson's Disease.....

**13 How many times have you fallen over in the last year ?**

- None
- Once or twice
- Three times or more
- Not sure

**14 How many different medications do you take every day?**

- None  One  Two  Three  Four or more

**15 Have you ever smoked?**

- Yes  No  (please go to question 17)

**16 Do you currently smoke?**

- Yes  No

**17 One unit of alcohol is approximately half a pint of beer / cider, one glass of wine or sherry, or a single whisky, gin etc.**

**Approximately how many units of alcohol do you have during the average week?..... units.**

## Section C - Questions about your health today

Under each heading, please tick the **ONE** box that best describes your health TODAY

### 1 Mobility

- I have no problems in walking about
- I have slight problems in walking about
- I have moderate problems in walking about
- I have severe problems in walking about
- I am unable to walk about

### 2 Self-care

- I have no problems with self-care
- I have slight problems washing or dressing myself
- I have moderate problems washing or dressing myself
- I have severe problems washing or dressing myself
- I am unable to wash or dress myself

### 3 Usual activities (e.g. work, study, housework, family or leisure)

- I have no problems doing my usual activities
- I have slight problems doing my usual activities
- I have moderate problems doing my usual activities
- I have severe problems doing my usual activities
- I am unable to do my usual activities

### 4 Pain / discomfort

- I have no pain or discomfort
- I have slight pain or discomfort
- I have moderate pain or discomfort
- I have severe pain or discomfort
- I have extreme pain or discomfort

### 5 Anxiety / depression


- I am not anxious or depressed
- I am slightly anxious or depressed
- I am moderately anxious or depressed
- I am severely anxious or depressed
- I am extremely anxious or depressed

## Section C - Your health today (continued)

- We would like to know how good or bad your health is TODAY
- The scale is numbered 0 to 100
- 100 means the best health you can imagine
- 0 means the worst health you can imagine
- Mark an X on the scale to indicate how your health is TODAY
- Now, please write the number you marked on the scale in the box below

YOUR HEALTH TODAY =

The best health  
you can imagine



The worst health  
you can imagine

## Section D - Your contact with your GP surgery

1. During the last 3 months did you talk to a doctor or nurse at your general practice on your own behalf, either in person or by telephone?

Yes  No  (If no, please go to section E)

If yes, approximately how many times did this happen in the last 3 months?

- Once
- Twice
- Three times
- Four or more times

## Section E - Some questions on how you feel

For each item below, please tick the box opposite the reply that comes closest to how you have been feeling over the past week. Don't take too long over the answers: your immediate reaction will probably be most accurate.

**Tick only one box in each section**

**1. I feel tense or 'wound up':**

- Most of the time
- A lot of the time
- From time to time
- Not at all

**2. I feel as if I am slowed down:**

- Nearly all of the time
- Very often
- Sometimes
- Not at all

**3. I still enjoy things I used to:**

- Definitely as much
- Not quite as much
- Only a little
- Hardly at all

**4. I get a sort of frightened feeling like butterflies in the stomach:**

- Not at all
- Occasionally
- Quite often
- Very often

**5. I get a sort of frightened feeling as if something bad is about to happen:**

- Very definitely
- Yes, but not too badly
- A little, but it doesn't worry me
- Not at all

**6. I have lost interest in my appearance:**

- Definitely
- I don't take so much care as I should do
- I might not take quite as much care
- I take just as much care

**7. I can laugh and see the funny side of things:**

- As much as I always could
- Not quite so much now
- Definitely not so much now
- Not at all

**8. I feel restless, as if I have to be on the move**

- Very much indeed
- Quite a lot
- Not very much
- Not at all

**9. Worrying thoughts go through my mind:**

- A great deal of the time
- A lot of the time
- From time to time but not too often
- Only occasionally

**10. I look forward with enjoyment to things:**

- As much as I ever did
- Rather less than I used to
- Definitely less than I used to
- Hardly at all

**11. I feel cheerful:**

- Not at all
- Not often
- Sometimes
- Most of the time

**12. I get sudden feelings of panic**

- Very often indeed
- Quite often
- Not very often
- Not at all

**13. I can sit at ease and feel relaxed:**

- Definitely
- Usually
- Not often
- Not at all

**14. I can enjoy a good book, radio or TV programme:**

- Often
- Sometimes
- Not often
- Very seldom

**15. I feel lonely:**

- All the time
- Often
- Sometimes
- Never

## Section F - Some questions about difficulties you may have

Here are a few things some people find difficult to do without help.

Do you or *would* you have difficulty with these activities?

	No Difficulty	Some Difficulty	Unable to do alone
1 Washing yourself all over	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
2 Cutting your own toenails	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
3 Getting on a bus	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
4 Going up and down stairs	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
5 Doing heavy housework	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
6 Shopping & carrying heavy bags	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
7 Preparing and cooking a hot meal	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
8 Reaching an overhead shelf	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
9 Tying a good knot in a piece of string	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>

**10 Do you have any problems with your balance?**

No  Yes

**11 Can you see well enough to recognise a friend across a road?**

Yes, without glasses  Yes, with glasses  No

## Section G- Some questions about your attitudes to exercise and health

Please tick one box to indicate how strongly you agree or disagree with each statement

	<i>Strongly agree</i>	<i>Slightly agree</i>	<i>Unsure</i>	<i>Slightly disagree</i>	<i>Strongly disagree</i>
1. Doing exercise is satisfying and rewarding to me	<input type="checkbox"/>				
2. Doing exercise regularly is good for me	<input type="checkbox"/>				
3. There is little I can do to make up for the physical losses that come with age	<input type="checkbox"/>				
4. Exercising regularly can be helpful for my health	<input type="checkbox"/>				
5. Exercising regularly can help me to get out of doors	<input type="checkbox"/>				
6. Exercising regularly can help me to control my weight or to lose weight	<input type="checkbox"/>				

## Section H - Some questions about physical activity

- 1** How many times did you take a walk outside *during the last week*?  
(include walking related to other activities e.g. for shopping, travel to work etc)  
.....times last week
- 2** How long did such a walk usually last? .....minutes
- 3** Did you take a walk that lasted longer than 1 hour *during the last month*?  
Yes  No
- 3a** If yes, how many times did you do that? .....times in the last month
- 4** Do you walk a dog?  
Yes  No
- 5** Do you have someone with whom you can go for a walk, or do other physical activities?  
Always   
Often   
Sometimes   
Never
- 6** Do you ride a bicycle?  
Yes  No  (please go to question 7)
- 6a** If yes, how many times did you cycle last week? .....times
- 6b** How long on average did you cycle for each time? .....minutes
- 6c** How would you describe your cycling pace?  
Slow   
Average   
Fast
- 7** Do you go swimming?  
Yes  No  (please go to question 8)
- 7a** If yes, how many times did you swim last week? .....times
- 7b** How long on average did you swim for each time?.....minutes

**7c How would you describe your swimming speed?**

Slow   
 Average   
 Fast

**8 Do you have a garden or allotment?**

Yes  No  (please go to question 9)

**8a If yes, how many hours, on average, a week do you spend doing gardening?**

In summer.....hours In winter.....hours

**9 Have you participated in any sporting activities in the last week?**

Yes  No  (if no, please go to question 10)

**9a If yes, what kind of sporting activity? .....****9b How many hours approximately did you spend participating in sporting activities in the last week?**

Less than 1 hour in the last week   
 ..... hours in the last week

**10 How often did you perspire during physical activity in the last week?**

Never   
 1-2 times   
 3-4 times   
 5 or more times

**11 Do you have a staircase in your home?**

Yes  No

**11a Do you climb stairs regularly (at least once per day)?**

Yes  No  (go to section I)

**11b If yes, approximately how many times per day do you climb the stairs?**

..... times per day

## Section I – Some questions about your belief in your ability to exercise

How sure are you that you will do each of the following:

		Very Sure	Pretty Sure	A little Sure	Not at all Sure
1	Exercise regularly (3 times a week for 20 minutes)	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
2	Exercise when you are feeling tired	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
3	Exercise when you are feeling under pressure to get things done	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
4	Exercise when you are feeling down or depressed	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
5	Exercise when you have too much work to do at home	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
6	Exercise when there are other more interesting things to do	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
7	Exercise when your family or friends do not provide any support	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
8	Exercise when you don't really feel like it	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
9	Exercise when you are away from home (e.g. visiting, on holiday)	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>

## Section J – Finally, some questions about you & your living circumstances

### 1 What is your current marital status?

Married (or living with someone as a couple)

Widowed

Divorced or separated

Single

Other

If other, please describe.....

### 2 How many people in your household, including yourself, are there

Aged under 18 .....

Aged 18-64.....

Aged 65 or over.....

### 3 Who lives in your household with you? (please tick all that apply)

I live on my own  (please go to question 4)

My husband / wife / partner

Other family members

Other adults

### 4 Do you have someone with whom you would be able to discuss a very personal and serious problem?

Yes  No

### 5 At what age did you finish your continuous full-time education at school, college or university?

14 or under  15

16  17

18  19 or over

## More questions about you & your living circumstances

### 6 Do you have any qualifications?

Yes  No  (Please go to question 7)

**If yes, which of these qualifications do you have?** If you have **any** of the qualifications listed, please tick **every** box that applies. If your UK qualifications are not listed, tick the box that contains its nearest equivalent. If you have qualifications from outside the UK, tick the 'Foreign qualifications' box and the nearest UK equivalents (if known).

- 1 - 4 O levels / CSEs / GCSEs (any grades), Entry Level, Foundation Diploma
- NVQ Level 1, Foundation GNVQ, Basic Skills
- 5+ O levels (passes) / CSEs (grade 1) / GCSEs (grades A\*- C), School Certificate, 1 A level / 2 - 3 AS levels / VCEs, Higher Diploma
- NVQ Level 2, Intermediate GNVQ, City and Guilds Craft, BTEC First / General Diploma, RSA Diploma
- Apprenticeship
- 2+ A levels / VCEs, 4+ AS levels, Higher School Certificate, Advanced Diploma
- NVQ Level 3, Advanced GNVQ, City and Guilds Advanced Craft, ONC, OND, BTEC National, RSA Advanced Diploma
- Degree (for example BA, BSc), Higher degree (for example MA, PhD, PGCE)
- NVQ Level 4 - 5, HNC, HND, RSA Higher Diploma, BTEC Higher Level
- Professional qualifications (for example teaching, nursing, accountancy)
- Other vocational / work-related qualifications
- Foreign qualifications
- No qualifications

### 7 What is your employment status?

- In full time employment
- In part time employment
- Seeking work
- Looking after home or family
- Retired
- Student
- Not working due to long-term sickness or disability
- Other (please describe) .....

**Answer question 8 for your main job, or if you are not working, your last main job.**

Your main job is the job in which you usually work (worked) the most hours.

**8 What is (was) your full and specific job title?**

For example, PRIMARY SCHOOL TEACHER, CAR MECHANIC, DISTRICT NURSE, STRUCTURAL ENGINEER

Do not state your grade or pay band.

.....

**8a Briefly describe what you do (did) in your main job.**

.....

**8b At your workplace, what is (was) the main activity of your employer or business?**

For example, PRIMARY EDUCATION, REPAIRING CARS, CONTRACT CATERING, COMPUTER SERVICING. If you are (were) a civil servant, write GOVERNMENT

.....

.....

**9 Do you, or the people you live with, own or rent your own home?**

Own (with or without a mortgage)

Rent from council or housing association

Rent privately

Other , please describe.....

**10 Do you have to cut back spending or borrow money to pay your electricity, gas, telephone or council tax bills?**

Always

Often

Occasionally

Never

**11 In total, how many cars or vans are owned, or available for use, by members of your household?**

None  One  Two  Three  Four or more

**11 Do you yourself drive a car or van?**

Never  Occasionally  Most days  Every day

**12 What is your ethnic group?**

Please choose **one** section from **A to E**, then tick  **one** box to best describe your ethnic group or background.

**A White**

- English / Welsh / Scottish/ Northern Irish / British  
 Irish  
 Gypsy or Irish Traveller  
 Any other White background, write in .....

**C Asian / Asian British**

- Indian  
 Pakistani  
 Bangladeshi  
 Chinese  
 Any other Asian background, write in .....

**E Other ethnic group**

- Arab  
 Any other ethnic group, write in .....

**B Mixed /multiple ethnic groups**

- White and Black Caribbean  
 White and Black African  
 White and Asian  
 Any other Mixed /multiple ethnic background, write in .....

**D Black / African / Caribbean / Black British**

- African  
 Caribbean  
 Any other Black / African / Caribbean background, write in .....

**Please write below any other comments you have on your health or this questionnaire**

**Thank you for filling in this questionnaire.**

# PACE-UP *study*

## *Health and lifestyle 3 month survey*

---

Study IDNO \_\_\_\_\_

**Thank you for filling in this questionnaire.**

**It will take you about 15 minutes to complete.**

**Please feel free to write comments by any question.**

**All information will be kept strictly confidential.**

**Please enter your date of birth**    \_\_\_\_ / \_\_\_\_ / \_\_\_\_

**Please enter today's date**        \_\_\_\_ / \_\_\_\_ / \_\_\_\_

**Thank you**

*Usual activity group*

## Section A - Some general questions about your health

Please put a tick in the box next to the most appropriate answer for each question.



### 1 How is your health in general?

- |           |                          |
|-----------|--------------------------|
| Very good | <input type="checkbox"/> |
| Good      | <input type="checkbox"/> |
| Fair      | <input type="checkbox"/> |
| Poor      | <input type="checkbox"/> |
| Very poor | <input type="checkbox"/> |

### 2 How much physical or bodily pain have you had in the past 4 weeks?

- |                       |                          |
|-----------------------|--------------------------|
| None                  | <input type="checkbox"/> |
| Very mild or mild     | <input type="checkbox"/> |
| Moderate              | <input type="checkbox"/> |
| Severe or very severe | <input type="checkbox"/> |

### 3 In the past four weeks, how much did pain interfere with your normal activities?

- |                          |                          |
|--------------------------|--------------------------|
| Not at all               | <input type="checkbox"/> |
| A little bit             | <input type="checkbox"/> |
| Moderately               | <input type="checkbox"/> |
| Quite a bit or extremely | <input type="checkbox"/> |

## Section B - Questions about your health today

Under each heading, please tick the **ONE** box that best describes your health **TODAY**

### 1 Mobility

- I have no problems in walking about
- I have slight problems in walking about
- I have moderate problems in walking about
- I have severe problems in walking about
- I am unable to walk about

### 2 Self-care

- I have no problems with self-care
- I have slight problems washing or dressing myself
- I have moderate problems washing or dressing myself
- I have severe problems washing or dressing myself
- I am unable to wash or dress myself

### 3 Usual activities (e.g. work, study, housework, family or leisure)

- I have no problems doing my usual activities
- I have slight problems doing my usual activities
- I have moderate problems doing my usual activities
- I have severe problems doing my usual activities
- I am unable to do my usual activities

### 4 Pain / discomfort

- I have no pain or discomfort
- I have slight pain or discomfort
- I have moderate pain or discomfort
- I have severe pain or discomfort
- I have extreme pain or discomfort

### 5 Anxiety / depression


- I am not anxious or depressed
- I am slightly anxious or depressed
- I am moderately anxious or depressed
- I am severely anxious or depressed
- I am extremely anxious or depressed

## Section B - Continued: about your health today

We would like to know how good or bad your health is TODAY

- The scale is numbered 0 to 100
- 100 means the best health you can imagine
- 0 means the worst health you can imagine
- Mark an X on the scale to indicate how your health is TODAY
- Now, please write the number you marked on the scale in the box below

YOUR HEALTH TODAY =



## Section C - Some questions on injuries and health

These questions ask about any injuries or changes in your health that you may have had in the 3 months that you have been involved in this study.

In the last 3 months have you had any of the following:

- 1 A fall? Yes  No
- 1a If yes, how many times? .....times in the last 3 months
- 2 Any fractures (broken bones)? Yes  No
- 2a If yes, please give details of what bones were injured  
 .....  
 .....
- 3 Any sprains or injuries? Yes  No
- 3a If yes, please give details of the sprain or injury  
 .....

## Some questions on injuries and health continued

If you have not had a fall, fracture, sprain or injury, please go to question 6.

If you have had a fall, fracture, sprain or injury, please go to question 4.

4. Did you or your family have to pay for anything as a result of your fall(s), fracture(s), sprain(s) or injury (ies)? (Please consider any costs linked to your continuing care or recovery)

Yes  No

- 4a. If yes, roughly how much did you spend?.....

- 4b. What was this spent on.....  
.....

5. In the past 3 months did you have to stop doing your usual activities due to a fall, fracture, sprain or injury?

Yes  No

- 5a. If yes, how many days did you stop your usual activities? .....days

6. In the last 3 months have you noticed a deterioration in any health problems that you already had at the start of this research project?

Yes  No

- 6a. If yes, please give details  
.....  
.....

7. In the last 3 months have you noticed an improvement in any health problems that you already had at the start of this research project?

Yes  No

- 7a. If yes, please give details  
.....  
.....

## Section D - Some questions on how you feel

For each item below, please tick the box opposite the reply that comes closest to how you have been feeling over the past week. Don't take too long over the answers: your immediate reaction will probably be most accurate.

**Tick only one box in each section**

**16. I feel tense or 'wound up':**

- |                   |                          |
|-------------------|--------------------------|
| Most of the time  | <input type="checkbox"/> |
| A lot of the time | <input type="checkbox"/> |
| Time to time      | <input type="checkbox"/> |
| Not at all        | <input type="checkbox"/> |

**17. I feel as if I am slowed down:**

- |                        |                          |
|------------------------|--------------------------|
| Nearly all of the time | <input type="checkbox"/> |
| Very often             | <input type="checkbox"/> |
| Sometimes              | <input type="checkbox"/> |
| Not at all             | <input type="checkbox"/> |

**18. I still enjoy things I used to:**

- |                    |                          |
|--------------------|--------------------------|
| Definitely as much | <input type="checkbox"/> |
| Not quite as much  | <input type="checkbox"/> |
| Only a little      | <input type="checkbox"/> |
| Hardly at all      | <input type="checkbox"/> |

**19. I get a sort of frightened feeling like butterflies in the stomach:**

- |              |                          |
|--------------|--------------------------|
| Not at all   | <input type="checkbox"/> |
| Occasionally | <input type="checkbox"/> |
| Quite often  | <input type="checkbox"/> |
| Very often   | <input type="checkbox"/> |

**20. I get a sort of frightened feeling as if something bad is about to happen:**

- |                                   |                          |
|-----------------------------------|--------------------------|
| Very definitely                   | <input type="checkbox"/> |
| Yes, but not too badly            | <input type="checkbox"/> |
| A little, but it doesn't worry me | <input type="checkbox"/> |
| Not at all                        | <input type="checkbox"/> |

**21. I have lost interest in my appearance:**

- |  |                          |
|--|--------------------------|
| Definitely                               | <input type="checkbox"/> |
| I don't take so much care as I should do | <input type="checkbox"/> |
| I might not take quite as much care      | <input type="checkbox"/> |
| I take just as much care                 | <input type="checkbox"/> |

**22. I can laugh and see the funny side of things:**

- |                            |                          |
|----------------------------|--------------------------|
| As much as I always could  | <input type="checkbox"/> |
| Not quite so much now      | <input type="checkbox"/> |
| Definitely not so much now | <input type="checkbox"/> |
| Not at all                 | <input type="checkbox"/> |

**23. I feel restless, as if I have to be on the move**

- Very much indeed
- Quite a lot
- Not very much
- Not at all

**24. Worrying thoughts go through my mind:**

- A great deal of the time
- A lot of the time
- From time to time but not too often
- Only occasionally

**25. I look forward with enjoyment to things:**

- As much as I ever did
- Rather less than I used to
- Definitely less than I used to
- Hardly at all

**26. I feel cheerful:**

- Not at all
- Not often
- Sometimes
- Most of the time

**27. I get sudden feelings of panic**

- Very often indeed
- Quite often
- Not very often
- Not at all

**28. I can sit at ease and feel relaxed:**

- Definitely
- Usually
- Not often
- Not at all

**29. I can enjoy a good book, radio or TV programme:**

- Often
- Sometimes
- Not often
- Very seldom

**30. I feel lonely:**

- All the time
- Often
- Sometimes
- Never

## Section E - Some questions about your attitudes to exercise and health

Please indicate how strongly you agree or disagree with each statement

Please tick one box to indicate how strongly you agree or disagree with each statement

	<i>Strongly agree</i>	<i>Slightly agree</i>	<i>Unsure</i>	<i>Slightly disagree</i>	<i>Strongly disagree</i>
7. Doing exercise is satisfying and rewarding to me	<input type="checkbox"/>				
8. Doing exercise regularly is good for me	<input type="checkbox"/>				
9. There is little I can do to make up for the physical losses that come with age	<input type="checkbox"/>				
10. Exercising regularly can be helpful for my health	<input type="checkbox"/>				
11. Exercising regularly can help me to get out of doors	<input type="checkbox"/>				
12. Exercising regularly can help me to control my weight or to lose weight	<input type="checkbox"/>				

## Section F – Some questions about your belief in your ability to exercise

How sure are you that you will do each of the following:

		Very Sure	Pretty Sure	A little Sure	Not at all Sure
1	Exercise regularly (3 times a week for 20 minutes)	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
2	Exercise when you are feeling tired	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
3	Exercise when you are feeling under pressure to get things done	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
4	Exercise when you are feeling down or depressed	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
5	Exercise when you have too much work to do at home	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
6	Exercise when there are other more interesting things to do	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
7	Exercise when your family or friends do not provide any support	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
8	Exercise when you don't really feel like it	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
9	Exercise when you are away from home (e.g. visiting, on holiday)	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>

## Section G - Some questions about physical activity

- 6** How many times did you take a walk outside during the last week?  
(include walking related to other activities) .....times last week
- 2** How long did such a walk usually last? .....minutes
- 3** Did you take a walk that lasted longer than 1 hour during the last month?  
Yes  No
- 3a** If yes, how many times did you do that? .....times last month
- 4** Do you have someone with whom you can go for a walk, or do other physical activities?  
Always  Often  Sometimes  Never
- 5** Do you ride a bicycle? Yes  No  (please go to question 6)
- 5a** If yes, how many times did you cycle last week? .....times
- 5b** How long on average did you cycle for each time? .....minutes
- 5c** How would you describe your cycling pace?  
Slow  Average  Fast
- 6** Do you go swimming? Yes  No  (please go to question 7)
- 6a** If yes, how many times did you swim last week? .....times
- 6b** How long on average did you swim for each time?.....minutes
- 6c** How would you describe your swimming speed?  
Slow  Average  Fast

**7 Have you participated in any sporting activities in the last week?**Yes  No  (if no, please go to question 8)**7a If yes, what kind of sporting activity? .....****7b How many hours approximately, did you spend participating in sporting activities in the last week?**Less than 1 hour in the last week  ..... hours in the last week **8 How often did you perspire during physical activity in the last week?**Never  1-2 times  3-4 times  5 or more times **9. In the last 3 months (since you have been taking part in the PACE-UP trial) do you think that your walking and physical activity has:**Decreased a lot Decreased a little Stayed about the same Increased a little Increased a lot

## Section H - Some questions about the money you have spent to do with walking and other physical activity

**7 In the past 3 months, did you pay for any membership fees to do with walking?**

No  (please go to question 2) Yes  (please go to question 1a)

**1a. If yes, how much did you spend? .....**

**1b. How often do you tend to pay this amount? (circle the correct frequency below)**

Weekly / Monthly/ Annually / Each time / It is a one off / Don't know / Other

If other, please specify.....

**2. In the past 3 months, did you pay for any individual classes, entrance fees or groups to do with walking?**

*(if not included in membership fees above)*

No  (please go to question 3) Yes  (please go to question 2a)

**2a. If yes, how much did you spend? .....**

**2b. How often do you tend to pay this amount? (please circle the correct frequency below)**

Weekly / Monthly/ Annually / Each time / It is a one off / Don't know / Other

If other, please specify.....

**3. In the past 3 months, did you pay for shoes or clothing to do with walk**

No  (please go to question 4) Yes  (please go to question 3a)

**3a. If yes, how much did you spend? .....**

**3b. How often do you tend to pay this amount? (please circle the correct frequency below)**

Weekly / Monthly/ Annually / Each time / It is a one off / Don't know / Other

If other, please specify.....

**4. In the past 3 months, did you have to pay for food or drink to do with walking?**

No  (please go to question 5) Yes  (please go to question 4a)

**4a. If yes, how much did you spend? .....**

**4b. How often do you tend to pay this amount? (please circle the correct frequency below)**

Weekly / Monthly/ Annually / Each time / It is a one off / Don't know / Other  
If other, please specify.....

**5. In the past 3 months, did you have to pay for anything else to do with walking?**

No  (please go to question 6) Yes  (please go to question 5a)

**5a. If yes, what else did you have to pay for? .....**

**5b. How much did you spend? .....**

**5b. How often do you tend to pay this amount? (please circle the correct frequency below)**

Weekly / Monthly/ Annually / Each time / It is a one off / Don't know / Other

If other, please specify.....

**6. In the past 3 months, did you spend money on other kinds of physical activity?**

No  Yes  (please go to question 5a)

**6a. If yes, what other kinds of physical activity did you spend money on?**

(please list all that apply) .....


**6b. If yes, roughly how much did you spend in total on other kinds of physical activity over the past 3 months?**

.....  
.....

**13. In the past 3 months do you think that your spending on walking and physical activity has:**

Increased a lot   
Increased a little   
Stayed about the same   
Decreased a little   
Decreased a lot

**Please write below any other comments you have on  
your health or this questionnaire**

A large, empty rectangular box with a black border, intended for the respondent to write any additional comments on their health or the questionnaire.

**Thank you for filling in this questionnaire.**

# PACE-UP study

## *Health and lifestyle 3 month survey*

---

Study IDNO \_\_\_\_\_

**Thank you for filling in this questionnaire.**

**It will take you about 15 minutes to complete.**

**Please feel free to write comments by any question.**

**All information will be kept strictly confidential.**

**Please enter your date of birth**    \_\_\_\_ / \_\_\_\_ / \_\_\_\_

**Please enter today's date**        \_\_\_\_ / \_\_\_\_ / \_\_\_\_

**Thank you**

*Pedometer by post group*

## Section A - Some general questions about your health

Please put a tick in the box next to the most appropriate answer for each question.



### 8 How is your health in general?

- |           |                          |
|-----------|--------------------------|
| Very good | <input type="checkbox"/> |
| Good      | <input type="checkbox"/> |
| Fair      | <input type="checkbox"/> |
| Poor      | <input type="checkbox"/> |
| Very poor | <input type="checkbox"/> |

### 2 How much physical or bodily pain have you had in the past 4 weeks?

- |                       |                          |
|-----------------------|--------------------------|
| None                  | <input type="checkbox"/> |
| Very mild or mild     | <input type="checkbox"/> |
| Moderate              | <input type="checkbox"/> |
| Severe or very severe | <input type="checkbox"/> |

### 3 In the past four weeks, how much did pain interfere with your normal activities?

- |                          |                          |
|--------------------------|--------------------------|
| Not at all               | <input type="checkbox"/> |
| A little bit             | <input type="checkbox"/> |
| Moderately               | <input type="checkbox"/> |
| Quite a bit or extremely | <input type="checkbox"/> |

## Section B - Questions about your health today

Under each heading, please tick the **ONE** box that best describes your health **TODAY**

### 1 Mobility

- I have no problems in walking about
- I have slight problems in walking about
- I have moderate problems in walking about
- I have severe problems in walking about
- I am unable to walk about

### 9 Self-care

- I have no problems with self-care
- I have slight problems washing or dressing myself
- I have moderate problems washing or dressing myself
- I have severe problems washing or dressing myself
- I am unable to wash or dress myself

### 10 Usual activities (*e.g. work, study, housework, family or leisure*)

- I have no problems doing my usual activities
- I have slight problems doing my usual activities
- I have moderate problems doing my usual activities
- I have severe problems doing my usual activities
- I am unable to do my usual activities

### 11 Pain / discomfort

- I have no pain or discomfort
- I have slight pain or discomfort
- I have moderate pain or discomfort
- I have severe pain or discomfort
- I have extreme pain or discomfort

### 12 Anxiety / depression


- I am not anxious or depressed
- I am slightly anxious or depressed
- I am moderately anxious or depressed
- I am severely anxious or depressed
- I am extremely anxious or depressed

## Section B - Continued: about your health today

We would like to know how good or bad your health is TODAY

- The scale is numbered 0 to 100
- 100 means the best health you can imagine
- 0 means the worst health you can imagine
- Mark an X on the scale to indicate how your health is TODAY
- Now, please write the number you marked on the scale in the box below

YOUR HEALTH TODAY =



## Section C - Some questions on injuries and health

These questions ask about any injuries or changes in your health that you may have had in the 3 months that you have been involved in this study.

**In the last 3 months have you had any of the following:**

1 A fall? Yes  No

1a If yes, how many times? .....times in the last 3 months

2 Any fractures (broken bones)? Yes  No

2a If yes, please give details of what bones were injured

.....  
 .....

3 Any sprains or injuries? Yes  No

3a If yes, please give details of the sprain or injury

.....

## Some questions on injuries and health continued

If you have not had a fall, fracture, sprain or injury, please go to question 6.

If you have had a fall, fracture, sprain or injury, please go to question 4.

4. Did you or your family have to pay for anything as a result of your fall(s), fracture(s) sprain(s) or injury(ies)? (Please consider any costs linked to your continuing care or recovery)

Yes  No

- 4a. If yes, roughly how much did you spend?.....

- 4b. What was this spent on?.....

5. In the past 3 months did you have to stop doing your usual activities due to a fall, fracture, sprain or injury?

Yes  No

- 5a. If yes, how many days did you stop your usual activities? .....days

- 6 In the last 3 months have you noticed a deterioration in any health problems that you already had at the start of this research project?

Yes  No

- 6a If yes, please give details

.....  
 .....

- 7 In the last 3 months have you noticed an improvement in any health problems that you already had at the start of this research project?

Yes  No

- 7a If yes, please give details

.....  
 .....

## Section D - Some questions on how you feel

For each item below, please tick the box opposite the reply that comes closest to how you have been feeling over the past week. Don't take too long over the answers: your immediate reaction will probably be most accurate.

**Tick only one box in each section**

**31. I feel tense or 'wound up':**

- Most of the time
- A lot of the time
- Time to time
- Not at all

**32. I feel as if I am slowed down:**

- Nearly all of the time
- Very often
- Sometimes
- Not at all

**33. I still enjoy things I used to:**

- Definitely as much
- Not quite as much
- Only a little
- Hardly at all

**34. I get a sort of frightened feeling like butterflies in the stomach:**

- Not at all
- Occasionally
- Quite often
- Very often

**35. I get a sort of frightened feeling as if something bad is about to happen:**

- Very definitely
- Yes, but not too badly
- A little, but it doesn't worry me
- Not at all

**36. I have lost interest in my appearance:**

- Definitely
- I don't take so much care as I should do
- I might not take quite as much care
- I take just as much care

**37. I can laugh and see the funny side of things:**

- As much as I always could
- Not quite so much now
- Definitely not so much now
- Not at all

**38. I feel restless, as if I have to be on the move**

- Very much indeed
- Quite a lot
- Not very much
- Not at all

**39. Worrying thoughts go through my mind:**

- A great deal of the time
- A lot of the time
- From time to time but not too often
- Only occasionally

**40. I look forward with enjoyment to things:**

- As much as I ever did
- Rather less than I used to
- Definitely less than I used to
- Hardly at all

**41. I feel cheerful:**

- Not at all
- Not often
- Sometimes
- Most of the time

**42. I get sudden feelings of panic**

- Very often indeed
- Quite often
- Not very often
- Not at all

**43. I can sit at ease and feel relaxed:**

- Definitely
- Usually
- Not often
- Not at all

**44. I can enjoy a good book, radio or TV programme:**

- Often
- Sometimes
- Not often
- Very seldom

**45. I feel lonely:**

- All the time
- Often
- Sometimes
- Never

## Section E - Some questions about your attitudes to exercise and health

Please indicate how strongly you agree or disagree with each statement

Please tick one box to indicate how strongly you agree or disagree with each statement

	<i>Strongly agree</i>	<i>Slightly agree</i>	<i>Unsure</i>	<i>Slightly disagree</i>	<i>Strongly disagree</i>
14. Doing exercise is satisfying and rewarding to me	<input type="checkbox"/>				
15. Doing exercise regularly is good for me	<input type="checkbox"/>				
16. There is little I can do to make up for the physical losses that come with age	<input type="checkbox"/>				
17. Exercising regularly can be helpful for my health	<input type="checkbox"/>				
18. Exercising regularly can help me to get out of doors	<input type="checkbox"/>				
19. Exercising regularly can help me to control my weight or to lose weight	<input type="checkbox"/>				

## Section F – Some questions about your belief in your ability to exercise

How sure are you that you will do each of the following:

		Very Sure	Pretty Sure	A little Sure	Not at all Sure
1	Exercise regularly (3 times a week for 20 minutes)	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
2	Exercise when you are feeling tired	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
3	Exercise when you are feeling under pressure to get things done	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
4	Exercise when you are feeling down or depressed	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
5	Exercise when you have too much work to do at home	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
6	Exercise when there are other more interesting things to do	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
7	Exercise when your family or friends do not provide any support	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
8	Exercise when you don't really feel like it	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
9	Exercise when you are away from home (e.g. visiting, on holiday)	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>

## Section G - Some questions about physical activity

- 13** How many times did you take a walk outside during the last week?  
(include walking related to other activities e.g. for shopping, travel to work etc)  
.....times last week
- 2** How long did such a walk usually last? .....minutes
- 3** Did you take a walk that lasted longer than 1 hour during the last month?  
Yes  No
- 3a** If yes, how many times did you do that? .....times last month
- 4** Do you have someone with whom you can go for a walk, or do other physical activities?  
Always  Often  Sometimes  Never
- 5** Do you ride a bicycle?  
Yes  No  (please go to question 6)
- 5a** If yes, how many times did you cycle last week? .....times
- 5b** How long on average did you cycle for each time? .....minutes
- 5c** How would you describe your cycling pace?  
Slow  Average  Fast
- 6** Do you go swimming?  
Yes  No  (please go to question 7)
- 6a** If yes, how many times did you swim last week? .....times
- 6b** How long on average did you swim for each time?.....minutes
- 6c** How would you describe your swimming speed?  
Slow  Average  Fast
- 7** Have you participated in any sporting activities in the last week?  
Yes  No  (if no, please go to question 8)

7a If yes, what kind of sporting activity? .....

7b How much time approximately did you spend participating in sporting activities in the last week?

.....hours .....minutes

8 How often did you perspire during physical activity in the last week?

Never  1-2 times  3-4 times  5 or more times

9. In the last 3 months (since you have been taking part in the PACE-UP trial) do you think that your walking and physical activity has:

Decreased a lot

Decreased a little

Stayed about the same

Increased a little

Increased a lot

## Section H - Some questions about the money you have spent to do with walking and other physical activity

**14** In the past 3 months, did you pay for any membership fees to do with walking?

No  (please go to question 2) Yes  (please go to question 1a)

**1a.** If yes, how much did you spend? .....

**1b.** How often do you tend to pay this amount? (please circle the correct frequency below)

Weekly / Monthly/ Annually / Each time / It is a one off / Don't know / Other

If other, please specify.....

**2.** In the past 3 months, did you pay for any individual classes, entrance fees or groups to do with walking? (if not included in membership fees above)

No  (please go to question 3) Yes  (please go to question 2a)

**2a.** If yes, how much did you spend? .....

**2b.** How often do you tend to pay this amount? (please circle the correct frequency below)

Weekly / Monthly/ Annually / Each time / It is a one off / Don't know / Other

If other, please specify.....

**3** In the past 3 months, did you pay for shoes or clothing to do with walking?

No  (please go to question 4) Yes  (please go to question 3a)

**3a.** If yes, how much did you spend? .....

**3b.** How often do you tend to pay this amount? (please circle the correct frequency below)

Weekly / Monthly/ Annually / Each time / It is a one off / Don't know / Other

If other, please specify.....

**4 In the past 3 months, did you have to pay for food or drink to do with walking?**

No  (please go to question 5) Yes  (please go to question 4a)

**4a. If yes, how much did you spend?** .....

**4b. How often do you tend to pay this amount?** (please circle the correct frequency below)

Weekly / Monthly/ Annually / Each time / It is a one off / Don't know / Other

If other, please specify.....

**5 In the past 3 months, did you have to pay for anything else to do with walking?**

No  (please go to question 6) Yes  (please go to question 5a)

**5a. If yes, what else did you have to pay for?** .....

**5b. How much did you spend?** .....

**5b. How often do you tend to pay this amount?** (please circle the correct frequency below)

Weekly / Monthly/ Annually / Each time / It is a one off / Don't know / Other

If other, please specify.....

**6. In the past 3 months, did you spend money on other kinds of physical activity?**

No  Yes  (please go to question 5a)

**6a. If yes, what other kinds of physical activity did you spend money on?** (please list all that apply) .....

**6b. If yes, roughly how much did you spend in total on other kinds of physical activity over the past 3 months?**

.....

.....

**20. In the past 3 months do you think that your spending on walking and physical activity has:**

Increased a lot

Increased a little

Stayed about the same

Decreased a little

Decreased a lot

## Section I - Some questions about taking part in the PACE-UP trial

1. How did you find wearing the pedometer? (please tick as many as you feel apply)

- |  |                          |
|--|--------------------------|
| I found it helpful                       | <input type="checkbox"/> |
| I found it difficult to remember to wear | <input type="checkbox"/> |
| I found it difficult to use              | <input type="checkbox"/> |
| I found it a nuisance                    | <input type="checkbox"/> |
| I enjoyed wearing the pedometer          | <input type="checkbox"/> |
| I found it uncomfortable to wear         | <input type="checkbox"/> |

Any other comments about wearing the pedometer?.....

.....

2. In the past 3 months, how much time have you spent working out how to use the pedometer?

..... (hours) .....(minutes)

3. In the past 3 months, how much time have you spent planning your increase in walking / step-count?

..... (hours) .....(minutes)

4. How did you find writing your step-counts in the PACE-UP physical activity diary? (please tick as many as apply)

- |   |                          |
|---|--------------------------|
| I found it helpful                          | <input type="checkbox"/> |
| I found it difficult to remember to fill in | <input type="checkbox"/> |
| I found it a nuisance                       | <input type="checkbox"/> |
| I enjoyed writing in the diary              | <input type="checkbox"/> |

Any other comments about writing in the PACE-UP physical activity diary?

.....

.....

## More questions about taking part in the PACE-UP trial

5. In the past 3 months, how often did you fill out the PACE-UP physical activity diary? .....
6. In the past 3 months, how long did you spend on average filling out the PACE-UP physical activity diary each time you did it .....(minutes)

**Please write below any other comments you have on the PACE-UP trial or this questionnaire**

**Thank you for filling in this questionnaire.**

# PACE-UP study

## *Health and lifestyle 3 month survey*

---

Study IDNO \_\_\_\_\_

Thank you for filling in this questionnaire.

It will take you about 15 minutes to complete.

Please feel free to write comments by any question.

All information will be kept strictly confidential.

Please enter your date of birth    \_\_\_\_ / \_\_\_\_ / \_\_\_\_

Please enter today's date        \_\_\_\_ / \_\_\_\_ / \_\_\_\_

**Thank you**

*Nurse intervention group*

## Section A - Some general questions about your health

Please put a tick in the box next to the most appropriate answer for each question.



### 15 How is your health in general?

- |           |                          |
|-----------|--------------------------|
| Very good | <input type="checkbox"/> |
| Good      | <input type="checkbox"/> |
| Fair      | <input type="checkbox"/> |
| Poor      | <input type="checkbox"/> |
| Very poor | <input type="checkbox"/> |

### 2 How much physical or bodily pain have you had in the past 4 weeks?

- |                       |                          |
|-----------------------|--------------------------|
| None                  | <input type="checkbox"/> |
| Very mild or mild     | <input type="checkbox"/> |
| Moderate              | <input type="checkbox"/> |
| Severe or very severe | <input type="checkbox"/> |

### 3 In the past four weeks, how much did pain interfere with your normal activities?

- |                          |                          |
|--------------------------|--------------------------|
| Not at all               | <input type="checkbox"/> |
| A little bit             | <input type="checkbox"/> |
| Moderately               | <input type="checkbox"/> |
| Quite a bit or extremely | <input type="checkbox"/> |

## Section B - Questions about your health today

Under each heading, please tick the ONE box that best describes your health TODAY

### 1 Mobility

- I have no problems in walking about
- I have slight problems in walking about
- I have moderate problems in walking about
- I have severe problems in walking about
- I am unable to walk about

### 16 Self-care

- I have no problems with self-care
- I have slight problems washing or dressing myself
- I have moderate problems washing or dressing myself
- I have severe problems washing or dressing myself
- I am unable to wash or dress myself

### 17 Usual activities (e.g. work, study, housework, family or leisure)

- I have no problems doing my usual activities
- I have slight problems doing my usual activities
- I have moderate problems doing my usual activities
- I have severe problems doing my usual activities
- I am unable to do my usual activities

### 18 Pain / discomfort

- I have no pain or discomfort
- I have slight pain or discomfort
- I have moderate pain or discomfort
- I have severe pain or discomfort
- I have extreme pain or discomfort

### 19 Anxiety / depression

- I am not anxious or depressed
- I am slightly anxious or depressed
- I am moderately anxious or depressed
- I am severely anxious or depressed
- I am extremely anxious or depressed


## Section B - Continued: about your health today

We would like to know how good or bad your health is TODAY

- The scale is numbered 0 to 100
- 100 means the best health you can imagine
- 0 means the worst health you can imagine
- Mark an X on the scale to indicate how your health is TODAY
- Now, please write the number you marked on the scale in the box below

YOUR HEALTH TODAY =

The best health you can imagine



The worst health you can imagine

## Section C - Some questions on injuries and health

These questions ask about any injuries or changes in your health that you may have had in the 3 months that you have been involved in this study.

In the last 3 months have you had any of the following:

- 1 A fall? Yes  No
- 1a If yes, how many times? .....times in the last 3 months
- 2 Any fractures (broken bones)? Yes  No
- 2a If yes, please give details of what bones were injured  
 .....  
 .....
- 3 Any sprains or injuries? Yes  No
- 3a If yes, please give details of the sprain or injury  
 .....

## Some questions on injuries and health continued

If you have not had a fall, fracture, sprain or injury, please go to question 6.

If you have had a fall, fracture, sprain or injury, please go to question 4.

4. Did you or your family have to pay for anything as a result of your fall(s), fracture(s), sprain(s) or injury(ies)? (Please consider any costs linked to your continuing care or recovery)

Yes  No

If yes, roughly how much did you spend?.....

What was this spent on? .....

5. In the past 3 months did you have to stop doing your usual activities due to a fall, fracture, sprain or injury?

Yes  No

If yes, how many days did you stop your usual activities? .....days

6. In the last 3 months have you noticed a deterioration in any health problems that you already had at the start of this research project?

Yes  No

- 6a If yes, please give details

.....  
.....

7. In the last 3 months have you noticed an improvement in any health problems that you already had at the start of this research project?

Yes  No

- 7a If yes, please give details

.....  
.....

## Section D - Some questions on how you feel

For each item below, please tick the box opposite the reply that comes closest to how you have been feeling over the past week. Don't take too long over the answers: your immediate reaction will probably be most accurate.

**Tick only one box in each section**

### 46. I feel tense or 'wound up':

- |                   |                          |
|-------------------|--------------------------|
| Most of the time  | <input type="checkbox"/> |
| A lot of the time | <input type="checkbox"/> |
| Time to time      | <input type="checkbox"/> |
| Not at all        | <input type="checkbox"/> |

### 47. I feel as if I am slowed down:

- |                        |                          |
|------------------------|--------------------------|
| Nearly all of the time | <input type="checkbox"/> |
| Very often             | <input type="checkbox"/> |
| Sometimes              | <input type="checkbox"/> |
| Not at all             | <input type="checkbox"/> |

### 48. I still enjoy things I used to:

- |                    |                          |
|--------------------|--------------------------|
| Definitely as much | <input type="checkbox"/> |
| Not quite as much  | <input type="checkbox"/> |
| Only a little      | <input type="checkbox"/> |
| Hardly at all      | <input type="checkbox"/> |

### 49. I get a sort of frightened feeling like butterflies in the stomach:

- |              |                          |
|--------------|--------------------------|
| Not at all   | <input type="checkbox"/> |
| Occasionally | <input type="checkbox"/> |
| Quite often  | <input type="checkbox"/> |
| Very often   | <input type="checkbox"/> |

### 50. I get a sort of frightened feeling as if something bad is about to happen:

- |                                   |                          |
|-----------------------------------|--------------------------|
| Very definitely                   | <input type="checkbox"/> |
| Yes, but not too badly            | <input type="checkbox"/> |
| A little, but it doesn't worry me | <input type="checkbox"/> |
| Not at all                        | <input type="checkbox"/> |

### 51. I have lost interest in my appearance:

- |  |                          |
|--|--------------------------|
| Definitely                               | <input type="checkbox"/> |
| I don't take so much care as I should do | <input type="checkbox"/> |
| I might not take quite as much care      | <input type="checkbox"/> |
| I take just as much care                 | <input type="checkbox"/> |

### 52. I can laugh and see the funny side of things:

- |                            |                          |
|----------------------------|--------------------------|
| As much as I always could  | <input type="checkbox"/> |
| Not quite so much now      | <input type="checkbox"/> |
| Definitely not so much now | <input type="checkbox"/> |
| Not at all                 | <input type="checkbox"/> |

**53. I feel restless, as if I have to be on the move**

- Very much indeed
- Quite a lot
- Not very much
- Not at all

**54. Worrying thoughts go through my mind:**

- A great deal of the time
- A lot of the time
- From time to time but not too often
- Only occasionally

**55. I look forward with enjoyment to things:**

- As much as I ever did
- Rather less than I used to
- Definitely less than I used to
- Hardly at all

**56. I feel cheerful:**

- Not at all
- Not often
- Sometimes
- Most of the time

**57. I get sudden feelings of panic**

- Very often indeed
- Quite often
- Not very often
- Not at all

**58. I can sit at ease and feel relaxed:**

- Definitely
- Usually
- Not often
- Not at all

**59. I can enjoy a good book, radio or TV programme:**

- Often
- Sometimes
- Not often
- Very seldom

**60. I feel lonely:**

- All the time
- Often
- Sometimes
- Never

## Section E - Some questions about your attitudes to exercise and health

Please indicate how strongly you agree or disagree with each statement

Please tick one box to indicate how strongly you agree or disagree with each statement

	<i>Strongly agree</i>	<i>Slightly agree</i>	<i>Unsure</i>	<i>Slightly disagree</i>	<i>Strongly disagree</i>
<b>21. Doing exercise is satisfying and rewarding to me</b>	<input type="checkbox"/>				
<b>22. Doing exercise regularly is good for me</b>	<input type="checkbox"/>				
<b>23. There is little I can do to make up for the physical losses that come with age</b>	<input type="checkbox"/>				
<b>24. Exercising regularly can be helpful for my health</b>	<input type="checkbox"/>				
<b>25. Exercising regularly can help me to get out of doors</b>	<input type="checkbox"/>				
<b>26. Exercising regularly can help me to control my weight or to lose weight</b>	<input type="checkbox"/>				

## Section F – Some questions about your belief in your ability to exercise

How sure are you that you will do each of the following:

		Very Sure	Pretty Sure	A little Sure	Not at all Sure
1	Exercise regularly (3 times a week for 20 minutes)	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
2	Exercise when you are feeling tired	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
3	Exercise when you are feeling under pressure to get things done	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
4	Exercise when you are feeling down or depressed	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
5	Exercise when you have too much work to do at home	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
6	Exercise when there are other more interesting things to do	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
7	Exercise when your family or friends do not provide any support	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
8	Exercise when you don't really feel like it	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
9	Exercise when you are away from home (e.g. visiting, on holiday)	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>

## Section G - Some questions about physical activity

**20 How many times did you take a walk outside during the last week?**

(include walking related to other activities e.g. for shopping, travel to work etc)

.....times last week

**2 How long did such a walk usually last? .....minutes**

**3 Did you take a walk that lasted longer than 1 hour during the last month?**

Yes  No

**3a If yes, how many times did you do that? .....times last month**

**4 Do you have someone with whom you can go for a walk, or do other physical activities?**

Always  Often  Sometimes  Never

**5 Do you ride a bicycle?**

Yes  No  (please go to question 6)

**5a If yes, how many times did you cycle last week? .....times**

**5b How long on average did you cycle for each time? .....minutes**

**5c How would you describe your cycling pace?**

Slow  Average  Fast

**6 Do you go swimming?**

Yes  No  (please go to question 7)

**6a If yes, how many times did you swim last week? .....times**

**6b How long on average did you swim for each time?.....minutes**

**6c How would you describe your swimming speed?**

Slow  Average  Fast

**7 Have you participated in any sporting activities in the last week?**

Yes  No  (if no, please go to question 8)

**7a If yes, what kind of sporting activity? .....**

**7b How many hours approximately, did you spend participating in sporting activities in the last week?**

Less than 1 hour in the last week  ..... hours in the last week

**8 How often did you perspire during physical activity in the last week?**

Never  1-2 times  3-4 times  5 or more times

**9. In the last 3 months (since you have been taking part in the PACE-UP trial) do you think that your walking and physical activity has:**

Decreased a lot

Decreased a little

Stayed about the same

Increased a little

Increased a lot

## Section H - Some questions about the money you have spent to do with walking and other physical activity

**21 In the past 3 months, did you pay for any membership fees to do with walking?**

No  (please go to question 2) Yes  (please go to question 1a)

**1a. If yes, how much did you spend?** .....

**1b. How often do you tend to pay this amount?** (please circle the correct frequency below)

Weekly / Monthly/ Annually / Each time / It is a one off / Don't know / Other

If other, please specify.....

**2. In the past 3 months, did you pay for any individual classes, entrance fees or groups to do with walking?** (if not included in membership fees above)

No  (please go to question 3) Yes  (please go to question 2a)

**2a. If yes, how much did you spend?** .....

**2b. How often do you tend to pay this amount?** (please circle the correct frequency below)

Weekly / Monthly/ Annually / Each time / It is a one off / Don't know / Other

If other, please specify.....

**3 In the past 3 months, did you pay for shoes or clothing to do with walking?**

No  (please go to question 4) Yes  (please go to question 3a)

**3a. If yes, how much did you spend?** .....

**3b. How often do you tend to pay this amount?** (please circle the correct frequency below)

Weekly / Monthly/ Annually / Each time / It is a one off / Don't know / Other

If other, please specify.....

**4 In the past 3 months, did you have to pay for food or drink to do with walking?**

No  (please go to question 5) Yes  (please go to question 4a)

**4a. If yes, how much did you spend?** .....

**4b. How often do you tend to pay this amount?** (please circle the correct frequency below)

Weekly / Monthly/ Annually / Each time / It is a one off / Don't know / Other

If other, please specify.....

**5 In the past 3 months, did you have to pay for anything else to do with walking?**

No  (please go to question 6) Yes  (please go to question 5a)

**5a. If yes, what else did you have to pay for?** .....

**5b. How much did you spend?** .....

**5b. How often do you tend to pay this amount?** (please circle the correct frequency below)

Weekly / Monthly/ Annually / Each time / It is a one off / Don't know / Other

If other, please specify.....

**6. In the past 3 months, did you spend money on other kinds of physical activity?**

No  Yes  (please go to question 5a)

**6a. If yes, what other kinds of physical activity did you spend money on?** (please list all that apply) .....

**6b. If yes, roughly how much did you spend in total on other kinds of physical activity over the past 3 months?**  
.....

**27. In the past 3 months do you think that your spending on walking and physical activity has:**

Increased a lot   
 Increased a little   
 Stayed about the same   
 Decreased a little   
 Decreased a lot

## Section I - Some questions about taking part in the PACE-UP trial

7. How did you find wearing the pedometer? (please tick as many as apply)

- |  |                          |
|--|--------------------------|
| I found it helpful                       | <input type="checkbox"/> |
| I found it difficult to remember to wear | <input type="checkbox"/> |
| I found it difficult to use              | <input type="checkbox"/> |
| I found it a nuisance                    | <input type="checkbox"/> |
| I enjoyed wearing the pedometer          | <input type="checkbox"/> |
| I found it uncomfortable to wear         | <input type="checkbox"/> |

Any other comments about wearing the pedometer?.....

.....

8. In the past 3 months, how much time have you spent working out how to use the pedometer? ..... (hours) .....(minutes)

9. In the past 3 months, how much time have you spent planning your increase in walking / step-count? ..... (hours) .....(minutes)

10. How did you find writing your step-counts in the PACE-UP physical activity diary? (please tick as many as apply)

- |   |                          |
|---|--------------------------|
| I found it helpful                          | <input type="checkbox"/> |
| I found it difficult to remember to fill in | <input type="checkbox"/> |
| I found it a nuisance                       | <input type="checkbox"/> |
| I enjoyed writing in the diary              | <input type="checkbox"/> |

11. In the past 3 months, how often did you fill out the PACE-UP physical activity diary? .....

12. In the past 3 months, how long did you spend on average filling out the PACE-UP physical activity diary each time you did it ..... (minutes)

Any other comments about writing in the PACE-UP physical activity diary?

.....

13. Did you visit the nurse for the PACE-UP trial?

- Yes  No  (If no, please go to the end of the questionnaire).

**14. How did you find seeing the nurse for the PACE-UP trial appointments?**  
(please tick as many as apply)

- I found it helpful
- I found it difficult to get to the appointments
- I found it a nuisance
- I felt that seeing the nurse helped me to walk more

**Any other comments about seeing the nurse?** .....

.....

**15. Did you travel by car to see the nurse last time you attended for the PACE-UP trial?**

Yes  No  (If no, please go to question 10).

**9a. Did you have to pay for parking while you had the consultation?**

Yes  No  (If no, please go to question 10).

**9b. If yes, how much did it cost to park?** .....

**16. Did you walk to see the nurse last time you attended for the PACE-UP trial?**

Yes  No  (If no, please go to question 11).

**10a. If yes, how long did you spend walking (there and back)?** .....(in minutes)

**17. Did you use public transport (bus, train, tram, tube, taxi) to travel to see the nurse last time you attended for the PACE-UP trial?**

Yes  No  (If no, please go to question 12).

**11a. If yes, what type of ticket or fare did you buy or use to travel to visit the nurse last time you attended for the PACE-UP trial?**

- Single ticket
- Return ticket
- Season ticket
- Other ticket type
- Don't know

**11b. What was the total cost of this journey (to and from visiting the nurse)?**

.....

## Some more questions about taking part in the PACE-UP trial

18. How long did it take you, in total, to travel to and from the practice the last time you visited the nurse for the PACE-UP trial ..... minutes

19. How long did you have wait at the practice before meeting the nurse last time for the PACE-UP trial ? ..... minutes

20. Still thinking about the last time you met the nurse for the PACE-UP trial, how long did the meeting last? ..... minutes

21. Did you have to pay someone to look after a child or other family member in order to be able to attend the consultation?

Yes  No  (If no, please go to the end of the questionnaire).

15a If yes, how much did you pay for your child or family member to be looked after the last time you visited the nurse for the PACE-UP trial? .....

**Please write below any other comments you have on the  
PACE-UP trial or this questionnaire**

**Thank you for filling in this questionnaire.**

# PACE-UP study

## *Health and lifestyle 12 month survey*

---

Study IDNO \_\_\_\_\_

**Thank you for filling in this questionnaire.**

**It will take you about 15 minutes to complete.**

**Please feel free to write comments by any question.**

**All information will be kept strictly confidential.**

**Please enter your date of birth**    \_\_\_\_ / \_\_\_\_ / \_\_\_\_

**Please enter today's date**        \_\_\_\_ / \_\_\_\_ / \_\_\_\_

**Thank you**

## Section A - Some general questions about your health

Please put a tick in the box next to the most appropriate answer for each question.



### 22 How is your health in general?

- |           |                          |
|-----------|--------------------------|
| Very good | <input type="checkbox"/> |
| Good      | <input type="checkbox"/> |
| Fair      | <input type="checkbox"/> |
| Poor      | <input type="checkbox"/> |
| Very poor | <input type="checkbox"/> |

### 2 How much physical or bodily pain have you had in the past 4 weeks?

- |                       |                          |
|-----------------------|--------------------------|
| None                  | <input type="checkbox"/> |
| Very mild or mild     | <input type="checkbox"/> |
| Moderate              | <input type="checkbox"/> |
| Severe or very severe | <input type="checkbox"/> |

### 3 In the past four weeks, how much did pain interfere with your normal activities?

- |                          |                          |
|--------------------------|--------------------------|
| Not at all               | <input type="checkbox"/> |
| A little bit             | <input type="checkbox"/> |
| Moderately               | <input type="checkbox"/> |
| Quite a bit or extremely | <input type="checkbox"/> |

## Section B - Questions about your health today

Under each heading, please tick the ONE box that best describes your health TODAY

### 1 Mobility

- I have no problems in walking about
- I have slight problems in walking about
- I have moderate problems in walking about
- I have severe problems in walking about
- I am unable to walk about

### 23 Self-care

- I have no problems with self-care
- I have slight problems washing or dressing myself
- I have moderate problems washing or dressing myself
- I have severe problems washing or dressing myself
- I am unable to wash or dress myself

### 24 Usual activities (e.g. work, study, housework, family or leisure)

- I have no problems doing my usual activities
- I have slight problems doing my usual activities
- I have moderate problems doing my usual activities
- I have severe problems doing my usual activities
- I am unable to do my usual activities

### 25 Pain / discomfort

- I have no pain or discomfort
- I have slight pain or discomfort
- I have moderate pain or discomfort
- I have severe pain or discomfort
- I have extreme pain or discomfort

### 26 Anxiety / depression


- I am not anxious or depressed
- I am slightly anxious or depressed
- I am moderately anxious or depressed
- I am severely anxious or depressed
- I am extremely anxious or depressed

## Section B - Your health today (continued)

- We would like to know how good or bad your health is TODAY
- The scale is numbered 0 to 100
- 100 means the best health you can imagine
- 0 means the worst health you can imagine
- Mark an X on the scale to indicate how your health is TODAY
- Now, please write the number you marked on the scale in the box below

YOUR HEALTH TODAY =

The best health  
you can imagine



The worst health  
you can imagine

## Section C - Some questions on injuries and health

These questions ask about any injuries or changes in your health that you may have had in the 12 months that you have been involved in this study.

In the last 12 months have you had any of the following:

- 1 **A fall?** Yes  No
- 1a **If yes, how many times?** .....times in the last 12 months
- 2 **Any fractures (broken bones)?** Yes  No
- 2a **If yes, please give details of what bones were injured**  
.....  
.....
- 3 **Any sprains or injuries?** Yes  No
- 3a **If yes, please give details of the sprain or injury**  
.....

## Some more questions on injuries and health

If you have not had a fall, fracture, sprain or injury, please go to question 6.

If you have had a fall, fracture, sprain or injury, please go to question 4.

4. **Did you or your family have to pay for anything as a result of your fall(s), fracture(s), sprain(s) or injury(ies)?** (Please consider any costs linked to your continuing care or recovery)

Yes  No

If yes, roughly how much did you spend?.....

What was this spent on?.....

5. **In the past 12 months did you have to stop doing your usual activities due to a fall. Fracture, sprain or injury?**

Yes  No

If yes, how many days did you stop your usual activities? .....days

- 6 **In the last 12 months have you noticed a deterioration in any health problems that you already had at the start of this research project?**

Yes  No

- 6a **If yes, please give details**

.....  
 .....

- 7 **In the last 12 months have you noticed an improvement in any health problems that you already had at the start of this research project?**

Yes  No

- 7a **If yes, please give details**

.....  
 .....

## Section D - Some questions on how you feel

For each item below, please tick the box opposite the reply that comes closest to how you have been feeling over the past week. Don't take too long over the answers: your immediate reaction will probably be most accurate.

**Tick only one box in each section**

**61. I feel tense or 'wound up':**

- |                   |                          |
|-------------------|--------------------------|
| Most of the time  | <input type="checkbox"/> |
| A lot of the time | <input type="checkbox"/> |
| Time to time      | <input type="checkbox"/> |
| Not at all        | <input type="checkbox"/> |

**62. I feel as if I am slowed down:**

- |                        |                          |
|------------------------|--------------------------|
| Nearly all of the time | <input type="checkbox"/> |
| Very often             | <input type="checkbox"/> |
| Sometimes              | <input type="checkbox"/> |
| Not at all             | <input type="checkbox"/> |

**63. I still enjoy things I used to:**

- |                    |                          |
|--------------------|--------------------------|
| Definitely as much | <input type="checkbox"/> |
| Not quite as much  | <input type="checkbox"/> |
| Only a little      | <input type="checkbox"/> |
| Hardly at all      | <input type="checkbox"/> |

**64. I get a sort of frightened feeling like butterflies in the stomach:**

- |              |                          |
|--------------|--------------------------|
| Not at all   | <input type="checkbox"/> |
| Occasionally | <input type="checkbox"/> |
| Quite often  | <input type="checkbox"/> |
| Very often   | <input type="checkbox"/> |

**65. I get a sort of frightened feeling as if something bad is about to happen:**

- |                                   |                          |
|-----------------------------------|--------------------------|
| Very definitely                   | <input type="checkbox"/> |
| Yes, but not too badly            | <input type="checkbox"/> |
| A little, but it doesn't worry me | <input type="checkbox"/> |
| Not at all                        | <input type="checkbox"/> |

**66. I have lost interest in my appearance:**

- |  |                          |
|--|--------------------------|
| Definitely                               | <input type="checkbox"/> |
| I don't take so much care as I should do | <input type="checkbox"/> |
| I might not take quite as much care      | <input type="checkbox"/> |
| I take just as much care                 | <input type="checkbox"/> |

**67. I can laugh and see the funny side of things:**

- |                            |                          |
|----------------------------|--------------------------|
| As much as I always could  | <input type="checkbox"/> |
| Not quite so much now      | <input type="checkbox"/> |
| Definitely not so much now | <input type="checkbox"/> |
| Not at all                 | <input type="checkbox"/> |

**68. I feel restless, as if I have to be on the move**

- Very much indeed
- Quite a lot
- Not very much
- Not at all

**69. Worrying thoughts go through my mind:**

- A great deal of the time
- A lot of the time
- From time to time but not too often
- Only occasionally

**70. I look forward with enjoyment to things:**

- As much as I ever did
- Rather less than I used to
- Definitely less than I used to
- Hardly at all

**71. I feel cheerful:**

- Not at all
- Not often
- Sometimes
- Most of the time

**72. I get sudden feelings of panic**

- Very often indeed
- Quite often
- Not very often
- Not at all

**73. I can sit at ease and feel relaxed:**

- Definitely
- Usually
- Not often
- Not at all

**74. I can enjoy a good book, radio or TV programme:**

- Often
- Sometimes
- Not often
- Very seldom

**75. I feel lonely:**

- All the time
- Often
- Sometimes
- Never

## Section E - Some questions about your attitudes to exercise and health

Please indicate how strongly you agree or disagree with each statement

Please tick one box to indicate how strongly you agree or disagree with each statement

	<i>Strongly agree</i>	<i>Slightly agree</i>	<i>Unsure</i>	<i>Slightly disagree</i>	<i>Strongly disagree</i>
<b>28. Doing exercise is satisfying and rewarding to me</b>	<input type="checkbox"/>				
<b>29. Doing exercise regularly is good for me</b>	<input type="checkbox"/>				
<b>30. There is little I can do to make up for the physical losses that come with age</b>	<input type="checkbox"/>				
<b>31. Exercising regularly can be helpful for my health</b>	<input type="checkbox"/>				
<b>32. Exercising regularly can help me to get out of doors</b>	<input type="checkbox"/>				
<b>33. Exercising regularly can help me to control my weight or to lose weight</b>	<input type="checkbox"/>				

## Section F – Some questions about your belief in your ability to exercise

How sure are you that you will do each of the following:

		Very Sure	Pretty Sure	A little Sure	Not at all Sure
1	Exercise regularly (3 times a week for 20 minutes)	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
2	Exercise when you are feeling tired	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
3	Exercise when you are feeling under pressure to get things done	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
4	Exercise when you are feeling down or depressed	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
5	Exercise when you have too much work to do at home	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
6	Exercise when there are other more interesting things to do	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
7	Exercise when your family or friends do not provide any support	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
8	Exercise when you don't really feel like it	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
9	Exercise when you are away from home (e.g. visiting, on holiday)	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>

## Section G - Some questions about physical activity

- 27 **How many times did you take a walk outside *during the last week*?**  
(include walking related to other activities) .....times last week
- 2 **How long did such a walk usually last? .....**minutes
- 3 **Did you take a walk that lasted longer than 1 hour *during the last month*?**  
Yes  No
- 3a **If yes, how many times did you do that? .....**times last month
- 4 **Do you have someone with whom you can go for a walk, or do other physical activities?**  
Always  Often  Sometimes  Never
- 5 **Do you ride a bicycle?** Yes  No  (please go to question 6)
- 5a **If yes, how many times did you cycle last week? .....**times
- 5b **How long on average did you cycle for each time? .....**minutes
- 5c **How would you describe your cycling pace?**  
Slow  Average  Fast
- 6 **Do you go swimming?** Yes  No  (please go to question 7)
- 6a **If yes, how many times did you swim last week? .....**times
- 6b **How long on average did you swim for each time?.....**minutes
- 6c **How would you describe your swimming speed?**  
Slow  Average  Fast
- 7 **Have you participated in any sporting activities in the last week?**  
Yes  No  (if no, please go to question 8)
- 7a **If yes, what kind of sporting activity? .....**
- 7b **How many hours approximately, did you spend participating in sporting activities in the last week?**  
Less than 1 hour in the last month  ..... hours in the last month

**8 How often did you perspire during physical activity in the last week?**

Never  1-2 times  3-4 times  5 or more times

**9. In the last 12 months (since you have been taking part in the PACE-UP trial) do you think that your walking and physical activity has:**

Decreased a lot

Decreased a little

Stayed about the same

Increased a little

Increased a lot

## Section H - Some questions about the money you have spent to do with walking and other physical activity

**28 In the past 3 months, did you pay for any membership fees to do with walking?**

No  (please go to question 2) Yes  (please go to question 1a)

**1a. If yes, how much did you spend?** .....

**1b. How often do you tend to pay this amount?** (please circle the correct frequency below)

Weekly / Monthly/ Annually / Each time / It is a one off / Don't know / Other

If other, please specify.....

**2. In the past 3 months, did you pay for any individual classes, entrance fees or groups to do with walking?** (if not included in membership fees above)

No  (please go to question 3) Yes  (please go to question 2a)

**2a. If yes, how much did you spend?** .....

**2b. How often do you tend to pay this amount?** (please circle the correct frequency below)

Weekly / Monthly/ Annually / Each time / It is a one off / Don't know / Other

If other, please specify.....

**3. In the past 3 months, did you pay for shoes or clothing to do with walking?**

No  (please go to question 4) Yes  (please go to question 3a)

## Some more questions about the money you have spent to do with walking and other physical activity

3a. If yes, how much did you spend? .....

3b. How often do you tend to pay this amount? *(please circle the correct frequency below)*

Weekly / Monthly/ Annually / Each time / It is a one off / Don't know / Other

If other, please specify.....

4 In the past 3 months, did you have to pay for food or drink to do with walking?

No  *(please go to question 5)* Yes  *(please go to question 4a)*

4a. If yes, how much did you spend? .....

4b. How often do you tend to pay this amount? *(please circle the correct frequency below)*

Weekly / Monthly/ Annually / Each time / It is a one off / Don't know / Other

If other, please specify.....

5 In the past 3 months, did you have to pay for anything else to do with walking?

No  *(please go to question 6)* Yes  *(please go to question 5a)*

5a. If yes, what else did you have to pay for? .....

5b. How much did you spend? .....

5b. How often do you tend to pay this amount? *(please circle the correct frequency below)*

Weekly / Monthly/ Annually / Each time / It is a one off / Don't know / Other

If other, please specify.....

6. In the past 3 months, did you spend money on other kinds of physical activity?

No  Yes  *(please go to question 5a)*

6a. If yes, what other kinds of physical activity did you spend money on? *(please list all that apply)* .....

6b. If yes, roughly how much did you spend in total on other kinds of physical activity over the past 3 months? .....

**Thank you for filling in this questionnaire.**

# PACE-UP study

## *7 day physical activity questionnaire*

---

Study IDNO \_\_\_\_\_

**Please can you fill out this questionnaire just AFTER you have finished wearing the accelerometer for 7 days.**

There are 2 short sections, each asking about your physical activity over the 7 days when you were wearing the accelerometer. It will take you about 5 minutes.

Please answer each question as best you can from memory, you do not need to look back at your diary or calculate anything.

Please feel free to write comments by any question.

All information will be kept confidential.

**Please enter your date of birth**    \_\_\_\_ / \_\_\_\_ / \_\_\_\_

**Please enter today's date**        \_\_\_\_ / \_\_\_\_ / \_\_\_\_

**Thank you**

## Section 1: International Physical Activity Questionnaire

The questions will ask you about the time you spent being physically active in the **last 7 days**. Please answer each question even if you do not consider yourself to be active. Please think about the activities you do at work, as part of your housework and gardening, to get from place to place, and in your spare time for recreation, exercise or sport.

Think about all the **vigorous** activities that you did in the **last 7 days**. **Vigorous** physical activities refer to activities that take hard physical effort and make you breathe much harder than normal. Think *only* about those physical activities that you did for at least 10 minutes at a time.

1. During the **last 7 days**, on how many days did you do **vigorous** physical activities like heavy lifting, digging, aerobics, or fast bicycling?

\_\_\_\_\_ **days per week**

No vigorous physical activities → **Skip to question 3**

2. How much time did you usually spend doing **vigorous** physical activities on one of those days?

\_\_\_\_\_ **hours per day**

\_\_\_\_\_ **minutes per day**

Don't know / Not sure

Think about all the **moderate** activities that you did in the **last 7 days**. **Moderate** activities refer to activities that take moderate physical effort and make you breathe somewhat harder than normal. Think *only* about those physical activities that you did for at least 10 minutes at a time.

3. During the **last 7 days**, on how many days did you do **moderate** physical activities like carrying light loads, bicycling at a regular pace, or doubles tennis? Do not include walking.

\_\_\_\_\_ **days per week**

No moderate physical activities → **Skip to question 5**

4. How much time did you usually spend doing **moderate** physical activities on one of those days?

\_\_\_\_\_ **hours per day**

\_\_\_\_\_ **minutes per day**

Don't know / Not sure

Think about the time you spent **walking** in the **last 7 days**. This includes at work and at home, walking to travel from place to place, and any other walking that you might do solely for recreation, sport, exercise, or leisure.

5. During the **last 7 days**, on how many days did you **walk** for at least 10 minutes at a time?

\_\_\_\_\_ **days per week**

No walking → ***Skip to question 7***

6. How much time did you usually spend **walking** on one of those days?

\_\_\_\_\_ **hours per day**

\_\_\_\_\_ **minutes per day**

Don't know / Not sure

The last question is about the time you spent **sitting** on weekdays during the **last 7 days**. Include time spent at work, at home, while doing course work and during leisure time. This may include time spent sitting at a desk, visiting friends, reading, or sitting or lying down to watch television.

7. During the **last 7 days**, how much time did you spend **sitting** on a **week day**?

\_\_\_\_\_ **hours per day**

\_\_\_\_\_ **minutes per day**

Don't know / Not sure

## Section 2: General Practice Physical Activity Questionnaire

1. Please tell us about the type of physical activity involved in your work

		Please mark one box only
a	I am not in employment (e.g. retired, retired for health reasons, unemployed, full-time carer etc)	
b	I spend most of my time at work sitting (e.g. in an office)	
c	I spend most of my time at work standing or walking. However, my work does not require much physical effort (eg. shop assistant, hair dresser, security guard, childminder)	
d	My work involves definite physical effort including handling of heavy objects and use of tools (e.g plumber, electrician, carpenter, cleaner, hospital nurse, gardener, postal delivery workers etc)	
e	My work involves vigorous physical activity including handling of very heavy objects e.g. scaffolder, construction worker, refuse collector etc.)	

2. During the last week, how many hours did you spend on each of the following activities? Please answer whether you are in employment or not.

		None	Some but less than 1 hour	More than 1 but less than 3 hours	3 hours or more
a	Physical exercise such as swimming, jogging, aerobics, football, tennis, gym workout etc				
b	Cycling, including cycling to work and during leisure time				
c	Walking including walking to work, shopping, for pleasure etc				
d	Housework / Childcare				
e	Gardening / DIY				

3. How would you describe your usual walking pace? Please tick one box only.

Slow pace (i.e. less than 3 mph)	Steady average pace	Brisk pace	Fast pace (i.e. over 4 mph)

## Explanation of patient and public involvement across the study

Patient and public involvement across the study is described in our publication of the main results,<sup>93</sup> and is reproduced here under the terms of the Creative Commons Attribution Licence (CC BY 4.0).


Pilot work with older primary care patients from three general practices was carried out ahead of seeking trial funding, with focus groups at each practice discussing ideas for a pedometer-based PA intervention. Patients were enthusiastic about the study and felt that the postal approach to recruitment and the interventions offered would be acceptable. They had input into aspects of the study design; for example, they encouraged us to offer participants in the usual-care arm a pedometer at the end of the follow-up period, and they encouraged us to recruit couples as well as individuals, and to allow couples to attend nurse appointments together.

One of the patient advisors was a TSC member, and was involved in discussions about recruitment and study conduct, as well as advising about patient materials, the dissemination of results to participants and safety reporting mechanisms.


The burden of the intervention was assessed by all participants in the nurse group with a questionnaire as part of the process evaluation, and by samples of both intervention groups as part of the qualitative evaluation of intervention participants.<sup>162</sup>

All participants were provided with timely feedback of their individual trial results after completion of the 12-month follow-up, including their PA and body size measurements over the trial duration. Summaries of results for the whole trial were disseminated to all trial participants as A4 feedback sheets after completion of the baseline assessments and after analysis of the main results. A trial website ([www.paceup.sgul.ac.uk/](http://www.paceup.sgul.ac.uk/)) has been created, and details have been circulated to participants. This also provides a summary of the trial results and details about further trial follow-up. All publications relating to the trial are provided on the website.


## Appendix 2 Results



**FIGURE 17** Trial procedures and complex intervention components.



**FIGURE 18** Residuals from the 12-month models for steps and weekly MVPA in  $\geq 10$ -minute bouts. (a) Steps model: distribution of residual; (b) steps model: standardised normal probability plot; (c) weekly MVPA in  $\geq 10$ -minute bouts; and (d) weekly MVPA in  $\geq 10$ -minute bouts. (*continued*)



**FIGURE 18** Residuals from the 12-month models for steps and weekly MVPA in  $\geq 10$ -minute bouts. (a) Steps model: distribution of residual; (b) steps model: standardised normal probability plot; (c) weekly MVPA in  $\geq 10$ -minute bouts; and (d) weekly MVPA in  $\geq 10$ -minute bouts.

**TABLE 23** The number of days with  $\geq 540$  minutes' accelerometer wear time by treatment group at baseline, 3 months and 12 months

Number of days with $\geq 540$ minutes' wear time	Time point, number of participants in each trial arm (%)								
	Baseline			3 months			12 months		
	Control (n = 338)	Postal delivery (n = 339)	Nurse support (n = 346)	Control (n = 318)	Postal delivery (n = 317)	Nurse support (n = 319)	Control (n = 323)	Postal delivery (n = 312)	Nurse support (n = 321)
1				0	2 (0.6)	3 (1)	1 (0.3)	0	1 (0.3)
2				2 (0.6)	9 (3)	6 (2)	1 (0.3)	1 (0.3)	2 (0.6)
3				9 (3)	8 (3)	3 (1)	5 (2)	4 (1)	2 (0.6)
4				21 (7)	16 (5)	11 (3)	16 (5)	20 (6)	14 (4)
5	29 (9)	39 (12)	40 (12)	37 (12)	25 (8)	35 (11)	42 (13)	38 (12)	35 (11)
6	85 (25)	83 (24)	84 (24)	64 (20)	79 (25)	67 (21)	78 (24)	57 (18)	79 (25)
7	224 (66)	217 (64)	222 (64)	185 (58)	178 (56)	194 (61)	180 (56)	192 (62)	188 (59)
$\geq 5$	338 (100)	339 (100)	346 (100)	286 (90)	282 (89)	296 (93)	300 (93)	287 (92)	302 (94)

**TABLE 24** Summary data for main outcome and ancillary outcome variables

Outcome	Time point, mean number of participants in each trial arm (SD)								
	Control group			Postal delivery group			Nurse-support group		
	Baseline	3 months	12 months	Baseline	3 months	12 months	Baseline	3 months	12 months
Accelerometry data ( <i>n</i> )	338	318	323	339	317	312	346	319	321
Daily step count	7379 (2696)	7327 (2688)	7246 (2671)	7402 (2476)	8086 (3014)	8010 (2922)	7653 (2826)	8707 (3206)	8131 (3228)
Total weekly minutes of MVPA in ≥ 10-minute bouts	84 (97)	87 (101)	89 (94)	92 (90)	136 (125)	129 (124)	105 (116)	164 (154)	138 (141)
Daily sedentary time (minutes)	613 (68)	614 (70)	616 (72)	614 (71)	614 (74)	617 (71)	619 (78)	613 (77)	620 (79)
Daily wear time (minutes)	789 (73)	795 (78)	791 (76)	787 (78)	798 (84)	800 (80)	797 (84)	805 (85)	807 (89)
Clinical measurements ( <i>n</i> )	338		323	339		314	346		321
BMI (kg/m <sup>2</sup> )	27.7 (5.4)		27.5 (5.2)	28 (5.5)		27.7 (5.6)	27.6 (5.2)		27.5 (5.2)
Fat mass (kg)	26 (10.3)		25.8 (9.8)	26.8 (11.0)		26.5 (11.2)	26 (10.6)		25.6 (11.1)
Waist circumference (cm)	93.1 (14.3)		93.4 (14.7)	94.1 (13.9)		94.3 (14.1)	93.2 (13.2)		93.7 (13.4)
Questionnaire data ( <i>n</i> )	335	316	318	335	312	311	342	310	319
HADS anxiety score	4.8 (3.3)	4.7 (3.4)	4.7 (3.4)	4.6 (3.3)	4.4 (3.3)	4.4 (3.4)	4.6 (3.6)	4.4 (3.5)	4.5 (3.9)
HADS depression score	3.9 (2.8)	2.7 (2.6)	2.6 (2.9)	3.8 (2.6)	2.4 (2.7)	2.4 (2.6)	3.9 (2.9)	2.4 (2.9)	2.6 (3.0)
EQ-5D score	0.8 (0.1)	0.8 (0.1)	0.8 (0.2)	0.9 (0.1)	0.9 (0.1)	0.8 (0.1)	0.9 (0.1)	0.8 (0.1)	0.8 (0.1)
Exercise self-efficacy score	22.3 (7.0)	20.4 (6.7)	21.0 (7.1)	22.1 (7.2)	21.4 (6.7)	21.7 (7.0)	22.0 (7.3)	22.9 (6.7)	22.4 (7.1)
Self-reported pain	0.9 (0.8)	0.9 (0.8)	1.0 (0.8)	1.0 (0.8)	1.0 (0.8)	1.0 (0.8)	0.9 (0.8)	1.0 (0.8)	1.0 (0.8)

**Notes**

Accelerometry data are adjusted for the day of the week and day order of wearing the accelerometer, with participant as a random effect in a multilevel model.

At baseline, data were available for all participants for accelerometry variables, BMI and waist circumference. Fat mass was available for 335, 337 and 346 participants in the control, postal delivery and nurse-support groups, respectively. There were no clinical measurements at 3 months. At 12 months, fat mass was available in the control, postal delivery and nurse-support groups for 319, 308 and 320 participants, respectively.

Questionnaire variables were missing for varying numbers of participants at each time point.

Full references for the HADS anxiety and depression scores, EQ-5D scores and exercise self-efficacy are given in the trial protocol.<sup>20</sup>

**TABLE 25** Physical activity measured by self-report IPAQ and GPPAQ measurements

Questionnaire	Trial arm								
	Control group			Postal delivery group			Nurse-support group		
	Baseline	3 months	12 months	Baseline	3 months	12 months	Baseline	3 months	12 months
<b>IPAQ</b>	<b>(N = 279)</b>	<b>(N = 234)</b>	<b>(N = 274)</b>	<b>(N = 270)</b>	<b>(N = 225)</b>	<b>(N = 251)</b>	<b>(N = 284)</b>	<b>(N = 241)</b>	<b>(N = 257)</b>
<i>Total weekly minutes of, mean (SD)</i>									
Vigorous and moderate activity in ≥ 10-minute bouts	194 (310)	242 (387)	237 (365)	159 (266)	191 (315)	204 (294)	167 (259)	227 (340)	214 (361)
Walking in ≥ 10-minute bouts	323 (327)	370 (336)	365 (336)	316 (326)	357 (292)	389 (320)	307 (275)	417 (308)	371 (307)
<i>Achieved at least 150 minutes of, n (%)</i>									
Vigorous + moderate activity in ≥ 10-minute bouts	102 (37)	93 (40)	112 (41)	86 (32)	85 (38)	108 (43)	101 (36)	89 (37)	99 (39)
Achieved at least 150 minutes of walking in ≥ 10-minute bouts	178 (64)	160 (68)	192 (70)	176 (65)	168 (75)	198 (79)	193 (68)	201 (83)	197 (77)
<b>GPPAQ</b>	<b>(N = 322)</b>	<b>(N = 308)</b>	<b>(N = 315)</b>	<b>(N = 318)</b>	<b>(N = 296)</b>	<b>(N = 303)</b>	<b>(N = 333)</b>	<b>(N = 305)</b>	<b>(N = 318)</b>
<i>Physical Activity Index, n (%)</i>									
Active	44 (14)	37 (12)	49 (16)	36 (11)	36 (12)	51 (17)	34 (10)	39 (13)	41 (13)
Including walking: active	93 (29)	94 (31)	103 (33)	79 (25)	92 (31)	101 (33)	90 (27)	102 (33)	96 (30)

TABLE 26 Sensitivity and imputation analyses for the primary outcome (step count at 12 months)

Analysis	Participants (N)	Comparison between trial arms					
		Postal delivery vs. control		Nurse support vs. control		Nurse support vs. postal delivery	
		Effect (95% CI)	p-value	Effect (95% CI)	p-value	Effect (95% CI)	p-value
<b>Analysis based on all participants with follow-up data</b>							
<i>Minimum daily wear time 540 minutes</i>							
At least 5 days at baseline and 1 day at 12 months	956	642 (329 to 955)	< 0.001	677 (365 to 989)	< 0.001	36 (-277 to 349)	0.82
At least 5 days at baseline and 5 days at 12 months	889	607 (285 to 930)	< 0.001	732 (412 to 1051)	< 0.001	124 (-198 to 446)	0.45
<i>Minimum daily wear time of 600 minutes</i>							
At least 5 days at baseline and 1 day at 12 months	877	675 (352 to 997)	< 0.001	714 (392 to 1036)	< 0.001	39 (-283 to 362)	0.81
At least 5 days at baseline and 5 days at 12 months	760	752 (411 to 1093)	< 0.001	796 (456 to 1136)	< 0.001	44 (-295 to 384)	0.80
Model adjusting for change in wear time between baseline and 12 months	956	579 (273 to 885)	< 0.001	637 (332 to 941)	< 0.001	58 (-248 to 363)	0.71
<b>Analyses based on all randomised participants: missing step counts imputed for participants with no follow-up data at 12 months</b>							
<i>Missing at random</i>							
Imputed using treatment group, baseline steps, sex, age, practice, month baseline accelerometry	1023	638 (324 to 953)	< 0.001	679 (367 to 992)	< 0.001	41 (-270 to 352)	0.80
Imputed using treatment group, baseline steps, sex, age, practice, month baseline accelerometry, NS-SEC, self-reported pain and fat mass <sup>a</sup>	1013	673 (356 to 989)	< 0.001	686 (372 to 1000)	< 0.001	13 (-303 to 330)	0.94
<i>Missing not at random, using extreme assumptions for missing data</i>							
<i>Control group: 12-month step count equal to baseline step count</i>							
Both intervention groups: 12-month step count changes by							
-1500 steps	1023	651 (338 to 964)	< 0.001	783 (472 to 1095)	< 0.001	132 (-181 to 445)	0.41
Same as baseline step count	1023	771 (458 to 1084)	< 0.001	892 (580 to 1204)	< 0.001	121 (-192 to 434)	0.45
+1500 steps	1023	890 (577 to 1203)	< 0.001	1000 (688 to 1312)	< 0.001	110 (-203 to 423)	0.49
a Of the 67 participants with inadequate accelerometry at 12 months, baseline data for the NS-SEC were also missing for 10 participants, and so imputed values were not available for these 10 participants when including the NS-SEC as a predictor.							

## Appendix 3 Economic evaluation

**TABLE 27** Resource use and cost components of 'set-up costs'

Activity (trial arm applicable to)	Sources of data		Trial arm
	Resource use	Unit cost (£)	
Design			
Designing of intervention	Time spent by designers (diaries, administrative records)	Salary cost (PSSRU, administrative records)	Two intervention arms
Designing of participants' handbooks and diaries			
Designing of nurse trainers' handbooks	<ul style="list-style-type: none"> <li>Time spent by designers (diaries, administrative records)</li> <li>Number of handbooks (administrative records)</li> </ul>	<ul style="list-style-type: none"> <li>Salary cost (PSSRU, administrative records)</li> <li>Price per handbook (administrative records)</li> </ul>	Pedometer plus nurse group
Setting up GP practices			
Planning for recruitment of practices	Time spent by recruiters (diaries, administrative records)	Salary cost (PSSRU, administrative records)	All trial arms
Visits to recruit six practices	<ul style="list-style-type: none"> <li>Time spent by recruiters (diaries, administrative records)</li> <li>Number of round trips to practices (administrative records)</li> </ul>	<ul style="list-style-type: none"> <li>Salary cost (PSSRU, administrative records)</li> <li>Fare per round trip (TfL tariff guide, administrative records)</li> </ul>	
Searching practice computers to identify participants	Time spent by practice managers and trial staff (diaries, administrative records)	Salary cost (PSSRU, administrative records)	
Identify households from anonymised address list	Time spent by trial staff (diaries, administrative records)	Salary cost (administrative records)	
Practice staff members review lists for exclusion	Time spent by practice staff (administrative records)	Salary cost (PSSRU)	
Printing letters at practice	<ul style="list-style-type: none"> <li>Time spent by practice administrative and trial staff (diaries, administrative records)</li> <li>Number of printed letters (administrative records)</li> </ul>	<ul style="list-style-type: none"> <li>Salary cost (PSSRU, administrative records)</li> <li>Cost per printed letter (invoice)</li> </ul>	
Packing envelopes with leaflets and letters	<ul style="list-style-type: none"> <li>Time spent by practice administrative staff and trial staff (diaries, administrative records)</li> <li>Number of envelopes (administrative records)</li> <li>Number of postal stamps (administrative records)</li> <li>Number of information leaflets (administrative records)</li> </ul>	<ul style="list-style-type: none"> <li>Salary cost (PSSRU, administrative records)</li> <li>Price per envelope (administrative records)</li> <li>Price per postal stamp (administrative records)</li> <li>Price per information leaflets (administrative records)</li> </ul>	All trial arms
Preparing rooms at practices for trial	<ul style="list-style-type: none"> <li>Time spent by trial staff (diaries, administrative records)</li> <li>Number of office cabinets (administrative records)</li> <li>Number of round trips to practices (administrative records)</li> </ul>	<ul style="list-style-type: none"> <li>Salary cost (administrative records)</li> <li>Price per cabinet (administrative records)</li> <li>Fare per round trip (TfL tariff guide)</li> </ul>	

continued

TABLE 27 Resource use and cost components of 'set-up costs' (continued)

Activity (trial arm applicable to)	Sources of data		Trial arm
	Resource use	Unit cost (£)	
Training			
Training of trial manager	<ul style="list-style-type: none"> <li>Time spent by trainers of internal training programme (diaries, administrative records)</li> <li>Time spent by trial manager (diaries, administrative records)</li> <li>Number of external courses attended (administrative records)</li> </ul>	<ul style="list-style-type: none"> <li>Salary cost (administrative records)</li> <li>Course fee (administrative records)</li> </ul>	All trial arms
Preparation of nurse training course	Time spent by course trainers (diaries, administrative records)	Salary cost (administrative records)	Pedometer plus nurse group
Mini training day of nurses	<ul style="list-style-type: none"> <li>Time spent by course trainers (diaries)</li> <li>Time spent by nurses (administrative records)</li> <li>Number of round trips to training centres (administrative records)</li> <li>Number of pedometers (administrative records)</li> </ul>	<ul style="list-style-type: none"> <li>Salary cost (PSSRU, administrative records)</li> <li>Fare per round trip (TfL tariff guide, administrative records)</li> <li>Price per pedometer (administrative records)</li> </ul>	
Full training day of nurses	<ul style="list-style-type: none"> <li>Time spent by course trainers (diaries, administrative records)</li> <li>Time spent by nurses (administrative records)</li> <li>Number of round trips to training centre (administrative records)</li> <li>Number of refreshments (administrative records)</li> </ul>	<ul style="list-style-type: none"> <li>Salary cost (PSSRU, administrative records)</li> <li>Fare per round trip (TfL tariff guide, administrative records)</li> <li>Cost of refreshment (administrative records)</li> </ul>	
Training for an absentee nurse	<ul style="list-style-type: none"> <li>Time spent by course trainers (diaries, administrative records)</li> <li>Time spent by nurse (administrative records)</li> <li>Number of round trips to training centre (administrative records)</li> </ul>	<ul style="list-style-type: none"> <li>Salary cost (PSSRU, administrative records)</li> <li>Fare per round trip (TfL tariff guide, administrative records)</li> </ul>	Pedometer plus nurse group
Discussion of nurses' recorded sessions (nurse group)	<ul style="list-style-type: none"> <li>Time spent by course trainers (diaries, administrative records)</li> <li>Time spent by nurse (administrative records)</li> <li>Duration of telephone calls (administrative records)</li> </ul>	<ul style="list-style-type: none"> <li>Salary cost (PSSRU, administrative records)</li> <li>Telephone charge per minute (BT tariff guide)</li> </ul>	
Follow-up half-day training (nurse group)	<ul style="list-style-type: none"> <li>Time spent by course trainers (diaries, administrative records)</li> <li>Time spent by nurse (administrative records)</li> <li>Number of round trips to training centre (administrative records)</li> <li>Number of refreshments (administrative records)</li> </ul>	<ul style="list-style-type: none"> <li>Salary cost (PSSRU, administrative records)</li> <li>Fare per round trip (TfL tariff guide, administrative records)</li> <li>Cost of refreshment (administrative records)</li> </ul>	
Training of research assistants (all trial arms)	<ul style="list-style-type: none"> <li>Time spent by course trainers (diaries, administrative records)</li> <li>Time spent by research assistants (administrative records)</li> </ul>	Salary cost (administrative records)	

BT, British Telecom; PSSRU, Personal Social Services Research Unit; TfL, Transport for London.

**TABLE 28** Components of the cost of delivering care and sources of data by trial arm

Components	Sources of data		Trial arm
	Resource use	Unit cost (£)	
Envelopes for posting pedometers	Number used (administrative records)	Price per envelope (invoice)	Two intervention arms
Stamps for posting pedometers	Number used (administrative records)	Price per stamp (invoice)	
Pedometers posted to participants (including replacements)	Number used (administrative records)	Price per pedometer (invoice)	
Replacement batteries for pedometer	Number used (administrative records)	Price per battery (invoice)	
Patient handbooks posted to participants	Number given out (administrative records)	Cost per handbook (administrative records)	
Walking plan/diary posted to participants	Number posted (administrative records)	Cost per walking plan (administrative records)	
Time of nurse consultation with participants	Duration of each ( $n = 3$ ) consultation (nurse data base)	Salary cost for nurse (PSSRU 2014) <sup>103</sup>	
Time of research assistants to arrange a consultation appointment for participants	Time spent by three research assistants (diary)	Salary cost (administrative records)	
Telephone calls by research assistants to arrange a consultation appointment for participants	Duration of telephone calls (administrative records)	Telephone charge per minute [BT tariff guide (average of landline/mobile phone)]	Pedometer plus nurse-support arm

BT, British Telecom; PSSRU, Personal Social Services Research Unit.

**TABLE 29** Health provider cost of health service use

Components	Source of data		Trial arm
	Resource use	Unit cost (£) <sup>a</sup>	
GP consultations	Number of GP consultations (GP data)	Cost per GP consultation (PSSRU 2014) <sup>103</sup>	All three trial arms
Nurse consultations <sup>b</sup>	Number of nurse consultations (GP data)	Cost per nurse consultation (PSSRU 2014) <sup>103</sup>	
Hospital admissions	Number of elective and emergency hospital admissions by diagnosis or procedure (GP data)	Cost of hospital admission [determined by type of diagnosis and/or related procedure ( <i>NHS Reference Costs 2014–15</i> ) <sup>102</sup> ]	
A&E visits	Number of A&E visits (GP data)	Cost per A&E admission ( <i>NHS Reference Costs 2014–15</i> ) <sup>102</sup>	
Outpatient referrals	Number of outpatient visits by department (GP data) <sup>c</sup>	Cost per outpatient visit ( <i>NHS Reference Costs 2014–15</i> ) <sup>102</sup>	

a The unit cost for hospital admissions, outpatient visits (for referrals) and A&E visits will be generated primarily from NHS reference costs by identifying the procedures relevant to the diagnosis related (based on clinical opinion) to the use of health care. The type of health-care use (elective or non-elective, consultant led or not) will be accounted for as appropriate.

b Nurse consultations excludes the PA consultations conducted as part of the trial.

c Based on discussion with the trial team [with input from a GPs – TH's (principal investigator) experience], it was assumed that each outpatient referral generates one outpatient visit.

**TABLE 30** Personal costs of participating in the interventions or control arms of the trial

Components	Source of data		Trial arm
	Resource use	Unit cost	
Time working out how to use pedometer	Duration (3-month questionnaire)	Wage rate of participants (ONS 2015 <sup>207</sup> )	Both intervention arms
Time planning how to increase walking/step count			
Time filling in PACE-UP diary			
Parking fees to visit nurse	Number of nurse visits (nurse database)	Parking charge per last visit (3-month questionnaire)	Pedometer plus nurse support group
Time spent in consultation with nurse <sup>a</sup>	Duration of the three consultations (nurse database)	Wage rate of participants (ONS 2015)	
Time travelling (irrespective of mode of transport) to visit nurse <sup>b</sup>	Duration travelling (3-month questionnaire); number of nurse visits (nurse database)		
Transportation cost (for those who took public transport) of attending the nurse visit	Number of nurse visits (nurse database)	Fare for last nurse visit (3-month questionnaire)	
Time waiting time prior to consultation with nurse	Duration of waiting time at last visit to nurse (3-month questionnaire); number of nurse visits (nurse database)	Wage rate of participants (ONS 2015)	
Child care during nurse visits	Number of nurse visits (nurse database)	Child care charge for last nurse visit (3-month questionnaire)	

a The nurse consultations took place in weeks 0, 5 and 9.

b To avoid double-counting, data on the time spent walking to the nurse consultation are excluded.

**TABLE 31** Resource use and cost components of 'set-up cost'<sup>a</sup>

Activity (trial arm applicable to)	Resource	Total quantity	Group, cost (£) per participant	
			Nurse support	Postal delivery
Design <sup>b</sup>				
Designing of intervention (both intervention arms)	Professor × 1	0.5 days	4.43	4.43
	Readers × 3	1 day		
	Senior lecturers × 3	3.5 days		
	Consultants × 2	1 day		
Designing of participants' handbooks and diaries (both intervention groups)	Professor × 3	1.5 days	3.56	3.56
	Readers × 2	1 day		
	Senior lecturers × 3	2 days		
	Consultants × 2	0.5 days		
Designing of nurse trainers handbooks (nurse-support group)	Senior lecturers × 1	1 day	2.74	0.00
	Consultants × 1	0.5 days		
	Handbooks	9 handbooks	0.19	0.00

TABLE 31 Resource use and cost components of 'set-up cost'<sup>a</sup> (continued)

Activity (trial arm applicable to)	Resource	Total quantity	Group, cost (£) per participant	
			Nurse support	Postal delivery
Setting up GP practices				
Planning for recruitment of practices (all trial arms)	Professor × 1	1 hour	0.99	0.99
	Senior lecturer × 1	5 hours		
	Consultants × 2	5 hours		
Visits to recruit six practices (all trial arms)	Senior lecturers × 2	13 hours	1.47	1.47
	Trial manager × 1	7 hours		
	Consultant × 1	5 hours		
	Round trips to practices (by all)	25 hours	0.10	0.10
Searching practice computers to identify participants (all trial arms)	Senior lecturer × 1	6 hours	0.71	0.71
	Trial manager × 1	6 hours		
	Practice manager × 6	6 hours		
Identify households from anonymised address list (all trial arms)	Senior lecturer × 1	32 hours	2.28	2.28
	Trial manager × 1	32 hours		
Practice staff reviews lists for exclusion (all trial arms)	GP × 5 (for sorting out two practices)	20 hours	4.50	4.00
	Nurse × 10 (for sorting out other five practices)	50 hours	1.96	1.96
Printing letters at practice (all trial arms)	Trial manager × 1	64 hours	1.57	1.57
	Practice administrative staff × 2	4 hours		
	Number of printed letters	24,000	0.94	0.94
Packing envelopes with leaflets and letters (all trial arms)	Trial manager × 1	240 hours	7.04	7.04
	Research assistants × 2	56 hours		
	Practice administration staff × 11	27.5 hours		
	Cost of envelopes	£497.30	0.49	0.49
	Cost of Postal stamps	£5530.50	5.41	5.41
	Cost of Information leaflets	£5973.00	5.84	5.84
Preparing rooms at practices for trial (all trial arms)	Round trip to practices by research assistant	14 trips	0.04	0.04
	Research assistants × 2	– <sup>c</sup>	0.11	0.11
Training				
Training of trial manager (all trial arms)	Trial manager × 1	4 days	1.51	1.51
	Senior lecturer × 1	2 days		
Preparation of nurse training course (nurse-support group)	Trial manager × 1	1 day	9.63	0.00
	Senior lecturer × 1	2 days		
	Reader × 1	0.5 days		
	Consultants × 2	2 days		

continued

TABLE 31 Resource use and cost components of 'set-up cost'<sup>a</sup> (continued)

Activity (trial arm applicable to)	Resource	Total quantity	Group, cost (£) per participant		
			Nurse support	Postal delivery	
Mini training day of nurses (nurse-support group)	Nurses × 11	33 hours	7.46	0.00	
	Trial manager × 1	17.33 hours			
	Senior lecturer × 1	17.33 hours			
	Round trips to the training centre (by tutors)	16 hours	0.19	0.00	
	Pedometers given to nurses	12 hours	0.04	0.00	
Full training day of nurses (nurse-support group)	Nurses × 10	107.5 hours	22.99	0.00	
	Reader × 1	1 hour			
	Senior lecturer × 1	10 hours			
	Consultants × 2	22.5 hours			
	Round trips for training by nurses × 10	10 trips	0.12	0.00	
	Round trips for training by consultants × 2	2 trips	0.13	0.00	
	Refreshments	1 set	0.26	0.00	
	Training for an absentee nurse (nurse-support group)	Nurse × 1	10 hours	2.47	0.00
		Trial manager × 1	11.33 hours		
Research assistant × 1		11.33 hours			
Round trips to training centre		2 trips	0.02	0.00	
Discussion of nurses' recorded sessions (nurse-support group)	Senior lecturer × 1	0.5 days	3.78	0.00	
	Consultants × 2	1 day			
	Nurses × 9	4.5 days	0.99	0.00	
	Senior lecturer × 1	0.5 days			
	Consultants × 2	1 day			
	Duration of telephone calls	270 minutes	0.09	0.00	
Follow-up half-day training (nurse-support group)	Nurses × 9	4.5 days	7.70	0.00	
	Trial manager × 1	0.5 days			
	Senior lecturer × 1	0.5 days			
	Consultants × 2	1 day			
	Nurse time travelling × 9	6.75 hours	0.78	0.00	
	Round trips to training centre (nurses)	9 trips	0.10	0.00	
	Refreshment	1 set	0.15	0.00	
	Training of research assistants (all trial arms)	Research assistant × 3	6.6 days	1.91	1.91
Senior lecturer × 1		0.5 days			
Reader × 1		0.5 days			
Trial manager × 1		4 days			
Total cost per participant			104.64	44.83	

a Data source: interviews with the trial principal investigator and trial manager, review of trial records, diaries and routine administrative records.

b Design was included as materials could not be used wholesale from a previous study and we judged that this may occur in the future, following further learning from this trial.

c Value removed at present to maintain confidentiality.

**TABLE 32** Components of delivery cost of intervention (postal delivery group)

Components	Resource (from administrative records)	Quantity of resource	Unit cost (£) (data source)	Analysis				
				3-month		12-month		
				Total cost (£)	Cost (£) per participant	Total cost (£)	Cost (£) per participant	
Envelopes for posting pedometers (including replacements)	Number of envelopes	426	0.03 (invoice)	12.78	0.04	12.78	0.04	
Stamps for posting pedometer	Number of stamps	426	2.50 (invoice)	1065.00	3.14	1065	3.14	
Pedometers (including replacements) given to participants	Number of pedometers	426	1/4 <sup>a</sup> (invoice)	426.00	1.26	1704	5.03	
Replacement batteries for pedometer	Number of replacement batteries	11	0.67 (invoice)	7.37	0.02	7.37	0.02	
Patient handbooks	Number of handbooks	339	0.80 (administrative records)	271	0.80	271	0.80	
Step count diary	Number of diaries	339	1.30 (administrative records)	440.70	1.30	440.70	1.30	
Total cost (£) per participant					6.56		10.33	

a £1 was the pro rata unit cost for 3 months and £4 was the pro rata unit cost for 12 months. As pedometers were required only for the period of analysis, but could be used beyond, their costs were spread over their expected lifetime, following Sharples *et al.* (2014).<sup>208</sup> As pedometers had an expected lifetime of 2 years, the average cost of pedometer was multiplied by 13 (intervention period in weeks)/104 [life expectancy of pedometer (in weeks) – based on experience from the PACE-LIFT trial], in the case of the 3-month analysis and 52 out of 104 for the 12-month analysis.

**TABLE 33** Components of delivery cost of intervention (nurse-support group)

Components	Resource (data source)	Quantity of resource	Unit cost (£) (data source)	Analysis			
				3-month		12-month	
				Total cost (£)	Cost (£) per participant	Total cost (£)	Cost (£) per participant
Pedometers given to participants	Number of pedometers (administrative records)	346	1/4 <sup>a</sup> (invoice)	346.00	1.00	1384	4.00
Patient handbooks	Number of handbooks (administrative records)	346	0.80 (administrative records)	277.00	1.00	277	1.00

continued

**TABLE 33** Components of delivery cost of intervention (nurse-support group) (*continued*)

Components	Resource (data source)	Quantity of resource	Unit cost (£) (data source)	Analysis			
				3-month		12-month	
				Total cost (£)	Cost (£) per participant	Total cost (£)	Cost (£) per participant
Step count diary	Number of diaries (administrative records)	346	1.30 (administrative records)	449.80	1.30	449.80	1.30
Research assistants' time to arrange consultation	Time spent by research assistants (diary)	50.46 hours	16.51 (administrative records)	833.07	2.41	833.07	2.41
Telephone calls by research assistants to arrange consultation	Duration of telephone calls (administrative records)	3027.5 minutes	0.11 (BT tariff) <sup>a</sup>	333.03	0.96	333.03	0.96
Cost of nurse visit per participant (project database for nurse group)					43.00		42.00
Total cost per participant					49.67		51.67

BT, British Telecom.

<sup>a</sup> £1 was the pro rata unit cost for 3 months and £4 was the pro rata unit cost for 12 months.**TABLE 34** Costs to participants of participating in interventions and PA

Intervention-related participant costs	Trial arm, mean cost (£) (SD)		
	Control (N = 323)	Postal delivery (N = 312)	Nurse support (N = 321)
Time working out how to use pedometer	0 (0)	2 (6)	1 (3)
Time planning how to increase walking/step count	0 (0)	5 (15)	3 (4)
Time filling in the PACE-UP diary	0 (0)	51 (80)	58 (122)
Parking fees to visit nurse	0 (0)	0 (0)	0.11 (0.73)
Time spent in consultation with nurse	0 (0)	0 (0)	10 (5)
Time travelling (irrespective of mode of transport) to visit nurse	0 (0)	0 (0)	11 (10)
Transportation cost (for those who took public transport) of attending the nurse visit	0 (0)	0 (0)	0.13 (1.33)
Time waiting time prior to consultation with nurse	0 (0)	0 (0)	3 (4)
Child care during nurse visits	0 (0)	0 (0)	0.3 (3.21)
Personal costs of participation in PA	411 (817)	492 (1293)	333 (684)
Personal costs from falls/fractures/sprains/injuries	17 (103)	22 (184)	6 (40)

TABLE 35 Health service use by trial arm with unit costs

Health service use	Trial arm (quantity)			Unit cost (£), weighted average (Q1–Q3)	Source for unit cost
	Control (N = 323)	Postal delivery (N = 312)	Nurse support (N = 321)		
Outpatient referrals (total) <sup>a</sup>	164	158	186		
Ophthalmology	10	18	15	86 (70–99)	<i>NHS Reference Costs 2014–15<sup>102</sup></i>
Urology	4	3	6	99 (76–116)	
General medicine	4	0	2	157 (120–187)	
ENT	9	6	12	92 (70–109)	
Podiatry	9	7	7	44 (27–45)	
Trauma and orthopaedics	14	13	10	113 (88–133)	
Physiotherapy	26	33	37	46 (35–50)	
Nephrology	0	1	0	145 (94–178)	
Oral surgery	0	2	0	115 (85–142)	
Gynaecology	6	7	14	134 (104–164)	
Audiology	4	6	7	104 (55–174)	
Colorectal surgery	1	5	1	117 (83–135)	
Neurology	8	8	5	174 (136–204)	
Cardiology	12	5	4	131 (92–154)	
Gastroenterology	6	2	6	130 (99–153)	
Rheumatology	4	6	7	135 (99–150)	
Dermatology	1	8	7	98 (74–109)	
General surgery	4	1	3	125 (98–165)	
Endocrinology	2	1	2	144 (100–167)	
Neurosurgery	2	0	0	181 (138–228)	
Oncology	8	5	11	133 (97–165)	
Psychotherapy	1	0	0	100 (47–217)	
Respiratory medicine	4	6	3	150 (107–181)	
Clinical neurophysiology	2	0	1	165 (107–197)	
Programmed pulmonary rehabilitation	0	0	1	20 (12–31)	
Pain management	2	0	4	135 (82–164)	
Allergy service	0	1	0	149 (126–175)	
Dietetics	2	2	3	62 (38–76)	
Vascular surgery	2	1	4	149 (100–176)	
Mental illness	1	1	1	234 (181–256)	

continued

TABLE 35 Health service use by trial arm with unit costs (continued)

Health service use	Trial arm (quantity)			Unit cost (£), weighted average (Q1–Q3)	Source for unit cost
	Control (N = 323)	Postal delivery (N = 312)	Nurse support (N = 321)		
Clinical genetics	1	0	1	429 (248–601)	
Clinical haematology	2	1	0	160 (93–189)	
Spinal surgery services	0	1	0	142 (112–164)	
Maxillofacial surgery	0	0	1	111 (70–133)	
Plastic surgery	1	1	1	93 (68–109)	
Clinical immunology	0	1	0	215 (140–243)	
Interventional radiology	1	0	0	192 (88–260)	
Breast surgery	9	4	5	139 (103–166)	
Tropical medicine	0	1	0	202 (203–203)	
Clinical psychology	1	0	3	177 (116–245)	
Old age psychiatry	0	1	2	108 (108–108)	
Referral to A&E	1	0	0	135 (54–166)	
Community-based referrals (total) <sup>b</sup>	27	19	21		
District nurse	1	3	2	39 (31–43)	PSSRU's <i>Unit Costs of Health and Social Care 2014</i> <sup>103</sup>
Community podiatrist	4	3	8	42 (35–58)	PSSRU's <i>Unit Costs of Health and Social Care 2014</i> <sup>103</sup>
Community dietitian	0	2	0	80 (53–96)	NHS Reference Costs 2014–15 <sup>102</sup>
Smoking cessation (nurse-support group)	5	3	4	14	15.5 minutes' nurse time; PSSRU's <i>Unit Costs of Health and Social Care 2014</i> <sup>103</sup>
Healthy lifestyle (nurse-support group)	0	2	0	14	15.5 minutes' nurse time; PSSRU's <i>Unit Costs of Health and Social Care 2014</i> <sup>103</sup>
Community gynaecologist	5	1	0	134 (104–164)	NHS Reference Costs 2014–15 <sup>102</sup>
Community physiotherapist	7	4	1	52 (44–58)	PSSRU's <i>Unit Costs of Health and Social Care 2014</i> <sup>103</sup>
Community diabetic	1	0	0	69 (38–93)	NHS Reference Costs 2014–15 <sup>102</sup>
DESMOND diabetes programme	4	0	6	230	Gillett <i>et al.</i> (2010) <sup>209</sup> (inflated to 2014)
Expert patient programme	0	1	0	302	Richardson <i>et al.</i> (2008) <sup>210</sup> (inflated to 2014)

TABLE 35 Health service use by trial arm with unit costs (continued)

Health service use	Trial arm (quantity)			Unit cost (£), weighted average (Q1–Q3)	Source for unit cost
	Control (N = 323)	Postal delivery (N = 312)	Nurse support (N = 321)		
Primary care – excludes practice visits related to delivery and participation in the intervention (total) <sup>c</sup>	2074	1748	2094		
GP (11.7 minutes)	1743	1436	1729	42	PSSRU's <i>Unit Costs of Health and Social Care 2014</i> <sup>103</sup>
GP nurse (15.5 minutes)	331	312	365	14	PSSRU's <i>Unit Costs of Health and Social Care 2014</i> <sup>103</sup>
A&E visit <sup>d</sup>	49	36	46	124	NHS Reference Costs 2014–15 <sup>102</sup>
Non-elective hospital admissions (total) <sup>e,f</sup>	12	4	20		
Biliary acute pancreatitis	0	0	3	2037 (1247–2492)	NHS Reference Costs 2014–15 <sup>102</sup>
Cardiac catheterisation for coronary artery disease	1	0	1	2643 (1980–3028)	
Chest pain	0	1	0	490 (370–563)	
Abdominal pain	0	0	1	718 (922–1298)	
Acute ST segment elevation myocardial infarction	2	0	0	1497 (1102–1740)	
Transient ischaemic attack	0	0	1	878 (643–994)	
Guillain–Barré syndrome	0	0	1	1571 (1069–1792)	
Pneumonia	1	0	0	1894 (1406–2238)	
Epilepsy	1	0	0	1125 (788–1266)	
Stroke and cerebrovascular accident	1	0	0	2817 (2018–3396)	
UTI	0	0	1	1530 (1187–1755)	
Detached retina	0	0	1	908 (303–1935)	
Anxiety states	0	0	1	1393 (984–1628)	
Infective endocarditis	1	0	0	4480 (2351–5906)	
Acute appendicitis	0	0	1	3017 (2459–3365)	
IUD removed	0	0	1	1780 (1142–2135)	
Ankle fracture	1	0	0	3762 (3109–4271)	
No procedure (NES)	4	3	8	611 (408–726)	

continued

TABLE 35 Health service use by trial arm with unit costs (continued)


Health service use	Trial arm (quantity)			Unit cost (£), weighted average (Q1–Q3)	Source for unit cost
	Control (N = 323)	Postal delivery (N = 312)	Nurse support (N = 321)		
Elective hospital admissions (total) <sup>e,g</sup>	10	2	3		
Cardiac catheterisation	2	0	0	2086 (1185–2709)	<i>NHS Reference Costs 2014–15</i> <sup>102</sup>
Percut translum balloon angioplasty multicoronary	1	0	0	1813 (880–2233)	
Inguinal hernia	0	1	0	2121 (1682–2392)	
Coronary artery bypass graft operations	0	1	0	9310 (7369–9929)	
Laparoscopic cholecystectomy	3	0	0	2567 (2082–2924)	
Endarterectomy of femoral artery (NEC)	0	0	2	6028 (4593–7209)	
Malignant neoplasm of female breast for chemotherapy	1	0	0	1780 (856–2139)	
Endarterectomy of carotid artery (NEC)	1	0	0	3911 (2986–4497)	
Neurophysiological operation (NOS)	2	0	0	1497 (1111–2118)	
Ovarian cancer	0	0	1	1469 (741–1966)	
Total resource use (all health service use)	2336	1967	2370		

ENT, ear, nose and throat; IUD, intrauterine device; NES, not elsewhere classified; NOS, not otherwise specified; UTI, urinary tract infection.


- a Outpatient referrals: when appropriate, linked to outpatient service descriptions in the reference costs (and reviewed by principal investigator) and weighted by average for consultant-/non-consultant-led attendances taken; referrals to private sector excluded ( $n = 1$ ).
- b Community referral services: costed as referenced; if service use was unclear, a NHS hospital outpatient department was assigned by the principal investigator.
- c Primary care: GP visits – 11.7 minutes; nurse visits – 15.5 minutes.
- d A&E visit: as the reason for A&E visits was not recorded, an average A&E visit cost for 2013–14 was assigned.
- e Hospital admissions: the principal investigator (blind to the study group) reviewed all hospital admissions, and provided either a 'best guess diagnosis/procedure' or listed 'unknown' ( $n = 2$ ). As details on the type of procedure or severity of the symptoms were not available, a weighted (by activity) average of all of the possible scores/procedures was used to derive the average cost for elective.
- f Emergency admissions: the unit cost is a weighted average of the non-elective short-stay and non-elective long-stay admissions, as the length of stay was unclear.
- g Hospital admissions without a procedure: treated as non-elective short-stay admissions ( $\leq 1$  day). When the hospital admission code was unclear, the diagnosis was reviewed by the principal investigator for advice on the nearest appropriate code.

#### Notes

Unit costs are rounded to the nearest whole number and presented in the 2013–14 price year. The health service use presented in this table refers to the base-case sample. All of the data are based on participant-specific GP records for the trial period with different assumptions and approaches for costing by type of service use.



**FIGURE 19** Cost-effectiveness plane for nurse support vs. postal delivery at 12 months.



**FIGURE 20** Cost-effectiveness acceptability curve showing the probability of within-trial cost-effectiveness for nurse support vs. postal delivery at different willingness-to-pay threshold levels.

TABLE 36 Within-trial sensitivity analyses (at 12 months)

Parameter	Comparison by trial arm, mean (95% CI)								
	Postal delivery vs. control			Nurse support vs. control			Nurse support vs. postal delivery		
	Incremental cost (£)	Incremental QALY	ICER	Incremental cost (£)	Incremental QALY	ICER	Incremental cost (£)	Incremental QALY	ICER
Base case	-91 (-215 to 33)	-0.0043 (-0.0172 to 0.0087)	Less costly, but less effective than control	126 (-37 to 290)	-0.0066 (-0.0201 to 0.0068)	Intervention dominated by control	217 (8 to 354)	-0.0024 (-0.0156 to 0.0109)	Nurse support dominated by postal delivery
Whole sample (all randomised)	-40 (-169 to -89)	-0.0070 (-0.0195 to 0.0054)	Less costly, but less effective than control	150 (-6 to 306)	-0.0093 (-0.0222 to 0.0036)	Intervention dominated by control	190 (48 to 332)	-0.0023 (-0.0148 to 0.0102)	Nurse support dominated by postal delivery
Health service use, including only GP data on referrals and admissions	-55 (-166 to -56)	-0.0043 (-0.0172 to 0.0087)	Less costly, but less effective than control	129 (-17 to 275)	-0.0066 (-0.020 to 0.0068)	Intervention dominated by control	184 (61 to 307)	-0.0024 (-0.0156 to 0.0109)	Nurse support dominated by postal delivery
Health service use, including only self-reported serious adverse effects	21 (-65 to 107)	-0.0043 (-0.0172 to 0.0087)	Intervention dominated by control	144 (65 to 224)	-0.0066 (-0.020 to 0.0068)	Intervention dominated by control	123 (47 to 200)	-0.0024 (-0.0156 to 0.0109)	Nurse support dominated by postal delivery
Health service use, including only GP data on adverse effects	-11 (-107 to 85)	-0.0043 (-0.0172 to 0.0087)	Less costly, but less effective than control	64 (-15 to 142)	-0.0066 (-0.020 to 0.0068)	Intervention dominated by control	74 (13 to 135)	-0.0024 (-0.0156 to 0.0109)	Nurse support dominated by postal delivery
Excluding all health service use costs	55.2 (55 to 55.4)	-0.0043 (-0.0172 to 0.0087)	Intervention dominated by control	156.2 (-154 to 158)	-0.0066 (-0.0201 to 0.0068)	Intervention dominated by control	101 (99 to 103)	-0.0024 (-0.0156 to 0.0109)	Nurse support dominated by postal delivery
Changing cost perspective (both participant – all participant costs – and NHS costs)	36 (-177 to 250)	-0.0043 (-0.0172 to 0.0087)	Intervention dominated by control	107 (-97 to 311)	-0.0066 (-0.020 to 0.0068)	Intervention dominated by control	71 (-150 to 291)	-0.0024 (-0.0156 to 0.0109)	Nurse support dominated by postal delivery

Parameter	Comparison by trial arm, mean (95% CI)								
	Postal delivery vs. control			Nurse support vs. control			Nurse support vs. postal delivery		
	Incremental cost (£)	Incremental QALY	ICER	Incremental cost (£)	Incremental QALY	ICER	Incremental cost (£)	Incremental QALY	ICER
Changing cost perspective [both participant (part; this excludes time costs of working out how to use pedometer, diary and planning to increase work) and NHS costs]	-22 (-235 to 191)	-0.0043 (-0.0172 to 0.0087)	Less costly, but less effective than control	47 (-157 to 250)	-0.0066 (-0.020 to 0.0068)	Intervention dominated by control	69 (-152 to 289)	-0.0024 (-0.0156 to 0.0109)	Nurse support dominated by postal delivery
Combination of excluding all health service use cost and including all participant costs (minus health service use cost borne by participants)	179 (-1 to 361)	-0.0043 (-0.0172 to 0.0087)	Intervention dominated by control	153 (24 to 281)	-0.0066 (-0.020 to 0.0068)	Intervention dominated by control	-27 (-203 to 149)	-0.0024 (-0.0156 to 0.0109)	Less costly but less effective than control
Pedometer lasts for 1 year (equivalent to pedometers not being reusable and the full cost of pedometer borne in year 1)	-86 (-210 to 38)	-0.0043 (-0.0172 to 0.0087)	Less costly, but less effective than control	130 (-33 to 294)	-0.0066 (-0.0201 to 0.0068)	Intervention dominated by control	216 (80 to 353)	-0.0024 (-0.0156 to 0.0109)	Nurse support dominated by postal delivery
Pedometer lasts for 4 years (double length of life considered in the base case)	-93 (-218 to 31)	-0.0043 (-0.0172 to 0.0087)	Less costly, but less effective than control	124 (-39 to 287)	-0.0066 (-0.0201 to 0.0068)	Intervention dominated by control	218 (81 to 354)	-0.0024 (-0.0156 to 0.0109)	Nurse support dominated by postal delivery

## Summary of methods of the economic model by Anokye, Lord and Fox-Rushby<sup>130</sup>

Anokye *et al.*<sup>130</sup> developed a Markov model to follow a cohort of physically inactive but healthy adults over their remaining lifetime. To see the impact of an intervention on costs and effects, the model is run twice – once with the intervention and once without the intervention, as a control. The model adopted a NHS perspective, based costs in 2010–11 prices (£) and used a 3.5% discount rate.

For the intervention, a cohort of 100,000 people aged 33 years (the average age of people in trials of brief interventions designed to increase PA) are ‘run in’ for 1 year, with the proportion of people becoming active in each arm reflecting evidence on effectiveness [i.e. achieving a minimum of 150 minutes of at least moderately intensive PA or at least 75 minutes of vigorously intensive PA per week (current guidance of sufficient PA)].

The model represented the most robustly evidenced risk reductions achievable from PA (i.e. in CHD, stroke and type 2 diabetes mellitus). Those people who are physically active at the end of the ‘run in’ period went on to have a longer life expectancy and better quality of life as a result of risk reductions. The model assumed that no one developed disease during the run-in period, although deaths from other causes could occur.

From the beginning of year 1 (cycle 2), each person in each cycle could be in one of six states: (1) event free (no CHD, stroke or type 2 diabetes mellitus), (2) non-fatal CHD, (3) non-fatal stroke, (4) type 2 diabetes mellitus, (5) death related to CVD and (6) death from non-CVD causes, each of which had defined annual risks of moving to another state. Data on the RRs (Relative Risks) of developing each disease condition were estimated from epidemiological studies measuring baseline PA (exposure) and related to subsequent onset of CHD, stroke or type 2 diabetes mellitus (outcomes) over a 10-year period.

Although PA can change over time, this was not explicitly modelled, as the impact of changing habits is captured in the cohort RR estimates. Three Finnish studies<sup>211–213</sup> followed up people who were either inactive or active for a number of years, and found that the relationship between activity and outcomes somewhat diluted as people moved in and out of PA over time.

The model assumed that a proportion of CHD and stroke events were immediately fatal, whereas this was not the case for a diagnosis of type 2 diabetes mellitus, although all of those surviving either a CVD-related event or diagnosis with type 2 diabetes mellitus faced increased CVD-related and non-CVD-related mortality risks. For simplicity, the model assumed that individuals experienced only one type of disease (although they could face multiple events within this disease).

Estimates of lifetime costs and QALYs were derived from the model through weighting time spent in each health state for different parts of the cohort by annual costs and utility values associated with each state. To these, we added the costs of intervention delivery and a short-term (1-year) gain in QALYs, through mental health improvement, arising from participation in PA (see Pavey *et al.*<sup>132</sup> for estimation).

Data to populate the model were derived from a variety of sources:

1. effectiveness and cost of brief advice (to increase PA) delivered in primary care – from systematic literature review and meta-analysis
2. cost and utility estimates of disease conditions – economic evaluations conducted for existing guidelines for CVD and diabetes mellitus, and science-based guidelines on PA and health; rates of disease were converted to probabilities<sup>214</sup>
3. relative risks of each disease for physically active people and inactive people were based on cohorts that were followed up for 19 (CHD, stroke) and 12 (diabetes mellitus) years;<sup>211,212,215</sup> RRs were assumed to hold for 10 years, in the base case, after which no benefit was derived

4. probabilities for developing disease conditions in inactive people were derived by adjusting the UK general population age-specific incidence rates<sup>216-218</sup> using the attributable risk fraction;<sup>219</sup> probabilities for active people used the RR data<sup>211,212,215</sup>
5. the probability that a primary stroke or CHD event was fatal<sup>216</sup> was assumed to be independent of PA, as a result of a lack of data
6. probability of CVD and non-CVD mortality – RRs of stroke and CHD<sup>220</sup> and type 2 diabetes mellitus<sup>216</sup> mortality among people with stroke, CHD or type 2 diabetes mellitus were used to adjust age-specific probabilities for 'healthy people', as represented in UK interim life tables.

Deterministic sensitivity analyses explored the effectiveness of the intervention, the health impacts of PA, the starting age of the cohort, the discount rate and costs. Uncertainties around all parameters in the model (except for baseline mortality) were addressed simultaneously using PSA (with 10,000 Monte Carlo simulations).

The main results concluded that additional QALYs through brief advice could be bought at an average cost of £1730 for a cohort of 100,000 people from the age of 33 years over their remaining lifetime. Conclusions that this was a 'good buy' only changed when the assumption of short-term QALYs gained was dropped, when the cost-effectiveness ratio fell to £27,000 per QALY. Further details can be seen in Anokye *et al.*<sup>130</sup>

**TABLE 37** Parameter values for the long-term cost-effectiveness model

Parameter	Value (95% CI)	Source of data
<b>RRs of</b>		
Becoming active (at year 1)		This study (PACE-UP)
Postal delivery vs. control	1.8 (1.4 to 2.3)	
Nurse support vs. control	1.7 (1.3 to 2.2)	
Nurse support vs. postal delivery	0.9 (0.7 to 1.3)	
Disease (active vs. inactive)		
CHD	0.90	Hu <i>et al.</i> (2003) <sup>211</sup>
Stroke	0.86	Hu <i>et al.</i> (2005) <sup>212</sup>
Diabetes mellitus	0.67	Hu <i>et al.</i> (2007) <sup>213</sup>
Non-CVD-related mortality after:		
Non-fatal CHD	1.71	Brønnum-Hansen <i>et al.</i> (2001) <sup>220</sup>
Non-fatal stroke	1.71	
Diabetes mellitus	1.49	Pries <i>et al.</i> (2009) <sup>221</sup>
CVD-related mortality after:		
Non-fatal CHD	3.89	Brønnum-Hansen <i>et al.</i> (2001)
Non-fatal stroke	3.89	
Diabetes mellitus	2.61	Pries <i>et al.</i> (2009) <sup>221</sup>


continued

TABLE 37 Parameter values for the long-term cost-effectiveness model (continued)

Parameter	Value (95% CI)	Source of data
<b>Fatality cases (%)</b>		
CHD		
59–64	11.55	Ward <i>et al.</i> (2005) <sup>222</sup>
65–74	21.07	
≥ 75	14.76	
Stroke		
55–64	23.28	Ward <i>et al.</i> (2005) <sup>222</sup>
65–74	23.47	
≥ 75	23.42	
<b>Incidence rates for (%)</b>		
CHD		
59–64	0.63	Ward <i>et al.</i> (2005); National Clinical Guideline Centre (2011) <sup>223</sup>
65–74	0.97	
≥ 75	0.97	
Stroke		
59–64	0.29	
65–74	0.69	
≥ 75	1.43	
Diabetes mellitus		
59	0.06	Gonzalez <i>et al.</i> (2009) <sup>224</sup>
60–69	0.10	
70–79	0.11	
≥ 80	0.11	
Quality of life		
Age-specific quality of life		
59–64	0.82	Health Survey for England (2011) <sup>225</sup>
65–74	0.78	
≥ 75	0.72	
Health state utility weight		
Healthy	1.00	Ward <i>et al.</i> (2005); National Clinical Guideline Centre (2011) <sup>222,223</sup>
CHD (first event)	0.80	
Post CHD (first event)	0.92	
Stroke (first event)	0.63	
Post stroke (first event)	0.65	
Diabetes mellitus	0.90	
Short-term psychological benefit of achieving 150 minutes of MVPA per week	0.01	This study (PACE-UP)

**TABLE 37** Parameter values for the long-term cost-effectiveness model (*continued*)

Parameter	Value (95% CI)	Source of data
Annual cost (£)		
Control	467 (365 to 569)	This study (PACE-UP)
Post	376 (307 to 445)	
Nurse	593 (473 to 714)	
CHD (first event)	4248	National Clinical Guideline Centre (2011) <sup>223</sup>
Post CHD (first event)	485	
Stroke (first event)	10,968	
Post stroke (first event)	2409	
Diabetes mellitus	979	

**FIGURE 21** Cost-effectiveness acceptability curve showing the probability of lifetime cost-effectiveness for the nurse support group compared with the postal delivery group at different willingness-to-pay threshold levels.



## Appendix 4 Generalisability

Adapted from Normansell *et al.*<sup>148</sup> This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (<http://creativecommons.org/licenses/by/4.0/>), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (<http://creativecommons.org/publicdomain/zero/1.0/>) applies to the data made available in this article, unless otherwise stated.

### Telephone interview schedule for non-participants

Introduction:

Clarify purpose of interview, gain verbal consent and confirm anonymity and confidentiality.

Opening questions:

1. What did you think of the information that we originally sent you about the PACE-UP study?
2. Can you tell me a bit more about what influenced your decision not to take part in the study?
3. Did you discuss participating in research with anyone else?

Reasons for not participating:

Using the completed questionnaire, explore the reasons already given, including:

1. I do not have time
2. I cannot/am not interested in increasing my physical activity
3. I am already very physically active
4. I am not interested in research
5. I do not want to be put in a group by chance.

Additional possible reasons for not-participating:

Offer a number of other predefined reasons for non-participation and explore further any positive responses:

1. Lack of time.
2. Unable or not interested in increasing PA.
3. Already active.
4. Not interested in research.
5. Do not want to be put in a group by chance.
6. Length of programme.
7. Travel difficulties.
8. Wearing a physical activity monitor.
9. Unpleasant/unsafe walking environment.
10. Programme is not relevant to you.
11. Programme is not for your age group.
12. Programme would clash with work/being away from home.
13. Medical problems prevent participation.

Trial design questions:

1. Venue.
2. Exercise type.
3. Group activity.
4. Anything else that would have facilitated participation?

End:

Summary and invite any final comments.

## Non-participant health and physical activity survey



### *Health and physical activity survey*

---

**Study IDNO** \_\_\_\_\_

Although you have decided not to take part in our research project, it would be very helpful if you could answer the questions below. We will then be able to see what sort of people did NOT take part and why not. This could help us to improve our research in future to make it suitable to a wider range of people. You do not have to answer any questions if you prefer not to.

**Thank you for filling in this questionnaire.  
It will take you about 5 to 10 minutes.**

Please feel free to write comments by any question.

All information will be kept confidential.

**Please enter your date of birth**    \_\_\_\_ / \_\_\_\_ / \_\_\_\_

**Please enter today's date**        \_\_\_\_ / \_\_\_\_ / \_\_\_\_

**Thank you**

## Section A - Some general questions about your health

Please put a tick in the box next to the most appropriate answer for each question.



How is your health in general?

- Very good
- Good
- Fair
- Poor
- Very poor

Are your day-to-day activities limited because of a health problem or disability which has lasted, or is expected to last, at least 12 months?

Include problems related to old age.

- Yes, limited a lot
- Yes, limited a little
- No

3 Approximately how tall are you?.....

4 Approximately how much do you weigh?.....

5 Do you currently smoke?

- Yes  No

6 During the last 3 months did you talk to a doctor or nurse at your general practice on your own behalf, either in person or by telephone?

- Yes  No  (If no, please go to section B)

6a If yes, approximately how many times did this happen in the last 3 months?

- Once  Twice  Three times  Four or more times

## Section B - specific questions about your health

Have you ever been told by a doctor or nurse that you have any of these conditions?  
(Please tick all that apply to you)

YES

- |                                       |                          |
|---------------------------------------|--------------------------|
| Angina .....                          | <input type="checkbox"/> |
| A heart attack .....                  | <input type="checkbox"/> |
| Other heart problems.....             | <input type="checkbox"/> |
| Stroke.....                           | <input type="checkbox"/> |
| High blood pressure.....              | <input type="checkbox"/> |
| Chronic bronchitis.....               | <input type="checkbox"/> |
| Asthma .....                          | <input type="checkbox"/> |
| Diabetes.....                         | <input type="checkbox"/> |
| Arthritis .....                       | <input type="checkbox"/> |
| Cancer (apart from skin cancer) ..... | <input type="checkbox"/> |
| Depression.....                       | <input type="checkbox"/> |
| Parkinson's Disease.....              | <input type="checkbox"/> |

**13 Can you see well enough to recognise a friend across a road?**

Yes, without glasses       Yes, with glasses       No

**14 Do you have any problems with your balance?**

Yes       No

**15 How many times have you fallen over in the last year ?**

None   
Once or twice   
Three times or more   
Not sure

**16 How many different medications do you take every day?**

None     One     Two     Three     Four or more

## Section C - Questions about your health today

Under each heading, please tick the **ONE** box that best describes your health **TODAY**

### 1 Mobility

- I have no problems in walking about
- I have slight problems in walking about
- I have moderate problems in walking about
- I have severe problems in walking about
- I am unable to walk about

### 2 Self-care

- I have no problems with self-care
- I have slight problems washing or dressing myself
- I have moderate problems washing or dressing myself
- I have severe problems washing or dressing myself
- I am unable to wash or dress myself

### 3 Usual activities (e.g. work, study, housework, family or leisure)

- I have no problems doing my usual activities
- I have slight problems doing my usual activities
- I have moderate problems doing my usual activities
- I have severe problems doing my usual activities
- I am unable to do my usual activities

### 4 Pain / discomfort

- I have no pain or discomfort
- I have slight pain or discomfort
- I have moderate pain or discomfort
- I have severe pain or discomfort
- I have extreme pain or discomfort

### 5 Anxiety / depression

- I am not anxious or depressed
- I am slightly anxious or depressed
- I am moderately anxious or depressed
- I am severely anxious or depressed
- I am extremely anxious or depressed

## Section D - Some questions about physical activity

**1 Please tell us about the type of physical activity involved in your work** (Please tick one box only)

- a) I am not in employment (e.g. retired, retired for health reasons, unemployed, full-time carer etc)
- b) I spend most of my time at work sitting (e.g. in an office)
- c) I spend most of my time at work standing or walking. However, my work does not require much physical effort (e.g. shop assistant, hair-dresser, security guard).
- d) My work involves definite physical effort including handling of heavy objects & tools (e.g. plumber, electrician, carpenter, cleaner, hospital nurse, gardener, postal delivery workers etc).
- e) My work involves vigorous physical activity including handling of very heavy objects e.g. scaffolder, construction worker, refuse collector etc.)

**2 During the last week, how many hours did you spend on each of the following activities?**  
Please answer whether you are in employment or not

		None	Some but less than 1 hour	More than 1 but less than 3 hours	3 hours or more
a	Physical exercise such as swimming, jogging, aerobics, football, tennis, gym workout etc				
b	Cycling, including cycling to work and during leisure time				
c	Walking including walking to work, shopping, for pleasure etc				
d	Housework / Childcare				
e	Gardening / DIY				

**3 How would you describe your usual walking pace?** Please tick one only.

Slow pace (i.e less than 3 mph)	Steady average pace	Brisk pace	Fast pace (i.e. over 4 mph)

**4 Do you have someone with whom you can go for a walk, or do other physical activities?**

Always	Often	Sometimes	Never

## Section E – Some questions about why you do not want to take part in this physical activity trial

I do not want to take part in this physical activity trial because:

(Please tick one box on each line)

	Yes	No	Not sure
1 I do not have time	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
2 I cannot increase my physical activity	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
3 I am not interested in increasing my physical activity	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
4 I am already very physically active	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
5 I am not interested in research	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
6 I do not want to be put in a group by chance	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>

The following reasons are important to me for not wanting to take part in the trial:

.....

.....

Could we contact you sometime in the next 3 months to arrange an interview to ask you in more detail about your reasons for not wanting to take part in the trial?

Yes, you can contact me  No, you cannot contact me

If yes please provide contact details below:

Home Tel..... Mobile..... Email.....

## Section F- Some questions about your attitudes to exercise and health

Please tick one box to indicate how strongly you agree or disagree with each statement

	<i>Strongly agree</i>	<i>Slightly agree</i>	<i>Unsure</i>	<i>Slightly disagree</i>	<i>Strongly disagree</i>
1. Exercising regularly can be helpful for my health	<input type="checkbox"/>				
2. Doing exercise is satisfying and rewarding to me	<input type="checkbox"/>				
3. There is little I can do to make up for the physical losses that come with age	<input type="checkbox"/>				
4. Exercising regularly can help me to control my weight or to lose weight	<input type="checkbox"/>				

## Section G – Finally, some questions about you & your living circumstances

### 1 What is your current marital status?

Married (or living with someone as a couple)

Widowed

Divorced or separated

Single

Other

If other, please describe.....

### 2 How many people in your household, including yourself, are there

Aged under 18 ..... Aged 18-64.....

Aged 65 or over.....

### 3 At what age did you finish your continuous full-time education at school, college or university?

14 or under  15

16  17

18  19 or over

### 4 What is your employment status?

In full time employment

In part time employment

Seeking work

Looking after home or family

Retired

Student

Not working due to long-term sickness or disability

Other (please describe) .....

### 5 Do you, or the people you live with, own or rent your own home?

Own (with or without a mortgage)

Rent from council or housing association

Rent privately

Other, please describe.....

**10 What is your ethnic group?**

Choose **one** section from **A to E**, then tick  **one** box to best describe your ethnic group or background.

**A White groups**

- English / Welsh / Scottish/ Northern Irish / British  
 Irish  
 Gypsy or Irish Traveller  
 Any other White background, write in .....  
 .....

**C Asian / Asian British Caribbean /**

- Indian  
 Pakistani  
 Bangladeshi  
 Chinese Caribbean  
 Any other Asian background, write in .....  
 .....  
 .....

**E Other ethnic group**

- Arab  
 Any other ethnic group, write in .....  
 .....

**B Mixed /multiple ethnic**

- White and Black Caribbean  
 White and Black African  
 White and Asian  
 Any other Mixed /multiple ethnic background, write in .....  
 .....

**D Black / African / Black British**

- African  
 Caribbean  
 Any other Black / African / background, write in

**Please write below any other comments you have on your health or this questionnaire**

**Thank you for filling in this questionnaire, please return it in the freepost envelope**

## Appendix 5 Process evaluation

**TABLE 38** Implementation process: training delivered to nurses

Training event	Time spent in minutes				Total, time spent in minutes
	PA guidance	Trial protocols	Safety reporting	BCT	
Pre-trial visit	20	30	0	0	50
Pre-trial reading	20	10	10	20	60
Nurse reflection	15	0	0	15	30
Training day – 13 September 2012	10	40	30	250	330
Training half-day – 18 January 2013	0	60	10	95	165
Training half-day – 21 May 2013	10	40	10	60	120
Training half-day – 24 September 2013	10	60	10	95	175
BCT trainer individual feedback	0	0	0	30	30
<b>Total time (minutes)</b>	<b>85</b>	<b>240</b>	<b>70</b>	<b>565</b>	<b>960</b>
<b>Total time (hours and minutes)</b>	<b>1 hour 25 minutes</b>	<b>4 hours 0 minutes</b>	<b>1 hour 10 minutes</b>	<b>9 hours 25 minutes</b>	<b>16 hours</b>

**TABLE 39** Fidelity: content delivered in nurse intervention group sessions in accordance with nurse checklists

Fidelity item	Session		
	1	2	3
Attended session, <i>n/N</i> (%)	330/346 (95)	296/346 (86)	263/346 (76)
Mean number of items completed (range)	11 (10–11)	6 (5–6)	6 (5–6)
Participant reported that they had used pedometer and diary 'every day' or 'sometimes', <i>n/N</i> (%)		285/296 (96)	258/263 (98)

**TABLE 40** Nurse-support and postal intervention group PA diary return and use

Diary return and use	Trial arm, <i>n</i> (%)	
	Postal delivery group ( <i>N</i> = 339)	Nurse-support group ( <i>N</i> = 346)
Number of diaries returned	268 (79)	281 (81)
Targets altered	4 (1)	89 (32)
Target increased	0 (0)	9 (3)
Target decreased	4 (1)	80 (29)

**TABLE 41** Pedometer use from questionnaire data

Used pedometer during the 12-week intervention	Trial arm, <i>n</i> (%)	
	Postal delivery group ( <i>N</i> = 294)	Nurse-support group ( <i>N</i> = 303)
Every day or most days	238 (81)	269 (89)
A few days or occasionally	44 (15)	30 (10)
Never	12 (4)	4 (1)

**TABLE 42** Duration of sessions

Session	Nurse self-report			Audio-recording				
	Number of Participants	Mean time in minutes (SD)	Range (minutes)	Median time in minutes (IQR)	Number of Participants	Mean time in minutes (SD)	Range (minutes)	Median time in minutes (IQR)
1	320	30 (4)	10–55	25 (20–30)	10	21 (6)	12–29	22 (15–26)
2	211	24 (3)	7.5–45	20 (15–25)	7	21 (7)	10–29	23 (17–24)
3	256	22 (4)	5–60	20 (15–25)	5	14 (5)	9–21	12 (10–16)

IQR, interquartile range.

**Notes**

Fifty-eight participants attended as 29 couples and their consultation times have been halved for comparison with individual consultation times.

Six participants attended as three couples (all in session 1) and their consultation times have been halved for comparison with individual consultation times. Their consultation durations were 27 minutes, 44 minutes and 57 minutes (mean 43 minutes).

## Nurse and patient alliance questionnaires



### Consultation Experience – Patient Form Patient no.....

**Instructions:** Here are some statements about your Physical Activity Consultations with the nurse.  
For each statement, please circle the number that matches your own experience.

	Strongly disagree	Disagree	Neither agree nor disagree	Agree	Strongly agree
1. My physical activity nurse and I worked together on setting goals that were important to me	1	2	3	4	5
2. The difficulties that prevented me from increasing my physical activity were too great to overcome	1	2	3	4	5
3. I felt heard, understood and respected by my physical activity nurse	1	2	3	4	5
4. In our meetings together, we discussed everything I wanted to discuss	1	2	3	4	5
5. I understand how to make lasting changes in my activity levels	1	2	3	4	5
6. The approach taken by my physical activity nurse suited me	1	2	3	4	5
7. I feel able to keep up the physical activity changes I have already made	1	2	3	4	5
8. I feel confident now that I can continue to make positive changes in physical activity without the nurse	1	2	3	4	5
9. I feel confident about overcoming obstacles to increasing my activity levels in future	1	2	3	4	5
10. The pedometer I used in the PACE-UP study was helpful to me	1	2	3	4	5
11. The diary I used in the PACE-UP study was helpful to me	1	2	3	4	5
	Far too many	Too many	Just right	Too few	Far too few
12. The number of appointments with the physical activity nurse was	1	2	3	4	5

Any other comments?



**Instructions:** For each of the following statements, please circle the number that matches your own experience of meetings with the patient

	Strongly disagree	Disagree	Neither agree nor disagree	Agree	Strongly agree
1. The patient and I worked together on setting goals that were important to the patient	1	2	3	4	5
2. The difficulties that prevented the patient from increasing their physical activity were too great to overcome	1	2	3	4	5
3. The patient felt heard, understood and respected	1	2	3	4	5
4. In our meetings together, the patient discussed everything they wanted to discuss	1	2	3	4	5
5. The patient understands how to make lasting changes in activity levels	1	2	3	4	5
6. The approach to making change suited the patient	1	2	3	4	5
7. The patient feels able to keep up the physical activity changes they have already made	1	2	3	4	5
8. The patient feels confident to continue to make positive changes in physical activity on their own	1	2	3	4	5
9. The patient feels confident about overcoming obstacles to increasing activity levels in future	1	2	3	4	5
10. The pedometer used in the PACE-UP study was helpful to the patient	1	2	3	4	5
11. The diary used in the PACE-UP trial was helpful to the patient	1	2	3	4	5
	Far too many	Too many	Just right	Too few	Far too few
12. The number of appointments with the physical activity nurse was	1	2	3	4	5

Any other comments?



## Consultation Experience – Nurse Questionnaire Extra Questions

### for Couples

Patient no..... and Patient no.....

How many sessions did they attend together? ..... sessions

**Instructions:** For each of the following statements, please circle the number that matches your own experience of meetings with the couple

	Strongly disagree	Disagree	Neither agree nor disagree	Agree	Strongly agree
Seeing them together was helpful for them both	1	2	3	4	5
Seeing them together made the consultation more difficult for me	1	2	3	4	5
Seeing them together helped with their motivation	1	2	3	4	5
Seeing them together made it more difficult for them to set individual targets if they needed to	1	2	3	4	5
Seeing them together was an efficient use of time	1	2	3	4	5

Any other comments about seeing them together as a couple?

## Nurse session checklists

# PACE-UP – Checklist for nurses

Session One: First Steps		
Date..... Nurse initials ..... Patient IDNO.....		
Seen as individual or couple .....		
Content of session (20-30 minutes)	Page(s) in patient handbook or diary	Completed?
1. Health benefits and personal benefits of increasing walking.	Handbook P 3	
2. <i>Optional patient handout on advantages and disadvantages.</i>	<i>Handout</i>	
3. How much physical activity should adults and older adults do?	Handbook P 4	
4. What is moderate intensity physical activity, how does it relate to step-count?	Handbook P 4	
5. Aims of the PACE-UP programme, setting goals relating to patient's baseline steps, reviewing their baseline step-count.	Handbook P 5	
6. Tailoring the programme, are the PACE-UP goals appropriate? Would they like to go slower or faster?	Handbook P 5	
7. How to safely increase walking.	Handbook P 6	
8. Teach use of pedometer.	Diary P 2	
9. Recording walks and daily steps in the PACE-UP diary.	Diary P 3	
10. Ideas to increase walking & daily step-count.	Diary P 4 & 6	
11. <i>Optional discussion &amp; patient handout on rewards for making change.</i>	<i>Handout</i>	
12. Final check: Summarise what has been agreed and check patient understanding.		
13. Plan date / time for next meeting 4 weeks and contact details. Remind patient to bring pedometer and diary.		

Date /time of next meeting.....

Approximately how long did the session take? ..... minutes

Any other comments / reminders for next meeting.

## PACE-UP – Checklist for nurses

Session Two: Continuing the Changes		
Date..... Nurse initials ..... Patient IDNO.....		
Seen as individual or couple .....		
Content of session (20 Minutes)	Page(s) in patient handbook or diary	Completed?
1. Review step-count and walking goals in patient diary.	Diary P 3,5,7,9	
2. Encourage progress in increasing walking and achieving step-count goals		
3. Troubleshoot any problems with pedometer or diary.		
4. Review target and agree goals for next month	Handbook P5 (or diary 11,13,15,17)	
5. <i>Optional patient handout on barriers and facilitators to increasing physical activity</i>	<i>Handout</i>	
6. <i>Optional patient handout on pacing and avoiding boom and bust</i>	<i>Handout</i>	
7. <i>Optional patient handout on building confidence to change</i>	<i>Handout</i>	
8. Final check: Summarise what has been agreed and check patient understanding		
9. Arrange date / time for next meeting. Remind patient to bring pedometer and diary.		

Date /time of next meeting.....

Approximately how long did the session take? ..... minutes

Did the patient use the pedometer and diary?

Everyday  Sometimes  Not at all

Comment .....

Did the patient achieve their step-count goal?

Yes  No

Comment .....

Any other comments / reminders for next meeting.

## PACE-UP – Checklist for nurses

Session Three: Building lasting habits		
Date..... Nurse initials ..... Patient IDNO.....		
Seen as individual or couple .....		
Content of session (20 Minutes)	Page(s) in patient handbook or diary	Completed?
1. Review step-count and walking goals in patient diary	Diary 11,13,15,17	
2. Review overall progress over the sessions	Diary 3-17	
3. Encourage progress in increasing walking and achieving step-count goals		
4. Troubleshoot any problems with pedometer or diary		
5. <i>Optional patient handout on barriers and facilitators to increasing physical activity</i>	<i>Handout</i>	
6. <i>Optional patient handout on pacing and avoiding boom and bust</i>	<i>Handout</i>	
7. <i>Optional patient handout on preparing for setbacks</i>	<i>Handout</i>	
8. <i>Optional handout on building lasting habits</i>	<i>Handout</i>	
9. Setting goals: maintaining current activity or increasing further?	Handbook P5 or Diary P19	
10. Remind the patient about PACE-UP trial follow-up (research assistant to contact in 3-4 weeks)		

Approximately how long did the session take? ..... minutes

Since the last session, did the patient use the pedometer and diary?

Everyday  Sometimes  Not at all

Comment .....

Did the patient achieve their step-count goal?

Yes  No

Comment .....

Any other comments



IDNO.....

Date of birth .....

### Pedometer use in last 12 months – usual physical activity group

You have been in the usual physical activity group in the PACE-UP trial. We have not yet given you a pedometer for you to use to monitor your step-count. We know that some people may already have a pedometer. We are interested to find out how many people in PACE-UP this applies to.

1. Had you used a pedometer (step-counter) before the trial started?

Yes  No

2. Have you obtained a pedometer in the last 12 months?

Yes  No

3. Did you use a pedometer during the last 12 months?

Yes  (please go to Question 4) No  (please turn over)

4. If yes, how often did you use a pedometer during the last 12 months?

Every day or most days of the week

At least once a week

At least once a month

Less than once per month

If you have worn a pedometer, can you give us some details about when and why you wear it?.....

.....

..... P.T.O.

If there are any other comments that you would like to make about wearing or using a pedometer, please write them here.

.....  
.....  
.....  
.....  
.....

Thank you for taking part in the PACE-UP trial. When we receive your accelerometer back, we will be sending you a pedometer to keep, along with feedback on your physical activity levels from the accelerometer that you have worn.



IDNO.....

Date of birth .....

### **Pedometer use in last 12 months – pedometer by post group**

You were posted out a pedometer and a 12-week diary to use about 12 months ago by the researcher. We are interested in how often you have used the pedometer over the past year and whether you have found it helpful.

#### **1. Had you used a pedometer before the trial started?**

Yes  No

#### **2. For the 12 week period of the diary:**

How often did you wear the pedometer?

Every day or most days for the 12 weeks

At least a few days each week for the 12 weeks

Occasionally

Never

#### **3. For the last 9 months, since the diary finished:**

How often did you wear the pedometer?

Every day or most days of the week

At least once a week

At least once a month

Less than once per month

Never

If you have worn the pedometer since you stopped using the diary, can you give us some details about when and why you wear it?

.....

..... P.T.O

**4. Please indicate how strongly you agree or disagree with each statement by ticking one of the boxes**

	<b>Strongly Agree</b>	<b>Slightly Agree</b>	<b>Unsure</b>	<b>Slightly Disagree</b>	<b>Strongly Disagree</b>
The pedometer is helpful for monitoring physical activity	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
The pedometer is easy to use	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Using the pedometer can help you to increase your walking	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
The pedometer is difficult to wear with some clothes	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
I would recommend a pedometer to others who are trying to walk more	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>

If there are any other positive or negative comments that you would like to make about wearing or using the pedometer, please write them here.

.....

.....

.....

.....



IDNO.....

Date of birth .....

### **Pedometer use in last 12 months – physical activity nurse group**

You were given a pedometer and a 12-week diary to use about 12 months ago by your physical activity nurse. We are interested in how often you have used the pedometer over the past year and whether or not you have found it helpful.

#### **5. Had you used a pedometer before the trial started?**

Yes  No

#### **6. For the 12 week period of the diary and while you were in contact with the nurse:**

How often did you wear the pedometer?

Every day or most days for the 12 weeks

At least a few days each week for the 12 weeks

Occasionally

Never

#### **7. For the last 9 months, since you have stopped seeing the physical activity nurse:**

How often did you wear the pedometer?

Every day or most days of the week

At least once per week

At least once a month

Less than once per month

Never

If you have worn the pedometer since you stopped seeing the nurse, can you give us some details about when and why you wear it?

.....

..... P.T.O

**8. Please indicate how strongly you agree or disagree with each statement by ticking one of the boxes**

	<b>Strongly Agree</b>	<b>Slightly Agree</b>	<b>Unsure</b>	<b>Slightly Disagree</b>	<b>Strongly Disagree</b>
The pedometer is helpful for monitoring physical activity	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
The pedometer is easy to use	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Using the pedometer can help you to increase your walking	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
The pedometer is difficult to wear with some clothes	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
I would recommend a pedometer to others who are trying to walk more	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>

If there are any other positive or negative comments that you would like to make about wearing or using the pedometer, please write them here.

.....

.....

.....

.....

# Appendix 6 Qualitative evaluation

## Initial thoughts for nurse focus group: interview schedule

### Introductions

*Introduce ourselves.* Explain one will lead while the other takes notes, just in case the recording fails, etc.

*The main point of this session* is to find out what it was like to be involved in this study and to help patients to increase their physical activity using this particular method and this schedule of visits. It's important that you tell us what it was like, warts and all – so that we can let the team know what went well and what could have been better both for you and for your study patients. It's also important that we have all of your views – so if you disagree with what someone has said, then make sure we hear your perspective too. Hopefully, it will be a discussion between all of you, with us just throwing in a few questions to keep things going. OK?

*Anonymity and confidentiality.* Now say we won't use their names if we extract something they said for a paper – also, nobody but us will know who said what, and it won't be passed on to other members of the team.

*Tell them we're turning on the recorders.*

*Ask the nurses to introduce themselves for the recording.*

*PTO (please turn over) for the schedule itself.*

### The schedule

First of all, the training:

1. What stood out most for you from the actual training sessions?
  - i. What specific parts of the training do you recall as being particularly useful? (Challenge if they say 'all of it!' – must be precise).
  - ii. Was anything less useful or could be improved?
  - iii. Would you have liked anything more in the way of training or materials?
  - iv. What do you feel about the number of training sessions? (too many/not enough/about right?)
  - v. What did you feel about the balance of the training sessions between communication/behaviour change techniques and practical trial aspects (physical activity guidelines/using pedometers/handbooks/reporting adverse events etc.).
2. Did your physical activity consulting change as a result of the training or from being involved in the trial?
  - i. If so, how? If not, why not?
  - ii. Have any other aspects of your work changed?

Moving on to the nurse handbook and patient handbook and diary.

3. What was it like using the handbook/diary? (remind the nurses about the handbook/diary by showing it to them – have one copy to look at together, or else it will turn into individual silent reading sessions).
  - i. How did you find using it?
  - ii. How did the patients find it? What were the best bits? Which bits caused most difficulty? How did you get round this?
  - iii. How could the handbook be improved?

And now the pedometer and setting targets.

4. What about using the pedometer?

- i. How easy was it to explain to people how to use it?
- ii. How common were difficulties with the pedometer? What kind of difficulties did people have?
- iii. Were most people happy to wear the pedometer while coming to see you & keep a step-count record?
- iv. Were targets that we had suggested realistic for most people? Did a lot of people change their targets? If people changed them did they tend to set higher or lower targets?

Patient engagement.

5. How acceptable did patients find the intervention?

- i. Were any patients more responsive to the PA intervention than others?
  - What were the characteristics of someone who really ‘went for it’?
  - What about the characteristics of someone who really didn’t get on with it?
  - Did anyone say anything to you that hinted at why they didn’t like it?
  - Did you have experience of working with couples in the trial? How did you find this? What were the positive aspects? And the negative?

The trial protocol.

6. How about the trial protocol – the schedule for seeing patients (3 visits a month apart, first visit approximately 30 minutes, others approximately 20 minutes).

- i. Was it possible to do what was required of you in the time prescribed?
- ii. Were there enough sessions/too many?
- iii. Did most patients actually get the 3 visits at the right time? How did it vary between patients?
- iv. Did you have problems with non-attenders? How did you manage this?
- v. If things went wrong, how easy was it for you to get help/support from the study team?
- vi. How did you feel about having some of your sessions recorded? Was recording them or receiving feedback on the sessions helpful?

7. Some of you are also involved in NHS health checks at your practices, do you see this intervention as something that could be useful for those identified in health checks as needing to increase their physical activity levels?

- i. If yes, how could this work? If no, why not?

8. From the nurse perspective, if we were to do the trial again with different practices, or try to put the intervention into your routine practice . . .

- i. What would be the main things to keep?
- ii. The main things to change?

9. And from the patients’ perspective, as far as you can tell . . .

- i. What would be the main things to keep?
- ii. The main things to change?

10. Anything else that you think we have missed / that you want to tell us?

TABLE 43 Interview participant details

ID	Sex	Self-reported ethnicity	Group	Age (years)	Change in average steps per day from baseline to 12 months
1	Female	Any other white background	Nurse	48	+1697
2	Male	White British	Nurse	45	+113
3	Male	White British	Pedometer	53	+3708
4	Male	Bangladeshi	Pedometer	52	-234
5	Female	White British	Pedometer	57	+1718
6	Female	White British	Pedometer	51	-2141
7	Female	White British	Pedometer	60	-1808
8	Female	White British	Pedometer	65	-1781
9	Female	Black Caribbean	Pedometer	69	+243
10	Male	Black African	Nurse	64	-1920
11	Male	White British	Pedometer	70	+1543
12	Female	White and black Caribbean	Nurse	66	+1211
13	Female	White British	Pedometer	66	-446
14	Female	Any other white background	Nurse	49	+4756
15	Female	Any other white background	Nurse	49	-1097
16	Female	White British	Nurse	47	+1573
17	Female	Any other white background	Pedometer	66	-1027
18	Female	White British	Nurse	62	-2836
19	Female	White British	Pedometer	66	-1797
20	Male	White British	Nurse	52	+3924
21	Female	Black African	Nurse	47	+2962
22	Male	White British	Nurse	63	-2652
23	Female	White British	Pedometer	64	+226
24	Female	Any other white background	Pedometer	50	+1031
25	Male	White British	Pedometer	67	-955
26	Female	White British	Nurse	65	-2013
27	Male	White and Asian	Pedometer	61	-611
28	Female	Chinese	Nurse	72	+4062
29	Male	White British	Nurse	59	-493
30	Female	White British	Nurse	51	+3269
31	Male	White British	Pedometer	59	-756
32	Female	White British	Nurse	63	+1966
33	Female	White British	Nurse	49	-746
34	Female	Black Caribbean	Pedometer	73	+403
35	Female	White British	Nurse	64	+2100

continued

TABLE 43 Interview participant details (*continued*)

ID	Sex	Self-reported ethnicity	Group	Age (years)	Change in average steps per day from baseline to 12 months
36	Female	White British	Pedometer	64	+1639
37	Female	Indian	Pedometer	51	-1720
38	Female	White British	Pedometer	59	+539
39	Female	White British	Nurse	61	-1425
40	Male	White British	Nurse	48	-3826
41	Male	White British	Nurse	65	-43
42	Male	White British	Pedometer	72	-2133
43	Female	White British	Pedometer	48	+2253

ID, identifier.

# Appendix 7 Three-year follow-up

## Qualitative interview schedule: intervention group 3-year follow-up

Introduction:

1. Introduce self, explain you are calling from PACE-UP trial, confirm the name of the person.
2. Remind of initial consent to be approached for an interview in the 3-year follow-up consent letter.
3. Explain this is a telephone interview to discuss in a bit more detail their physical activity experiences since being involved in the trial. It should take no more than 20–25 minutes but explain that if they have lots of things they would like to feedback, then you have more time.
4. If participant happy to continue, thank them for their participation.
5. Explain that you would like to record the interview with their permission.

(Start recorder)

1. Explain you are now going to say their participant number for the benefit of the tape and ask them just to verbally confirm again that they happy to be interviewed and for a recording to be made.
2. Explain that everything they say will be kept confidential and any comments they make will be linked to an anonymous number rather than a name.
3. Explain that if the participant wants to stop the interview at any time it's not a problem at all and to just let the interviewer know.

Main questions:

1. Can you tell me about what physical activity you did last week? Was that a typical week for you?
2. Do you think taking part in the PACE-UP trial has changed the physical activity you are doing now?
3. Is there anything about the PACE-UP trial that you particularly remember? *i.e. take home message.*
4. Do still you use the pedometer, diary or handbook given to you after the PACE-UP trial? If so, how often do you use them? *If no, do you use anything else? i.e. phone, Fitbit.*
5. What normally motivates you to be physically active? Is that different to how it was before you participated in PACE-UP?
6. Would you recommend the PACE-UP trial to family and friends?
7. Are there any additional resources or support that you could suggest that might help to keep you physically active? *i.e. family, friends, text messages, online resources, annual visit to nurse, walking groups . . .*

Closing:

That was all the questions I had for you, is there anything else you would like to add or think I've missed?

Thank you for taking the time out to answer our questions, as a token of our thanks we will be sending a £10 high-street voucher to you within the next week.

### Prompts

#### Pedometer use

- In what way do you think the pedometer influences your physical activity?

## Barriers to being physically active

- Are there any barriers or difficulties you've had to overcome when it comes to physical activity?

## Motivation

- Do you set yourself any physical activity targets/goals? *If yes, prompt more.*
- Do you adopt any strategies to help you stay motivated to be physically active? *If yes, prompt more.*

## Peer/social support and physical activity

- Under question 5 if not discussed.

## Qualitative interview schedule: control group 3-year follow-up

Introduction:

1. Introduce self, explain you are calling from PACE-UP trial, confirm the name of the person.
2. Remind of initial consent to be approached for an interview in the 3 year follow-up consent letter.
3. Explain this is a telephone interview to discuss in a bit more detail their physical activity experiences since being involved in the trial. It should take no more than 20–25 minutes but explain that if they have lots of things they would like to feedback, then you have more time.
4. If participant happy to continue, thank them for their participation.
5. Explain that you would like to record the interview with their permission.

(Start recorder)

1. Explain you are now going to say their participant number for the benefit of the tape and ask them just to verbally confirm again that they happy to be interviewed and for a recording to be made.
2. Explain that everything they say will be kept confidential and any comments they make will be linked to an anonymous number rather than a name.
3. Explain that if the participant wants to stop the interview at any time it's not a problem at all and to just let the interviewer know.

Main questions:

1. Can you tell me about what physical activity you did last week? Was that a typical week for you?
2. Do you think taking part in the PACE-UP trial has changed the physical activity you are doing now?
3. Is there anything about the PACE-UP trial that you particularly remember? i.e. take home message.
4. What normally motivates you to be physically active? Is that different from how it was before you participated in PACE-UP?
5. As a participant in the study you will have received a pedometer, diary and handbook after the main trial was over. Did you find these resources helpful? Have you continued to use any of these resources? Do you use anything else? i.e. phone, Fitbit . . .
6. Would you recommend the PACE-UP trial to family and friends?
7. Are there any additional resources or support that you could suggest that might help to keep you physically active? i.e. family, friends, text messages, online resources, annual visit to nurse, walking groups . . .

Closing:

That was all the questions I had for you, is there anything else you would like to add or think I've missed?

Thank you for taking the time out to answer our questions, as a token of our thanks we will be sending a £10 high-street voucher to you within the next week.

### **Prompt sheet**

#### **Pedometer use**

- In what way do you think using a pedometer influences your physical activity?

#### **Barriers to being physically active**

- Are there any barriers or difficulties you've had to overcome when it comes to physical activity?

#### **Motivation**

- Do you set yourself any physical activity targets/goals? *If yes, prompt more.*
- Do you adopt any strategies to help you stay motivated to be physically active? *If yes, prompt more.*

#### **Peer/social support and physical activity**

- Under question 5 if not discussed.

**Three-year health and lifestyle questionnaire****PACE-UP+3*****Health and lifestyle survey***

---

Study IDNO \_\_\_\_\_

**Thank you for filling in this questionnaire.****It will take you about 10-15 minutes to complete.****Please feel free to write comments by any question.****All information will be kept strictly confidential.**

Please enter your date of birth \_\_\_\_ / \_\_\_\_ / \_\_\_\_

Please enter today's date \_\_\_\_ / \_\_\_\_ / \_\_\_\_

**Thank you**

This project was funded by the National Institute for Health Research Health Technology Assessment Programme (HTA) -  
Project number 10/32/02

## Section A - Some general questions about your health

Please put a tick in the box next to the most appropriate answer

for each question.



### 1 How is your health in general?

- Very good
- Good
- Fair
- Poor
- Very poor

### 2 How much physical or bodily pain have you had in the past 4 weeks?

- None
- Very mild or mild
- Moderate
- Severe or very severe

### 3 What is your current weight?

\_\_\_\_\_ kg

or \_\_\_\_\_ stones and \_\_\_\_\_ pounds

## Section B - Questions about your health today

Under each heading, please tick the ONE box that best describes your health TODAY

### 1 Mobility

- I have no problems in walking about
- I have slight problems in walking about
- I have moderate problems in walking about
- I have severe problems in walking about
- I am unable to walk about

### 2 Self-care

- I have no problems with self-care
- I have slight problems washing or dressing myself
- I have moderate problems washing or dressing myself
- I have severe problems washing or dressing myself
- I am unable to wash or dress myself

### 3 Usual activities (e.g. work, study, housework, family or leisure)

- I have no problems doing my usual activities
- I have slight problems doing my usual activities
- I have moderate problems doing my usual activities
- I have severe problems doing my usual activities
- I am unable to do my usual activities

### 4 Pain / discomfort

- I have no pain or discomfort
- I have slight pain or discomfort
- I have moderate pain or discomfort
- I have severe pain or discomfort
- I have extreme pain or discomfort

### 5 Anxiety / depression

- I am not anxious or depressed
- I am slightly anxious or depressed
- I am moderately anxious or depressed
- I am severely anxious or depressed
- I am extremely anxious or depressed

## Section C - Some questions on how you feel

Please tick the reply that comes closest to how you have been feeling over the past week. Don't take too long: your immediate reaction will probably be most accurate.

Tick only one box for each question

**1. I feel tense or 'wound up':**

Most of the time	<input type="checkbox"/>	A lot of the time	<input type="checkbox"/>
From time to time	<input type="checkbox"/>	Not at all	<input type="checkbox"/>

**2. I feel as if I am slowed down:**

Nearly all of the time	<input type="checkbox"/>	Very often	<input type="checkbox"/>
Sometimes	<input type="checkbox"/>	Not at all	<input type="checkbox"/>

**3. I still enjoy things I used to:**

Definitely as much	<input type="checkbox"/>	Not quite as much	<input type="checkbox"/>
Only a little	<input type="checkbox"/>	Hardly at all	<input type="checkbox"/>

**4. I get a sort of frightened feeling like butterflies in the stomach:**

Not at all	<input type="checkbox"/>	Occasionally	<input type="checkbox"/>
Quite often	<input type="checkbox"/>	Very often	<input type="checkbox"/>

**5. I get a sort of frightened feeling as if something bad is about to happen:**

Very definitely	<input type="checkbox"/>	Yes, but not too badly	<input type="checkbox"/>
A little, but it doesn't worry me	<input type="checkbox"/>	Not at all	<input type="checkbox"/>

**6. I have lost interest in my appearance:**

Definitely	<input type="checkbox"/>	I don't take so much care as I should	<input type="checkbox"/>
I might not take as much care	<input type="checkbox"/>	I take just as much care	<input type="checkbox"/>

**7. I can laugh and see the funny side of things:**

As much as I always could	<input type="checkbox"/>	Not quite so much now	<input type="checkbox"/>
Definitely not so much now	<input type="checkbox"/>	Not at all	<input type="checkbox"/>

**8. I feel restless, as if I have to be on the move**

Very much indeed	<input type="checkbox"/>	Quite a lot	<input type="checkbox"/>
Not very much	<input type="checkbox"/>	Not at all	<input type="checkbox"/>

**9. Worrying thoughts go through my mind:**

A great deal of the time	<input type="checkbox"/>	A lot of the time	<input type="checkbox"/>
From time to time, not too often	<input type="checkbox"/>	Only occasionally	<input type="checkbox"/>

**10. I look forward with enjoyment to things:**

As much as I ever did	<input type="checkbox"/>	Rather less than I used to	<input type="checkbox"/>
Definitely less than I used to	<input type="checkbox"/>	Hardly at all	<input type="checkbox"/>

**11. I feel cheerful:**

Not at all	<input type="checkbox"/>	Not often	<input type="checkbox"/>
Sometimes	<input type="checkbox"/>	Most of the time	<input type="checkbox"/>

**12. I get sudden feelings of panic**

Very often indeed	<input type="checkbox"/>	Quite often	<input type="checkbox"/>
Not very often	<input type="checkbox"/>	Not at all	<input type="checkbox"/>

**13. I can sit at ease and feel relaxed:**

Definitely	<input type="checkbox"/>	Usually	<input type="checkbox"/>
Not often	<input type="checkbox"/>	Not at all	<input type="checkbox"/>

**14. I can enjoy a good book, radio or TV programme:**

Often	<input type="checkbox"/>	Sometimes	<input type="checkbox"/>
Not often	<input type="checkbox"/>	Very seldom	<input type="checkbox"/>

**15. I feel lonely:**

All the time	<input type="checkbox"/>	Often	<input type="checkbox"/>
Sometimes	<input type="checkbox"/>	Never	<input type="checkbox"/>

## Section D – Some questions about your belief in your ability to exercise

How sure are you that you will do each of the following:

	Very Sure	Pretty Sure	A little Sure	Not Sure
1. Exercise regularly (3 times weekly for 20 mins)	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
2. Exercise when you are feeling tired	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
3. Exercise when you are under pressure	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
4. Exercise when you are feeling down	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
5. Exercise when you have too much work	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
6. Exercise when there are more interesting things to do	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
7. Exercise when family or friends do not provide any support	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
8. Exercise when you don't really feel like it	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
9. Exercise when you are away from home	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>

## Section E - Some questions on falls, injuries & illnesses

These questions ask about any falls, injuries or illnesses that you may have had in the last 12 months.

In the last 12 months have you had any of the following:

1 A fall? Yes  No

1a If yes, how many times? ..... times in the last 12 months

2 Any fractures (broken bones)? Yes  No

2a If yes, please give details of what bones were injured

.....  
.....

3 Any sprains or injuries? Yes  No

3a If yes, please give details of the sprain or injury

.....

6 Have you attended an Accident and Emergency department? Yes  No

If yes, please give details of what this was for and when.....

.....  
.....

5 Have you been admitted to hospital? Yes  No

If yes, please give details of what this was for and when.....

.....  
.....  
.....

## Section F - Some questions about physical activity

- 1 How many times did you take a walk outside *during the last week*?  
(include walking related to other activities) .....times last week
- 2 How long did such a walk usually last? .....minutes
- 3 Did you take a walk lasting longer than 1 hour *during the last month*?  
Yes  No
- 3a If yes, how many times did you do that? .....times last month
- 4 Do you have someone to go for a walk, or do other physical activities with?  
Always  Often  Sometimes  Never
- 5 Do you ride a bicycle? Yes  No  (please go to Qu. 6)
- 5a If yes, how many times did you cycle last week? .....times
- 5b How long on average did you cycle for each time? .....minutes
- 6 Do you go swimming? Yes  No  (please go to Qu.7)
- 6a If yes, how many times did you swim last week? .....times
- 6b How long on average did you swim for each time?.....minutes
- 7 Do you have a garden or allotment? Yes  No
- 7a If yes, how many hours, on average, a week do you spend gardening?  
In summer .....hours In winter .....hours
- 8 Have you participated in any sporting activities in the last week?  
Yes  No  (if no, please go to Qu. 9)
- 8a If yes, what kind of sporting activity? .....
- 8b How many hours approximately, did you spend participating in sporting activities in the last week?  
Less than 1 hour in the last week  ..... hours in the last week

**9 Do you have a hobby? (other than gardening or sports)?**Yes  No  (if no, please go to Qu.10)**9a If yes, what kind of hobby?**

.....

**9b How many hours a week approximately do you spend on it?**Less than 1 hour in the last week  ..... hours in the last week **10 Do you do odd jobs around the house yourself (e.g. painting and carpentry)?**Yes  No  (if no, please go to question 11)

If yes, for how many hours a week? .....hours weekly

**11 Do you do light housework, such as dusting and washing dishes?**Yes  No  (if no, please go to question 12)

If yes, for how many hours a week? .....hours weekly

**12 Do you do heavy housework, such as vacuuming, scrubbing floors?**Yes  No  (if no, please go to question 13)

If yes, for how many hours a week? .....hours weekly

**13 Did you use a pedometer during the last 12 months?**Yes  (please go to Qu. 14) No  (please go to Qu. 15)**14 If yes, how often did you use a pedometer during the last 12 months?**All the time About once a week About once a month Less frequently than once per month **15 Have you used any other device to measure or monitor your physical activity in the last 12 months?**Smart Phone Wrist worn device (e.g. fitbit, jawbone, axivity) Waist worn device Clip on device Other-Please specify below None 

.....

- 16. Have you had any significant life events in the last 12 months that you think may have affected your physical activity levels?** (Some examples are family bereavement, retirement, moved house, new long-term illness or disability, new grandchild).

**If yes, please give details of what has happened and how it has affected your physical activity.**

.....

.....

.....

**Thank you for filling in this questionnaire**

## Appendix 8 Discussion

### What is the potential benefit of our intervention on coronary heart disease and all-cause mortality?


Several systematic reviews have assessed the health benefits of walking based on pooling data from cohort studies. Typically, the RRs are 0.8 in people who are physically more active compared with those who are much less active. The difficulty of interpreting such analyses is their focus on comparing two extreme groups: the physically active versus those who are inactive. Zheng *et al.*<sup>197</sup> recognised the importance of studying the functional form of the dose–response effect of walking on the risk of developing CHD. They concluded that the risk of developing CHD decreases as the amount of brisk walking increases.<sup>197</sup> Specifically, Zheng *et al.*<sup>197</sup> concluded that 150 minutes of brisk walking per week reduces the incidence of CHD by 19% (a RR of 0.81, 95% CI 0.77 to 0.86); RR estimates were similar in both sexes and in older and younger subjects. From this, we can estimate (see below\*) that the increase of 33 minutes per week in the postal delivery group in our study at 12 months would be expected to reduce the participants' risk of developing CHD by 4.5% (95% CI 3.3% to 5.6%) if sustained. In a prospective study assessing the benefits of walking in a free-living population sample,<sup>198</sup> it was found that a higher daily step count measured by pedometer was linearly associated with reductions in all-cause mortality. Using the same method (see below\*\*) we estimate that the 643 step increase in our postal delivery group would result in a 4% (95% CI 1% to 7%) decrease in mortality.

\*From the paper by Zheng *et al.*,<sup>197</sup> we can take the fact that log (risk) increases linearly with minutes of MVPA and that increasing MVPA per week by 150 minutes reduces the risk by 19% (a RR of 0.81), to estimate that increasing MVPA by 33 minutes per week would result in a RR of  $0.81^{(33/150)} = 0.81^{0.22}$  (95% CI 0.77<sup>0.22</sup> to 0.86<sup>0.22</sup>) = 0.955 (95% CI 0.944 to 0.967). That is a 4.5% (95% CI 3% to 6%) reduction in the risk of developing CHD.

\*\*From the paper by Dwyer *et al.*,<sup>198</sup> the adjusted hazard ratio for all-cause mortality associated with an additional 1000 steps was 0.94 (95% CI 0.90 to 0.98). Using the same approach as above, an increase of 642 steps is estimated to reduce the risk by  $0.94^{(642/1000)} = 0.94^{(0.642)}$  (95% CI 0.90<sup>(0.642)</sup> to 0.98<sup>(0.642)</sup>) = 0.96 (95% CI 0.93 to 0.99). That is a 4% (95% CI 1% to 7%) reduction in all-cause mortality.





A decorative graphic consisting of numerous thin, parallel green lines that curve from the left side of the page towards the right, creating a sense of movement and depth.

**EME  
HS&DR  
HTA  
PGfAR  
PHR**

Part of the NIHR Journals Library  
[www.journalslibrary.nihr.ac.uk](http://www.journalslibrary.nihr.ac.uk)

*This report presents independent research funded by the National Institute for Health Research (NIHR). The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR or the Department of Health*

***Published by the NIHR Journals Library***